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Abstract	
	
Background:	With	an	estimated	10.4	million	incident	tuberculosis	(TB)	cases	in	2015,	
and	the	current	trajectory	of	1.5%/year	incidence	rate	decline,	new	TB	vaccines	are	
urgently	needed	 to	help	meet	 the	WHO	goal	of	 tuberculosis	elimination	by	2050.	
However,	 insufficient	 epidemiological	 evidence	 exists	 to	 inform	 TB	 vaccine	
development	strategies	and	to	assist	clinical	trial	site	selection	and	design.	Research	
to	 meet	 these	 data	 needs	 is	 critical	 to	 accelerate	 TB	 vaccine	 development.	 To	
maximise	 the	 future	 impact	of	new	TB	vaccines,	estimates	of	 the	population-level	
impact	 of	 vaccine	 characteristics	 and	 implementation	 strategies	 are	 needed	 to	
inform	design	of	TB	vaccine	target	product	profiles.	To	accelerate	and	de-risk	clinical	
trials,	 appropriate	 epidemiological	 data	 are	 required	 to	 inform	 trial	 site	 selection,	
sample	size	calculations	and	recruitment	strategy.		However,	data	availability	at	trial	
sites	is	limited,	and	prospective	studies	are	resource-intensive,	so	new	methods	are	
needed	to	collect	appropriate	data	to	inform	TB	vaccine	trial	design.	
To	inform	data-driven	development	strategies	for	new	TB	vaccines,	the	aims	of	this	
thesis	 were	 to	 1)	 estimate	 the	 epidemiological	 impact	 of	 new	 TB	 vaccine	
characteristics	 and	 implementation	 in	 China	 to	 inform	 design	 of	 target	 product	
profiles;	and	2)	to	develop	a	novel	epidemiological	spatial	mapping	tool	capable	of	
informing	 clinical	 trial	 design	 for	 new	 TB	 vaccines	 in	 low-income,	 high-burden	
settings.	
Methods:	A	deterministic,	age-structured,	Mycobacterium	tuberculosis	transmission	
model	 was	 developed	 and	 calibrated	 to	 age-stratified	 epidemiological	 and	
demographic	data	from	China.	This	was	employed	to	estimate	the	population-level	
epidemiological	impact	of	new	TB	vaccines	over	the	2025-2050	time	horizon,	through	
an	exploration	of	potential	vaccine	characteristics	and	implementation	strategies.		
A	new	methodology	for	empirical	data	collection	to	determine	spatial	distribution	of	
TB	notifications	was	developed.	The	electronic	PArticipant	Locator	application	(ePAL	
app)	combined	3,243	community-identified	points	of	 interest	with	high	 resolution	
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satellite	 maps,	 within	 an	 electronic	 tablet-based	 case	 report	 form.	 The	 app	 was	
integrated	 in	 to	 the	 National	 Tuberculosis	 Programme	 in	 Blantyre,	 Malawi,	 for	
collection	of	demographics,	health	status	and	coordinates	of	place	of	residence	for	
patients	≥18	years	initiating	TB	treatment.	Accuracy	of	ePAL-recorded	co-ordinates	
was	 evaluated	 against	 GPS	 coordinates	 obtained	 at	 the	 participant’s	 place	 of	
residence.	 	
Results:	Mathematical	 modelling	 predicted	 a	 shift	 towards	 a	 reactivation-driven,	
ageing	TB	epidemic	in	China	by	2050.	Vaccines	protective	against	disease,	effective	
post-infection	and	providing	at	least	5	years	protection	were	essential	for	achieving	
higher	levels	of	impact.	Vaccination	of	older	adults	provided	greater	population-level	
impact	 than	 vaccinating	 adolescents	 for	 all	 equivalent	 vaccines	 explored,	 even	 if	
much	lower	coverage	were	achieved	in	older	adult	vaccination.	Recommendations	
for	 post-infection	 vaccines	 were	 robust	 to	 substantial	 reductions	 in	 efficacy	 and	
duration	of	protection	in	older	adults,	whereas	for	pre-infection	vaccines	in	some	of	
these	scenarios	adolescent	vaccination	may	be	equivalent	or	preferred.	Vaccinating	
older	adults	with	post-infection	vaccines	provided	substantially	higher	impact	than	
pre-infection	vaccines.	
1,899	TB	patients	were	registered	using	ePAL	in	the	12-month	study	period,	with	high	
patient	 acceptance	 (98.7%,	 1,899/1,924).	 ePAL	 achieved	 clinic-based	 collection	 of	
patient	location	of	residence	accurate	to	a	median	of	84	metres	(IQR:	35-317	metres)	
in	 a	 high	 population	 density	 urban	 setting	 without	 a	 municipal	 address	 system.	
Advantages	 of	 the	 ePAL	 system	 included	 real-time	 availability	 of	 high-resolution	
spatial	data,	low	set	up	costs,	and	ease	of	use	by	health	staff	as	part	of	routine	TB	
registration.	 Data	 were	 used	 to	 identify	 areas	 with	 high	 TB	 burden,	 potentially	
suitable	for	TB	vaccine	trials.	
Conclusions:	 The	 research	 presented	 in	 this	 thesis	 informs	 the	 development	 of	
appropriate	TB	vaccines	and	target	populations	to	maximise	future	population-level	
impact.	A	prevention	of	disease	vaccine	efficacious	post-infection	and	delivered	to	
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older	adults	would	contribute	towards	maximising	population-level	impact	in	China.	
Adolescent-targeted	 tuberculosis	vaccines	are	 likely	 to	have	 low	 impact	 in	ageing,	
reactivation-driven	epidemics	like	China,	which	suggests	a	modification	of	the	current	
strategic	 focus	on	adolescents	 among	 certain	 funders.	 Clinical	 trials	 should	 assess	
disease	endpoints,	 include	M.tb-infected	 and	older	 adult	 populations,	 and	extend	
beyond	the	usual	2-3	years	follow	up.	To	support	design	of	disease	endpoint	trials,	
ePAL	may	provide	an	accurate,	easily	implementable,	low-cost	tool	for	identification	
of	areas	of	high	TB	burden	in	settings	without	addresses.		
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Summary	of	Chapter	1	
	
This	 chapter	 defines	 the	 context	 and	 rationale	 for	 the	 research	 presented	 in	 this	
thesis.	This	includes	a	discussion	of	tuberculosis	as	a	public	health	problem,	and	the	
potential	role	of	new	vaccines	in	tackling	the	burden	of	disease	within	the	context	of	
WHO	2035	and	2050	goals.	Two	key	epidemiological	research	needs	are	identified,	
and	 the	 rationale	 for	 the	 development	 of	 new	 mathematical	 models	 and	 an	
epidemiological	 tool	 to	help	 inform	and	accelerate	development	of	TB	vaccines	 is	
described.	The	two	overall	aims	of	the	thesis	are	defined,	and	translated	into	research	
objectives.	
An	 outline	 of	 the	 thesis	 to	 is	 provided	 help	 guide	 the	 reader,	 including	 a	 brief	
summary	of	the	chapters	and	research	papers.		
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CHAPTER	1 Introduction	
 Background	
The	 global	 Millennium	 Development	 Goal	 to	 halt	 and	 reverse	 tuberculosis	 (TB)	
incidence	trends	by	2015	was	achieved,	yet	with	an	estimated	10.4	million	incident	
TB	cases	and	1.8	million	deaths	in	2015,	a	substantial	burden	of	disease	still	exists.1	
The	 current	 trajectory	 of	 incidence	decline	 (1.5%/year)	will	 not	 achieve	 the	WHO	
2050	goal	of	eliminating	TB	as	a	public	health	problem,	defined	as	less	than	1	case	
per	 million	 population	 per	 year.	 Historical	 trends	 and	 mathematical	 modelling	
indicate	 that	with	socioeconomic	development	and	aggressive	scale-up	of	existing	
interventions,	up	to	10%	annual	reduction	could	potentially	be	achieved,2-4	but	falls	
short	of	the	20%	per	year	required	for	elimination	(Figure	1.1).5	Development	of	new	
tools,	such	as	new	TB	vaccines,	will	be	essential	for	achieving	these	goals.5		
	
	
	
Figure	1.1:	Reduction	in	incidence	rate	required	to	achieve	WHO	2050	goal	of	elimination	of	TB	as	a	
public	health	problem.	Reproduced	with	permission	from	Dye	et	al.	2013.5	
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The	existing	TB	vaccine,	Bacillus	Calmette-Guérin	 (BCG),	 is	delivered	to	more	than	
88%	of	BCG-eligible	newborns,	totalling	more	than	100	million	newborns	annually.6-8	
Meta-analyses	suggest	that	in	children	vaccinated	at	birth,	BCG	efficacy	is	59%	(95%	
confidence	 interval	 (CI),	42-71%)	against	pulmonary	TB	and	90%	(95%	CI,	23-99%)	
against	 extrapulmonary	 disease.9	 However,	 highly	 variable	 protection	 has	 been	
observed	in	adults,	ranging	by	setting	from	0%	to	80%	against	pulmonary	disease.9	
Given	 that	90%	of	 global	 TB	 incidence	occurs	 in	 the	adult	 (≥15	years)	population,	
there	is	a	clear	and	urgent	need	for	a	new	prophylactic	TB	vaccine	effective	in	adults.1	
The	new	TB	vaccine	pipeline	is	the	strongest	to	date,	with	13	candidates	currently	in	
clinical	trials.10	Yet	progression	of	vaccines	through	the	pipeline	remains	slow,	due	to	
limited	funding	and	the	technical	challenges	in	conducting	clinical	trials.	Particularly	
limiting	is	the	lack	of	an	immune	correlate	of	protection	and	relatively	low	incidence	
of	disease,	necessitating	large	efficacy	trials	with	long	periods	of	follow	up,	without	
prior	knowledge	of	whether	the	elicited	response	is	likely	to	be	protective.	
Key	activities	to	help	overcome	some	of	the	challenges	in	TB	vaccine	development	
have	been	identified	in	the	TB	Vaccine	Blueprint.11	Included	in	the	Blueprint	activities	
was	the	need	to	“determine	TB	prevalence	and	incidence,	select	trial	sites	and	choose	
target	populations	for	TB	vaccines	that	result	in	the	greatest	reduction	of	disease”.11	
This	constitutes	two	epidemiological	research	needs,	summarised	in	Box	1	below.	
Box	1:	Epidemiological	research	needs,	based	on	the	TB	Vaccine	Blueprint11	
1) Data-driven	 identification	of	vaccine	characteristics	and	target	populations	
for	vaccination	that	could	achieve	the	greatest	reduction	in	disease	burden.		
2) A	better	understanding	of	local	epidemiology	to	inform	the	selection	of	trial	
sites,	recruitment	populations	and	design	clinical	trials.	
	
For	 the	 first	 research	 need,	 mathematical	 modelling	 provides	 a	 data-driven	
framework	 for	 estimating	 the	 potential	 impact	 of	 vaccine	 characteristics	 and	
vaccination	 strategies,	 aiding	 identification	 of	 those	 likely	 to	 achieve	 the	 greatest	
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reduction	in	burden	(‘ideal’	candidates).	Where	‘ideal’	candidates	are	not	feasible,	
modelling	can	help	identify	characteristics	that	would	provide	a	minimum	desirable	
impact.	 This	 research	 is	needed	 to	 inform	development	of	 target	product	profiles	
(TPPs)	 for	 TB	 vaccines.	 TPPs	 are	 strategic	 documents	 outlining	 the	 desired	 and	
minimum	 vaccine	 label.	 Vaccine	 characteristics	 and	 implementation	 strategies	
considered	 in	 the	 TPP	 include,	 but	 are	 not	 limited	 to,	 the	 vaccine	 efficacy	 for	
prevention	of	 infection	or	disease,	whether	 the	vaccine	 is	effective	 in	populations	
uninfected	 or	 infected	 with	 Mycobacterium	 tuberculosis	 (M.tb),	 duration	 of	
protection,	and	target	populations	that	could	maximise	impact	(e.g.	age	groups).		
Existing	modelling	literature	explores	the	epidemiological	impact	of	a	variety	of	these	
vaccine	characteristics	in	global,	regional	and	country-level	settings,	but	in	any	given	
study	typically	only	a	subset	of	characteristics	was	explored,	limiting	use	for	informing	
vaccine	 development.	 A	 comprehensive	 exploration	 of	 possible	 vaccine	
characteristics	 and	 implementation	 strategies	 using	 mathematical	 modelling	 is	
required.		
Results	 from	a	phase	 III	 prophylactic	 TB	 vaccine	 trial	 in	China	are	 anticipated	 this	
year.12	 As	 more	 information	 becomes	 available	 about	 the	 characteristics	 of	 this	
vaccine,	mathematical	modelling	can	be	used	to	predict	future	impact.	China	is	the	
third	 largest	contributor	to	global	TB	 incidence,1	so	opportunities	to	maximize	the	
vaccine-avoidable	disease	burden	in	this	setting	could	also	have	a	sizeable	impact	on	
the	 global	 burden.	 Available	 TB	 vaccine	 modelling	 in	 China	 is	 limited,	 exploring	
relatively	 unrealistic	 profiles	 (for	 example	 assuming	 100%	 efficacy	 and	 lifelong	
protection),5,13	and	overlooking	the	dynamic	co-evolution	of	demographics	and	TB	
epidemiology	in	this	ageing	population.	Although	global-level	modelling	has	explored	
age	targeting	of	vaccination	to	infants	versus	adolescents	and	adults,14,15	given	the	
ageing	 populations	 in	 several	 of	 the	WHO	 high	 TB	 burden	 countries	 (e.g.	 China,	
Russia,	Brazil	 and	Thailand),1,16	 it	 is	 surprising	 that	 vaccinating	older	 adults	or	 the	
elderly	 has	 not	 been	 explored.	 A	 significant	 research	 gap	 clearly	 exists	 in	 fully	
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exploring	the	impact	of	vaccine	characteristics	and	age	targeting	of	vaccination	in	this	
setting.		
Target	 product	 profiles,	 ideally	 informed	by	mathematical	modelling	 as	 described	
above,	are	 translated	 in	 to	clinical	development	plans	 (CDPs)	designed	to	develop	
appropriate	 candidates	 ready	 for	 delivery	 to	 identified	 target	 populations.	 As	
highlighted	 in	 the	 TB	 vaccine	 Blueprint’s	 second	 epidemiological	 research	 need,	
designing	such	trials,	selecting	trial	sites,	and	identifying	recruitment	populations	all	
require	appropriate	epidemiological	data.		
There	is	a	substantial	global	burden	of	TB	disease,	but	relatively	low	incidence	rate	
compared	to	other	diseases	such	as	malaria,	therefore	clinical	trials	for	prevention	of	
TB	 disease	 can	 be	 long,	 large,	 expensive,	 and	 challenging	 to	 design.	 As	 has	 been	
discussed	in	the	literature,	there	is	a	dearth	of	trial-ready	research	sites	with	known	
sufficient	 TB	burden	 for	 vaccine	 trials.17	 Country	 and	 regional	 level	 programmatic	
tuberculosis	data,	and	prevalence	surveys	where	available,	can	be	used	to	identify	
regions	 experiencing	 a	 trial-suitable	 burden	 of	 disease.	 However,	 data	 of	 greater	
granularity	 and	 specific	 to	 communities	where	 recruitment	 is	 planned	 is	 needed.	
Such	 data	 inform	 sample	 size	 calculations	 that	 balance	 the	 risk	 of	 failure	 from	
insufficient	 endpoints	 against	 minimising	 costs	 and	 the	 number	 of	 participants	
exposed	to	the	investigational	product.	Such	data	can	also	help	direct	recruitment	
through	 identification	 of	 geographical	 hotspots	 in	 the	 intended	 recruitment	
populations	(e.g.	HIV-negative	populations	or	specific	age	groups).	
However,	data	with	such	granularity	are	rarely	available.	Prospective	prevalence	or	
incidence	studies	are	considered	the	gold	standard,	but	are	expensive,	inflexible	once	
initiated	and	can	take	months	to	years	from	inception	to	delivery	of	results.	Readily	
available	TB	notification	data	can	be	collected	from	national	tuberculosis	programme	
(NTP)	 clinic	 records,	 but	 clinic	 catchment	 areas	 may	 be	 large,	 descriptions	 of	
residence	unclear,	and	patients	may	not	always	seek	care	in	their	local	community	
due	to	stigma	associated	with	the	disease.	In	many	low-	and	middle-income	countries	
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where	 formal	 address	 systems	 are	 not	 in	 place,	 verbal	 descriptions	 of	 place	 of	
residence	are	collected	in	clinic	records	(e.g.	‘Near	Maketa	market,	by	the	bus	station	
look	for	the	maize	mill	and	ask	for	Mr	X’).	However,	a	study	in	Malawi	has	highlighted	
the	difficulty	in	accurately	identifying	place	of	residence	from	such	descriptions,	with	
two	 research	 assistants	 only	 able	 to	 identify	 the	 cluster	 (mean	 cluster	 size:	 1,342	
adults)	 in	 which	 the	 participant	 was	 resident	 for	 40.3%	 and	 68.2%	 of	 129	 ART-
initiators.18	Therefore,	existing	data	may	be	of	limited	use	for	improving	granularity	
of	available	data	for	study	design.		
In	 the	 same	 research	 site	 in	Malawi,	 a	 low	 cost	 “Map	 book”	 was	 developed	 for	
identification	of	place	of	residence,	and	was	found	to	improve	the	accuracy	of	cluster	
residency	 identification	to	97%	(95%	CI,	90-100%).	Already	this	rapid	and	 low	cost	
approach	 could	 greatly	 improve	 the	 granularity	 of	 TB	 notification	 data	 in	 low	
resource,	high	burden	settings.	However,	this	concept	could	be	further	developed,	
with	the	aim	of	providing	granularity	closer	to	the	household	level,	combined	with	
information	 regarding	 patient	 characteristics	 and	 real-time	 reporting.	 Such	 a	
validated,	 low	cost,	rapidly	 implementable	tool	could	meet	the	need	for	 improved	
data	 to	 inform	 TB	 vaccine	 clinical	 trial	 design	 and	 recruitment	 of	 TPP-identified	
populations.		
 Rationale	for	the	present	study	
Development	of	new	TB	vaccines	to	reduce	the	burden	of	adult	TB	disease	is	a	clear	
and	 urgent	 public	 health	 need.	 However,	 to	 inform	 TPPs	 for	 new	 TB	 vaccines,	
research	to	fully	explore	the	vaccine	characteristics	and	target	populations	that	could	
provide	 the	 greatest	 epidemiological	 impact	 is	 required.	 In	 terms	 of	 target	
populations,	given	the	ageing	demographics	 in	several	high	burden	countries	 (e.g.	
China),	 comparing	 vaccinating	 the	 currently	 prioritised	 adolescent	 population	 to	
vaccinating	older	adult	populations	is	an	important	research	gap.	To	help	carry	these	
TPPs	through	to	implementable	clinical	trials,	appropriate	data	are	needed	to	inform	
trial	 design	 and	 identify	 recruitment	 population	 hotspots.	 Given	 the	 expense	 and	
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time	requirement	of	prospective	prevalence	and	incidence	studies,	development	of	
a	low-cost,	rapidly	implementable	tool	to	be	able	to	identify	hotspots	in	these	target	
populations	for	recruitment	could	improve	TB	vaccine	trial	design	and	reduce	costs.	
This	thesis	describes	mathematical	modelling	to	estimate	the	potential	impact	of	new	
TB	vaccines,	and	identifies	vaccine	profiles	and	target	populations	that	could	result	
in	 the	 greatest	 reduction	 in	 TB	 disease	 burden	 in	 China;	 and	 develops	 a	 new	
methodology	for	empirical	data	collection	for	determining	spatial	distribution	of	TB	
notifications	in	potential	trial	populations.		
Overall,	 this	 research	will	 provide	an	 important	 contribution	 towards	 fulfilling	 the	
epidemiological	research	needs	to	ensure	appropriate	TB	vaccines	are	developed	for	
and	delivered	to	populations	that	could	maximise	population-level	impact	of	new	TB	
vaccines.	
 Thesis	aims		
In	order	 to	 facilitate	data-driven	development	 strategies	 for	new	TB	vaccines,	 the	
overall	aims	of	this	research	were	to	estimate	the	potential	epidemiological	impact	
of	new	TB	vaccine	characteristics	and	target	populations	in	China,	to	identify	those	
predicted	to	provide	the	greatest	reduction	in	TB	disease;	and	to	generate	a	novel	
epidemiological	spatial	mapping	tool	capable	of	informing	clinical	trial	design	for	new	
TB	vaccines	in	low-income,	high-burden	settings	with	limited	availability	of	relevant	
data.	
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This	translated	into	two	streams	of	work,	each	with	a	defined	aim:	
1. Generate	 mathematical	 models	 of	 age-stratified	 demography	 and	 TB	
epidemiology	to	explore	the	population-level	epidemiological	impact	of	vaccine	
characteristics	 and	 implementation	 strategies	 for	 potential	 new	 TB	 vaccines,	
using	China	as	a	case	study.	
2. Development	 and	 evaluation	 of	 a	 low-cost,	 rapidly	 implementable	 TB	 spatial	
mapping	application	(‘app’)	in	Blantyre,	Malawi,	capable	of	mapping	the	place	of	
residence	of	populations	experiencing	disease	outcomes	relevant	to	TB	vaccine	
clinical	trials.	
 Thesis	objectives	
Aim	1	(modelling	to	inform	vaccine	characteristics	and	implementation)	was	achieved	
through	the	following	objectives:	
1. Conduct	a	systematic	review	of	the	TB	vaccine	mathematical	modelling	literature	
to	a)	summarise	existing	literature	exploring	the	effect	of	vaccine	characteristics	
and	implementation	on	the	potential	epidemiological	impact	of	new	TB	vaccines,	
and	b)	identify	research	needs	with	respect	to	mathematical	modelling	of	possible	
vaccine	 characteristics	 and	 implementation	 strategies	 for	 new	 TB	 vaccines	
(Chapter	2).	
2. a)	 Develop	 a	 mathematical	 model	 calibrated	 to	 epidemiological	 and	
demographic	 temporal	 and	 age	 distribution	 trends	 in	 China,	 accounting	 for	
uncertainty	 in	 natural	 history	 parameters,	 to	 predict	 the	 evolution	 of	 the	 TB	
epidemic	over	the	2050	time	horizon	(Chapter	3).	
b) Using	 the	 calibrated	China	 TB	model,	 simulate	 the	 introduction	of	 new	TB	
vaccines	to	investigate	the	population-level	epidemiological	impact	of	varying	TB	
vaccine	characteristics	identified	in	objective	1	(Chapter	3).		
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c) Identify	the	combination	of	vaccine	characteristics	that	would	be	most	likely	
to	deliver	pre-specified	minimum	incidence	rate	reductions	compared	to	the	no	
new	vaccine	baseline	in	2050	(Chapter	3).	
3. Using	 the	 calibrated	 model	 of	 the	 TB	 epidemic	 in	 China	 and	 main	 vaccine	
characteristics	 (objective	2),	 investigate	 the	 impact	of	 age-targeted	 vaccination	
programmes	 to	 adolescents	 versus	 older	 adults	 on	 population-level	 TB	
epidemiology	(Chapter	4).	
Aim	2	 (development	of	epidemiological	 tool	 for	 informing	 future	 trial	design)	was	
achieved	through	the	following	objectives:	
4. a)	 Develop	 and	 implement	 a	 novel,	 low	 resource,	 rapidly	 implementable	 and	
easy	 to	 use	 app	 for	 spatial	 mapping	 of	 the	 place	 of	 residence	 of	 TB	 cases	
registering	for	treatment	in	Blantyre,	Malawi	(Chapter	5).	
b)	 Evaluate	the	accuracy	of	patient	coordinates	measured	via	the	app	compared	
to	the	gold	standard	of	measurements	taken	using	GPS	at	the	patient’s	place	of	
residence	(Chapter	5)	
c)	 Based	upon	place	of	residence	collected	using	the	app,	generate	spatial	maps	
of	disease	numbers	and	rates	 in	populations	potentially	relevant	for	TB	vaccine	
trial	recruitment.	(Chapter	5).	
 Thesis	outline	
This	is	a	research	paper	style	thesis,	submitted	in	accordance	with	London	School	of	
Hygiene	and	Tropical	Medicine	regulations.	As	such,	submitted	and	published	articles	
are	 included	 without	 adaptation;	 therefore,	 although	 minimised	 where	 possible,	
some	repetition	exists	between	chapters.	Chapters	containing	research	papers	are	
structured	around	the	manuscript,	starting	with	an	introduction	to	provide	context	
for	 the	 paper	 within	 the	 thesis,	 followed	 by	 the	 manuscript,	 and	 finally	 any	
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supplementary	materials	associated	with	the	paper	and/or	unpublished	additional	
analyses	and	discussion.	
The	 thesis	 consists	 of	 four	 sections,	 and	 contains	 six	 chapters,	which	 include	 one	
published,	 one	 submitted,	 and	 one	 unpublished	 manuscript.	 The	 first	 section	
(Chapters	1	and	2)	comprises	the	background	materials,	aims	and	objectives	of	the	
work.	 Section	 two	 (Chapters	 3	 and	 4)	 reports	 on	 the	 mathematical	 modelling	
research	conducted	to	inform	characteristics	and	implementation	of	new	TB	vaccines	
in	China.	Section	three	(Chapter	5)	reports	the	development,	validation	and	results	
of	the	novel	spatial	mapping	tool	for	informing	TB	vaccine	trial	recruitment.	Finally,	
section	 four	 (Chapter	 6)	 provides	 discussion,	 conclusions,	 policy	 implications	 and	
future	work.	A	more	detailed	outline	of	each	chapter	follows.	
Chapter	1:	This	first	chapter	provides	a	brief	overview	of	the	epidemiological	and	TB	
vaccine	development	context	within	which	this	research	resides,	and	the	research	
needs	 identified.	 These	 provide	 the	 rationale	 for	 the	 aims	 of	 this	 PhD	 and	 the	
objectives	identified	to	achieve	those	aims.		
Chapter	2:	The	background	to	the	thesis	includes	an	overview	of	tuberculosis	disease	
burden,	 the	need	for	new	TB	vaccines,	and	for	new	tools	and	data	to	provide	the	
evidence	base	for	development	and	implementation	planning	for	new	TB	vaccines.	
This	 chapter	 includes	 research	 paper	 1,	 a	 systematic	 review	 published	 in	 Human	
Vaccines	 and	 Immunotherapeutics,	 summarising	 the	 modelling	 literature	 of	 the	
epidemiological	impact	of	new	TB	vaccines	and	implementation	strategies	(objective	
1).19	This	is	followed	by	a	summary	of	the	current	options	for	epidemiological	data	
collection	tools	to	inform	trial	recruitment	of	populations.	Research	gaps	in	both	of	
these	areas	are	identified.	
Citation	(paper	1):	Harris	RC,	Sumner	T,	Knight	GM,	and	White	RG.	Systematic	review	
of	mathematical	models	exploring	the	epidemiological	impact	of	future	TB	vaccines.	
Hum	Vaccin	Immunother	2016;	12(11):	2813-32.	
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Chapter	3:	This	chapter	describes	the	development	of	 the	mathematical	model	of	
age-stratified	TB	demographics	and	epidemiology	in	China.	Modelled	epidemiological	
projections	to	2050	without	introduction	of	new	TB	vaccines	are	described	(objective	
2a).	 Using	 this	 calibrated	 epidemiological	 model,	 the	 population-level	
epidemiological	 impact	of	 a	wide	 range	of	 vaccine	 characteristics	was	explored	 in	
depth,	and	incidence	and	mortality	results	in	terms	of	absolute	and	rate	reductions	
in	incidence	and	mortality	are	reported	(objective	2b	and	c).		
Chapter	4:	This	chapter	reports	a	further	adapted	version	of	the	China	vaccine	model,	
exploring	the	impact	of	vaccination	of	adolescents	(15-19	years)	versus	older	adults	
(60-64	years)	with	new	TB	vaccines	(objective	3).	A	subset	of	vaccines,	selected	based	
upon	the	results	of	the	modelling	in	chapter	3,	are	explored	in	this	chapter.	This	work	
is	reported	as	research	paper	2,	currently	under	review	at	the	Lancet	Global	Health.		
Citation	(paper	2):	Harris	RC,	Sumner	T,	Knight	GM,	Evans	T,	Cardenas	V,	Chen	C,	and	
White	 RG.	New	 tuberculosis	 vaccines	 –	 the	 impact	 of	 age	 targeted	 vaccination	 in	
China	and	implications	for	vaccine	development.	Under	review	
As	 a	 body	 of	 work,	 these	 models	 give	 insight	 in	 to	 the	 characteristics	 and	
implementation	 strategies	 for	 new	 TB	 vaccines	 that	 need	 to	 be	 developed	 to	
maximise	 population	 level	 impact.	 The	 results	 are	 indicative	 of	 populations	 and	
endpoints	important	for	clinical	trials,	which	are	the	focus	of	the	next	section	of	the	
thesis.	This	next	section	describes	the	tool	developed	for	mapping	key	populations	
experiencing	outcomes	relevant	to	TB	vaccine	clinical	trials.	
Chapter	5:	This	chapter	reports	the	development	and	evaluation	results	(objective	4)	
of	ePAL	(electronic	PArticipant	Locator),	a	novel,	low	cost,	rapidly	implementable	and	
easy	to	use	app	for	spatial	mapping	of	the	place	of	residence	of	TB	cases	registering	
for	 treatment	 in	 Blantyre,	 Malawi.	 The	 development	 and	 evaluation	 results	 are	
reported	as	research	paper	3.	The	results	of	12	months	data	collection	by	NTP	TB	
officers	using	ePAL	in	Blantyre,	Malawi	are	summarised	in	this	chapter.	This	includes	
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spatial	 heatmaps	 (objective	 4c)	 of	 all	 TB,	 and	demographic	 and	 clinical	 subgroups	
relevant	to	TB	trial	recruitment	populations	or	outcomes.		
Citation	 (paper	3):	Harris	RC,	 Kaswaswa	K,	 Choko	AT,	Molineux	A,	MacPherson	P,	
Webb	E,	 Shonga	W,	White	RG*,	and	Corbett	EL*.	Development	and	evaluation	of	
novel	software	to	identify	place	of	residence	for	clinic-based	TB	patients	in	Blantyre,	
Malawi.	(proposed	authors,	author	order	and	title.	In	review	with	co-authors.	*Joint	
senior	authors)		
Chapter	6:	This	chapter	summarises	the	research	undertaken	in	the	thesis	and	the	
implications	of	the	results	for	the	TB	vaccine	development	community.	Key	findings,	
strengths,	 limitations	 and	 contributions	 to	 the	 field	 are	 discussed.	 I	 provide	
recommendations	for	development	of	TB	vaccines	from	the	perspective	of	vaccine	
developers,	 clinical	 triallists	 and	 country-level	 decision	 makers.	 Opportunities	 for	
future	research	are	identified	and	discussed.	
 Contribution	of	the	author	
The	need	for	mathematical	modelling	research	to	support	TB	vaccine	development	
was	 identified,	 and	 initial	 research	 questions	 developed,	 by	myself	 and	 Professor	
Richard	 White.	 These	 research	 questions	 evolved	 during	 the	 PhD	 based	 upon	
research	 needs	 identified	 from	 the	 systematic	 literature	 review,	 and	 feedback	 by	
stakeholders	 and	 collaborators	 (including	 Aeras,	 BMGF,	 WHO	 and	 TBVI).	 From	
previous	 work,	 I	 had	 identified	 the	 need	 for	 new	 solutions	 for	 generating	
epidemiological	data	to	support	TB	vaccine	clinical	trial	design,	which	was	fortuitously	
married	 with	 the	 idea	 for	 an	 electronic	 mapping	 tool	 proposed	 by	 Professor	 Liz	
Corbett	and	Dr	Peter	MacPherson.	
Contributors	to	the	research	presented	in	the	three	research	papers	are	detailed	in	
their	 respective	 cover	 pages.	 For	 all	 three	 papers,	 I	 wrote	 the	 first	 draft	 and	
incorporated	changes	based	upon	co-author	review.	
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Summary	of	Chapter	2	
	
In	this	chapter,	 I	provide	a	detailed	exploration	of	the	research	context,	beginning	
with	an	outline	of	tuberculosis	as	a	global	public	health	problem,	the	need	for	new	
TB	 vaccines,	 and	 for	 new	 tools	 and	 data	 to	 provide	 the	 evidence	 base	 for	
development	 and	 implementation	 planning	 for	 new	 TB	 vaccines.	 This	 chapter	
includes	 research	paper	1,	 a	 systematic	 review	published	 in	Human	Vaccines	 and	
Immunotherapeutics,	 summarising	 the	modelling	 literature	of	 the	epidemiological	
impact	 of	 new	 TB	 vaccines	 and	 implementation	 strategies	 (objective	 1).1	 This	 is	
followed	by	a	 summary	of	 the	 current	options	 for	epidemiological	data	 collection	
tools	to	inform	trial	recruitment	of	populations.	Research	gaps	in	both	of	these	areas	
are	identified	(objective	1).	
Citation	 (research	 paper	 1):	 Harris	 RC,	 Sumner	 T,	 Knight	 GM,	 and	 White	 RG.	
Systematic	review	of	mathematical	models	exploring	the	epidemiological	impact	of	
future	TB	vaccines.	Hum	Vaccin	Immunother	2016;	12(11):	2813-32.	
This	 chapter	 is	derived	 in	part	 from	an	article	 I	published	 in	Human	Vaccines	and	
Therapeutics	 on	 22nd	 July	 2016,	 available	 online:	 http://wwww.tandfonline.com	
10.1080/21645515.2016.1205769.	
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CHAPTER	2 Background	
2.1 Tuberculosis	natural	history	
The	vast	majority	of	tuberculosis	(TB)	disease	in	humans	is	caused	by	the	bacterial	
pathogen	 Mycobacterium	 tuberculosis	 (M.tb).2	 There	 are	 seven	 other	 related	
Mycobacterium	species,	some	of	which	are	also	capable	of	causing	disease	to	varying	
degrees.2	TB	disease	symptoms	depend	upon	factors	such	as	the	site	of	infection,	but	
common	 symptoms	 include	 night	 sweats,	 weight	 loss,	 chronic	 cough	 and	
haemoptysis.3	Confirmation	of	TB	disease	is	most	commonly	via	one	or	a	combination	
of	 chest	 x-ray,	 sputum	 smear	 testing,	 culture,	 and	 Genexpert	 nucleic	 acid	
amplification	test.	
M.tb	 transmission	 occurs	 via	 the	 airborne	 route,	 when	 infected	 droplet	 nuclei	
expulsed	(e.g.	coughing,	shouting)	from	the	lungs	of	an	individual	with	pulmonary	or	
laryngeal	TB	disease	are	inhaled	into	the	lungs	of	another	individual.	The	likelihood	
of	a	transmission	event	is	dependent	on	the	infectiousness	of	the	individual	with	TB	
disease,4	 susceptibility	 and	 extent	 of	 exposure	 of	 the	 exposed	 individual,	 and	
environmental	factors.5	Infectiousness	can	be	modified	by	the	location	of	disease	foci	
(i.e.	 pulmonary	 vs.	 extrapulmonary),	 bacterial	 load,	 comorbidities	 (e.g.	 HIV),	 and	
clinical	symptoms	such	as	cough;	whereas	susceptibility	is	mostly	associated	with	co-
morbidities	of	 the	exposed	 individual	 (e.g.	HIV,	malnutrition)	and	other	exposures	
that	may	weaken	the	lungs	(e.g	indoor	air	pollution,	smoking).6-8	Exposure	to	infected	
droplets	is	related	to	proximity	and	duration	of	exposure	to	infected	individuals.5	The	
persistence	of	infected	droplet	nuclei	in	the	air	may	be	influenced	by	abiotic	factors	
such	as	ventilation,	humidity	and	exposure	to	ultraviolet	light.9	In	combination,	these	
factors	determine	the	likelihood	of	a	transmission	event.	
Unlike	many	 infectious	diseases	 that	have	 relatively	 short	 incubation	periods	 (e.g.	
cholera,	influenza),	M.tb	infection	can	remain	latent	for	extended	periods	of	time.10	
In	fact,	the	majority	of	individuals	infected	with	M.tb	never	develop	disease.	The	age-
weighted	 lifetime	risk	of	progression	 to	pulmonary	disease	has	been	estimated	at	
Chapter	2:	Background	 40	
12%	 in	 low	transmission	settings.10	This	 risk	 is	elevated	 in	certain	populations,	 for	
example	 the	 risk	 of	 progression	 in	 HIV	 co-infected	 populations	 is	 estimated	 at	
approximately	10%	per	year.11	The	risk	of	developing	disease	also	varies	by	age	at	
infection	and	time	since	infection,	with	incubation	periods	becoming	shorter	in	older	
age	 groups.10,12	 Risk	 of	 progression	 to	 disease	 is	 highest	 in	 the	 first	 year	 after	
infection,	falling	year-on-year	beyond	this.11-14	
Rapid	 primary	 (“fast”)	 progression	 to	 disease	 occurs	 when	 bacterial	 replication	
produces	symptomatic	disease	relatively	rapidly	after	entry	into	the	lungs;	whereas	
reactivation	(“slow”)	progression	is	characterised	by	an	extended	period	in	the	latent	
state.	Latency	involves	the	establishment	of	granuloma,	formed	when	M.tb	bacteria	
replicate	intracellularly	in	alveolar	macrophages	and	initiate	cytokine	recruitment	of	
both	innate	and	adaptive	immune	cells.15	Eventually	a	state	of	equilibrium	is	attained	
between	dormant	M.tb	bacteria	contained	within	the	granuloma	core	and	the	host	
immune	 system.	 Disruption	 of	 this	 equilibrium	 leads	 to	 bacterial	 replication	 and	
development	of	“reactivation”	active	disease.11	
Pulmonary	disease	 is	 the	most	 frequent	presentation.	Given	the	airborne	route	of	
M.tb	 transmission,	 pulmonary	 cases	 are	 the	 most	 infectious,	 particularly	 those	
testing	positive	by	sputum	smear	microscopy.	In	2015,	approximately	15%	of	notified	
TB	cases	occurred	at	extrapulmonary	sites,	such	as	miliary	TB	and	TB	meningitis.16	
Though	the	proportion	of	extrapulmonary	disease	is	higher	at	the	age	extremes,	due	
to	immature	immunity	in	children	and	immunosenescence	in	the	elderly.16,17	
Without	 treatment,	 smear	 negative	 10-year	 case	 fatality	 is	 estimated	 at	 20%,	
increasing	up	to	70%	in	smear	positive	disease.18	Including	those	receiving	treatment	
and	those	remaining	untreated,	the	global	case	fatality	ratio	in	2015	was	estimated	
at	17%,	ranging	from	5%	to	>20%	by	country.16	
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2.2 Tuberculosis	as	a	global	public	health	concern		
Tuberculosis	disease	(TB)	has	become	the	largest	single-pathogen	cause	of	mortality	
globally,19	responsible	for	1.8	million	deaths	in	2015.	During	the	same	period,	there	
were	 an	 estimated	 10.4	 million	 incident	 TB	 cases,	 including	 480,000	 multi-drug	
resistant	 (MDR)	 cases.	 Although	 the	 current	 burden	 of	 disease	 remains	 the	most	
immediate	public	health	concern,	a	substantial	reservoir	of	latent	TB	infection	(LTBI)	
exists,	 estimated	 at	 approximately	 1.7	 billion	 of	 the	 global	 population.20	 This	
population	 remains	 at	 risk	 of	 developing	 reactivation	 disease,	 so	 should	 be	
considered	when	planning	for	TB	prevention	in	the	long	term.	
Regional	heterogeneity	exists	in	the	distribution	of	TB	burden.	South-East	Asia	and	
sub-Saharan	Africa	contributed	46%	and	26%	of	 the	global	 incident	cases	 in	2015,	
respectively.19	More	specifically,	six	countries	account	for	60%	of	incident	TB	cases:	
India,	 Indonesia,	 China,	 Nigeria,	 Pakistan	 and	 South	 Africa.	 Populations	 in	 sub-
Saharan	Africa	have	experienced	some	of	the	highest	TB	 incidence	rates,	 reaching	
834/100,000	population	per	year	in	South	Africa.19		
Heterogeneity	also	exists	 in	 the	distribution	of	disease	within	populations,	due	 to	
environmental,	biological	and	social	risk	factors.	Environmental	risk	factors	include	
exposure	 to	 smoking	 or	 indoor	 air	 pollution,	 and	 collectively	 are	 thought	 to	 be	 a	
contributory	risk	factor	for	an	estimated	38.1%	of	TB	cases	across	the	pre-2015	WHO	
22	high	burden	countries	(HBCs).21	Key	biological	factors	that	weaken	immunity	and	
therefore	 increase	the	risk	of	TB	 infection	and	progression	to	disease	 include	HIV,	
malnutrition	and	age-related	factors.	HIV	exists	as	a	co-morbidity	in	11%	of	TB	cases	
globally,19	and	is	estimated	to	be	associated	with	the	highest	reported	relative	risk	
(RR)	of	disease	(RR:	26.7).21	For	some	countries	in	Africa,	the	population	attributable	
fraction	(PAF)	for	HIV	is	estimated	at	greater	than	50%	of	cases.	Although	the	relative	
risk	of	TB	associated	with	malnutrition	is	much	lower	(RR:	3.2)	than	HIV,	due	to	the	
prevalence	of	malnutrition	across	the	22	HBCs,	it	is	associated	with	the	highest	PAF	
(26.9%).	 Immunological	 changes	 with	 age	 also	 influence	 the	 risk	 of	 disease,	 with	
immune	immaturity	in	infants	and	immune	senescence	in	older	adults	and	the	elderly	
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increasing	 the	 risk	of	development	of	primary	or	 reactivation	disease.17	However,	
given	the	population	demographic	structure	at	the	global	 level,	and	the	burden	of	
HIV	co-infection	in	younger	adults,	90%	of	TB	cases	globally	are	estimated	to	occur	in	
adults.19	
Social	factors	also	play	an	important	role	in	the	risk	of	infection,	as	contact	patterns	
with	groups	with	higher	disease	rates,	such	as	particular	age	or	social	groups,	can	
influence	 the	 risk	 of	 exposure	 and	 therefore	 infection.	 In	 addition,	 time	 spent	 in	
particular	 settings	 with	 crowding	 or	 poor	 ventilation	 can	 increase	 the	 risk	 of	
infection.5	This	is	particularly	pronounced	in	prison	populations	or	crowded	places	of	
residence,	 and	 may	 also	 be	 associated	 with	 crowded	 social	 locations	 such	 as	
workplaces	or	churches.22		
2.3 Global	TB	targets	
Since	 the	 WHO	 1993	 declaration	 identifying	 tuberculosis	 as	 a	 “public	 health	
emergency	of	international	concern”,	significant	investments	have	been	made	in	the	
global	fight	against	tuberculosis,23	with	funding	almost	doubling	in	the	last	decade,	
reaching	USD	6.5	billion	in	2016.19		
The	WHO’s	 commitment	 to	 tackle	 the	burden	of	TB	was	enshrined	 in	Millennium	
Development	Goal	(MDG)	6c,	aiming	to	“halt	and	begin	to	reverse	the	incidence	of	
TB	by	2015”.	This	principal	global	goal	was	accomplished	ahead	of	time	 in	2012.24	
Concurrently	with	the	MDGs,	additional	targets	were	set	by	the	Stop	TB	Partnership,	
aiming	 for	 a	 50%	 reduction	 by	 2015	 in	 both	 TB	 prevalence	 and	 mortality	 rates	
compared	to	1990	levels,	and	the	longer-term	target	of	elimination	of	TB	as	a	public	
health	problem	by	2050	(<1	case	per	million	population	per	year).19	Globally,	both	
targets	were	narrowly	missed,	with	TB	prevalence	falling	by	42%	and	TB	mortality	
falling	by	47%.19		
Although	significant	progress	has	been	made	at	the	global	level,	clear	discrepancies	
exist	 in	 regional	 and	 country-level	 attainment	 of	 the	MDG	 6c	 and	 2015	 Stop	 TB	
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targets.	TB	incidence	trends	were	falling	at	the	regional	level	in	all	six	WHO	regions	
in	2015,	but	several	countries	had	not	achieved	the	reversal	of	trend,	including	six	of	
the	 WHO	 22	 HBCs:	 Democratic	 Republic	 of	 Congo,	 Mozambique,	 Nigeria,	
Afghanistan,	Pakistan	and	Bangladesh.25	The	Stop	TB	prevalence	targets	were	met	in	
the	region	of	the	Americas	(AMR),	South-East	Asia	(SEAR)	and	Western	Pacific	(WPR),	
but	were	missed	in	the	remaining	three	regions	and	in	59%	of	the	22	HBCs.	Mortality	
targets	were	attained	 in	 the	 same	 regions	plus	 the	Eastern	Mediterranean	 region	
(EMR),	but	were	missed	in	50%	of	HBCs.25	Despite	meeting	the	2015	goals,25	 India	
and	China	still	contribute	27%	and	9%	of	global	burden,	respectively.	Consideration	
of	these	geographical	differences	will	be	important	in	tackling	region-	and	country-
level	variation.		
Post-2015,	although	the	Stop	TB	target	of	TB	elimination	by	2050	still	stands,25	new	
milestones	 and	 targets	 have	 been	 developed	 in	 tandem	with	 the	 UN	 sustainable	
Development	Goals	(SDGs)	as	checkpoints	on	the	road	to	elimination	(Table	2.1).26	
SDG	3.3	aims	to	“end	the	epidemic	of…	tuberculosis”	by	2030,	with	the	indicator	for	
progress	defined	as	90%	 reduction	 in	number	of	 TB	deaths	 and	80%	 reduction	 in	
incidence	rate	compared	to	2015.26		
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Table	2.1:	WHO	End	TB	and	Stop	TB	goals	for	reduction	in	epidemiological	burden	of	TB	from	2020	
to	205019,25	
	 End	TB	strategy	milestones	and	targets19,26	
Stop	TB	
strategy25	
Target	 2020	 2025	 2030	 2035	 2050	
Reduction	in	absolute	number	
of	TB	deaths	compared	to	2015	 35%	 75%	 90%	 95%	 -	
Reduction	in	TB	incidence	rate	
compared	to	2015	 20%	 50%	 80%	 90%	 -	
Incidence	rate	target	
<85	per	
100,000	
population	
per	year	
<55	per	
100,000	
population	
per	year	
<20	per	
100,000	
population	
per	year	
<10	per	
100,000	
population	
per	year	
<1	per	
million	
population	
per	year	
	
Progress	in	reducing	the	global	burden	of	TB	has	been	slower	than	anticipated,	with	
the	annual	rate	of	incidence	decline	estimated	at	1.5%	in	2015.19	To	achieve	the	2020	
milestone	 and	2025	 target,	 an	 acceleration	 to	 4-5%	annual	 decline	 is	 required	by	
2020,	increasing	to	10%/year	by	2025	(Figure	2.1).26	Historical	trends	are	indicative	
of	the	feasibility	of	declines	of	approximately	10%	per	year	through	socioeconomic	
development	and	implementation	of	current	tools.27,28	In	modelling	studies,	annual	
reductions	of	6%	have	been	projected	as	feasible	by	implementation	of	the	Global	
Plan,29	though	up	to	10%	per	year	could	be	considered	feasible	with	aggressive	scale	
up	of	existing	interventions	and	improved	social	protection.27,29,30	
Beyond	2025,	assuming	the	previous	goals	are	achieved,	reductions	of	17%	per	year	
will	be	required	to	meet	2035	targets.30	Looking	further	ahead	to	the	2050	goals,	a	
20%	 decline	 per	 year	 from	 2015	 has	 been	 estimated	 as	 necessary	 to	 achieve	
elimination	 by	 2050.31	 This	 is	 beyond	 the	 acceleration	 that	 has	 been	 achieved	
historically	or	has	been	estimated	to	be	possible	with	existing	measures	in	modelling	
studies,	 therefore	 novel	 tools	 will	 be	 essential	 to	 reach	 the	 WHO	 2050	 goal	 of	
elimination	of	TB	as	a	public	health	problem.31		
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Figure	2.1:	WHO	global	trends	required	to	achieve	2025	and	2035	goals.	Reprinted	with	
permission,	from	the	WHO	End	TB	Strategy,	WHO/HTM/TB/2015.19,	
http://www.who.int/tb/End_TB_brochure.pdf?ua=1,	Accessed	3rd	January	2017.	26	
	
New	tools	with	the	potential	to	contribute	to	TB	care	and	prevention	include	new	
vaccines,	new	drugs	and	regimens,	improved	diagnostics,	and	measures	to	prevent	
reactivation	disease	in	those	latently	infected.		
With	 the	 current	 global	 burden	 of	 latent	 infection	 alone,	 TB	 incidence	 would	 be	
anticipated	to	decline	only	as	far	as	16.5	cases	per	100,000	population	per	year	by	
2035	and	8.3	cases	per	100,000	population	per	year	by	2050;20	therefore	measures	
to	reduce	reactivation	of	latent	infection	will	be	important	for	achieving	elimination.	
In	settings	with	a	significant	pool	of	latent	infection,	the	Abu-Raddad	modelling	study	
suggests	that	only	mass	isoniazid	preventative	treatment	(IPT)	or	mass	vaccination	of	
this	population	with	a	new	effective	vaccine	could	come	close	to	achieving	the	2050	
targets.32	IPT	is	effective,	but	adherence	issues	and	duration	of	protection	may	limit	
its	potential	impact,	and	widespread	use	as	monotherapy	could	lead	to	development	
of	 resistance.33	 With	 the	 anticipation	 of	 longer-term	 protection	 and	 reduced	
adherence	 issues,	vaccines	could	provide	 impact	 in	a	more	sustainable	manner.	 In	
another	modelling	study,	results	indicated	that	a	combination	of	measures	to	tackle	
latent	TB	and	active	disease	may	be	needed	to	achieve	the	WHO	2050	goals	at	the	
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global	level.31	The	WHO	suggests	that	“moving	forward	to	the	2035	targets	requires…	
effective	 pre-	 and	 post-exposure	 vaccines”,	 in	 addition	 to	 better	 diagnostics,	
treatment	regimens	and	LTBI	treatment.26	
2.4 BCG:	an	effective	vaccine	for	prevention	of	TB?	
Unlike	many	other	high-burden	 infectious	diseases,	 an	effective	 vaccine	exists	 for	
tuberculosis:	 Bacillus	 Calmette-Guérin	 (BCG).	 BCG	 is	 a	 live,	 attenuated	
Mycobacterium	bovis	vaccine,	used	for	neonatal	vaccination	as	part	of	the	Expanded	
Program	on	Immunization	(EPI)	schedule.	In	2015,	global	coverage	was	estimated	at	
88%,	with	 the	 vaccine	 provided	 to	 over	 100	million	 neonates	 annually	 to	 protect	
against	childhood	tuberculosis.34	Recent	meta	analyses	suggesting	59%	(95%	CI,	42-
71%)	vaccine	efficacy	against	pulmonary	TB,35	90%	(95%	CI,	23-99%)	efficacy	against	
miliary	 and	 meningeal	 TB,35,36	 	 and	 66%	 (95%	 CI,	 8-88%)	 efficacy	 against	 TB	
mortality.36	 BCG	 is	 estimated	 to	 prevent	 one	 case	 of	 miliary	 TB	 and	 one	 of	 TB	
meningitis	 in	 the	 first	 five	 years	 of	 life	 per	 9314	 and	 3453	 vaccinated	 children,	
respectively.37	 However,	 BCG	 has	 exhibited	 highly	 variable	 efficacy	 against	 adult	
pulmonary	 forms	of	 tuberculosis,	 ranging	 from	an	“absence	of	clinically	 important	
benefit”36	in	studies	in	Malawi	and	India,36,38,39	to	almost	80%	protection	in	the	UK	
MRC	 trial	 and	 in	 a	 North	 American	 Indian	 population.36,39,40	 Many	 factors	 may	
influence	 these	 age	 and	 regional	 differences	 in	 efficacy,	 but	 prior	 infection	 or	
exposure	 to	 environmental	 bacteria	 has	 been	 observed	 as	 an	 important	 factor	
associated	with	lower	efficacy	against	pulmonary	TB.35	
The	protective	effect	of	BCG	has	been	demonstrated	to	last	at	least	10	years,	with	
declining	efficacy	over	time.36	Five	studies	have	demonstrated	a	measurable	effect	
after	15	years,	but	loss	to	follow	up	and	insufficient	endpoints	after	10	years	limit	the	
conclusions	 that	 can	 be	 drawn	 based	 upon	 available	 data	 beyond	 10	 years	 after	
vaccination.		
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BCG	 is	 contraindicated	 in	 HIV-infected	 populations	 due	 to	 the	 increased	 risk	 of	
disseminated	BCG	disease.41	Therefore,	HIV-infected	children	and	adults	at	high	risk	
of	TB	remain	unprotected.	
A	 combination	 of	 variable	 geographical	 efficacy	 against	 adult	 disease,	 insufficient	
duration	 of	 efficacy	 to	 protect	 from	 birth	 to	 adulthood,	 and	 safety	 concerns	 in	
epidemiologically	important	populations,	mean	that	BCG	is	not	an	appropriate	tool	
for	 tackling	 the	 global	 burden	of	 adult	 TB	disease.	Given	 the	need	highlighted	by	
existing	models	for	a	new	vaccine	to	help	achieve	the	WHO	2050	targets	and	these	
limitations	in	the	use	of	BCG,	the	development	of	an	efficacious	novel	TB	vaccine	that	
can	protect	in	adulthood	is	a	clear	research	priority.	
2.5 The	TB	vaccine	pipeline	and	development	
Although	a	very	clear	and	urgent	need	exists	for	new	TB	vaccines,	particularly	those	
able	 to	 reduce	 the	burden	of	 TB	 in	 adults,	 no	new	prophylactic	 vaccine	has	been	
licensed	 since	BCG.	Only	 one	new	 candidate,	 the	 SRL-172	whole	 cell	 vaccine,	 has	
demonstrated	safety	and	efficacy	in	phase	III	studies	in	HIV-positive	populations,42	
but	the	agar-based	production	methodology	was	not	scalable.43	This	candidate	has	
since	been	adapted	for	broth-based	production,	re-entered	clinical	trials	as	candidate	
DAR-901,	and	is	currently	undergoing	a	phase	IIB	prevention	of	infection	study.44	
However,	 DAR-901	 is	 not	 the	 only	 vaccine	 in	 development,	 with	 13	 candidates	
currently	 in	 clinical	 trials,	 the	 TB	 vaccine	 pipeline	 is	 the	 strongest	 to-date.	 One	
candidate	 is	being	tested	in	a	phase	III	efficacy	trial,	two	candidates	 in	addition	to	
DAR-901	in	phase	IIB	proof	of	concept	trials,	four	are	undergoing	phase	IIA	safety	and	
immunogenicity	studies,	and	 five	are	 in	phase	 I	 first-in-human	safety	 trials	 (Figure	
2.2).45		
The	 phase	 III	 Vaccae	 candidate	 is	 currently	 under	 evaluation	 for	 efficacy	 against	
disease	in	10,000	participants	in	China,	with	results	anticipated	in	2017.46	In	addition,	
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the	M72-AS01E	and	VPM1002	 candidate	phase	 IIB	 studies,	 and	H4:IC31	phase	 IIA	
study,	are	expected	to	publish	results	within	the	next	year.47-49	
	
	
Figure	2.2:	New	TB	vaccine	pipeline	as	at	7th	October	2016.45	Reproduced	with	permission	from	
Aeras.	
	
Although	a	strong	business	case	has	been	made	for	investment	in	new	TB	vaccines,50	
resources	 to	 develop	 these	 candidates	 remain	 limited.	 Progression	 through	 the	
pipeline	is	slow,	in	part	due	to	limited	and	risk-averse	allocation	of	funding,	and	in	
part	 due	 to	 relatively	 low	 incidence	 rates	 and	 lack	 of	 a	 correlate	 of	 protection	
necessitating	large	efficacy	trials	with	long	duration	of	follow	up.		
Critical	 research	 activities	 to	 overcome	 some	 of	 the	 challenges	 in	 TB	 vaccine	
development	have	been	identified	in	the	TB	Vaccine	Blueprint.51	To	support	clinical	
trials	a	critical	activity	 identified	in	the	Blueprint	was	to	“determine	TB	prevalence	
and	incidence,	select	trial	sites	and	choose	target	populations	for	TB	vaccines	that	
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result	 in	the	greatest	reduction	of	disease”.51	This	constitutes	two	epidemiological	
research	needs:	
1) Data-driven	 identification	 of	 vaccine	 characteristics	 and	 target	 populations	
for	vaccination	that	could	achieve	the	greatest	reduction	in	disease	burden.		
2) A	better	understanding	of	local	epidemiology	to	inform	the	selection	of	trial	
sites,	recruitment	populations	and	design	clinical	trials.	
With	 several	 candidates	 progressing	 through	 phase	 IIB/III	 efficacy	 trials,	 research	
activities	 to	 fill	 these	data	needs	are	urgently	 required.	 In	 this	 thesis,	 I	aim	to	use	
mathematical	modelling	to	inform	which	vaccine	characteristics	and	implementation	
strategies	could	help	achieve	greatest	 reduction	 in	disease	burden,	and	develop	a	
novel	 tool	 to	 assist	 better	 understanding	 of	 local	 epidemiology	 to	 inform	 future	
clinical	trial	design	and	recruitment	of	the	target	populations	such	as	those	identified	
through	mathematical	modelling.	In	the	following	sections,	I	summarise	the	role	and	
existing	literature	of	mathematical	modelling	in	TB	vaccine	development	(section	2.6-
2.10,	and	the	tools	available	for	collecting	local	epidemiological	data	(section	2.11-
2.12),	 and	 identify	 the	 research	 gaps	 in	 these	 two	 areas	 leading	 to	 the	 specific	
research	aims	and	objectives	described	in	Chapter	1.	
2.6 Informing	TB	vaccine	Target	Product	Profiles	
Mathematical	modelling	provides	a	data-	and	logic-driven	framework	for	exploration	
of	the	epidemiological	impact	of	varying	vaccine	characteristics	and	implementation	
strategies.	With	maximisation	 of	 the	 reduction	 of	 disease	 burden	 as	 the	 primary	
goal,51	modelling	at	the	country	and	global	level	can	help	inform	decisions	in	vaccine	
development,	 clinical	 trial	 design	 including	 enrolment	 populations,	 and	
implementation	strategy.	This	mostly	occurs	through	the	use	of	modelling	to	inform	
the	vaccine	Target	Product	Profile	(TPP)	–	a	summary	of	the	desired	eventual	product	
labeling,	 critical	 for	 guiding	 efficient	 vaccine	 development	 strategy	 and	 ensuring	
development	 of	 products	 that	 are	 fit	 for	 purpose.	 TPPs	may	 include,	 but	 are	 not	
limited	 to,	 the	 strategic	 targets	 for	 key	 vaccine	 characteristics,	 such	 as	 vaccine	
efficacy,	duration	of	protection,	safety	profile	and	target	population.	
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Development	of	 a	TPP	 requires	 consideration	of	 three	main	 factors:	 the	 technical	
feasibility,	clinical	trial	feasibility	and	potential	population-level	impact	of	the	vaccine	
profiles	 under	 consideration.	 The	 former	 are	 mostly	 informed	 by	 laboratory	 and	
clinical	 trial	 scientific	 knowledge.	 Epidemiological	 mathematical	 modelling	 to	
estimate	the	future	impact	of	different	vaccine	profiles	can	provide	the	evidence	base	
to	identify	vaccine	profiles	capable	of	achieving	the	required	population-level	impact.	
In	TB	vaccine	development,	mathematical	modelling	has	been	invaluable	to	estimate	
the	potential	 future	 impact	of	new	TB	vaccines,	 forming	the	quantitative	basis	 for	
refocusing	 the	 current	 TB	 vaccine	 development	 strategy	 towards	 vaccination	 of	
adolescents/adults.52		
The	TPP	usually	specifies	the	‘minimum’	acceptable	and	the	‘ideal’	characteristics	for	
the	product	in	development.	Modelling	can	inform	the	TPP	‘minimum’	characteristics	
by	demonstrating	those	required	to	achieve	the	lowest	acceptable	level	of	impact,	
and	 the	 ‘ideal’	 based	 upon	 the	 characteristics	 required	 to	 maximise	 impact,	
combined	 with	 consideration	 of	 technical	 feasibility.	 For	 TB	 vaccines,	 TPP	
characteristics	 that	 can	 be	 informed	 by	modelling	 include	 duration	 of	 protection,	
vaccine	efficacy,	efficacy	 for	prevention	of	 infection	and/or	disease	 (‘effect	 type’),	
whether	the	vaccine	efficacy	is	modulated	by	the	infection	status	or	disease	history	
of	 the	 vaccinated	 individual	 (‘host	 infection	 status	 required	 for	 efficacy’),	 and	 the	
target	population	(e.g.	age	group)	for	vaccination.		
The	‘effect	type’	is	defined	as	the	natural	history	transition	that	the	vaccine	protects	
against:	prevention	of	infection	(POI),	prevention	of	disease	(POD),	or	both	(POI&D).	
This	 is	 dependent	 upon	 the	 antigens	 included	 in	 the	 vaccine,	 and	 may	 also	 be	
dependent	upon	the	vaccine	platform	(i.e.	attenuated	whole	cell,	subunit	vaccine,	
viral	vector).	The	anticipated	effect	type	of	a	candidate	will	affect	the	trial	endpoints	
during	 development,	 and	 the	 anticipated	 vaccine	 impact	 upon	 implementation.	
Precedent	exists	for	either	of	these	effect	types,	as	although	BCG	is	mostly	considered	
a	prevention	of	disease	vaccine,	some	efficacy	has	also	been	shown	against	infection,	
with	a	meta-analysis	of	14	studies	(n=3,855)	estimating	BCG	efficacy	against	infection	
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of	 19%	 (95%	 CI,	 8-29%).	 Therefore,	 BCG	 demonstrates	 that	 development	 of	 TB	
vaccines	effective	against	infection	or	disease	could	be	feasible.	
The	‘host	infection	status	required	for	efficacy’	is	defined	as	whether	the	vaccine	can	
induce	a	protective	immune	response	in	populations	that	have	never	been	infected	
with	 M.tb	 (pre-infection),	 populations	 previously	 or	 currently	 infected	 (post-
infection),	or	both	(pre-	and	post-infection).	Pipeline	candidates	have	been	trialed	in	
both	infected	and	uninfected	populations,	suggesting	that	both	types	of	candidates	
are	potentially	in	development.	In	terms	of	precedent,	BCG	is	most	effective	as	a	pre-
infection	 vaccine.	A	meta-analysis	 assessing	BCG	efficacy	 against	pulmonary	TB	 in	
school-age	children	estimated	efficacy	of	74%	(95%	CI:	63-81%)	when	only	including	
those	stringently	tested	for	infection,	whereas	without	stringent	testing	(i.e.	inclusion	
of	those	likely	to	be	latently	infected)	vaccine	efficacy	estimates	declined	to	45%	(95%	
CI:	-1	to	61%),	with	confidence	intervals	suggesting	no	significant	clinical	benefit.35	It	
is	unclear	whether	the	mechanism	of	this	reduced	efficacy	is	masking	or	blocking	by	
existing	immune	responses.		
Given	the	potential	for	long	latency	periods	of	M.tb	infection,	vaccines	effective	post-
infection	 could	 be	 a	 valuable	 TB	 prevention	 tool	 in	 this	 group	 at	 elevated	 risk	 of	
developing	disease.	Unlike	diseases	with	short	incubation	periods	such	as	measles	or	
influenza,	the	duration	of	M.tb	latency	could	allow	sufficient	time	for	identification	
and	immunisation	of	infected	individuals.	Although	a	precedent	for	a	post-infection	
vaccine	does	not	exist	in	TB,	vaccines	for	other	long-latency	diseases,	such	as	Human	
Papilloma	 Virus,	 have	 demonstrated	 post-infection	 efficacy.53,54	 Some	 TB	 vaccine	
candidates	contain	antigens	specific	to	the	latent	period	(e.g.	M72-AS01	vaccine).	
The	anticipated	vaccine	efficacy	and	duration	of	protection	of	 future	vaccines	are	
unknown.	However,	BCG	has	demonstrated	paediatric	efficacy	of	59-90%	depending	
upon	the	outcome	measure,	therefore	vaccines	with	efficacy	within	this	range	could	
be	 considered	 feasible.	 As	 discussed	 previously,	 BCG	 protection	 has	 been	
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demonstrated	to	last	at	least	10	years,	but	with	new	vaccines	the	type	or	robustness	
of	the	immune	response	induced	could	differ	considerably	from	BCG.	
Although	the	exact	characteristics	of	the	pipeline	vaccines	are	unknown,	there	are	
clear	 differences	 in	 anticipated	 characteristics,	 as	 indicated	 by	 vaccine	 candidate	
antigens,	trial	endpoints,	and	trial	recruitment	criteria.	For	example,	the	M72-AS01	
candidate	contains	possible	latency-phase	antigens,	and	the	phase	IIB	study	recruited	
Quantiferon	 (QFN)-positive	 adults	 (18-50	 years)	 to	 study	 TB	 disease	 outcomes.	
Therefore,	this	vaccine	is	anticipated	to	be	effective	for	prevention	of	disease	(POD),	
in	populations	already	latently	infected	with	M.tb	(‘post-infection’).	Conversely,	the	
Aeras-404	 candidate	 is	 currently	being	 trialed	 in	QFN-negative	adolescents	 (12-17	
years)	 to	 assess	 efficacy	 in	preventing	 infection,	 as	measured	by	QFN	 conversion.	
Hence	this	candidate	is	expected	to	be	effective	for	prevention	of	infection	(POI)	and	
in	populations	with	no	history	of	M.tb	infection	(‘pre-infection’).	A	summary	of	some	
of	the	key	characteristics	of	the	most	recent	trials	of	the	candidates	in	phase	IIB/III	
trials	are	summarized	in	Table	2.2	below.	These	trial	design	aspects	are	indicative	of	
some	 of	 the	 possible	 anticipated	 characteristics	 and	 target	 populations	 for	 these	
vaccines.	
Table	2.2:	Key	characteristics	of	current	trial	for	candidates	in	phase	IIB	and	III	in	July	2017	
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Vaccae46	 III	 Whole	cell	(M.vaccae)	 N/R	 Disease	 PSI	
15-65	
years	
DAR-90144	 IIB	 Whole	cell	(M.vaccae)	 Yes	
Infection	or	
disease	 PRI	
13-15	
years	
VPM-100249	 IIB	 Whole	cell	(rBCG)	 No	
Recurrent	
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PRI		
(PSI	
planned)	
Neonates	
(adults	
planned)	
M72-
AS01E47	 IIB	 Subunit	 Yes	 Disease	 PSI	
18-50	
years	
N/R:	Not	Reported,	PRI:	pre-infection,	PSI:	post-infection	
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2.7 Mathematical	modelling	to	estimate	population-level	vaccine	
impact	
The	 direction	 of	 impact	 of	 some	 of	 the	 described	 vaccine	 characteristics	 and	
implementation	 strategies	 can	 be	 logically	 predicted.	 For	 example,	 an	 inverse	
correlation	would	be	anticipated	between	burden	of	disease	and	vaccine	efficacy	or	
coverage.	To	quantify	such	relationships,	however,	requires	mathematical	modelling.	
Such	information	can	be	used	in	TPP	decision	making	to	estimate	vaccine	efficacies	
required	to	achieve	a	minimum	acceptable	level	of	epidemiological	impact,	and	for	
trade	offs	between	cost	of	vaccine	delivery	and	impact.	
The	 complexities	 of	 dynamic	 populations,	 epidemiology,	 and	 the	 interactions	
between	vaccine	characteristics,	make	predicting	the	impact	of	other	characteristics	
more	challenging,	especially	over	the	extended	time	frames	required	to	assess	the	
impact	of	TB	vaccines.	For	example,	the	relative	impact	of	vaccines	may	evolve	over	
time,	or	be	influenced	by	prevalence	of	infection	in	the	vaccinated	population,	which	
is	dependent	upon	age	at	 vaccination,	 contact	patterns	between	age	groups,	 and	
epidemiological	 trends	over	 time.	 Therefore,	mathematical	modelling	provides	 an	
appropriate	 framework	 for	 exploring	 the	 impact	 of	 these	 characteristics	 using	 an	
explicit	and	logical	approach.		
No	 systematic	 review	 of	 the	 modelling	 literature	 exploring	 the	 epidemiological	
impact	of	new	TB	vaccines	has	previously	been	conducted.	Therefore,	to	provide	such	
a	summary	and	to	identify	key	research	gaps,	I	conducted	a	systematic	review	based	
upon	the	following	research	question:	What	is	the	estimated	epidemiological	impact	
of	pipeline	or	theoretical	human	tuberculosis	vaccines,	as	estimated	by	mathematical	
modelling?	The	modelling	methods	employed	in	studies	identified	were	a	secondary	
outcome	of	interest,	to	inform	design	of	the	subsequent	research	study.	The	PICOS	
framework	for	this	research	question	is	summarized	in	Table	2.3	below.	
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Table	2.3:	PICOS	framework	for	systematic	review	research	question	
Limit	 Definition	
Population	 Humans,	any	age,	any	country	
Intervention	 Novel/theoretical/pipeline	TB	vaccines	
Not	single	efficacy	BCG-only	
Comparator	 No	intervention,	currently	available	interventions	(at	current	or	scaled-up	levels),	
or	other	theoretical	interventions.	
Outcome	 Tuberculosis	 epidemiological	 impact	 (incidence,	 prevalence,	 mortality,	 number	
needed	to	vaccinate,	cost	effectiveness)	
Not	Mycobacterium	bovis	
Not	immune	outcomes	
Time	 No	limit	
Study	Design	 Epidemiological	mathematical	models	
Not	within-host	impact	models	
Not	reviews/commentaries	
	
The	systematic	review	was	conducted	in	accordance	with	the	York	Centre	for	Reviews	
and	Dissemination	guidance	for	undertaking	reviews	in	healthcare.55	Detailed	search	
strategies	and	sifting	methodology	are	included	in	the	published	article	(section	2.8)	
and	 appendix	 A.	 An	 adapted	 risk	 of	 bias	 tool	 was	 developed	 for	 this	 study	 (see	
Appendix	A).		
The	 published	 systematic	 review	 follows	 (in	 section	 2.8).	 The	 review	 protocol,	
registered	online	on	the	PROSPERO	database	(reference:	CRD42016033266),	can	be	
found	in	Appendix	A.56	
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2.8 Systematic	review	of	the	TB	vaccine	modelling	literature	
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ABSTRACT
Mathematical models are useful for assessing the potential epidemiological impact of future tuberculosis
(TB) vaccines. We conducted a systematic review of mathematical models estimating the epidemiological
impact of future human TB vaccines. PubMed, Embase and WHO Global Health Library were searched, 3-
stage manual sifted, and citation- and reference-tracked, identifying 23 papers. An adapted quality
assessment tool was developed, with a resulting median study quality score of 20/28. The literature
remains divided as to whether vaccines effective pre- or post-infection would provide greatest
epidemiological impact. However, all-age or adolescent/adult targeted prevention of disease vaccines
achieve greater and more rapid impact than neonatal vaccines. Mass campaigns alongside routine
neonatal vaccination can have profound additional impact. Economic evaluations found TB vaccines
overwhelmingly cost-effective, particularly when targeted to adolescents/adults. The variability of impact
by setting, age group and vaccine characteristics must be accounted for in the development and delivery
of future TB vaccines.
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Introduction
Although Bacillus Calmette–Gu!erin (BCG) is a longstanding
cornerstone of the Expanded Programme on Immunization
(EPI) schedule, the only licensed vaccine against tuberculosis
(TB) disease, and one of the most widely used vaccines world-
wide, it provides variable protection against pulmonary forms
of tuberculosis disease and an uncertain duration of protec-
tion.1,2 Tuberculosis is responsible for the largest number of
annual deaths from a single infectious agent, estimated at
1.5 million in 2014, of which 91% were adults.3 Of 9.6 million
incident cases, 37% were undiagnosed or unreported.3 Hence
there remains a substantial unmet need for preventative meas-
ures such as new TB vaccines, particularly for protection
against pulmonary disease in adult populations, which is clini-
cally challenging to manage as well as being the source of most
on-going transmission. It is a widely held view that new TB
vaccines will be essential to the efforts to meet the World
Health Organization (WHO) End TB Strategy 2035 goals and
WHO 2050 goal of elimination of TB as a public health prob-
lem.3-5 With 15 candidates currently in clinical trials, including
one in each of phase IIb and III, the current TB vaccine pipeline
is the most promising to date.3
The ﬁeld is yet to see clinical efﬁcacy in a novel candidate
and the lack of an immunological correlate of protection for
TB makes identifying promising candidates challenging,
therefore clinical trials are long and costly, with limited guaran-
tee of success. Mathematical models are invaluable tools for
exploring the potential epidemiological impact of different
future vaccine proﬁles and implementation strategies. They can
inform the development of target product proﬁles and clinical
development plans leading to vaccine candidates ready for
licensure in the target populations in which they would have
the greatest population-level impact. Modeling results are also
important in advocating for vaccine development and
investment.
The TB vaccine pipeline consists of a variety of vaccine pro-
ﬁles. Novel TB vaccine proﬁles can be categorized into four
dimensions: the host infection status required for efﬁcacy (pre-,
post- or, pre- and post-infection: PRI, PSI and P&PI), an effect
type (prevention of infection, disease, or infection and disease:
POI, POD or POI&D), an efﬁcacy, and a duration of protection
(see Table 1 for deﬁnitions and abbreviations). Maximization
of vaccine efﬁcacy and duration of protection is obviously
desirable, but given the challenges faced in TB vaccine develop-
ment, a partially protective vaccine with limited duration of
protection is a likely outcome. Similarly, a P&PI and a POI&D
vaccine would have greatest impact, but given this may not be
possible, less is known about the relative advantages of efﬁcacy
with different host infection status and effect types, particularly
when considering extrinsic factors such as the age-structure
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and temporal trends of local epidemiology and other control
measures. Therefore, modeling is a logical framework for esti-
mating the inﬂuence of such factors on the population-level
impact of future vaccines. This is important for rational
development of target product proﬁles, minimum acceptable
proﬁles, identifying target populations for vaccination, and esti-
mating cost effectiveness of such vaccines.
As a growing ﬁeld of research, publication of mathematical
models assessing the potential impact of future TB vaccines has
increased in recent years, yet no systematic review exists of this
literature. Given the importance of this information for rational
decision making in TB vaccine development and the strength of
the current pipeline, a review of the literature was considered of
importance. We therefore conducted a systematic review of pub-
lished literature to answer the research question: what is the epi-
demiological impact of future human TB vaccines delivered to
any age group when compared to no vaccination, other future
vaccine proﬁles or other TB control interventions, as estimated
using mathematical models? The aim was to provide a summary
of the modeling methodology used, the characteristics of future
TB vaccines explored using modeling, and the comparative epi-
demiological impact of such novel vaccine proﬁles.
Methods
PICOS framework
The PICOS framework was employed to deﬁne the review
research question (Table S1). Searches were restricted to human
studies. The interventions of interest were future, new, pipeline
or theoretical vaccines for human tuberculosis. Papers exploring
the impact of a single, deﬁned-efﬁcacy BCG vaccine were
excluded; however, those exploring impact of a nominally BCG
vaccine but with varying vaccine efﬁcacy were considered for
inclusion as these could be considered reﬂective of other theoreti-
cal vaccines. A broad deﬁnition was applied for the comparator of
interest, therefore studies comparing new vaccines to no vaccine,
BCG-only, alternative new vaccines or alternative currently avail-
able interventions were considered. Only articles reporting epide-
miological outcomes, such as the impact on rates or absolute
numbers of incidence, prevalence or mortality, or alternatively
the number needed to vaccinate per case/death averted or cost-
effectiveness measures, were included. Within-host impact mod-
els exploring immunological outcomes were excluded. The
research question focused on the use of mathematical modeling
as the study design. Narrative reviews and commentaries were
excluded unless providing new modeling analyses or outcomes.
No limits were placed upon publication dates.
Search strategy
Three electronic healthcare sources (PubMed, Embase and
WHO Global Health Library) providing access to seven data-
bases (PubMed/Medline, Embase, African Index Medicus,
LILACS, SEARO Index Medicus, WPRO Index Medicus,
EMRO Index Medicus) were searched. A comprehensive search
strategy was developed using the deﬁned PICOS framework,
using free text and Mesh/Emtree/DeCS terms tailored by data-
base for groups of terms covering tuberculosis, vaccines and
modeling (Table S2). All searches were run with the “human”
ﬁlter, and the WHO Global Health Library search was limited
to regional databases to avoid duplication. No language or pub-
lication type limits were applied. Searches were conducted on
the 12th January 2016.
Study selection and data extraction
This research was conducted in accordance with the York Cen-
tre for Reviews and Dissemination guidance for undertaking
reviews in healthcare.6 Three-stage manual sifting of titles,
abstracts, then full texts was employed by the primary reviewer
to apply the pre-deﬁned inclusion/exclusion criteria described
in Table 2. Where uncertainty with regards to inclusion at full
text existed, a low threshold was used to trigger assessment by a
second reviewer (TS). Reasons for exclusion at the full text
stage were recorded. Data were extracted from eligible papers
into a piloted, standardized Excel database by a ﬁrst reviewer
(RH), and fully checked by a second (TS/RW). Reference lists
were hand searched and onward citation searching was con-
ducted using Web of Science for all included studies.
Table 1. Vaccine proﬁle deﬁnitions.
Vaccine characteristic Terminology Deﬁnition Abbreviation
Host infection status
required for efﬁcacy a
Pre-infection Protects when delivered to uninfected populations. Does not protect
when delivered to infected or previously infected populations.
PRI
Post-infection Protects when delivered to latent (and/or recovered) populations. Does
not protect when delivered to uninfected populations.
PSI
Pre- and post-infection Protects when delivered to uninfected, latently infected or recovered
populations
P&PI
Effect type (infection/disease
transition protected against)
Prevention of infection Effective against the acquisition of M.tb infection (uninfected to infected
state)
POI
Prevention of disease Prevents progression to active disease (uninfected or infected to disease
state)
POD
Prevention of infection and disease Prevents both infection and development of disease POI&D
Efﬁcacy Vaccine efﬁcacy Protection provided by the vaccine. Can be “take” or “degree” VE
Duration of protection Duration of protection Time during which vaccine remains efﬁcacious. May include waning of
protection
—
aM.tb exposure without infection, and immune priming with BCG or another vaccine, are not included within this deﬁnition, as exposure would not impact vaccine
response, and priming could be under the control of the public health system.
2814 R. C. HARRIS ET AL.
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Qualitative synthesis of extracted data was employed to pro-
duce a narrative summary of included literature.
In accordance with PRISMA methodology, a protocol sum-
mary is registered on PROSPERO (reference: CRD42016033266)
and the full protocol and PRISMA checklist are available in sup-
plementarymaterials (Supplementary appendix C and Table S4).7
Assessment of quality
We developed a new adapted tool for assessment of modeling study
quality and risk of bias (Table S3). This built upon previously pub-
lished frameworks for health relatedmodeling and health economic
modeling.8,9 By adding four more criteria to the Fone tool we
allowed a more in-depth consideration of deﬁnition of model set-
ting and population, appropriateness of modeling methodology
and structure, ﬁtting methodology, and reporting of conﬂicts of
interest, which are essential for assessing the reproducibility of the
model, alignment of the model and research question, and risks of
bias.8 To improve usability, the adapted tool presented contains the
questions to be considered for each of the 14 criteria and clear guid-
ance on the rating of zero, one or two for each criterion. If a criterion
was not relevant for a particular paper, a score of one was assigned
so as not to unduly bias the scores in either direction. Papers were
scored 0-2 on each of 14 criteria, giving a maximum score of 28
points. A quality of “low” (<14), “medium”(14-18), “high” (19-22)
or “very high” (>22) was assigned based upon the overall score.
Assessment of quality was conducted by one reviewer
(RCH), but with a low threshold for examining any uncertain
scores by a second reviewer (TS). The second reviewer also
Table 2. Inclusion and exclusion criteria applied in manual screening of articles.
Inclusion Criteria
Mathematical model
Systematic review of models of novel/future/hypothetical TB vaccine, or
commentary adding to the analyses/interpretation of models reported
elsewhere
Intervention is novel/future/hypothetical vaccine against tuberculosis
or of an unspeciﬁed novel TB intervention with characteristics in-line
with a vaccine
Reported outcomes are of the epidemiological impact of vaccine(s)
(e.g. incidence, prevalence, mortality, number needed to vaccinate,
cost effectiveness)
Exclusion Criteria
Within-host/immunological vaccine impact models
Review or commentary not adding to existing body of knowledge
TB epidemiological models not reporting impact of vaccine
TB epidemiological models reporting only interventions other than
vaccines
Model only reporting on impact of BCG with single known/ﬁxed efﬁcacy
Disease or infection caused by Mycobacterium bovis or other
non-Mycobacterium tuberculosis strain.
Pubmed: n = 843 Embase: n = 64 WHO GHL: n = 12
Total hits, n = 919
Records screened at abstract 
level, n = 128
Records screened at full text 
level, n = 37
Studies included, n = 17 
Studies removed  
756
Studies removed at abstract 
level: 91
Studies removed at full text level, n=20:
Single profile BCG only: 3
Full text not available: 2
2
Commentary: 6
No epidemiological outcomes: 5
Other: 2
Final studies included, n = 23 
Studies included from (n=6):
References: 3
3
Duplicates removed, abstracts 
screened level, n = 884
Figure 1. Summary of systematic screening of identiﬁed articles.
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reviewed one paper from each quality level to check for agree-
ment with the scoring and overall assessment of quality. Due to
potential conﬂicts of interest, one paper was also reviewed by a
third reviewer (SR).
Results
Screening process
A total of 919 records, comprising 884 unique articles after
removal of duplicates, were identiﬁed (Fig. 1). Title screening
removed 756 articles, and abstract screening a further 91, yield-
ing 37 articles for review at full text. Twenty articles were
excluded from the review during full text screening. The two
most common reasons for exclusion were commentaries pro-
viding no additional analysis (n D 6) and articles without epi-
demiological outcomes (n D 5). Reference and citation sear-
ching identiﬁed 6 additional articles for inclusion, therefore 23
research articles were included in the review (Table 3).
Although one BCG-based TB vaccine model exists from the
1960s,10 two models published in 1998 were the ﬁrst to explore
entirely novel TB vaccine proﬁles,11,12 and the majority (20/23)
of included papers have been published since 2000,4,13-31 moti-
vated by the promising late-stage pipeline and the push to
attain challenging WHO/Stop TB global TB targets.
Modeling methods (n D 23)
The included studies comprised 18 deterministic, compartmen-
tal, dynamic models constructed using difference or differential
equations,4,10-14,16-21,23-25,27-29 3 Markov decision tree analy-
ses,15,22,31 one a simple mathematical model including a ﬁxed
number of transmissions per case,30 and one statistical model.26
A subset of these papers (n D 5) present analytical solutions of
models and discuss the theoretical implications of a range of
factors on the impact of vaccines.11,13,17,25,26 These 5 papers do
not provide any quantitative estimates of the epidemiological
impact of novel vaccines and are not discussed further. A sum-
mary of model structures and ﬁtting methods is provided in
supplementary appendix A.
Vaccine characteristics (n D 18)
Modeled vaccine characteristics are summarized in Table 3. An
anticipated vaccine efﬁcacy in the range of 40–80% was most com-
monly modeled,10,12,15,18,20-22,27-31 though some explored the public
health impact of the extremes above15,20,29 or below 10,12,22,29 this
range. Vaccine efﬁcacy was modeled as ‘take’ (i.e. a proportion of
those vaccinated are completely protected, also known as an “all-
or-nothing” vaccine) in 6 studies,4,16,22,24,27,30 and as ‘degree’ (i.e.,
all vaccinees receive some protection from the vaccine, sometimes
known as a ‘leaky’ vaccine) in 8 studies.10,12,14,15,18,20,21,31 One study
modeled efﬁcacy as a combination of take and degree.28 The type
of vaccine efﬁcacy was not possible to identify in three stud-
ies.19,23,29 Those studies explicitly modeling vaccine coverage
tended to model coverage of 80–100%,10,12,15,20-22,27-31 though
some included lower coverages.12,20,27 Only one study assumed
coverage using data reﬂective of country- and age-speciﬁc access to
the healthcare system.27 Some studies use a combined parameter
(‘proportion effectively immunized’) of vaccine efﬁcacy multiplied
by coverage.4,16,19,23,24Where the proportion effectively immunized
was not reported, we estimated the approximate proportion at
ﬁve years after vaccine implementation. The scenarios of the pro-
portion effectively immunized spanned a wide range in most stud-
ies, ranging from a lower limit of 9–38% to upper limit of 70–
95%,10,20,22,24,27,29,30,32 though some studies did employ lower upper
limits,4,12,15,16 and some explored just a single scenario of propor-
tion effectively immunized within the range 44-70%.19,21,23,28,31 In
two studies it was not possible to estimate the proportion effectively
immunized.14,18
Most often, duration of vaccine protection was assumed to
be 10 years15,20,22,24,27,30,31 or lifelong,4,16,27,28 with some assum-
ing alternative scenarios including 5, 30 and 33 years protec-
tion.20,21,27,31 Seven articles did not report the duration of
protection modeled,10,12,16,18,19,23,29 but several appeared to use
lifelong protection.10,16,29 Waning of protection has been mod-
eled as either exact (all depart the vaccinated state exactly at the
end of duration),4,14,16,24,27,28,31 or linear or exponential waning
throughout the duration of protection.15,21,31
Many of the modeling studies explored the impact of multi-
ple vaccine proﬁles assuming various effect types and/or host
infection statuses required for efﬁcacy. The post-infection (PSI)
vaccines modeled assumed a prevention of disease (POD) vac-
cine effect,4,12,14,19-21,28 or prevention of infection and disease
(POI&D) effect.4,16 Pre-infection (PRI) vaccines have been mod-
eled assuming a prevention of infection (POI),4,12,16,18,23,24,29
POD,4,10,15,19,21,22,30,31 or POI&D vaccine effect.14,20,28 Com-
bined pre- and post-infection (P&PI) vaccines have been mod-
eled assuming a POI&D16 or POD12,19,21,23,27 vaccine effect. The
most frequently explored effect types were pre-infection vac-
cines with prevention of disease 4,10,15,19,21,22,30,31 or prevention
of infection 4,12,16,18,23,24,29 effect, and post-infection vaccines
with prevention of disease effect.4,12,14,19-21,28
Targeting of vaccination to populations with a speciﬁc host
infection status (n D 12) was common in the models identi-
ﬁed,4,10,12,16,18-21,24,28,29,31 as was targeting to speciﬁc age groups
(n D 12).10,12,15,18,19,21,22,24,27,28,30,31 Pre-infection vaccines were
most frequently targeted to neonates as they were a mostly
uninfected population,10,15,18,19,21-23,28,30,31 occasionally with an
adolescent boost21,31 or with a one-off mass campaign to all
ages.10,19,23,28 However, several studies included an analysis of
the impact of pre-infection vaccines in adolescent,24 high
risk,18 or all-ages mass vaccination campaigns or routine
immunization.12,20,21,28,29 Post-infection vaccines have mostly
been modeled as delivered to all ages,4,19-21,28 and in several
studies age targeting is not stated but is thought to be delivered
to all ages.4,14,16 Pre- and post-infection vaccines have been
modeled as delivered to neonates,23,27 neonates with short term
all-age mass campaigns,12,23 routine adolescent vaccination
with adult mass campaigns,27 or delivered to all ages.19,21
Setting and population (n D 18)
Three were global studies,12,14,16 two regional studies (e.g.
WHO regions),19,21 one in low- and middle-income coun-
tries,27 four based upon hypothetical high burden set-
tings,4,10,20,28 three were set in South Africa,15,22,24 one in
Japan,30 one in Zambia,31 one in a hypothetical township,29 one
2816 R. C. HARRIS ET AL.
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in a developed country,18 and one where the setting was not
clearly stated.23 Two of the afore-mentioned studies also
reported on country- (China, India and South Africa) or
region-level models in addition to the main model reported.4,12
Only two of the 18 studies consider heterogeneous social
mixing patterns: one included mixing by HIV status,12 and one
household model considers different mixing patterns during
community, diurnal interactions and familial interactions at
night.29
A small number of studies included risk groups within the
modeled population. HIV status is largely neglected in TB vac-
cine modeling, a surprising fact given its importance as a driver
of the TB epidemic in Africa and parts of Asia, but perhaps
linked to this population being largely excluded from vaccine
trials. One model targeted vaccination exclusively to the HIV-
negative population.24 Only four models explicitly include HIV
stratiﬁcation.12,15,27,31 Two of the Markov decision tree models
included the impact of HIV on TB natural history parameters,
and assumed that the vaccine was equally efﬁcacious in early-
stage HIV infection and HIV uninfected individuals, but had
zero efﬁcacy in patients with AIDS.15,31 Two globally-focused
dynamic models included HIV strata, one of which did not
alter vaccine efﬁcacy in the HIV stratum,12 and the other
accounted for immunocompromise through reduced vaccine
efﬁcacy in HIV-infected patients.27 Two of the models with
HIV strata did not explicitly include antiretroviral therapy
(ART) in the model.12,31 The Ditkowsky study assumed 58%
ART coverage which provided a 75% and 9.8% decrease in
HIV-related annual mortality for those with early HIV and
clinical AIDS, respectively, and a 61% reduction in the risk of
progression to clinical AIDS (with associated higher risks of TB
disease).15 In the Knight model, receipt of ART doubled life
expectancy, decreased rates of progression to TB disease or
death, and halved the reduction in vaccine efﬁcacy experienced
due to HIV infection.27 Aggressive ART scale up was assumed
between 2012 and 2020, increasing from the 2009 coverage
value in each country by half the difference between the 2009
value and 100%.27
Epidemiological impact of future TB vaccines (n D 18)
Fourteen studies had the epidemiological impact4,12,16,18-
21,23,28,29 and/or cost effectiveness 15,22,27,31 of future TB vaccine
candidates as a primary focus. Three studies explored the
impact of a variable efﬁcacy BCG vaccination.10,24,30 One strain
competition model explored impact of differential vaccine
effectiveness by strain.14 Details of the vaccine proﬁles and out-
comes discussed are summarized in Table 3.
i. Age targeting: Neonatal versus all ages, adolescents
or adults
Only one study offered a clear comparison of targeting a given
vaccine to neonates compared to adolescents/adults.27 Two
studies model the impact of vaccines delivered to neonates
compared to delivery to all ages.21,28
In the study by Knight et al., implementation of routine ado-
lescent vaccination with periodic mass adult campaigns was
found to have a much greater impact than routine neonatal
vaccination with a prevention of disease vaccine in low- and
middle-income countries across the 2024-50 time horizon.27
For example, a 60% efﬁcacious vaccine providing 10 years pro-
tection could prevent 17 million (range 11–24m) cases between
2024-2050 when delivered to adolescent/adults compared to
just 0.89 million (range 0.42–1.58m) when delivered to neo-
nates.27 The vaccine coverage differed in each age targeting sce-
nario, based upon data from current vaccination campaigns
relevant to those populations and so might be considered a
more realistic reﬂection of achievable coverage. There are likely
greater cost and logistical implications of delivering an adoles-
cent/adult vaccine than a routine neonatal vaccine, however in
this study it was found that due to the greater impact achieved
when vaccinating older age groups, all of the vaccine proﬁles
explored in this age group had a cost effective price per vaccine
dose, whereas for neonatal vaccination some of the shorter
durations of protection and lower vaccine efﬁcacies were not
considered cost effective. It was noted in the article that some
conclusions may be timeframe dependent, as those receiving
neonatal vaccination with long durations of protection would
only just be reaching the age of high TB risk in 2050.
As would be expected, vaccinating all ages had a greater
impact (80% incidence rate reduction over a 35-year time hori-
zon) compared to vaccinating neonates with an adolescent
boost (39% incidence rate reduction) with a POD vaccine in
the Abu-Raddad study.21 Though it should be noted that the
number vaccinated would be much greater in the all-ages sce-
nario. In the other neonatal vs. all-ages study,28 routine neona-
tal vaccination was compared to a one-off mass campaign for
uninfected individuals of all ages with a POI&D vaccine. In this
study, mass vaccination of all ages initially provides greater epi-
demiological impact than neonatal vaccination. As the vacci-
nated cohort ages out the incidence rates rebound, whereas
with sustained routine neonatal vaccination incidence rates
continue to decline, and provide greater impact than a one-off
mass campaign after approximately 20 years.28
No studies were found comparing vaccinating neonates to
all ages or adults with prevention of infection vaccines, or of
combining such age targeting with targeting of post-infection
populations.
ii. Addition of mass campaigns or boosters to routine
neonatal vaccination
Three studies found that the addition of one-off mass vaccina-
tion campaigns on top of neonatal routine vaccination could
have profound effects on population-level impact.19,23,28 In a
South-East Asian study exploring impact of a pre-infection pre-
vention of disease vaccine over a 35 year time horizon, an inci-
dence rate reduction of approximately 65% was predicted with
a neonatal vaccine, compared to >90% when adding a one-off
mass campaign at launch.19 In another study, addition of a
one-off mass vaccination campaign to the routine neonatal pro-
gram (with 70% of the population protected in each group)
increased the reduction in incidence rate from around a quarter
to approximately 85% over 25 years.23 In the Lietman study,
addition of a one-off mass campaign to routine neonatal vacci-
nation greatly increased the short-term impact of the
program.28
One study assessed the impact of an adolescent booster in
addition to neonatal vaccination, which in a Markov model
2824 R. C. HARRIS ET AL.
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was found to double the number of cases averted compared to
neonatal vaccination alone.31
iii. Host infection status required for efﬁcacy: Pre-infection,
post-infection or pre- and post-infection
Eight studies report a comparison of vaccines effective in differ-
ent host infection statuses,4,12,14,16,19-21,28 of which six report
clear comparisons between vaccines effective pre- versus post-
infection.4,16,19-21,28
Exploring the impact on disease incidence, three studies sug-
gest post-infection vaccines would have the greatest
impact,4,20,28 two suggest pre-infection would provide greatest
impact,19,21 and one suggests that either could have greater
impact, dependent upon the rate of treatment of active dis-
ease.16 The six studies allowing comparison are described
below.
iii.a. Post-infection vaccines leading to greater impact on
disease incidence (n D 3). The Ziv, Lietman and Dye (2013)
models report post-infection vaccines as providing greater
impact on disease incidence than pre-infection vaccines.4,20,28
Ziv et al., compared the effect of POD vaccines targeted to
uninfected (pre-infection) or infected (post-infection) popula-
tions in a hypothetical high burden setting with 28-50% latently
infected and 40-60% of active cases treated and cured, and
reported that post-infection vaccines would have a greater and
more rapid effect on cumulative number of incident cases than
pre-infection vaccines.20 After 10 years, post-infection vaccines
prevented 34% of cumulative cases compared to 23% by pre-
infection vaccines.20 Given 28-50% of the population were
latently infected, the number vaccinated with the post-infection
vaccine will be lower in most scenarios, therefore greater
impact on overall disease incidence is achieved despite being
given to fewer individuals. Age targeting, vaccine efﬁcacy and
coverage of target population were identical between scenarios
and both were assumed to prevent development of disease,
though in the pre-infection scenario the vaccine was addition-
ally assumed to have POI activity, and therefore was a POI&D
vaccine.
Similarly, in the Lietman study the pre-infection vaccine was
POI&D whereas the post-infection vaccine was POD-only, but
again, when comparing otherwise identical vaccines, post-
infection vaccination provided the largest and fastest impact on
the disease incidence rate.28 In a background of 50% successful
cure of active disease, comparing 88% coverage of latents
with a post-infection vaccine, to vaccinating 88% of newborns
with a pre-infection vaccine, impact was observed more rapidly
with the post-infection vaccine, and 60 years later the disease
rates with a post-infection vaccine were still lower.28 The sizes
of the latent and newborn populations are not reported, but
they are unlikely to be equal, therefore the number of people
effectively vaccinated and therefore the number needed to vac-
cinate per case averted in each of these scenarios could be very
different. Even if routine neonatal pre-infection vaccination
was preceded by a one-off mass campaign, the initial impact
was still not as large as the post-infection vaccine, but in this
scenario after 40 years the overall incidence rate reduction was
similar.
In a study by Dye et al., in a “typical high burden country”
with 110 cases per 100,000 population per year and 65% case
detection, of which 70% are cured, effective immunization of
25%/year of the uninfected population (pre-infection) with a
POI vaccine reduced disease incidence rates to 130/million
population/year, whereas as little as 14%/year effective immu-
nization of latents (post-infection) with a POD vaccine reduced
the incidence much further to 20/million population/year.4
In all three studies reporting greater impact of post infection
vaccines, the proportion assumed effectively immunized was
lower in the post-infection vaccine target group.4,20,28 There-
fore, even with lower coverage, post-infection achieved greater
impact than pre-infection vaccines.
iii.b. Pre-infection vaccines leading to greater impact on
disease incidence (n D 2). In the Abu-Raddad and Young
models,19,21 pre-infection vaccines demonstrated greater
impact on disease incidence than post-infection vaccines. In
the Abu-Raddad model, campaigns targeted at latently infected
individuals (post-infection) compared to mass vaccination
campaigns using pre-infection or P&PI vaccines, predicted
incidence rate reductions of 37%, 80% and 92% over a 35 year
time horizon, respectively.21 The Young study was also a South
Asian model, which compared the impact of otherwise-identi-
cal PRI, PSI and P&PI vaccines implemented in 2015.19 The
model estimated an incidence rate of approximately 20, 50, and
14 per 100,000 population per year in 2050, indicating that the
most effective vaccine in this scenario would also be a pre-
infection or P&PI vaccine.19 Though it should be noted that
there was some ambiguity in the article as to the vaccine sched-
ule, therefore there may be confounding due to differences in
schedules modeled. Both the Abu-Raddad and Young models
assumed that the pre-infection vaccines were prevention of dis-
ease vaccines, so would not have had a direct effect on
infection.
iii.c. Research indicating a possible reason for such contrasting
results (n D 1). A ‘global’ study excluding sub-Saharan Africa
found that at low active disease treatment rates pre-infection
vaccines providing lifetime protection had greater impact on
disease incidence rates than equivalent targeting of post-infec-
tion vaccines.16 However, when treatment rates of active disease
were increased, reducing the proportion of disease from recent
infection compared to reactivation, the post-infection vaccine
was reported to have greater impact on disease incidence. We
discuss this more below.
iii.d. Other factors inﬂuencing comparison of impact of pre- or
post- infection vaccines. Although the proportions effectively
immunized (coverage multiplied by vaccine efﬁcacy) did not
differ markedly between studies favoring pre- or post-infection
vaccines, the proportion of the population latently infected will
co-determine the number of people that would receive either a
pre- or post-infection vaccine, and could be an important cause
of differences. However, only two of these six studies reported
the assumed infection prevalence.16,20
Time horizon could be important for this comparison. As
demonstrated in the Ziv and Lietman models,20,28 even though
post-infection vaccines may have greater initial impact, the
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2825
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impact of the vaccine types sometimes converge over longer
time horizons due to the greater time lag before impact is
observed with pre-infection vaccines. However, all six studies
explore outcomes over a narrow horizon of 35-43 years and
therefore between-study differences in the impact of pre- vs.
post-infection vaccines do not appear attributable to time hori-
zon.4,16,19-21,28 Durations of protection, and effect type for post-
infection or pre-infection vaccines all vary between models, but
were also somewhat similar in both groups.
iv. Disease stage protected against: POI, POD or POI&D
Dye et al. (2000) compared POI and POD vaccines with 70%
effective immunization in a mass campaign followed by neona-
tal vaccination. In this study, the incidence rate reduction was
greater with the POD vaccine than the POI vaccine over a 25
year time horizon.23 In the Murray et al. global model, sus-
tained mass vaccination with 66% coverage of uninfected indi-
viduals for a POI vaccine prevented fewer cases (10.5m-37.0m
cases averted with 20-80% vaccine efﬁcacy over a 17 year time
horizon) than a POD vaccine with mass campaigns scaling up
to 80% coverage over 10 years followed by annual neonatal vac-
cination (16.2m-51.6m cases averted); a trend also reﬂected in
the regional estimates presented.12 However, it must be noted
that there are difﬁculties in identifying whether these are equiv-
alent comparisons given the differences in schedule, size and
infection status of population receiving vaccine and coverage.
Several models explored POI or POD vaccines compared to
a POI&D vaccine. As would be expected since it is a combina-
tion of mechanisms, a number of the studies found the POI&D
vaccine to be most effective.4,14 Those ﬁnding more impact on
disease with the POD vaccine than the POI&D vaccine were
likely confounded by favorable targeting of the vaccines to
latently infected individuals in the POD scenario.20,28
v. Time horizon of impact
The WHO/Stop TB global targets aim to reduce TB incidence
rates to 10 cases per 100,000 population per year by 2035, and
less than 1 case per million population per year by 2050, termed
as tuberculosis elimination.3,5 Several of the studies explored
the potential contribution of future TB vaccines to achieving
the Stop TB 2050 target, but all were published prior to release
of the WHO End TB strategy containing the 2035 goals, so
none directly address these targets. In two papers by Dye et al.,
it was shown that pre-infection POI vaccines to interrupt trans-
mission were unlikely to reach elimination, as even with com-
plete transmission interruption in 2015 an incidence of >100/
million/year would still be expected by 2050.4,16 In the Dye
model, a post-infection vaccine giving full and permanent pro-
tection to 14% of the latently infected population per year was
estimated to reduce incidence to 20/million/year by 2050, and
if combined with treatment of active disease, or a pre-infection
vaccine, would achieve elimination by 2050.4 In country-spe-
ciﬁc models, results suggested that a post-infection vaccine (or
mass preventative therapy) could achieve elimination targets in
China and India.4 These models suggest that a post-infection
vaccine, or either vaccine effect type combined with treatment
of active cases, may be capable of reaching the WHO 2050
elimination goals.4 However, similar models for South Africa
and the USA suggested that elimination was not considered
feasible in these settings with novel vaccines.4 Results from
both the Young and Knight models indicated that none of the
scenarios explored would achieve incidence rates lower than
around 10-20/100,000/year by 2050.19,27
vi. Settings
There was clear variability in vaccine epidemiological impact by
setting. Knight et al. demonstrated a larger proportion and
absolute number of cases would be averted by vaccines in low-
income countries than middle-income countries.27 In Japan,
95% coverage of a BCG-like vaccine with 40-80% vaccine efﬁ-
cacy was considered not cost effective as it could only avert 10-
47 cases per 100,000 children vaccinated over a 10-year hori-
zon.30 Whereas with 92% coverage of a 70% POD vaccine in
the Zambian setting, cases averted were much higher at 199
cases per 100,000 vaccinated at birth;31 though it should be
noted that the Zambian model analyzed a longer 30-year time
horizon. Three models explored the cost effectiveness of adding
booster vaccines in South Africa, but outcomes are not compa-
rable with the Japanese and Zambian models.15,22,24 In two
regional models, for each of the vaccine proﬁles explored the
greatest numbers of cases and deaths avoided were in Asia/
Western Paciﬁc, followed by sub-Saharan Africa (see
Table 3).12,21 Much lower absolute numbers of cases were
avoidable in the other regions, with the next largest impact
observed in the Eastern Mediterranean region where cases
averted were around a third of those in sub-Saharan Africa.21
vii. Economic models
A small number of published studies evaluated the economics
of future TB vaccines (n D 7/18),10,15,22,24,27,30,31 with the
majority (n D 6/7) evaluating cost effectiveness of new vaccines
(either future or BCG based) using either static,15,22,30,31 or
dynamic models.24,27 Optimization techniques were also used
to consider costs associated with different control schemes.10
With the exception of one model exploring a very low efﬁcacy
vaccine and one exploring infant vaccination in a low burden
setting,22,30 those evaluating cost effectiveness found new TB
vaccines to be an overwhelmingly cost effective intervention,
whether from the health system24,27 or societal perspec-
tive.15,27,31 More than half of the models included societal costs,
highlighting that much of the economic burden of TB disease
falls on the TB patient due to the long durations of treatment.
The populations considered in these economic models were
either theoretical10 or setting speciﬁc (South Africa,15,22,24 Zam-
bia31 or Japan30) with only one model considering multiple set-
tings (low- and middle-income countries).27 Cost effectiveness
of vaccines was highly dependent on vaccine characteristics
such as efﬁcacy (with lower efﬁcacy linked to higher
costs),7,15,22,24,30 setting-speciﬁc burden of disease,30 and eco-
nomic considerations such as discount rate,22,30,31 and time
horizon.31
It is important to know the minimum acceptable vaccine
efﬁcacy for designing clinical trials and when making imple-
mentation decisions. Two South African Markov model thresh-
old analyses of new vaccine boosters demonstrated that the
booster strategy would be more effective, and either cost neutral
or more expensive if the booster vaccine demonstrated a vac-
cine efﬁcacy of approximately 40% or above.15,22 The Knight
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2827
Chapter	2:	Background	 73	
	
et al. study provided contour plots demonstrating the vaccine
efﬁcacies and durations of protection for which the vaccines
would have an above-zero price at which the vaccine would be
cost effective.27 All vaccines in the ranges vaccine efﬁcacy 20-
100% and duration of 5 years to lifelong were cost effective,
and even cost saving above 20% vaccine efﬁcacy and 10 years
duration, when delivered to adolescents and adults.27 However,
the neonatal vaccination program was only cost effective at
higher values of these vaccine characteristics, with no cost effec-
tive vaccine price for a region of the plane where vaccine efﬁ-
cacy and/or duration were relatively low.
Studies identiﬁed post-hoc (n D 2)
For completeness, one unpublished study and one study pub-
lished after the review search date were identiﬁed. The study
published in March 2016 explores the impact of spatial ‘hot-
spot’ targeting compared to random allocation of an adult
POD vaccine in Gujarat, India.33 This model did not compare
vaccine effect types or host infection status or age targeting, but
is the ﬁrst to explore spatial targeting of vaccines, and suggests
spatial targeting could increase impact by 17% in the base case
scenario in this setting.33
The unpublished study is an exploration of the epidemiolog-
ical impact of different future TB vaccine proﬁles when targeted
to adolescents (15 year olds) compared to older adults (60 year
olds) in China.34 This model is a dynamic transmission model
incorporating heterogeneous social mixing patterns by age,
age-speciﬁc natural history parameters, and ﬁtted to age-strati-
ﬁed epidemiological data, and will contribute to the literature
on vaccine age targeting and impact of pre- versus post-infec-
tion vaccines.
Quality assessment (n D 23)
Using the adapted quality assessment tool, scores ranged from
11 to 25 out of 28 (Table 4). Two were considered low qual-
ity,19,23 eight of medium quality,4,13,17,18,25,26,28,29 six high qual-
ity,10,11,14,16,20,30 and seven of very high quality.4,12,15,21,22,27,31
The median score was 20/28, equivalent to high quality. As the
tool was not perfectly suited to analytical papers, the sensitivity
of the median score was assessed by excluding analytical
papers, and the overall score did not change. The major gaps
observed were deﬁnitions of the population and intervention,
ﬁtting methodology, uncertainty and sensitivity analyses, data
sources, and conﬂicts of interest and funding. Comprehensive
uncertainty and sensitivity analyses were lacking in many
studies. Further discussion is included in the supplementary
appendix B.
Discussion
Modeling the epidemiological impact of future TB vaccines is a
relatively young but growing ﬁeld, used to inform rational deci-
sion making in portfolio strategy, prioritization of resources,
and global target setting. To date, the literature remains divided
as to whether vaccines effective pre-infection or post-infection
would provide the greatest epidemiological impact. However,
all-age or adolescent/adult targeted prevention of disease
vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. Mass campaigns or boosters
added to routine neonatal vaccination can have profound addi-
tional epidemiological impact. With the exception of one very
low efﬁcacy vaccine and one low burden setting, economic eval-
uations found new TB vaccines to be overwhelmingly cost
effective, particularly when targeted to adolescent/adult age
groups. The variability of impact by setting, age group vacci-
nated, vaccine characteristics and time frame, must be taken
into account in the development and delivery of future
vaccines.
Given the importance of indirect effects in this research
question, the majority of the 23 included studies captured
transmission through development of dynamic models.
Some potential geographical bias was observed, as several
either excluded sub-Saharan Africa or were based upon an
Asia-like epidemic. Although the avoidable burden of dis-
ease may be higher in Asia, the high disease rates and
slower progress toward global targets in the African region
may mean that this region would be in greatest need of
new interventions such as vaccines to meet the WHO 2035
and 2050 targets.3 Epidemiological outcomes were indicative
of considerable heterogeneity by setting, highlighting the
importance of setting-speciﬁc modeling for decision making.
Only four of the models incorporated HIV strata,12,15,27,31
yet globally 12% of all TB cases are HIV co-infected, of
which three-quarters are found in the African Region.3 It is
currently unknown what effect HIV-infection may have on
vaccine efﬁcacy, but it is generally thought that it may be
lower in this population. Therefore, models without HIV
structure may overestimate vaccine impact, and models
including this structure are a useful tool to conduct sensi-
tivity analyses around HIV-related assumptions.
Historically, novel TB vaccine development has focused pri-
marily on vaccination in infancy. However, more recently a
shift in thinking has led to the prioritization of older age groups
in clinical trials and development plans. For prevention of dis-
ease vaccines, this is supported by the modeling literature,
which demonstrates that all-age or adolescent/adult targeted
POD vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. This is epidemiologically con-
sistent given that in many settings adults comprise the majority
of the disease burden and their primarily pulmonary disease is
a greater source ofM.tb transmission than the extra-pulmonary
disease prevalent in children,3 therefore delivery of POD vac-
cines directly to the adult population provides relatively imme-
diate impact, whereas there is usually a lag of 10-20 years
before any impact of long (>10 years) duration of protection
neonatal vaccination can be seen.
From an implementation perspective, neonatal and adoles-
cent vaccines could potentially be incorporated into existing
delivery platforms, but developing a platform for delivery of
adult vaccination could have serious resource implications.
Although this is an important consideration, one model has
demonstrated that adolescent/adult vaccine targeting would be
more cost effective than neonatal vaccination with a POD vac-
cine.27 Alternatively, several models suggest that addition of
one-off mass campaigns for all ages at initiation of routine neo-
natal vaccination could have a profound effect on the
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population-level impact.19,23,28 No models were identiﬁed com-
paring age targeted POI vaccines or combining age targeting
with targeting to post-infection populations. It was also noticed
by the authors that none of the models explored targeted vacci-
nation of older adults or the elderly, which is surprising given
that several high burden countries are undergoing population
aging (e.g., China, Indonesia) and the higher risk of developing
active disease in this age group.
Our ﬁnding that the modeling literature was equivocal as
to whether post-infection4,20,28 or pre-infection19,35 vaccines
would have greatest epidemiological impact is interesting and
may have important implications. Given the complexity of the
studies, it is not possible to conﬁdently identify the study differ-
ences that explain these diverse ﬁndings. However, there are 2
factors that we believe are likely to be most important. Firstly,
the underlying epidemiology of the population and, in particu-
lar, factors affecting the proportion of disease due to primary
disease and rapid progression versus reactivation or relapse, are
likely to be inﬂuential. This was best illustrated in Dye and Wil-
liams,16 in this study the authors increased rates of treatment of
active disease, which resulted in a switch from greater impact
from a pre-infection vaccine to greater impact from a post-
infection vaccine (Dye and Williams, ﬁgure 6 panels a and b –
by comparing new TB cases per million in 2050 in panel a ver-
sus b at increasing treatment rates per TB case). Increasing the
treatment of active disease reduced transmission and the pro-
portion of disease arising from primary infection (versus reacti-
vation). We recreated this by coding up this model (not shown)
showing that, for the same overall disease burden, when a
greater proportion of disease was due to reactivation the post-
infection vaccines were predicted to have the greater impact
across the full range of rates of treatment of active disease
explored. Secondly, the proportion of the population latently
infected will co-determine the number of people that would
beneﬁt from either a pre- or post-infection vaccine. However,
only two of these six models report the infection preva-
lence.16,20 Another factor that could help explain this difference
is that most of the six models compared assume no relapse
from the recovered class, but in the two models assuming
relapse,4,19 it is possible that relapse rates and assumptions as
to whether this group is protected by post-infection vaccina-
tion, could affect the relative impact of pre- versus post-infec-
tion vaccines. Further, although no major differences were
identiﬁed here, time horizon, vaccine efﬁcacy, and duration of
protection assumptions could also potentially inﬂuence pre- vs.
post-infection outcomes. Given the difﬁculties we have had in
identifying the reasons why these models are making conﬂict-
ing predictions, there is a clear need that these assumptions are
reported carefully in future vaccine modeling studies, and if
this question is important for vaccine development planning,
there may be a need for a controlled modeling study focusing
on this question.
From the vaccine development perspective, although a vac-
cine effective both pre- and post-infection would be the ideal
scenario, pipeline candidates with either pre- or post-infection
efﬁcacy could have value, and modeling could be used to assess
their relative value in different settings. Further, if a candidate
could potentially exhibit different efﬁcacy in infected versus
uninfected populations, efﬁcacy estimates from trials could be
confounded by the balance between primary and reactivation
disease in the trial setting. Or worse, if the recruited population
is limited to either infected or uninfected individuals it is con-
ceivable that a candidate’s development could be discontinued
due to poor efﬁcacy in one population without knowing
whether the candidate would have shown better efﬁcacy in the
other group. Therefore, if proven safe and immunogenic in
both infected and uninfected populations, ideally both should
be recruited into clinical trials and the study powered to esti-
mate vaccine efﬁcacy separately for those IGRA or TST positive
versus negative at recruitment to improve generalizability to
other settings. However, this could make trials infeasibly large,
in which case enrolling both uninfected and infected popula-
tions, but powering the trial on the primary endpoint in one
population, and looking for trend, safety and immunogenicity
in the other population as secondary endpoints may be prefera-
ble to using a combined endpoint.
Upon implementation, sustained campaigns speciﬁcally tar-
geting either uninfected (with a pre-infection vaccine) or
latently infected populations (with a post-infection vaccine)
may not be feasible. To identify such populations, TST or
IGRA testing would be required. Such tests come with cost and
organizational implications, and neither are perfect tests for
latency or the absence of infection.36 Blanket vaccination to
ensure the target population is captured would be an alterna-
tive, but empirical data and modeling would be needed to assess
the costs of vaccine wastage, and consideration given to the
ethics of vaccinating individuals unable to derive direct beneﬁt
from vaccination.
Regarding prevention of disease versus prevention of
infection vaccines, although several studies include vaccines
with these different effect types, there tend to be other
simultaneous changes in the vaccine proﬁles or targeting,
such as age or infection status targeting, which confound
the comparison of the impact of these two vaccine types.
However, overall the studies suggest that prevention of dis-
ease vaccines tend to have a quicker and greater epidemio-
logical impact than prevention of infection vaccines over
the time horizons explored.
Theoretically, it is possible that there could be a genetic pre-
disposition responsible for both ability to control M.tb latent
infection and to respond to a vaccine. For a POD vaccine, this
would become apparent in efﬁcacy trials, as there would be no
impact of such a vaccine on the disease endpoint. However, for
POI vaccine studies with an infection endpoint, such a scenario
could reduce infection rates, but have little impact on popula-
tion level burden of disease as the vaccine may not be effective
in those individuals most likely to progress to disease if
infected. None of the POI vaccine models explored the poten-
tial scenario where vaccine efﬁcacy is linked to likelihood to
progress to disease, but this could be an interesting avenue for
future research.
Although the relative impact of vaccine proﬁles to one
another is informative for rational development of portfolio
strategy, the absolute impact of such programs is important for
understanding the potential role of such new technologies in
achieving global targets and for advocacy for investment. Novel
TB vaccines have the potential to provide an important contri-
bution toward achieving the WHO 2035 and 2050 goals. Yet
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2829
Chapter	2:	Background	 75	
	
given the ambitious nature of the 2050 targets, even novel vac-
cines may require synergistic pairing with other interventions
to achieve elimination in most modeled scenarios. Due to the
sizeable global pool of latent infection, even a complete trans-
mission block may not achieve elimination because of the con-
tinued burden from reactivation disease. Therefore, prevention
of reactivation disease through vaccination or preventative
treatment of latently infected individuals will be essential to
elimination strategy.
Cost must also be considered when planning implementa-
tion of new TB vaccines, therefore health economic models will
be essential. With the exception of one low-efﬁcacy vaccine
study and one low burden setting,22,30 the studies identiﬁed
found new TB vaccines to be an overwhelmingly cost effective
intervention. The results of threshold analyses are highly con-
text dependent. However, in one analysis of low and middle
income settings, vaccines targeted to adolescents and adults
were shown to be cost effective as low as 20% vaccine efﬁcacy
and ﬁve years duration of protection, whereas infant vaccines
required higher efﬁcacies and longer durations to cross this
threshold over the time horizons considered.27
An adapted tool was developed to assess quality and risk of
bias of included studies for the purposes of this review to sys-
tematically assess reporting, methodological and risk of bias
factors. The majority of included papers were scored as
medium or high quality. The major gaps observed highlight for
future studies the importance of thorough reporting and the
conduct of comprehensive uncertainty and sensitivity analyses.
It is hoped that this quality assessment tool will be of broad use
in future systematic reviews assessing epidemiological models
of other interventions and diseases.
The main limitation of this review was the conduct of inde-
pendent sifting and data extraction by a single reviewer. The
authors recognize that sifting by two independent reviewers
remains the gold standard for systematic reviews.6 However,
due to resource constraints this was not possible, but a very low
threshold was applied for directing sifting queries to a second
reviewer. In addition, the review was ﬁrst conducted in 2014 and
then repeated in 2016, therefore duplication of sifting by the
same primary reviewer was expected to reduce the likelihood of
missing relevant literature. It was found that the study quality
assessment tool developed was not as well suited to assessment
of analytical models as several domains were not applicable,
leading to a higher likelihood of scoring ‘medium’ quality.
Several research gaps were identiﬁed in this analysis of the
available literature. The lack of a clear explanation for the polari-
zation of outcomes for pre-infection and post-infection vaccines
is troubling, therefore a model to explore which key determi-
nants within the model impact these outcomes would be an
important addition to the literature. None of the models pre-
sented explicitly explored the potential impact of targeting vac-
cines to older adult or elderly populations. Such a model would
be pertinent for a country such as China, which has high disease
burden, an aging population, and has only been brieﬂy explored
in one sub-model in the literature. Future vaccines could be
important in tackling multi-drug resistance disease through pre-
vention of transmission or disease, yet drug resistance was not
explored in any of the models identiﬁed. Few of the models
included non-random social mixing patterns, and none
considered the potential impact of evolving mixing patterns on
the impact of vaccines. Some studies have explored the epidemi-
ological impact of vaccine age targeting in sub-Saharan Africa;
however, these models were either missing HIV structure, did
not explore reduction of vaccine efﬁcacy in HIV-infected indi-
viduals, only considered vaccination of uninfected populations,
or were static models. Given HIV co-infection and high forces of
M.tb infection are fundamental to the epidemic in many sub-
Saharan African countries, there is a need for a comprehensive
model incorporating these important elements.
Conclusion
Mathematical modeling has been used to understand how the
epidemiological impact of future vaccines could be altered by
vaccine characteristics, vaccine age targeting, and epidemiologi-
cal setting. It has also proved important for exploring the
potential role of new vaccines for achieving the WHO 2050
goal of tuberculosis elimination. Such modeling should be inte-
gral to the development of future TB vaccines, informing ratio-
nal decision making by cross-product bodies, academia,
industry and policy makers for the development, investment
and implementation of pipeline vaccines.
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2.9 Systematic	review	update	
The	systematic	review	searches	were	updated	on	the	19th	July	2017	to	identify	any	
additional	published	literature.	Two	new	studies	published	in	2017	were	identified,	
one	modelling	neonatal	versus	all-age	vaccination	strategies	in	China,57	and	another	
regional-level	model	exploring	infant	versus	adolescent	(15	year	olds)	vaccination.58		
The	methods	and	results	of	these	studies	are	summarised	in	Table	2.4,	and	explored	
in	depth	in	the	discussion	in	Chapters	3	and	4.	
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Table	2.4:	Summary	of	the	two	additional	new	TB	vaccine	modelling	studies	identified	in	the	systematic	review	2017	update	
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Adolescent	vaccine	consistently	averted	
more	cases	than	neonatal	over	this	time	
period.	Largest	number	of	cases	averted	
2025-50	 was	 in	 African	 region	 (AFR),	
smallest	 number	 in	 Western	 Pacific	
region	 (WPR).	 Biggest	 difference	
between	 vaccination	 strategies	 was	 in	
WPR	 (81%),	 smallest	 difference	 was	 in	
AFR	(53%).	Estimate	from	graph	approx.	
80m	 cases	 averted	 with	 adolescent	
vaccination	 and	 approx	 30m	 with	
neonatal	vaccination	
15	
year	
olds	
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2.10 Modelling	literature	summary	
In	summary,	the	existing	body	of	mathematical	modelling	literature	does	not	provide	
a	 comprehensive	 and	 comparable	 exploration	 of	 the	 population-level	
epidemiological	impact	of	the	vaccine	characteristics	and	implementation	strategies	
required	 to	 inform	 vaccine	 TPPs	 and	 clinical	 trial	 design.	 In	 particular,	 questions	
remain	with	regards	to	the	relative	impact	of	pre-	versus	post-infection	vaccines,	and	
of	vaccines	with	varying	combinations	of	efficacy	against	infection	and	disease,	in	the	
context	of	different	durations	of	protection.	Also,	no	models	explore	the	impact	of	
vaccinating	 older	 adults	 or	 the	 elderly,	 which	 is	 a	 potentially	 epidemiologically	
important	population	over	the	time	horizons	of	TB	vaccine	modelling.	
With	phase	III	trial	results	in	China	due	within	the	next	year,	such	models	are	needed	
for	estimation	of	the	potential	future	impact	of	such	vaccines,	and	planning	for	future	
implementation.	China	is	the	third	largest	contributor	to	global	TB	incidence	and	a	
rapidly	ageing	population,	yet	no	modelling	literature	exists	exploring	the	potential	
impact	 of	 targeting	 older	 adults	with	 new	 TB	 vaccines,	 and	 the	 China	 TB	 vaccine	
modelling	 literature	 explores	 an	 extremely	 limited	 subset	 of	 vaccine	 types	 with	
insufficient	demographic	and	epidemiological	age	complexity.31,57		
Therefore,	in	the	next	section	of	this	thesis	(chapters	3	and	4)	I	develop	a	dynamic	
transmission	model	fitted	to	age-structured	demographic	and	epidemiological	data	
from	 China,	 to	 explore	 the	 future	 dynamics	 of	 the	 TB	 epidemic	 in	 China	 and	 the	
potential	 impact	 of	 varying	 vaccine	 characteristics	 in	 this	 setting	 (Chapter	 3,	
objectives	2a-c).	To	explore	the	impact	of	implementation	strategies,	this	model	is	
adapted	 to	 explore	 the	 impact	 of	 the	 current	 strategic	 focus	 on	 adolescent	
vaccination	compared	to	targeting	older	adults	(Chapter	4,	objective	5).	
Additional	research	questions	remain	with	regards	to	the	impact	of	vaccines	in	high	
HIV-prevalence	settings	and	the	impact	of	new	TB	vaccines	on	multi-drug	resistance.	
These,	however,	were	beyond	the	scope	of	this	thesis,	and	are	discussed	in	further	
work	(Chapter	6).	
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2.11 Translating	TB	vaccine	modelling	into	trial	design	
The	 exploration	 of	 the	 TB	 vaccine	modelling	 literature	 identified	 adolescents	 and	
adults	as	an	important	age	group	for	vaccine	targeting	and	has	shown	that	prevention	
of	 disease	 vaccines	 are	 likely	 to	 provide	 the	 greatest	 and	most	 rapid	 impact.	 The	
results	 from	 the	 existing	 modelling	 literature,	 in	 conjunction	 with	 the	 modelling	
results	that	will	be	presented	in	chapters	3	and	4,	provide	a	clear	indication	of	the	
importance	of	developing	vaccines	for	key	target	populations	and	are	suggestive	of	
prevention	of	disease	outcomes	as	the	most	epidemiologically	important	endpoint.	
These	 target	 populations	 and	 desired	 outcomes	 must	 then	 be	 translated	 in	 to	
appropriate	 design	 of	 clinical	 trials.	 As	 highlighted	 by	 the	 two	 epidemiological	
research	 needs	 identified	 from	 the	 TB	 Vaccine	 Blueprint	 (see	 Box	 1,	 Chapter	 1),	
mathematical	modelling	 can	 inform	 the	 ideal	 characteristics	 and	 populations,	 but	
then	 epidemiological	 data	 is	 needed	 to	 select	 research	 sites	 and	 identify	 disease	
hotspots	in	the	planned	enrolment	population,	to	inform	sample	size	calculations	and	
recruitment	plans.		
Spatial	variation	in	the	burden	of	tuberculosis	(TB)	is	well	recognised	at	national	and	
regional	 levels	 as	 a	 result	 of	 government	 surveillance	 systems.	 However,	 such	
heterogeneity	is	often	poorly	understood	at	the	local	level,	such	as	between	areas	
within	a	city.	A	small	number	of	studies	have	demonstrated	such	local	variations	exist	
for	TB	disease	 in	sub-Saharan	Africa.	For	example,	 in	Cape	Town,	South	Africa,	39	
enumerator	districts	 (across	 two	communities)	with	an	average	population	of	900	
inhabitants,	 reported	 adult	 TB	 notification	 rates	 ranging	 between	 0	 and	
2,847/100,000	adults	per	year.59	Similar	variations	were	reported	 in	a	settlement-
level	study	in	the	Gambia,	where	rates	in	settlements	of	4,000-68,000	people	ranged	
from	 48	 to	 239/100,000	 population/year.60	 The	 potential	 for	 such	 large	 local	
variations	highlights	 the	need	 for	 local-level	 burden	of	 disease	 information	 in	 the	
planned	vaccine	trial	enrolment	population.		
Given	the	 importance	of	prevention	of	disease	vaccine	trials,	epidemiological	data	
regarding	TB	disease	are	required,	including	spatial	granularity	and	stratified	by	key	
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population	 characteristics	 of	 interest	 for	 vaccine	 development	 (e.g.	 age	 and	 HIV	
status).	 Incidence	 rate	 data	 in	 the	 planned	 recruitment	 population	 are	 the	 gold	
standard	for	informing	sample	size	calculations,	as	they	are	directly	indicative	of	the	
likely	rate	of	accrual	of	endpoints	in	the	trial.	Where	incidence	data	are	not	available,	
notification	rate	or	prevalence	data	can	also	provide	an	indication	of	likely	rates	to	
de-risk	sample	size	calculations.	In	the	next	section,	I	explore	the	available	options	
for	collecting	such	data	and	the	strengths	and	limitations	of	those	tools.	
2.12 Available	studies	and	tools	for	collecting	spatial	data	for	
recruitment	populations	
Several	existing	study	designs,	databases	and	tools	are	available	for	collecting	spatial	
data	 to	 inform	 design	 of	 clinical	 trials	 to	 recruit	 the	 populations	 identified	 in	 the	
vaccine	 TPP.	 These	 include	 already	 available	 data	 sources	 such	 as	 National	
Tuberculosis	Programme	(NTP)	or	Health	and	Demographic	Surveillance	Site	(HDSS)	
data,	prospective	data	collection	through	initiation	of	a	new	epidemiological	study,	
or	the	possibility	of	adapting	available	spatial	map	tools	to	assist	data	collection.	The	
advantages	and	disadvantages	of	 these	approaches	are	detailed	 in	Table	2.5,	 and	
summarized	briefly	below.	
Existing	studies	exploring	spatial	distribution	of	TB	cases	mostly	use	either	HDSS	data	
or	Global	Positioning	Systems	(GPS)	to	record	coordinates	at	the	patient’s	place	of	
residence.	There	are	54	HDSS	sites	globally,61	but	such	sites	are	a	limited	resource	
and	not	all	sites	have	sufficient	incidence	of	TB	disease	or	clinical	trial	capacity	for	a	
TB	 vaccine	 clinical	 trial.	 Measuring	 GPS	 coordinates	 at	 the	 home	 is	 a	 resource-
intensive	 and	 logistically	 complex	method	 of	 collecting	 spatial	 data.59,62,63	 Due	 to	
these	resource	and	logistical	limitations,	such	detailed	prospective	TB	case	mapping	
in	non-enumerated	populations	is	uncommon.		
Patients’	addresses	are	widely	recorded	at	TB	registration	in	the	NTP,	but	these	data	
are	rarely	used	for	spatial	analysis	and	in	areas	without	official	address	systems,	the	
accuracy	 of	 such	 descriptions	 is	 often	 low.	 This	 was	 demonstrated	 by	 a	 study	
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comparing	 verbal	 descriptions	 in	 the	 clinic	 register	 to	 GPS	 readings	 taken	 at	 the	
home.64	 Two	 study	 staff	 were	 unable	 to	 categorise	 the	 patient’s	 cluster	 (approx.	
1,300	population)	of	residence	from	verbal	descriptions	for	31.8%	and	59.7%	of	the	
129	 participants,	 and	 agreement	 between	 the	 study	 staff	 was	 only	 61.5%.64	 This	
demonstrated	the	severe	limitations	of	retrospective	spatial	mapping	with	national	
registry	data.		
The	gold	standard	for	informing	clinical	trial	sample	size	calculations	and	identifying	
where	to	recruit	the	enrolment	population	would	be	a	prospective	incidence	study.	
However,	there	is	rarely	enough	time	when	initiating	clinical	trials	to	allow	for	the	
time	needed	to	conduct	an	incidence	study.	Prevalence	surveys	may	be	faster,	but	
are	not	as	directly	applicable	to	sample	size	calculations	as	incidence	or	notification	
rates,	 and	 still	 require	 substantial	 resources.	 Both	 incidence	 and	 prevalence	
prospective	studies	are	expensive	and	time	consuming,	so	may	delay	the	start	of	a	
clinical	trial.	Often	there	is	insufficient	time	and	resource	available	to	conduct	such	
prospective	studies.	
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Table	2.5:	Summary	of	existing	studies	or	tools	that	could	be	employed	to	collect	spatial	TB	burden	data	
Tool/Study	 Description	 Strengths	 Limitations	
National	
Tuberculosis	
Programme	
data	
Routinely	
collected	data	
when	new	
patient	registers	
for	treatment	
with	the	TB	
programme	
• Readily	available,	continuously	collected	
• Most	high	burden	settings	 routinely	 collect	 these	
data	
• Aggregated	 data	 usually	 report	 paediatric	 and	
adult	 burden	 separately,	 and	 registers	 usually	
record	age.	
• Usually	aggregated	data	are	stratified	by	type	of	TB	
(pulmonary/extrapulmonary)	
• Lack	 of	 spatial	 granularity	 as	 clinics	 may	 cover	
broad	 areas,	 and	 in	 low	 income	 settings	without	
address	 systems	 they	 may	 only	 record	 verbal	
descriptions	of	location	of	residence.	
• Misses	those	cases	that	do	not	seek	care		
• Demonstrated	in	Blantyre,	Malawi,	to	be	difficult	to	
identify	 area	 of	 residence	 from	 the	 verbal	
descriptions.64	
Health	and	
Demographic	
Surveillance	
Site	(HDSS)	
data	
Enumerated	
HDSS	sites	can	
link	cases	
reported	in	
clinics	to	GPS-
captured	place	
of	residence	
• Provides	spatial	data	to	the	household	level	
• Usually	good	coverage	and	continuously	collected	
• Often	 collect	 large	 amounts	 of	 demographic	 and	
additional	 risk	 factor	 data	 as	 part	 of	 the	 HDSS	
survey	rounds	
• Usually	sites	with	capacity	to	conduct	clinical	trials	
• Very	 limited	 number	 of	 sites,	 not	 always	
sufficiently	high	TB	burden.	
• Misses	those	cases	that	do	not	seek	care		
• Expensive	to	put	enumeration	system	in	place,	so	
only	 low	cost	 if	piggy-backed	to	a	 larger	research	
study.	
Prospective	
study	
(incidence	or	
prevalence)	
Design	and	
development	of	
an	incidence	or	
prevalence	study	
to	prospectively	
collect	the	
required	data	
• Can	collect	data	 in	 the	 recruitment	population	of	
interest	and	in	locations	able	to	conduct	a	clinical	
trial	 and	 with	 known	 regional	 high	 burden	 of	
disease.	
• A	well-executed	study	should	capture	all	cases	(i.e.	
no	issues	of	missing	those	not	seeking	care)	
• Outcomes	can	be	designed	to	match	the	planned	
study	endpoints	
• Very	expensive	
• Time	 consuming	 to	 set	 up	 and	 conduct	 study.	
Incidence	 studies	 in	 particular	 may	 need	 long	
durations	of	follow	up.	There	may	not	be	sufficient	
time	or	budget	ahead	of	a	clinical	trial	to	allow	for	
this.	
• Is	a	one	off	study,	 is	not	continuously	updated	so	
data	become	out	of	date	very	quickly.	
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GPS	
collection	of	
place	of	
residence	
Using	GPS	
handsets	to	
collect	
coordinates	at	
the	home	of	
patients	
registering	for	
NTP	treatment	
• Provides	precise	location	of	place	of	residence	
	
• Time	and	resource	heavy	
• Complicated	 logistics	 of	 ensuring	 availability	 of	
field	 staff	 to	 return	 to	 home	 of	 all	 patients	
immediately	 after	 registration,	 or	 difficulties	 of	
following	up	at	a	later	date.	
• If	 conducted	 by	 enrolling	 patients	 initiating	
treatment	at	 the	NTP,	would	also	miss	 those	not	
seeking	care	
Open	Street	
Map	
A	free	open-
access	online	
pictographic	
map	system.		
• Flexible	 tool	 where	 structures	 and	 POIs	 can	 be	
added	in	areas	where	there	are	insufficient	data	
• Free	and	open	access	
• Requires	internet	connection	to	update	maps	
• Pictographic	 representation	 of	 roads	 and	
structures	 can	 be	 difficult	 to	 use,	 especially	 for	
populations	with	low	map	literacy.	
• Currently	no	system	in	place	for	collecting	sensitive	
patient	data.	
Google	Maps	 A	free	open-
access	online	
satellite	image-
based	map	
system.		
• High	resolution	maps	in	a	variety	of	views/formats	
• Can	zoom	to	see	more/less	detail	
• Can	see	topography	and	details	in	satellite	images	
• Can	add	on	points	of	interest	
• Free	and	open	access	
	
• Assumes	map	literacy	
• Assumes	 sufficient	points	of	 interest	 to	orientate	
within	map	
• Requires	 high	 speed	 and	 reliable	 mobile	 data,	
which	 is	 often	 not	 available	 or	 very	 expensive	 in	
setting	of	interest	for	TB	vaccine	efficacy	trials,	or	
computer	with	good	connection	
• Currently	no	system	in	place	for	using	Google	maps	
to	collect	sensitive	patient	data	
Mapbook64	 A	series	of	paper	
maps	with	
points	of	
• Mapped	 points	 of	 interest	 identified	 by	 the	
community	 improve	 ease	 of	 use	 of	 maps	 in	 this	
• Only	 maps	 patient	 to	 a	 cluster	 of	 approximately	
1,300	 people,	 rather	 than	 to	 the	 street	 or	
household	level.	
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interest	and	
study	clusters	
marked,	used	in	
clinics	to	identify	
whether	
patients	are	
from	cluster		
community	without	address	system	and	with	 low	
map	literacy	
• Can	see	topography	and	details	in	satellite	images	
• Demonstrated	to	be	highly	accurate	when	used	for	
patients	 starting	 ART	 treatment	 in	 Blantyre,	
Malawi.	
• Only	 identifies	 residence	 for	 patients	 in	 28	 study	
clusters	
• Paper	 based	 maps	 and	 data	 collection,	 not	
automated,	 slow	to	update,	and	not	very	easy	 to	
share	data	
• Cannot	zoom	in	to	see	more	detail	
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A	 new	approach	 is	 needed	 to	 be	 able	 to	 prospectively	 collect	 place	 of	 residence,	
ideally	integrated	in	the	NTP	to	keep	costs	and	logistical	issues	to	a	minimum.	Several	
tools	 are	 available	 that	 could	 be	 used	 to	 collect	 place	 of	 residence	 at	 time	 of	
registration	 for	 TB	 care.	 These	 include	 open	 street	 maps,	 Google	 maps	 and	 the	
Blantyre	Map	book.	As	described	in	Table	2.5,	these	tools	can	provide	high	resolution	
identification	of	place	of	residence,	and	in	most	cases	are	flexible	to	be	able	to	add	
additional	points	of	interest	to	help	users	orientate	themselves	in	the	map.	However,	
populations	 in	 low	 income	 areas	with	 high	 burden	of	 disease	may	 have	 low	map	
literacy,	therefore	such	tools	may	not	allow	ease	of	use.	Mobile	data	connectivity	is	
also	an	issue	in	many	low	income	areas	with	high	burden	of	disease.	Both	open	street	
map	and	Google	maps	require	internet	connectivity	and	use	large	volumes	of	mobile	
data	to	load	the	maps,	therefore	in	many	low	income	settings	these	map	systems	are	
not	 sufficiently	 reliable,	 or	 too	expensive	 to	 run.	 There	may	also	be	 challenges	 in	
using	this	open	access	software	to	collect	personally	identifiable	information	for	TB	
patients,	as	such	data	must	be	collected,	transferred	and	stored	in	a	highly	secure	
manner	to	protect	patient	data.	
The	Map	book	system	was	designed	to	overcome	some	of	these	issues,	by	using	easy	
to	use	paper	maps	annotated	with	locally	known	points	of	interest,	and	with	paper-
based	collection	of	cluster	residency.64	This	is	feasible	for	a	limited	number	of	small	
areas,	but	in	itself	is	not	a	scaleable	approach.		
The	need	for	a	new,	low-cost,	easy	to	use	and	fast	to	implement	tool	for	collection	of	
spatial	epidemiological	data	to	inform	TB	vaccine	clinical	trial	design	was	identified,	
ideally	bringing	together	the	low	cost,	ease	of	use	and	community	engagement	of	the	
Map	 book	 system,	 but	 the	 scaleability,	 accuracy,	 and	 real	 time	 data	 collection	 of	
electronic	platforms.		
In	 chapter	 5	 of	 this	 thesis,	 I	 describe	 the	 development	 and	 evaluation	 of	 ePAL	
(electronic	PArticipant	Locator)	-	a	new	app	designed	for	rapid,	low	cost	collection	of	
the	 location	 of	 the	 TB	 patient’s	 place	 of	 residence	 as	 an	 integrated	 part	 of	 the	
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National	 Tuberculosis	 Programme.	 In	 Chapter	 5,	 I	 provide	 spatial	 mapping	 of	
tuberculosis	 notifications	 overall	 and	 in	 potential	 TB	 vaccine	 trial	 recruitment	
populations	from	the	first	12	months	of	data	collection	from	the	implementation	of	
ePAL	in	Blantyre,	Malawi.	
2.13 Epidemiological	tools	and	data	to	inform	the	development	of	TB	
vaccines	
In	 this	 chapter,	 I	 have	 described	 the	 public	 health	 need	 for	 new	 TB	 vaccines	 and	
challenges	in	their	development.	From	these	challenges,	two	clear	epidemiological	
research	needs	have	been	identified.	Firstly,	the	need	for	mathematical	modelling	of	
a	 comprehensive	 range	 of	 vaccine	 characteristics	 in	 China,	 in	 addition	 to	 a	
consideration	 of	 the	 impact	 of	 age	 targeting	 of	 vaccination	 to	 adolescents	 versus	
older	 adults,	 to	 inform	 maximisation	 of	 the	 potential	 future	 burden	 of	 pipeline	
vaccines.	 Secondly,	 the	 need	 for	 a	 new,	 low-cost,	 rapidly	 implementable	 tool	 for	
spatial	mapping	of	TB	cases,	to	allow	data-informed	sample	size	calculations,	ideally	
from	areas	with	hotspots	in	the	modelling-informed	target	populations.	
In	the	research	presented	in	this	thesis,	I	developed	a	dynamic	transmission	model	
to	explore	the	vaccine	characteristics	and	implementation	questions	identified	in	
the	literature	review	(Chapters	3	and	4),	and	a	novel	tool	for	spatial	mapping	of	the	
residence	of	TB	notifications	(Chapter	5).	
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Summary	of	Chapter	3	
	
In	this	chapter	I	describe	the	development	of	a	mathematical	model	of	age-stratified	
TB	 demographics	 and	 epidemiology	 in	 China.	 Firstly,	 modelled	 epidemiological	
projections	to	2050	without	introduction	of	new	TB	vaccines	are	described	(objective	
2a).	 Using	 this	 calibrated	 epidemiological	 model,	 the	 population-level	
epidemiological	 impact	of	 a	wide	 range	of	 vaccine	 characteristics	was	explored	 in	
depth,	and	incidence	and	mortality	results	in	terms	of	absolute	and	rate	reductions	
in	incidence	and	mortality	are	reported	(objective	2b	and	c).		
I	developed	the	modelling	research	in	this	chapter	as	described	below.	The	research	
question	 was	 identified	 based	 upon	 research	 gaps	 identified	 from	 the	 literature	
review	in	Chapter	2,	and	through	discussions	with	Willem	Hanekom	at	the	Bill	and	
Melinda	Gates	Foundation	(part-funder	of	the	work	in	this	chapter).	Collaborators	at	
Aeras,	 WHO	 and	 TBVI	 also	 contributed	 to	 scoping	 the	 research	 question	 and	
outcomes.	 The	methodology	was	 developed	 by	myself	with	 input	 from	 Professor	
Richard	 White,	 Dr	 Tom	 Sumner	 and	 Dr	 Gwenan	 Knight.	 I	 collected	 the	 data	 for	
parameterisation	 and	 calibration	 of	 the	model	 from	 secondary	 sources.	 The	 core	
model	structure	was	based	upon	a	model	developed	by	Knight	et	al.,1	but	with	major	
adaptations	 to	 capture	 the	 demographics	 and	 epidemiology	 in	 China	 and	 a	 wide	
variety	 of	 vaccine	 characteristics	 and	 implementation	 strategies,	 including	 ‘leaky’	
mechanisms	of	vaccine	efficacy	against	infection	and	disease,	incorporation	of	social	
mixing	patterns,	and	development	of	model	outcomes	(e.g.	incidence	rate	reduction,	
NNV).	 I	 carried	 out	 the	 model	 calibration,	 with	 guidance	 from	 Dr	 Tom	 Sumner.	
Interpretation	of	results	and	writing	of	the	chapter	were	my	own	with	feedback	from	
my	supervisors.		
The	results	presented	in	this	chapter	have	been	submitted	as	an	internal	report	to	
the	Bill	and	Melinda	Gates	Foundation	(BMGF),	and	presented	to	the	WHO	new	TB	
vaccine	advisory	group	(24th	May	2017)	
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CHAPTER	3: Epidemiological	impact	of	TB	vaccine	
characteristics	
3.1 The	need	to	inform	TB	vaccine	development	in	China	
As	discussed	in	Chapter	2,	China	is	the	third	largest	contributor	to	global	incident	TB,	
reporting	918,000	(range:	788,000-1,060,000)	new	cases	and	376,000	(range:	35,200-
41,500)	TB	deaths	in	2015.2	In	addition,	China	is	on	the	WHO	multidrug	resistant	TB	
high	 burden	 list.2	 It	 is	 anticipated	 that	 new	 vaccines	 would	 likely	 have	 similar	
prophylactic	efficacy	against	drug	sensitive	and	drug	resistant	TB,	therefore	a	new	
vaccine	could	be	an	important	part	of	preventative	measures	against	drug	sensitive,	
and	primary	and	acquired	drug	resistant	TB.		
China	is	also	a	WHO	high	burden	country	with	10%	of	the	current	population	aged	60	
years	or	above.3	The	proportion	of	 the	population	constituted	by	 the	elderly	 (≥65	
years)	is	anticipated	to	almost	triple	between	2010	and	2050,	to	23.9%	of	the	total	
population	In	China.4	
Although	the	population	proportion	aged	60	years	and	above	is	highest	in	developed	
countries,	 it	 has	 been	 estimated	 that	 by	 2050,	 nearly	 80%	 of	 the	 world’s	 older	
population	will	 be	 living	 in	 less	 developed	 regions.3	 Three	 of	 the	WHO’s	 high	 TB	
burden	countries	already	estimate	at	 least	1	 in	10	of	 their	population	are	aged	at	
least	 65	 years	 (China	 10%,	 Thailand	 10%,	 and	 Russia	 13.6%).2,5	With	 the	 ongoing	
demographic	ageing	occurring	globally,	including	in	many	countries	with	high	burden	
of	TB	disease,	the	results	of	such	modelling	in	China	could	be	indicative	of	possible	
future	 trends	 in	 other	 ageing	 countries	 (e.g.	 Thailand).	 A	 non-vaccine	model	 has	
estimated	that	in	the	future	there	is	the	potential	for	large	influence	of	reactivation	
disease	in	China’s	future	epidemic.6		
Given	China’s	important	contribution	to	global	TB	burden,	and	the	fact	that	there	is	
currently	a	TB	vaccine	candidate	in	phase	III	trials	in	China,7	there	are	surprisingly	few	
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research	 studies	 using	 modelling	 to	 estimate	 the	 potential	 impact	 of	 new	 TB	
vaccines.8	 The	majority	 of	modelling	 papers	 exploring	 potential	 future	 TB	 vaccine	
impact	are	in	global	or	India-like	settings,8	where	the	epidemic	remains	younger	adult	
and	new	infection	driven.	Modelling	in	China’s	epidemiological	setting	is	needed	to	
understand	 the	 characteristics	 required	 to	maximise	 the	 potential	 impact	 of	 new	
vaccines	 in	 this	 setting,	by	 informing	 target	product	profiles,	 clinical	development	
plans,	candidate	stage	gating	and	implementation	strategies.	
There	are	currently	13	candidates	 in	 the	clinical	development	pipeline	 for	new	TB	
vaccines,9	 representing	 a	 variety	 of	 antigens	 delivered	 through	 different	 vaccine	
modalities	(e.g.	whole	cell,	adjuvanted	protein,	viral	vector),	with	the	potential	for	
relatively	 diverse	 vaccine	 characteristics	 and	 indications.10	 However,	 scientific	
challenges	 in	 the	 current	 TB	 vaccine	 development	 environment,	 such	 as	 the	
complexity	of	the	natural	history	of	TB	disease	and	the	lack	of	an	immune	correlate	
of	protection,	mean	that	in	it	is	unlikely	that	early	successful	candidates	will	achieve	
all	desirable	vaccine	characteristics.	Therefore,	not	only	is	modelling	required	to	help	
maximise	vaccine	impact	by	informing	development	strategy,	modelling	can	also	help	
identify	the	characteristics	required	to	achieve	the	lowest	acceptable	level	of	impact	
to	inform	the	‘minimum’	profile	in	the	TPP,	which	is	important	for	informing	sample	
size	calculations	and	stage-gating	decisions	between	trial	phases.		
There	is	a	clear	need	for	TB	vaccine	modelling	in	China	to	inform	development	and	
possible	 implementation	of	 the	candidate	currently	 in	 trials,	and	of	other	pipeline	
candidates	that	could	potentially	be	developed	in	this	high	burden	country.	
Therefore,	modelling	was	conducted	to	fill	the	most	pressing	research	gap	for	TPP	
development,	 exploring	 vaccine	 efficacy	 against	 infection,	 vaccine	 efficacy	 against	
disease,	duration	of	protection,	and	the	relative	impact	of	pre-	versus	post-infection	
vaccines.	 This	 research	was	 also	 an	 opportunity	 to	 improve	 on	 the	modelled	 age	
specificities	of	the	model,	such	as	age	structured	demographics,	age-specific	contact	
patterns,	and	historical	trends	by	age	 in	burden	of	disease,	aiming	to	 improve	the	
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future	baseline	projections	in	this	first	piece	of	research	in	chapter	3,	and	to	allow	a	
more	detailed	exploration	of	age-targeting	of	 vaccines	 in	 chapter	4.	The	evidence	
generated	by	 this	work	 can	be	used	 to	 inform	evidence-based	 funding	 allocation,	
efficient	vaccine	development,	and	maximization	of	future	vaccine	impact.	 	
3.2 Aims	and	objectives		
The	research	presented	in	this	chapter	contributes	towards	the	first	aim	of	the	thesis,	
and	fulfils	thesis	objectives	2a-c	identified	in	Chapter	1:	
2.		a)	 Develop	 a	 mathematical	 model	 calibrated	 to	 epidemiological	 and	
demographic	 temporal	 and	 age	 distribution	 trends	 in	 China,	 accounting	 for	
uncertainty	 in	 natural	 history	 parameters,	 to	 predict	 the	 evolution	 of	 the	 TB	
epidemic	over	the	2050	time	horizon.	
b)	 	 	Using	 the	 calibrated	China	TB	model,	 simulate	 the	 introduction	of	new	TB	
vaccines	to	investigate	the	population-level	epidemiological	impact	of	varying	TB	
vaccine	characteristics	identified	in	objective	1.	
c)				Identify	the	combination	of	vaccine	characteristics	that	would	be	most	likely	
to	deliver	pre-specified	minimum	incidence	rate	reductions	compared	to	the	no	
new	vaccine	baseline	in	2050.	
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3.3 Methods	
3.3.1 Model	structure		
An	 age-structured	 dynamic	 compartmental	 transmission	 model	 (Figure	 3.1)	
described	 by	 a	 series	 of	 difference	 equations	 (section	 3.6.1)	 was	 developed	 and	
calibrated	 to	 epidemiological	 and	 demographic	 data	 from	 China	 to	 estimate	 TB	
burden	 in	 the	 baseline	 scenario	 (no	 new	 vaccine	 intervention)	 up	 to	 2050,	 and	 a	
series	of	vaccination	scenarios	implementing	new	TB	vaccines	2025-2050.	The	model	
structure	is	outlined	below.	The	model	was	programmed	in	R.11	
	
Consistent	with	other	models	 in	the	 literature,8	 the	natural	history	of	 tuberculosis	
was	 described	 by	 five	 epidemiological	 states:	 uninfected	 (S),	 latently	 infected	 (L),	
infectious	active	TB	disease	(I),	non-infectious	active	TB	disease	(NI),	and	recovered	
from	active	TB	disease	 (R)	 (Figure	3.1).	 The	uninfected	population	was	defined	as	
those	 never	 infected	 with	Mycobacterium	 tuberculosis,	 latent	 as	 the	 population	
remaining	infected	without	developing	clinical	symptoms,	infectious	disease	as	those	
with	 bacteriologically-positive	 pulmonary	 TB,	 non-infectious	 as	 patients	 with	
bacteriologically-negative	 pulmonary	 TB	 or	 extra-pulmonary	 TB,	 and	 recovered	 as	
those	who	have	either	 received	 successful	 treatment	or	naturally	 recovered	 from	
active	 disease.	 Each	 infection	 state	 was	 represented	 by	 an	 unvaccinated	 and	 a	
vaccinated	stratum,	and	age	was	modelled	in	single	years	from	0-100	years	to	provide	
granularity	in	demographic,	natural	history	and	vaccination	parameters.	
	
Newborns	entered	the	system	as	uninfected	at	rate	B[k],	where	k	is	the	calendar	year.	
Transmission	to	uninfected	individuals	occurred	at	rate	λ,	dependent	upon	the	age-
wise	proportion	of	the	population	with	infectious	disease	at	a	given	time	step,	the	
age-specific	 contact	 patterns	 (" #, % ) 	between	 the	 infectious	 and	 disease-free	
populations	 in	 that	 time	 step,	 and	 the	 probability	 of	 transmission	 per	 respiratory	
contact	 (z).	 Of	 the	 uninfected	 population	 becoming	 infected,	 a	 proportion	 (p)	
experienced	 fast	 progression	 directly	 to	 active	 disease	 and	 the	 remainder	 (1-p)	
entered	the	latent	state.	Latently	 infected	individuals	could	develop	active	disease	
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through	 ‘slow	 progression’	 of	 the	 existing	 infection	 (v)	 or	 ‘fast	 progression’	 upon	
reinfection	(λpx),	where	x	represents	protection	against	development	of	reinfection	
disease	due	to	the	immune	response	to	existing	infection.	For	all	new	active	cases,	
regardless	 of	 whether	 fast	 or	 slow	 progressors,	 a	 proportion	 (f)	 developed	
bacteriologically	 positive	 active	 disease,	 and	 the	 remainder	 (1-f)	 developed	
bacteriologically-negative	‘non-infectious’	disease.	Individuals	with	non-infectious	TB	
could	progress	to	infectious	disease	at	rate	w.		
As	 TB	 patients	 become	 rapidly	 non-infectious	 once	 initiating	 appropriate	
treatment,12	the	modelled	case	detection	(CDR)	and	effective	treatment	(CoT)	of	new	
active	cases	moved	the	population	successfully	detected	and	treated	directly	to	the	
recovered	state.	For	bacteriologically-negative	disease,	the	case	detection	ratio	(CDR)	
was	 scaled	 down	 by	 a	 factor	 e,	 as	 detection	 of	 bacteriologically	 negative	 and	
extrapulmonary	disease	is	lower.13,14	Undetected	cases	entered	the	relevant	active	
disease	 state	 and	 became	 prevalent	 cases.	 Prevalent	 cases	 could	 be	 removed	 by	
natural	 cure	 (n)	 to	 the	 recovered	state,	or	 removed	 from	the	system	by	TB	death	
(ui/uni)	 or	 all-cause	 mortality	 (u).	 Individuals	 with	 non-infectious	 disease	 could	
convert	to	infectious	disease	at	rate	w,	at	which	point	there	was	another	opportunity	
for	case	detection	at	the	bacteriologically-positive	disease	case	detection	rate	given	
the	likely	alteration	in	symptoms.		
The	 population	 in	 the	 recovered	 state	 could	 be	 reinfected	 at	 rate	 λx	 to	 develop	
primary	 active	 disease	 (p)	 or	 enter	 the	 latent	 pool	 (1-p).	 Relapse	 (r)	 from	 the	
recovered	state	to	return	to	the	active	disease	state	occurred	at	higher	rates	than	the	
latent	population	due	to	the	higher	risk	of	developing	disease	in	this	population.			
All-cause	mortality	 (u)	was	 age-specific	 and	 occurred	 at	 the	 same	 rates	 across	 all	
natural	history	states.	TB-related	mortality	occurred	in	infectious	or	non-infectious	
disease	states	at	rates	ui	and	uni,	respectively,	scaled	by	overall	(rmortTB)	and	age-
specific	calibration	factors	(uiscale).	
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Each	state	was	 represented	by	a	vaccinated	and	unvaccinated	stratum;	 therefore,	
vaccination	 was	 represented	 by	 a	 transition	 to	 the	 vaccinated	 stratum	
('(, ')	and	'.).	Vaccine	efficacy	was	modelled	as	“leaky”,	therefore	all	infection	and	
disease	states	were	possible	in	the	vaccinated	stratum,	but	vaccination	altered	the	
relevant	 natural	 history	 parameters	 to	 reduce	 progression	 to	 infection	 and/or	
disease.	 Vaccine	 efficacy	 against	 infection	 (effI)	 was	modelled	 by	multiplying	 the	
infection	parameter	(λ)	by	1-effI.	Vaccine	efficacy	against	disease	(effD)	was	applied	
in	 the	 same	 manner	 to	 development	 of	 disease	 parameters,	 which	 were	 the	
proportion	developing	primary	active	disease	(p),	and	risk	of	reactivation	from	the	
latent	(v)	and	recovered	(r)	classes.	Therapeutic	vaccination	was	not	considered,	so	
transition	 from	 unvaccinated	 to	 vaccinated	 strata	 was	 only	 possible	 for	 the	
susceptible,	 latent	 and	 recovered	 populations	 ('(, ')	and	'. ,	 respectively).	 Theta	
was	 equivalent	 to	 vaccine	 coverage	 in	 the	 given	 age	 group	 and	 year.	 Individuals	
departed	the	vaccinated	stratum	either	through	all-cause	mortality	(u)	or	reaching	
the	end	of	the	duration	of	protection	and	returning	to	the	unvaccinated	stratum	(d).	
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Figure	3.1:	Model	structure,	showing	the	unvaccinated	natural	history	stratum	(top)	and	the	
vaccinated	stratum	(bottom).	Figure	adapted	with	permission	from	Knight	et	al.	(2014)	1	
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3.3.2 Model	Parameters	
Key	model	parameters	are	summarised	below.	A	full	description	and	justification	of	
choice	of	parameter	ranges	are	provided	later	in	this	chapter	(section	3.6.2).	
Natural	history	parameter	ranges	 for	calibration,	detailed	 in	Table	3.7	were	based	
upon	 available	 literature,	 age-stratified	 where	 indicated	 by	 available	 data	 or	
biological	plausibility.	Social	mixing	between	age	strata	was	based	upon	social	mixing	
pattern	data	from	a	study	in	Southern	China.15	Treatment	success	was	based	upon	
historical	 data,	 and	 assumed	 to	 plateau	 beyond	 2011	 due	 to	 high	 success	 rates	
achieved	 (95%).16	 To	minimise	 short-term	 fluctuations	 in	 the	WHO-reported	 case	
detection	ratio	(CDR)	data,17	a	generalised	logistic	function	was	manually	fitted	to	the	
WHO	CDR	estimates	for	1990-2010.17	BCG	delivery	was	assumed	to	remain	constant,	
so	 was	 not	 explicitly	 modelled.	 Scaling	 factors	 for	 the	 contact	 matrix,	 overall	 TB	
mortality,	age-wise	TB	mortality,	and	case	detection	ratio	by	age	were	included	as	
calibration	parameters.	
3.3.3 	Model	calibration	
A	 two-stage	 calibration	 process	 was	 employed,	 with	 the	 first	 to	 calibrate	
demographics,	then	a	second	for	burden	of	TB	disease	trends.	Details	of	calibration	
data	and	justification	for	choice	of	methods	are	provided	in	section	3.6.3.	
In	the	first	stage,	manual	calibration	of	population	size	at	 initiation,	birth	rate	and	
death	rate	parameters,	was	used	to	fit	the	model	to	age-stratified	(0-14,	15-54,	55-
64	 and	 ≥65years)	 UN	 population	 division	 estimates	 for	 2010	 and	 projections	 for	
2050.18	
In	 the	 second	 stage,	 the	model	was	 calibrated	 to	 the	bacteriologically-positive	TB	
prevalence	rate	(≥15,	15-29,	30-59	and	≥60years)	in	2000	and	2010;19	TB	notification	
rate	(all-age,	0-14,	15-54,	55-64,	and	≥65	years)	in	2010;20	and	TB	mortality	rate	(all-
age,	0-14,	15-59	and	≥60	years)	in	2010.21	Country-specific	age-stratified	incidence	
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rates	are	not	reported	by	the	WHO,	therefore	the	model	was	fitted	to	the	WHO	2010	
all-age	incidence	rate	for	China.17	The	model	was	compared	to,	but	not	fitted	to,	LTBI	
survey	data	for	China,	due	to	uncertainties	in	the	sensitivity	and	specificity	of	the	LTBI	
tests	and	representativeness	of	the	LTBI	survey	sites.22		
Calibration	to	these	18	country-specific	epidemiological	data	sets	was	achieved	using	
an	adaptive	Approximate	Bayesian	Computation-Markov	Chain	Monte	Carlo	 (ABC-
MCMC)-based	method	using	a	modified	easyABC	package.23,24	First,	the	model	was	
run	 for	 one	 million	 randomly	 generated	 parameters	 sets	 and	 the	 likelihood	
calculated.	The	20	highest	likelihood	parameter	sets	were	then	used	as	seeds	for	an	
adaptive	ABC-MCMC.	Sequential	parallel	ABC-MCMC	chains	were	employed,	seeding	
with	 acceptances	 from	 the	previous	 chains	 and	adapting	 the	acceptance	 criterion	
until	a	full	model	fit	to	all	18	data	ranges	was	achieved.	From	the	2,152	model	fits	
achieved	 in	 the	 final	 set	 of	 parallel	 chains,	 1,000	 parameter	 sets	 were	 randomly	
selected	to	provide	median	estimates	and	uncertainty	ranges	reflective	of	parameter	
uncertainty	in	the	model.	
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3.3.4 Modelled	intervention	scenarios	
The	key	vaccine	characteristics	and	implementation	assumptions	are	summarized	in	
Table	3.1,	and	described	in	full	below.	
Table	3.1:	Vaccine	characteristics	and	implementation	assumptions	
Characteristic/Assumption	 Value		
Intrinsic	vaccine	characteristics	
Efficacy	 for	 prevention	 of	
infection	(VE-POI,	effI)	
Range:	0-100%	
Interval:	10%	(i.e.	0%,	10%,	20%	etc.)	
Efficacy	 for	 prevention	 of	
disease	(VE-POD,	effD)	
Range:	0-100%	
Interval:	10%	
Duration	of	protection	(D)	 Range:	2yrs-lifetime	
Values:	2yrs,	3,	5,	7,	10,	15,	20,	25,	lifelong	
Waning:	Exact,	no	Immunosenescent	waning	
Population	 protected	 by	
vaccine	
Pre-	and	post-infection	(P&PI),	pre-infection	(PRI)	
or	post-infection	(PSI)	
Type	of	protection	 Leaky	
Implementation	assumptions	
Epidemiological	setting	 China		
Year	of	vaccine	introduction	 2025	
Time	 horizon	 of	 vaccination	
scenarios	
2025-2050	
Vaccination	schedule	 Annual	 routine	 vaccination	 of	 9	 year	 olds	 from	
2025	onwards;	
Mass	vaccination	of	all	aged	³10	years	in	2025	&	
mass	campaigns	at	10-yearly	 interval	or	duration	
of	protection,	whichever	longer	(scenario	analysis	
with	5-yearly	mass	campaigns)	
Coverage	(θ[k,j])	 Routine:	80%	
Mass:	70%	
	
Based	upon	the	literature	review	in	chapter	2,	four	intrinsic	vaccine	characteristics	
were	varied	 in	 this	 research:	 vaccine	efficacy	 for	prevention	of	 infection	 (VE-POI),	
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vaccine	efficacy	for	prevention	of	disease	(VE-POD),	efficacy	by	host	infection	status	
(P&PI,	PRI	and	PSI),	and	duration	of	protection	(Figure	3.2).		
	
Both	POI	and	POD	vaccine	efficacies	were	varied	from	0-100%	in	10%	intervals	and	in	
combination	with	each	other	(i.e.	121	vaccine	efficacy	combinations).	Efficacy	was	
modelled	as	‘leaky’	protection	(otherwise	known	as	‘degree’	protection).	With	this	
type	of	protection,	vaccine	efficacy	was	implemented	as	a	percentage	reduction	in	
the	relevant	natural	history	parameters.	Prevention	of	infection	vaccine	efficacy	was	
applied	to	the	infection	parameter,	and	prevention	of	disease	efficacy	was	applied	to	
development	of	disease	parameters,	which	are	the	proportion	developing	primary	
active	disease,	and	risk	of	reactivation	from	the	latent	and	recovered	classes.	In	this	
‘leaky’	 protection	 model,	 the	 vaccinated	 population	 could	 develop	 infection	 and	
disease,	but	at	a	lower	rate	than	the	unvaccinated	population.	The	modelled	vaccines	
were	not	assumed	to	affect	infectiousness	of	disease,	severity	of	disease,	case	fatality	
ratio,	likelihood	of	natural	cure,	or	case	detection.	
Figure	3.2:	Four	main	new	TB	vaccine	characteristics	varied	in	
the	model	
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The	primary	vaccine	outcomes	were	reported	for	vaccines	effective	both	pre-	and	
post-infection	 (P&PI),	 modelled	 as	 vaccine	 ‘take’	 possible	 in	 susceptible,	 latently	
infected	 and	 recovered	 populations.	 As	 secondary	 analyses,	 pre-infection	 (PRI)	
vaccines	effective	only	in	susceptible	populations,	and	post-infection	(PSI)	vaccines	
only	effective	in	latently	infected	and	recovered	populations,	were	modelled.		
Impact	 of	 duration	of	 protection	on	 the	potential	 population-level	 impact	 of	 new	
vaccines	 is	 important	 information	 to	 inform	 the	 TPP.	 Duration	 of	 protection	 was	
assumed	to	be	2,	3,	5,	7,	10,	15,	20,	25	years	or	lifelong.	Duration	of	protection	was	
assumed	to	be	exact,	with	no	Immunosenescent	waning	in	elderly	populations.	
Vaccine	 implementation	 in	 China	 was	 assumed	 from	 2025	 to	 2050.	 Routine	 TB	
vaccination	was	delivered	to	nine	year	olds,	assumed	to	co-deliver	with	HPV	vaccine	
as	 part	 of	 the	 school-based	 vaccination	 platform.	 Although	 HPV	 is	 not	 currently	
implemented	 in	 China,	 WHO	 recommends	 delivery	 to	 ages	 9-13	 years,25	 and	
vaccination	at	the	lower	end	of	this	range	is	anticipated	long-term.26	Mass	campaigns	
vaccinating	 adolescents	 and	 adults	 (>9	 years	 old)	 were	 initiated	 in	 2025,	 and	
modelled	with	a	frequency	of	the	duration	of	protection	or	10	years,	whichever	was	
longer.	Although	this	covers	a	wider	age	group	than	might	be	anticipated	once	the	
vaccine	 is	 available,	 this	 ensures	 the	 peak	 ages	 of	 infection	 and	 disease	 will	 be	
covered	by	this	vaccination	campaign.	A	10-year	interval	between	mass	campaigns	
was	 considered	 the	 most	 feasible,	 informed	 by	 stakeholder	 experience	 of	 other	
campaigns.27,28	
As	 there	 is	 no	 existing	 HPV	 vaccination	 in	 China	 to	 inform	 coverage	 of	 routine	
vaccination,29	 the	 modelled	 coverage	 of	 routine	 vaccination	 was	 a	 conservative	
assumption	(80%),	based	upon	a	combination	of	gross	secondary	school	enrolment	
ratio	from	China	(94.3%)	and	the	HPV	coverage	achieved	in	9	year	olds	in	South	Africa	
(87%).30,31	Coverage	of	mass	vaccination	was	modelled	at	70%,	based	upon	expert	
opinion	and	the	lower	end	of	Menafrivac	mass	campaign	data	from	SSA	(70-98%	of	
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1-29	year	olds)	given	the	relatively	low	routine	elderly	influenza	vaccination	coverage	
in	China	(36-49%).32-35	
3.3.5 Outcomes	
In	order	to	inform	TB	vaccine	TPPs,	the	research	question	focused	on	identifying	the	
vaccine	characteristics	most	 likely	to	deliver	pre-specified	ranges	(e.g.	20-29%,	30-
39%	etc.)	of	population-level	reduction	in	TB	incidence	rate	in	2050.		Therefore,	the	
primary	outcomes	of	 interest	were	the	 incidence	rate	reduction	 in	2050	with	new	
vaccine	compared	to	no	new	vaccine	(presented	as	heat	maps),	and	the	combinations	
of	characteristics	required	to	achieve	pre-specified	ranges	of	incidence	rate	reduction	
(presented	as	example	TPP	tables).	
The	percentage	incidence	rate	reduction	compared	to	the	no	new	vaccine	baseline	
in	2050	was	estimated	for	all	evaluated	values	of	VE-POI,	VE-POD	and	duration	of	
protection,	with	the	median	and	range	estimated	for	each	from	the	1000	calibrated	
parameter	sets.	
The	definition	of	“lowest	acceptable	level	of	impact”	may	vary	depending	upon	the	
burden	 of	 disease,	 other	 care	 and	 prevention	 options	 available,	 and	 cost	 of	 the	
vaccine.	 China’s	 high	 DOTs	 coverage	 and	 treatment	 success	 leaves	 minimal	
opportunities	 for	 reducing	 burden	with	 currently	 available	 alternatives,	 therefore	
even	 relatively	 small	 reductions	 in	 disease	 burden	 through	 vaccine	 programmes	
could	 be	 of	 value.	 Discussion	 with	 stakeholders	 identified	 20-29%	 incidence	 rate	
reduction	in	2050	compared	to	no	new	vaccine	baseline	as	the	absolute	minimum	
level	of	impact	from	a	new	TB	vaccine	that	could	potentially	be	of	interest	(Personal	
communication,	Willem	Hanekom,	15th	December	2016).36	 This	was	 equivalent	 to	
reducing	incidence	from	a	modelled	no	new	vaccine	median	baseline	in	2050	of	34	
cases	per	100,000	population,	down	to	24-27	cases	per	100,000	population.		
From	 initial	 exploratory	 modelling,	 the	 shortest	 duration	 of	 protection	 able	 to	
achieve	this	minimum	impact	of	20-29%	IRR	was	identified	(5	years	protection,	when	
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mass	campaigns	were	10-yearly).	In	addition,	the	duration	of	protection	above	which	
minimal	additional	epidemiological	gains	could	be	achieved	was	also	identified	(10	
years	protection	with	10-yearly	mass	campaigns).	These	durations	were	used	to	limit	
the	number	of	scenarios	presented	in	later	analyses.	To	communicate	the	correlation	
between	 VE-POI	 and	 VE-POD,	 examples	were	 also	 given	 at	 the	 extremes	 of	 each	
vaccine	 efficacy	 range.	 These	were	 calculated	 for	 the	 vaccine	 scenarios	 using	 the	
model	outputs	from	all	1000	fitted	runs.	
Although	20-29%	was	the	absolute	lowest	acceptable	incidence	rate	reduction,	the	
level	of	incidence	rate	reduction	required	for	the	“minimum”	vaccine	profile	in	the	
TB	vaccine	TPP	is	not	yet	confirmed.	Therefore,	the	median	and	ranges	of	VE-POI	and	
VE-POD	 characteristics	 required	 to	 achieve	 incidence	 rate	 reductions	 in	 10%	
increments	from	20%	to	79%	were	investigated.		
In	clinical	trials,	the	trial	outcome	is	usually	either	M.tb	infection	or	TB	disease.	Rarely	
is	a	trial	designed	or	powered	to	measure	both.	Therefore,	 if	a	desired	population	
level	 impact	 is	 the	 goal,	 if	measuring	 just	 one	 of	 these	 endpoints,	 it	 is	 helpful	 to	
understand	any	risks	of	making	stage-gating	decisions	based	upon	a	single	endpoint.	
To	give	confidence	 that	a	vaccine	would	achieve	 the	required	 level	of	 impact,	 the	
measured	efficacy	outcome	could	be	benchmarked	against	the	modelled	median	for	
that	efficacy	in	a	‘worst	case’	scenario	for	the	two	unmeasured	characteristics.	The	
‘worst	case’	scenario	was	defined	as	zero	vaccine	efficacy	against	the	unmeasured	
endpoint	and	the	lowest	acceptable	duration	(5	years).		
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Primary	outcomes	(for	vaccines	effective	both	pre-and	post-infection):		
1. Percentage	 population-level	 TB	 incidence	 rate	 reduction	 in	 vaccine	 scenarios	
compared	to	no	new	vaccine	baseline	in	2050	(informs	heat	maps).	
2. Identify	shortest	duration	of	protection	able	to	deliver	at	least	20-29%	IRR	with	
10-yearly	mass	campaigns;	and	identify	the	duration	of	protection	above	which	
minimal	additional	epidemiological	gains	can	be	achieved	(informs	TPP	table).	
3. For	the	two	durations	of	protection	identified	in	primary	outcome	2:	Calculate	
median	 values	 and	 ranges	 for	 VE-POI	 and	 VE-POD	 required	 to	 achieve	 a	
population-level	 reduction	 in	 TB	 incidence	 rate	 in	 2050	 of	 20-80%	 in	 10%	
intervals	(informs	TPP	table).	
	
Secondary	outcomes:	
1. Cumulative	TB	cases	and	TB	deaths	averted	during	2025-2050		
2. Mortality	rate	reduction	in	2050	compared	to	no	new	vaccine	baseline	
3. Incidence	 rate	 reduction	 in	 2035	 compared	 to	 no	 new	 vaccine	 baseline	 and	
cumulative	cases	averted	2025-2035		
4. Maximum	achievable	and	 range	of	 incidence	 rate	 reduction	 for	 vaccines	with	
efficacy	POI-	or	POD-only	(as	distinct	from	efficacy	in	both).	
5. Minimum	 efficacy	 that	 would	 be	 required	 in	 one	 of	 the	 vaccine	 efficacy	
characteristics,	to	be	confident	that	a	vaccine	would	achieve	a	population-level	
reduction	in	TB	incidence	rate	of	20-80%	in	10%	intervals	in	2050	if	the	duration	
of	protection	and	the	unreported	vaccine	efficacy	were	at	a	minimum	(5	years	
and	0%,	respectively).		
6. Primary	outcomes	repeated	for	vaccines	effective	either	pre-infection	or	post-
infection.	
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3.3.6 Scenario	analyses	
In	the	main	analysis,	mass	campaigns	were	implemented	every	10	years	based	upon	
expert	opinion	(Personal	Communication,	teleconference,	28th	October	2016,	BMGF,	
WHO,	Aeras	and	TBVI).	However,	in	some	settings,	or	if	the	vaccine	were	shown	to	
be	 highly	 effective	 but	with	 short	 duration	 of	 protection,	 there	may	 be	 sufficient	
political	 will	 to	 deliver	mass	 campaigns	more	 frequently.	 A	 scenario	 analysis	 was	
conducted	 to	 explore	 the	 primary	 outcomes	 with	 frequency	 of	 mass	 campaigns	
shortened	to	the	shortest	frequency	considered	feasible,	which	was	every	five	years	
(Personal	Communication,	teleconference,	28th	October	2016,	BMGF,	WHO,	Aeras	
and	TBVI).		
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3.4 Results	
3.4.1 Baseline	(no	new	vaccine)	model		
The	baseline	model	fit	is	shown	in	Figure	3.3	to	Figure	3.7.	In	the	calibrated	model,	
the	incidence	rate	in	China	was	estimated	to	continue	to	decline	from	56.4	(UR:	51.6-
59.5)	per	100,000	 in	2025	to	33.8	 (UR:	27.8-37.9)	per	100,000	population	 in	2050	
(Figure	3.3).	During	the	same	period,	mortality	rates	were	predicted	to	decline	from	
2.0	 (UR:	1.2-3.2)	per	100,000	 in	2025	 to	1.1	 (UR:	0.6-2.0)	per	100,000	population	
(Figure	3.4).		
	
	
Figure	3.3:	Modelled	all-age	incidence	rate	per	100,000	population	2000-2050.	Black	circle	and	
vertical	bar	represents	WHO	estimates	and	ranges,	solid	horizontal	line	and	shaded	area	represent	
modelled	median	and	uncertainty	range.
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Figure	3.4:	Modelled	mortality	rate	per	100,000	population	2000-2050	for	all-age	population	(top	left,	black),	0-14	year	olds	(top	right,	red),	15-59	year	olds	(bottom	left,	
yellow),	and	³60	year	olds	(bottom	right,	green).	Black	circles	and	vertical	bars	represent	empirical	calibration	data	and	estimated	ranges,	solid	horizontal	lines	and	shaded	
areas	represent	modelled	medians	and	uncertainty	ranges.		
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Figure	3.5:	Modelled	notification	rate	per	100,000	population	2000-2050	for	all-age	population	(top	left,	black),	0-14	year	olds	(top	centre,	red),	15-54	year	olds	(top	
right,	yellow),	55-64	year	olds	(bottom	left,	green),	and	³65	year	olds	(bottom	centre,	blue).	Black	circles	represent	WHO	data	and	vertical	bars	the	estimated	ranges,	solid	
horizontal	lines	and	shaded	areas	represent	modelled	medians	and	uncertainty	ranges.	
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Figure	3.6:	Modelled	bacteriologically-positive	tuberculosis	prevalence	rate	calibration	in	2000	and	2010	for	³15	year	olds	(top	left,	black),	15-29	(top	right,	red),	30-59	
year	olds	(bottom	left,	yellow),	and	³60	year	olds	(bottom	right,	green).	Black	circles	and	bars	represent	empirical	calibration	data,	solid	horizontal	lines	and	shaded	areas	
represent	modelled	medians	and	uncertainty	ranges.	
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A	 B	 C	
	 	 	
D	 E	
Figure	3.7:	Demographic	fit	to	UN	population	
estimates	for	2010	and	2050	in	A.	0-14	year	olds,	B.	15-
54	year	olds,	C.	55-64	year	olds,	D.	≥65	year	olds,	and	
E.	the	overall	population.	
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Although	not	specifically	calibrated	to	all	six	age	groups	or	the	2000	and	2025	time	
points,	in	Figure	3.8	a	comparison	of	the	modelled	population	to	the	UN	population	
estimates	 and	 projections	 confirms	 the	 validity	 of	 the	 modelled	 demographics.4	
Population	ageing	is	clearly	visible	over	the	modelled	time	frame.	
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Figure	3.8:	Comparison	between	age-stratified	modelled	(red)	and	UN	population	estimates	(blue)	for	
2000	(top	right),	2025	(top	left)	and	2050	(bottom).	
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The	model	was	also	not	specifically	calibrated	to	prevalence	of	infection	data,	but	a	
comparison	of	the	age-stratified	modelled	2013	prevalence	of	infection	was	found	to	
very	closely	match	published	IGRA	data	from	a	study	in	the	same	year	(Figure	3.9).22	
The	 overall	 prevalence	 of	 infection	 in	 the	 population	 was	 15·7%	 (UR:	 12·8-18·7),	
ranging	from	1·3%	(UR:	1·0-1·6)	in	5-9	year	olds,	to	37·0%	(UR:	31·1-42·6)	in	≥70	year	
olds.	
	
Figure	3.9:	Age-stratified	latent	M.tb	infection	prevalence	in	2013,	modelled	and	empirical	data.	
Grey	bars	and	error	bars	denote	modelled	median	estimates	and	uncertainty	ranges.	Empirical	
data	from	Gao	et	al.	(2013)	are	TST	prevalence	as	blue	circles	and	Quantiferon	as	red	triangles.22	
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Results	from	the	epidemiological	model	are	explored	further	in	Chapter	4.	However,	
important	to	the	interpretation	of	the	vaccine-related	results	 in	this	chapter	is	the	
finding	 that	 China	 was	 demonstrated	 to	 be	 undergoing	 a	 transition	 from	 a	
transmission-driven	to	a	reactivation-driven	epidemic	(Figure	3.10).	In	2000,	28·6%	
(UR:	21·9-32·5)	of	all	cases	were	estimated	to	be	a	result	of	reactivation,	increasing	
to	 75·1%	 (UR:	 66·8-80·7)	 by	 2050.	 A	 change	 in	 age	 distribution	 of	 cases	was	 also	
observed	in	the	model,	due	to	the	coupling	of	high	but	declining	transmission	rates	
with	an	ageing	population	in	China.	In	2000,	75·8%	(UR:	71·3-81·0)	in	adolescents	and	
adults	(15-64	years),	whereas	by	2050	the	vast	majority	occurred	in	the	elderly	(³65	
years:	74·5%;	UR:	70·2-78·6).	In	the	year	of	vaccine	introduction,	less	than	1%	of	all	
new	cases	were	estimated	to	occur	in	the	vaccine-ineligible	age	group	(<9	years,	not	
shown).		
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Figure	3.10:	Proportion	of	all	new	active	cases	emerging	from	new	infections	(red)	versus	reactivation	of	
existing	infection	(black)	from	2000-2050.	Lines	are	median	values	and	shaded	areas	represent	the	
uncertainty	ranges.	
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3.4.2 New	TB	Vaccine	Scenarios	
3.4.2.1 Incidence	 rate	 reduction	with	 P&PI	 vaccine	 compared	 to	 no	 new	 vaccine	
baseline	in	2050		
The	predicted	reduction	in	incidence	rate	in	2050	compared	to	no	new	vaccine,	for	
P&PI	vaccines	of	two	years	to	lifelong	duration	of	protection,	by	percentage	vaccine	
efficacy	against	disease,	and	percentage	vaccine	efficacy	against	infection,	are	shown	
in	Figure	3.11	below.	
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Figure	3.11:	Median	incidence	rate	reduction	(%)	for	pre-	and	post-infection	vaccine	compared	to	no	
new	vaccine	baseline	in	2050,	by	percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	
against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel),	all	with	
10-yearly	mass	vaccination	campaigns.	
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With	 the	 profiles	 and	 implementation	 assumptions	 explored,	 new	 TB	 vaccines	
implemented	in	2025	reduced	incidence	rates	compared	to	a	no	new	vaccine	baseline	
by	a	maximum	of	79%	(UR:	77-81%)	by	2050,	reducing	incidence	to	7	(UR:	6-8)	cases	
per	 100,000	 population	 (100%	 VE	 against	 infection	 and	 disease,	 with	 10	 years	
protection)	(Figure	3.11,	centre	panel).	A	vaccine	with	20%	efficacy	against	infection	
and	disease	providing	2	years	duration	of	protection	could	achieve	as	little	as	3%	(UR:	
2-3%)	incidence	rate	reduction	(IRR)	in	2050	(Figure	3.11,	top	left	panel).	
For	the	absolute	minimum	acceptable	impact	of	a	20-29%	incidence	rate	reduction	
(Figure	 3.11,	 dark	 orange	 contour,	 equivalent	 to	 an	 incidence	 rate	 of	 27-30	 per	
100,000	population	in	2050)	to	be	achieved,	a	duration	of	protection	of	at	least	five	
years	would	be	required	assuming	mass	vaccination	every	10	years.	If	at	least	a	50-
59%	IRR	were	required,	at	least	seven	years	duration	of	protection	would	be	required	
(Figure	3.11,	light	yellow	contour).	With	two	years	duration	of	protection,	less	than	
10%	IRR	would	be	achievable,	regardless	of	vaccine	efficacies	(Figure	3.11,	top	left	
panel).	With	5	years	duration	of	protection,	a	vaccine	completely	protective	against	
infection	 and	 disease	 could	 achieve	 49%	 (UR:	 47-53%)	 IRR	 (Figure	 3.11,	 top	 right	
panel),	and	with	10	years	duration	of	protection	up	to	79%	(77-81%)	IRR	(Figure	3.11,	
centre	panel).	With	a	duration	of	protection	above	the	maximum	frequency	of	mass	
vaccination	 (i.e.	 above	 10	 years),	 a	 minimal	 difference	 in	 impact	 was	 observed	
compared	to	10	years	protection.	Based	upon	these	results,	vaccines	with	5	years	
(minimum	acceptable	impact)	and	10	years	(duration	above	which	achieve	minimal	
epidemiological	gains)	duration	of	protection	with	10-yearly	mass	campaigns	were	
explored	in	the	subsequent	analyses	of	primary	outcomes.	
For	a	pre-	and	post-infection	(P&PI)	vaccine,	Figure	3.11	shows	that	the	reduction	in	
incidence	is	mostly	dependent	on	the	vaccine	efficacy	for	prevention	of	disease,	with	
limited	sensitivity	to	VE-POI.	Although	increasing	VE-POI	does	increase	the	incidence	
rate	 reduction	 in	 2050,	 greater	 gains	 in	 impact	 are	 achieved	 with	 equivalent	
percentage	increases	in	VE-POD.	For	example,	with	10	years	duration	of	protection	
and	60%	vaccine	efficacy	against	both	infection	and	disease,	an	IRR	of	57%	(UR:	54-
60%)	would	be	expected;	increasing	VE-POD	to	80%	would	increase	the	IRR	to	68%	
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(UR:	 66-71%),	 whereas	 increasing	 VE-POI	 to	 80%	 would	 only	 provide	 a	 marginal	
improvement	to	an	IRR	of	58%	(UR:	55-61%).		
3.4.2.2 Median	values	for	VE-POI	and	VE-POD	of	protection	required	to	achieve	a	
given	population-level	reduction	in	TB	incidence	rate	
To	achieve	the	minimum	acceptable	20-29%	incidence	rate	reduction	in	2050	with	5	
years	duration	of	protection	and	10-yearly	mass	campaigns,	median	vaccine	efficacy	
for	prevention	of	disease	(VE-POD)	and	vaccine	efficacy	for	prevention	of	infection	
(VE-POI)	were	40%	and	60%,	respectively	(Table	3.2,	column	2).	Therefore,	a	vaccine	
with	5	years	protection,	40%	VE-POD	and	60%	VE-POI	would	be	very	likely	to	provide	
this	level	of	impact.	However,	these	vaccine	characteristics	are	highly	correlated	and	
therefore	the	ranges	are	wide	(0-60%	for	VE-POD	and	0-100%	for	VE-POI),	and	include	
all	 possible	 combinations	 that	 could	 potentially	 provide	 this	 level	 of	 impact.	 For	
example,	 for	 a	 vaccine	 effective	 against	 infection	only	 (i.e.	 VE-POD=0%),	 90-100%	
protection	would	be	required	to	achieve	this	impact,	whereas	with	a	vaccine	with	no	
protection	against	infection	(i.e.	VE-POI=0%),	40-60%	VE-POD	would	be	sufficient	to	
achieve	this	level	of	impact	(Table	3.3).		
Exploring	 the	 slightly	 higher	 incidence	 rate	 reduction	 of	 30-39%	 in	 2050,	median	
vaccine	characteristics	for	VE-POI	and	VE-POD	were	both	60%	(Table	3.2,	column	3).	
Comparison	with	 the	medians	 for	 20-29%	 incidence	 rate	 reduction	 demonstrated	
that	 an	 increase	 in	 protection	 against	 disease	 was	 most	 likely	 to	 provide	 the	
additional	impact.	However,	such	impact	is	achievable	even	with	no	vaccine	efficacy	
against	 infection	(lower	limit	of	VE-POI	=	0%),	as	long	as	sufficient	vaccine	efficacy	
against	disease	(60-80%)	 is	achieved.	Conversely,	 if	VE-POI	were	100%,	 it	could	be	
coupled	with	a	VE-POD	of	as	low	as	30%	(lower	limit	of	VE-POD	=	30%,	column	3)	to	
achieve	this	 level	of	 impact.	There	was	no	5-year	duration	scenario	with	 less	than	
30%	VE-POD	that	could	achieve	this	level	of	impact.	The	maximum	reduction	possible	
with	a	5-year	duration	vaccine	with	10-yearly	mass	vaccination	would	be	a	50-59%	
IRR	in	2050	(Table	3.2,	column	5),	which	would	require	100%	VE-POD,	and	any	level	
of	protection	against	infection	as	the	outcome	is	not	very	sensitive	to	VE-POI.	In	Table	
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3.2,	the	VE-POI	appears	to	oscillate	with	increasing	required	impact,	however,	this	is	
because	the	impact	is	driven	by	VE-POD,	so	VE-POI	can	vary	a	little	around	50-60%,	
with	the	exception	of	the	highest	impact,	which	ideally	required	a	slightly	higher	VE-
POI	(70%)	to	be	achievable.		
With	a	duration	profile	of	10	years	with	10-yearly	mass	campaigns,	an	incidence	rate	
reduction	of	20-29%	was	achieved	with	a	median	VE-POD	of	10%	(range	0-30%)	and	
VE-POI	50%	(range:	0-100%)	(Table	3.2).	The	median	VE-POD	was	substantially	lower	
than	with	5	years	duration	of	protection.	The	maximum	achievable	 incidence	rate	
reduction	with	5	years	protection	was	50-59%,	whereas	with	10	years	protection	as	
high	 as	 70-79%	 could	 be	 achieved,	 though	 would	 require	 a	 completely	 disease-
blocking	vaccine	(i.e.	VE-POD=100%).	
These	median	characteristics	and	ranges	can	 inform	the	 target	product	profile	 for	
new	TB	vaccines.	Once	the	required	levels	of	epidemiological	impact	(minimum	and	
possibly	ideal)	have	been	agreed,	the	median	characteristic	values	required	for	those	
levels	of	impact	would	be	indicative	of	the	typical	combined	characteristic	values	at	
which	the	incidence	rate	reduction	could	be	achieved.	The	ranges	provide	the	scope	
of	possible	values	of	the	characteristics	that	could	achieve	the	given	level	of	impact,	
and	 are	 important	 for	 trial	 design	 and	 endpoint	 selection,	 though	 should	 be	
interpreted	with	caution,	as	a	correlation	exists	between	these	characteristics.		
In	Table	3.4,	an	example	is	provided	of	possible	TPP	text,	including	these	medians,	
ranges,	and	annotation	referring	to	the	heat	maps	and	examples	demonstrating	the	
correlation	between	the	vaccine	characteristics.	The	example	TPP	text	is	provided	for	
20%	to	79%	(in	10%	steps)	 incidence	 rate	 reduction	 in	2050	compared	 to	no	new	
vaccine	baseline.	
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Table	3.2:	Median	and	range	of	vaccine	efficacies	required	to	achieve	20-80%	incidence	rate	reduction	(in	10%	steps)	in	2050	compared	to	no	new	vaccine	baseline	for	5	
and	10	year	durations	of	protection	and	10-yearly	mass	vaccination	campaigns	
Vaccine	
efficacy	
Median	 VE	 to	
achieve	20-29%	TB	
IRR	2050	(range)		
Median	 VE	 to	
achieve	30-39%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	40-49%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	50-59%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	60-69%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	70-79%	TB	
IRR	2050	(range)	
5	year	duration	vaccine	(with	10-yearly	mass	campaigns)	
VE-POD	 40%	(0-60%)	 60%	(30-80%)	 90%	(60-100%)	 100%	(100-100%)	 n/a	 n/a	
VE-POI	 60%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 n/a	 n/a	
10	year	duration	vaccine	(with	10	yearly	mass	campaigns)	
VE-POD	 10%	(0-30%)	 30%	(0-40%)	 40%	(20-50%)	 60%	(40-70%)	 80%	(60-80%)	 100%	(100-100%)	
VE-POI	 50%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 70%	(0-100%)	
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Table	3.3:	Median	and	range	of	vaccine	efficacies	required	to	achieve	20-50%	incidence	rate	reduction	(in	10%	steps)	in	2050	compared	to	no	new	vaccine	assuming	10-
yearly	mass	vaccination	campaigns	and	that	the	two	unmeasured	characteristics	(duration	and	one	vaccine	efficacy)	are	at	a	minimum		
Characteristic	
Characteristics	to	achieve	20-
29%	IRR	in	2050	
Characteristics	to	achieve	30-
39%	IRR	in	2050	
Characteristics	to	achieve	40-
49%	IRR	in	2050	
Characteristics	to	achieve	50-
59%	IRR	in	2050	
POI	as	trial	
outcome	
POD	as	trial	
outcome	
POI	as	trial	
outcome	
POD	as	trial	
outcome	
POI	as	trial	
outcome	
POD	as	trial	
outcome	
POI	as	trial	
outcome	
POD	as	trial	
outcome	
VE-POI	 100%	(90-100%)	 0%*	
Not	
achievable	 0%*	
Not	
achievable	 0%*	
Not	
achievable	 0%*	
VE-POD	 0%*	 50%	(40-60%)	 -	
70%	
(60-80%)	 -	
90%	
(80-100%)	 -	
100%	
(100-100%)	
Duration	 5yrs*	 5yrs*	 5yrs*	 5yrs*	 5yrs*	 5yrs*	 5yrs*	 5yrs*	
	
*Characteristic	assumed	at	minimum	as	not	measured	in	clinical	trial.	5	years	duration	is	the	lowest	capable	of	achieving	at	least	20-29%	IRR	in	
2050.	
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Table	3.4:	Suggested	TPP	values	for	VE-POI,	VE-POD	and	duration	of	protection	required	to	achieve	
20-29%,	50-59%	and	70-79%	incidence	rate	reduction	in	2050	with	10-yearly	mass	campaigns.	
Other	ranges	are	available	in	Appendix	B.	
Vaccine	
characteristic	
To	achieve	20-29%	TB	IRR	in	2050	
Shortest	
duration	
Revaccination	
duration	 Annotation	
Duration	of	
protection		 5	years	 10	years	 Consult	heat	maps	for	full	results.	
	
The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (20-29%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	
provide	 sufficient	 impact.	 For	 example,	with	 5	
years	duration	and	a	VE-POD	0%,	VE-POI	would	
need	to	be	90-100%.	With	VE-POI	0%,	a	VE-POD	
of	40-60%	would	be	required.	
Median	
VE-POD		
(range)	
40%	
(0-60%)	
10%	
(0-30%)	
Median	
VE-POI		
(range)	
60%	
(0-100%)	
50%	
(0-100%)	
	
Vaccine	
characteristic	
To	achieve	50-59%	TB	IRR	in	2050	
Shortest	
duration	
Revaccination	
duration	 Annotation	
Duration	of	
protection	 5	years	 10	years	
Consult	heat	maps	in	appendix	for	full	results.	
The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (50-59%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	
provide	 sufficient	 impact.	 For	 example,	with	 5	
years	duration	a	POI-only	vaccine	is	not	feasible,	
but	a	POD-only	vaccine	would	be	feasible	with	
VE-POD	100%.	
Median		
VE-POD		
(range)	
100%		
(100-100%)	
60%		
(40-70%)	
Median	
VE-POI		
(range)	
60%		
(0-100%)	
60%		
(0-100%)	
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Table	3.4	continued…	
Vaccine	
characteristic	
To	achieve	70-79%	TB	IRR	in	2050	
Shortest	
duration	
Revaccination	
duration	 Annotation	
Duration	of	
protection	 5	years	 10	years	
Consult	heat	maps	in	appendix	for	full	results.	
The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (70-79%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	
provide	sufficient	impact.	This	level	of	impact	is	
not	 possible	 with	 a	 5-year	 duration	 vaccine.	
However,	with	 10	 years	 duration	 a	 VE-POD	 of	
100%	would	be	required.	
Median		
VE-POD		
(range)	
n/a	 100%		(100-100%)	
Median	
VE-POI		
(range)	
n/a	 70%		(0-100%)	
	
3.4.2.3 Mortality	rate	reduction	compared	to	no	new	vaccine	baseline	in	2050	
Modelled	estimates	of	mortality	rate	reduction	(MRR)	in	2050	compared	to	the	no	
new	vaccine	baseline	were	similar	to	the	incidence	rate	reduction	estimates	in	terms	
of	 rate	 reduction	 and	 trends	 (Figure	 3.12).	 The	 MRRs	 for	 2-5	 years	 duration	 of	
protection	are	greater	 than	 the	equivalent	 incidence	 rate	 reductions,	whereas	 for	
seven	years	and	above	the	MRR	is	marginally	lower	than	the	incidence	rate	reduction.	
With	two	years	duration	of	protection	and	very	high	vaccine	efficacy	against	disease	
it	is	possible	to	achieve	a	MRR	of	22%	(UR:	20-23%),	and	with	5	years	protection	up	
to	55%	(UR:	53-58%).	
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Figure	3.12:	Median	mortality	rate	reduction	(%)	for	pre-	and	post-infection	vaccine	compared	to	no	new	vaccine	baseline	in	2050,	by	percentage	efficacy	against	
infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel).	Although	a	variety	of	durations	were	
explored,	2	years	(left	panel),	5	years	(centre	panel)	and	10	years	(right	panel)	duration	of	protection,	all	with	10-yearly	mass	vaccination	campaigns,	are	presented	here.	
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3.4.2.4 Cumulative	TB	cases	and	TB	deaths	averted	2025-2050		
Heat	maps	demonstrating	the	cumulative	number	of	cases	and	deaths	averted	2025-
2050	for	the	spectrum	of	vaccine	efficacies	and	durations	of	protection	of	2,	5	and	10	
years	 for	 P&PI	 vaccines	 can	 be	 found	 in	 Figure	 3.13	 and	 Figure	 3.14.	 A	 few	 key	
examples	are	given	below.	
A	P&PI	vaccine	with	100%	vaccine	efficacy	against	both	infection	and	disease	could	
avert	3.6	million	(UR:	3.1-3.9m)	cases	and	82,000	(UR:	45,000-147,000)	deaths	with	
two	years	duration	of	protection	(Figure	3.13	and	Figure	3.14,	left	panel),	7.7	million	
(UR:	6.7-8.4m)	and	173,000	(UR:	94,000-308,000)	deaths	with	five	years	protection	
(Figure	3.13	and	Figure	3.14,	centre	panel),	and	11.6	million	(UR:	10.2-12.6m)	cases	
and	270,000	(UR:	145,000-483,000)	deaths	by	2050	with	10	years	protection(Figure	
3.13	and	Figure	3.14,	right	panel).	At	the	lower	end	of	the	efficacy	spectrum,	a	vaccine	
with	20%	vaccine	efficacy	against	both	infection	and	disease	could	avert	1.0	million	
(UR:	0.8-1.1m)	cases	and	21,000	(UR:	11,000-38,000)	deaths	with	two	years	duration	
of	protection,	up	to	3.4	million	(UR:	3.0-3.9m)	cases	and	74,000	(UR:	40,000-135,000)	
deaths	with	10	years	duration	of	protection.		
A	vaccine	efficacy	of	60%	was	considered	an	achievable	target	with	new	vaccines,	
therefore	if	vaccine	efficacy	against	both	infection	and	disease	were	both	60%,	two	
to	ten	years’	protection	would	avoid	2.5	million	(UR:	2.2-2.7m)	to	8.2	million	(UR:	7.2-
9.1m)	 cases	 and	 56,000	 (UR:	 30,000-100,000)	 to	 185,000	 (UR:	 101,000-333,000)	
deaths	 during	 2025-2050.	 For	 a	 10	 year	 protection	 vaccine,	 if	 VE-POI	 were	 then	
increased	to	80%,	an	additional	0.2	million	cases	would	be	averted;	whereas	if	instead	
VE-POD	were	increased	to	80%,	an	additional	1.7	million	cases	would	be	averted.		
Additional	 years	 of	 protection	 would	 also	 avoid	 additional	 cases	 and	 deaths.	 For	
example,	for	a	100%	VE-POD	vaccine	the	average	annual	additional	number	of	cases	
averted	 when	 increasing	 duration	 from	 two	 to	 three	 years	 is	 1.5	 million.	 With	
increasing	 duration,	 the	 absolute	 number	 averted	 continues	 to	 increase,	 but	 the	
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additional	gains	per	year	added	are	smaller,	for	example,	increasing	from	seven	to	10	
years	protection	gains	on	average	0.7	million	additional	averted	cases	per	year.
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Figure	3.13:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2050	for	pre-	and	post-infection	vaccine	compared	to	no	new	vaccine	baseline,	by	
percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel).	Although	a	
variety	of	durations	were	explored,	2	years	(left	panel),	5	years	(centre	panel)	and	10	years	(right	panel)	duration	of	protection,	all	with	10-yearly	mass	vaccination	
campaigns,	are	presented	here.	
	
	133	
	
Figure	3.14:	Median	cumulative	number	of	deaths	averted	for	the	period	2025-2050	for	pre-	and	post-infection	vaccine	compared	to	no	new	vaccine	baseline,	by	
percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel).	Although	a	
variety	of	durations	were	explored,	2	years	(left	panel),	5	years	(centre	panel)	and	10	years	(right	panel)	duration	of	protection,	all	with	10-yearly	mass	vaccination	
campaigns,	are	presented	here.	
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3.4.2.5 Incidence	rate	reduction	and	cases	averted	by	2035	
Incidence	rate	reductions	were	estimated	 in	2035	(Figure	3.15),	 in	addition	to	the	
estimated	 cases	 averted	 for	 2025-2035	 (Figure	 3.16).	Overall,	 similar	 trends	were	
observed	in	terms	of	impact	achieved	by	prevention	of	infection	and	disease	efficacy	
characteristics	in	both	2035	and	2050.	However,	a	difference	was	seen	in	the	level	of	
reduction	achieved	and	patterns	by	duration	of	protection	between	these	two	time	
points.	When	 comparing	 the	 percentage	 incidence	 rate	 reduction	 to	 the	 no	 new	
vaccine	baseline	in	2035,	a	marginally	lower	incidence	rate	reduction	was	estimated	
for	 durations	 of	 five	 years	 and	 above,	 whereas	 a	 higher	 percentage	 reduction	 in	
incidence	rate	was	estimated	in	2035	than	2050	for	the	two	and	three	year	durations	
of	protection.	This	is	due	to	the	timing	of	vaccine	waning	relative	to	the	time	point	at	
which	 impact	 is	 measured.	 In	 2035,	 all	 vaccines	 had	 recently	 been	 boosted	 and	
therefore	populations	were	protected	in	all	duration	scenarios;	whereas	in	2050,	the	
shorter	vaccine	durations	had	already	waned	following	the	most	recent	(2045)	mass	
campaign.	
The	numbers	of	cases	averted	by	vaccination	2025-2035	are	shown	in	Figure	3.16.	In	
2035,	a	100%	vaccine	efficacy	two-year	duration	vaccine	could	avert	up	to	1.7	million	
(UR:	1.5-1.8m)	cases	(left	panel),	a	5-year	duration	vaccine	up	to	3.5	million	(UR:	3.1-
3.7m)	cases	(centre	panel),	and	a	10-year	duration	vaccine	up	to	5.6	million	(UR:	5.0-
6.0m)	cases	(right	panel).		
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Figure	3.15:	Median	incidence	rate	reduction	(%)	for	pre-	and	post-infection	vaccine	compared	to	no	new	vaccine	baseline	in	2035,	by	percentage	efficacy	
against	infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel).	Although	a	variety	
of	durations	were	explored,	2	years	(left	panel),	5	years	(centre	panel)	and	10	years	(right	panel)	duration	of	protection,	all	with	10-yearly	mass	vaccination	
campaigns,	are	presented	here.
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Figure	3.16:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2035	for	pre-	and	post-infection	vaccine	compared	to	no	new	vaccine	baseline,	by	
percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel).	Although	a	
variety	of	durations	were	explored,	2	years	(left	panel),	5	years	(centre	panel)	and	10	years	(right	panel)	duration	of	protection,	all	with	10-yearly	mass	vaccination	
campaigns,	are	presented	here.
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3.4.2.6 Achievable	impact	with	POI-only	or	POD-only	vaccines	
Incidence	rate	reductions	achieved	by	POD-only	(VE-POI=0%)	(Figure	3.17,	left	panel)	
and	 POI-only	 (VE-POD=0%)	 (Figure	 3.17,	 right	 panel),	 highlight	 again	 that	 for	
equivalent	profiles	the	achievable	impact	is	greater	with	a	POD	vaccine	than	POI.	
Assuming	 100%	 efficacy	 against	 disease	 (VE-POD=100%,	 VE-POI=0%),	 the	 10	 year	
duration	 of	 protection	 vaccine	 achieved	 78.4%	 (UR:	 76.6-80.4%)	 incidence	 rate	
reduction,	averting	11.6	(UR:	10.8-12.4)	million	cases	between	2025-2050.	Whereas	
with	 100%	 efficacy	 against	 infection	 (VE-POD=0%,	 VE-POI=100%)	 only	 27.6%	 (UR:	
23.0-34.7%)	 incidence	rate	reduction	would	be	expected,	averting	only	3.9	million	
cases	(UR:	3.6-4.1m).	The	number	of	cases	averted	by	a	100%	VE-POI	vaccine	were	
similar	to	a	POD-only	vaccine	with	a	vaccine	efficacy	of	approximately	20-30%	(Figure	
3.18).	
		
	
	
Figure	3.17:	Median	incidence	rate	reduction	for	pre-	and	post-infection	vaccine	compared	to	no	
new	vaccine	baseline	in	2050,	by	percentage	efficacy	against	disease	or	infection	(x-axes),	and	
duration	of	protection	(y-axis).	In	the	left	hand	panel,	efficacy	against	infection	was	held	at	zero	
(i.e.	POD-only),	and	in	the	right	hand	panel	efficacy	against	disease	was	held	at	zero	(i.e.	POI-only).	
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Figure	3.18:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2050	for	pre-	and	
post-infection	vaccine	compared	to	no	new	vaccine	baseline,	by	percentage	efficacy	against	
disease	or	infection	(x-axes),	and	duration	of	protection	(y-axis).	In	the	left	hand	panel,	efficacy	
against	infection	was	held	at	zero,	and	in	the	right	hand	panel	efficacy	against	disease	was	held	at	
zero.	
	
Taking	60%	vaccine	efficacy	as	a	more	realistic	efficacy	scenario	(Table	3.5),	a	POI-
only	vaccine	with	two	to	10	years’	protection	was	estimated	to	reduce	2050	incidence	
rates	by	2.9%	to	18.6%	and	avoid	0.8	to	2.5	million	cases.	The	equivalent	POD-only	
vaccine	was	estimated	to	provide	a	2050	incidence	rate	reduction	of	5.6%	to	53.3%	
and	avoid	2.2	to	7.5	million	cases,	up	to	three-times	as	many	cases	as	the	POI-only	
vaccine.	A	reduction	in	incidence	rate	of	at	least	20-29%	could	not	be	achieved	with	
a	60%	POI-only	vaccine	of	any	duration,	whereas	the	POD-only	vaccine	would	more	
than	achieve	this	with	a	vaccine	providing	5	years	protection.	
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Table	3.5:	Epidemiological	impact	of	POI-only	and	POD-only	vaccines	with	60%	vaccine	efficacy	
pre-	and	post-infection	
VE-POI	
(%)	
VE-POD	
(%)	
Duration	of	
protection	
(years)	
Percentage	incidence	
rate	reduction	in	2050	
compared	to	no	new	
vaccine	(uncertainty	
range)	
Millions	of	cases	
averted	2025-2050	
(uncertainty	range)	
60	 0	 2	 2.9	(2.4-3.8)	 0.8	(0.7-0.8)	
60	 0	 3	 4.3	(3.5-5.6)	 1.1	(1.0-1.1)	
60	 0	 5	 11.3	(9.3-14.6)	 1.6	(1.5-1.7)	
60	 0	 7	 17.0	(14.0-21.6)	 2.2	(1.9-2.6)	
60	 0	 10	 18.6	(15.4-23.7)	 2.5	(2.4-2.7)	
0	 60	 2	 5.6	(4.1-7.2)	 2.2	(1.9-2.4)	
0	 60	 3	 8.3	(6.1-10.6)	 3.1	(2.8-3.4)	
0	 60	 5	 31.7	(29.1-34.4)	 4.8	(4.4-5.1)	
0	 60	 7	 51.0	(48.8-53.2)	 6.0	(5.6-6.4)	
0	 60	 10	 53.3	(50.6-56.1)	 7.5	(7.0-8.1)	
	
3.4.2.7 Minimum	vaccine	efficacy	for	trial	design		
Assuming	the	‘worst	case’	scenario	for	duration	(5	years)	and	vaccine	efficacy	against	
disease	 (0%)	 and	 with	 vaccine	 efficacy	 against	 infection	 as	 a	 trial	 outcome,	 the	
benchmark	for	stage-gating	based	upon	VE-POI	was	estimated	to	be	100%	(90-100%)	
if	a	20-29%	reduction	in	incidence	rate	in	2050	was	required.	Conversely,	with	vaccine	
efficacy	against	disease	(VE-POD)	as	the	trial	outcome,	only	50%	(40-60%)	vaccine	
efficacy	would	be	required	to	be	confident	in	achieving	this	level	of	epidemiological	
impact.	With	 disease	 endpoints	 as	 the	 trial	 outcome,	 70%	 (60-80%)	 VE-POD	was	
estimated	 to	 provide	 confidence	 in	 achieving	 30-39%	 incidence	 rate	 reduction	 in	
2050,	 and	 up	 to	 50-59%	 reduction	 could	 be	 achieved	 with	 a	 vaccine	 blocking	
progression	to	disease	(VE-POD=100%).	With	vaccine	efficacy	against	infection	as	the	
outcome,	it	would	not	be	possible	to	be	confident	in	achieving	any	higher	IRR	than	
20-29%,	unless	the	vaccine	provided	more	than	5	years	duration	of	protection	or	VE-
POD	was	known.			
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3.4.2.8 Pre-infection	and	post-infection	vaccines	
The	 highest	 achievable	 incidence	 rate	 reduction	 with	 100%	 efficacious	 vaccines	
against	 both	 infection	 and	 disease	 (POI&D)	 with	 10	 years	 duration	 of	 protection	
compared	to	no	new	vaccine	baseline	in	2050	was	as	little	as	27%	(UR:	23-34%)	with	
a	pre-infection	vaccine,	whereas	with	a	post-infection	vaccine	achieved	71%	(UR:	70-
71%)	(Figure	3.19).	The	equivalent	P&PI	vaccine	reduced	incidence	rates	by	79%	(UR:	
77-81%).	These	were	associated	with	3.9	million	(UR:	3.5-4.7m),	9.3	million	(UR:	8.0-
10.4m)	and	11.6	million	(UR:	10.2-12.6m)	cumulative	cases	averted	between	2025	
and	2050	(See	Appendix	B	for	graphs).	
The	sensitivity	of	the	 incidence	rate	reduction	outcome	to	vaccine	efficacy	against	
disease	 and	 infection	 differ	 greatly	 between	 the	 three	 vaccine	 types.	 The	 post-
infection	 (PSI)	 vaccine	 contours	 are	 almost	 horizontal,	 indicating	 that	 the	 vaccine	
impact	comes	almost	exclusively	from	the	vaccine	efficacy	for	prevention	of	disease	
(Figure	 3.19,	 right	 panel).	 The	 incidence	 rate	 reduction	 outcome	 is	 much	 more	
sensitive	 to	both	 types	of	vaccine	efficacy	 for	a	PRI	vaccine	 (centre	panel),	with	a	
slightly	greater	sensitivity	to	vaccine	efficacy	for	prevention	of	infection.	Due	to	the	
large	 contribution	 of	 reactivation	 disease	 in	 already	 infected	 populations	 to	 the	
overall	burden,	the	P&PI	vaccine	heat	map	(left	panel)	most	closely	resembles	the	PSI	
results.	The	incidence	rate	reduction	heat	maps	for	PRI	and	PSI	vaccines	for	the	full	
range	of	durations	explored	are	provided	in	Appendix	B.	
Uncertainty	 ranges	 are	 provided	 for	 results	 throughout	 the	 text.	 In	 addition,	
uncertainty	ranges	 for	P&PI,	PRI	and	PSI	vaccines	 for	all	combinations	of	20%	and	
100%	for	both	vaccine	efficacies	and	durations	of	5	and	10	years	are	presented	in	
Figure	3.20.	
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Figure	3.19:	Median	incidence	rate	reduction	(%)	for	vaccines	compared	to	no	new	vaccine	baseline	in	2050,	by	percentage	efficacy	against	infection	(x-axis),	percentage	
efficacy	against	disease	(y-axis),	and	infection	status	of	protected	population	(as	indicated	in	top	left	corner	of	panel).	Pre-	and	Post-infection	(left	panel),	pre-infection	
(centre	panel)	and	post-infection	(right	panel)	vaccines,	all	with	10	years	of	protection	and	10-yearly	mass	campaigns,	are	presented	here.	
Incidence	rate	reduction		compared	to	2050	baseline	(%)	 0	 10	 20	 30	 40	 50	 60	 70	 80	 90	 100 
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Figure	3.20:	Medians	and	uncertainty	ranges	for	estimates	of	incidence	rate	reduction	in	2050	for	
combinations	of	durations	of	efficacy	of	5	years	and	10	years,	vaccine	efficacies	for	prevention	of	
infection	and	prevention	of	disease	of	20%	and	100%,	for	P&PI	(red),	PRI	(green)	and	PSI	(blue)	
vaccines.	
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3.4.2.9 Incidence	rate	reduction	in	2050	with	5-yearly	mass	campaigns	
Increasing	 the	 frequency	 of	 mass	 campaigns	 to	 every	 5	 years	 improved	 the	
achievable	 impact	 in	 all	 duration	 scenarios	below	10	 years	duration	of	protection	
(Figure	3.21).	For	the	two-year	duration	of	protection	vaccines,	the	IRR	more	than	
doubled	 (104-120%	 increase)	 when	 mass	 vaccination	 was	 conducted	 5-yearly	 as	
opposed	to	10-yearly.	For	3	to	7	year	duration	of	protection	vaccines,	the	incidence	
rate	reduction	achieved	increased	by	approximately	a	quarter	to	nearly	two	thirds.		
With	5-yearly	boosting,	even	the	shortest	duration	of	protection	explored	(2	years)	
was	 able	 to	 achieve	more	 than	 the	 absolute	minimum	 of	 20-29%	 incidence	 rate	
reduction.	 For	 20-29%	 incidence	 rate	 reduction,	 at	 least	 10%	 VE-POD	 is	 required	
(Table	3.6,	bottom	of	VE-POD	range),	so	a	prevention	of	infection-only	vaccine	could	
not	deliver	this	level	of	impact.	The	duration	at	which	the	achievable	impact	plateaus	
was	5	years,	for	which	the	results	for	VE-POI	and	VE-POD	are	almost	identical	to	the	
10-year	duration	vaccine	with	10-yearly	boosting	(Table	3.2	and	Table	3.6).		
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Figure	3.21:	Median	incidence	rate	reduction	(IRR,	%)	for	pre-	and	post-infection	vaccine	with	5-
yearly	mass	vaccination	campaigns	compared	to	no	new	vaccine	baseline	in	2050,	by	percentage	
efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	
protection	(as	indicated	in	top	left	corner	of	panel).		
	
Incidence	rate	reduction		compared	to	2050	baseline	(%)	 0	 10	 20	 30	 40	 50	 60	 70	 80	 90	 100 
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Table	3.6:	Median	and	range	of	vaccine	efficacies	required	to	achieve	20-80%	incidence	rate	reduction	(in	10%	steps)	in	2050	compared	to	no	new	vaccine	baseline	for	2	
and	5	year	durations	of	protection	and	5-yearly	mass	vaccination	campaigns	
Vaccine	
efficacy	
Median	 VE	 to	
achieve	20-29%	TB	
IRR	2050	(range)		
Median	 VE	 to	
achieve	30-39%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	40-49%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	50-59%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	60-69%	TB	
IRR	2050	(range)	
Median	 VE	 to	
achieve	70-79%	TB	
IRR	2050	(range)	
2	year	duration	vaccine	(with	5	year	mass	campaigns)	
VE-POD	 50%	(10-70%)	 70%	(50-90%)	 100%	(80-100%)	 Not	achievable	 Not	achievable	 Not	achievable	
VE-POI	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 Not	achievable	 Not	achievable	 Not	achievable	
5	year	duration	vaccine	(with	5	year	mass	campaigns)	
VE-POD	 10%	(0-30%)	 30%	(0-40%)	 40%	(20-50%)	 60%	(40-70%)	 90%	(80-100%)	 100%	(100-100%)	
VE-POI	 50%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 70%	(0-100%)	
Chapter	3:	Epidemiological	impact	of	TB	vaccine	characteristics																	 146	
3.5 Discussion	
3.5.1 Discussion	
A	 strategic,	 data-driven	 approach	 to	 the	development	 of	 new	TB	 vaccines	will	 be	
essential	to	ensure	evidence-based	maximisation	of	the	future	impact	of	TB	vaccines,	
by	 developing	 vaccines	 with	 the	 most	 appropriate	 characteristics	 and	 for	 the	
populations	most	in	need.	In	this	research,	I	explored	vaccine	intrinsic	characteristics	
in	the	target	product	profile	(duration	of	protection,	vaccine	efficacy	against	disease,	
and	 vaccine	 efficacy	 against	 infection)	 to	 estimate	 the	 potential	 population-level	
impact	 of	 new	 TB	 vaccines	 in	 China	 and	 to	 inform	 vaccine	 development	 directed	
towards	maximisation	of	impact	in	this	and	similar	settings.		
In	China,	vaccine	efficacy	for	prevention	of	disease	was	key	to	maximising	impact	on	
disease	burden	over	the	2025-2050	time	horizon,	and	provided	most	impact	when	
effective	post-infection	or	pre-	and	post-infection.	For	a	vaccine	effective	pre-	and	
post-infection	with	10-yearly	mass	campaigns,	at	least	5	years	duration	of	protection	
were	required	to	achieve	the	absolute	minimum	incidence	rate	reduction	of	20-29%	
in	 2050,	 and	 impact	 was	 maximised	 when	 mass	 campaign	 frequency	 equalled	
duration	of	protection.		
Required	 vaccine	 efficacies	 depend	 upon	 the	 minimum	 incidence	 rate	 reduction	
considered	acceptable,	but	medians	ranged	from	40%	to	100%	for	VE-POD	and	were	
mostly	50%	to	60%	for	VE-POI,	with	wide	ranges	around	both	due	to	the	different	
combinations	capable	of	achieving	such	impact,	given	these	two	characteristics	were	
correlated.	Impact	was	highly	sensitive	to	VE-POD	and	relatively	insensitive	to	VE-POI	
due	to	the	reactivation-driven	nature	of	the	epidemic	in	China.		
The	finding	that	duration	of	protection	of	5	years	would	be	required	with	10-yearly	
mass	campaigns	to	ensure	at	 least	20-29%	incidence	rate	reduction	has	 important	
implications	 for	 clinical	 trials.	Most	 efficacy	 studies	 plan	 for	 2-3	 years	 follow	 up,	
whereas	these	results	suggest	that	 follow	up	to	demonstrate	efficacy	of	at	 least	5	
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years	will	be	required.	Such	a	long	phase	IIB	or	phase	III	study	could	be	prohibitively	
expensive,	therefore	an	alternative	could	be	to	plan	for	a	2-3	year	efficacy	study	with	
clinical	or	immunological	follow	up	in	a	subset	of	patients	continued	up	to	5	years.	
Flexibility	would	be	required	in	the	trial	end	point,	with	selection	of	immunological	
versus	clinical	follow	up	contingent	upon	identification	of	a	correlate	of	protection.		
Alternatively,	 an	 implementation	 approach	 could	 be	 taken	 if	 longer	 trials	 are	 not	
feasible	 or	 a	 new	 vaccine	 is	 found	 to	 provide	 limited	 duration	 of	 protection.	 By	
increasing	 the	 frequency	of	mass	vaccination,	 the	 impact	of	vaccines	with	 shorter	
durations	of	protection	could	be	improved.	Assuming	mass	campaigns	every	5	years	
indicated	that	a	duration	of	protection	as	low	as	2	years	could	achieve	up	to	44%	(UR:	
42-46)	incidence	rate	reduction	in	2050,	assuming	100%	efficacy	against	infection	and	
disease.	The	same	impact	was	achieved	with	5	years	duration	of	protection	and	5-
yearly	mass	vaccination	as	with	10	years	duration	with	10-yearly	mass	vaccination,	
therefore	 shortfalls	 in	 duration	 of	 protection	 could	 be	 compensated	 for	 with	
increased	frequency	of	mass	campaigns,	as	long	as	coverage	is	maintained.	It	is	clear	
from	these	results	that	planning	for	longer	follow	up	in	clinical	trials	or	for	shorter	
intervals	between	mass	vaccination	campaigns	will	likely	be	necessary	to	maximise	
vaccine	impact,	and	should	be	planned	for	prospectively.	
Impact	 was	 maximised	 when	 mass	 campaign	 frequency	 equalled	 duration	 of	
protection.	As	expected,	durations	of	protection	longer	than	the	frequency	of	mass	
vaccination	(10	years)	did	not	provide	much	additional	epidemiological	gain.	In	these	
scenarios,	revaccination	occurred	at	the	duration	of	protection,	thus	the	proportion	
of	 the	 population	 protected	 was	 similar.	 From	 an	 epidemiological	 perspective,	
investment	in	longer	duration	vaccines	would	not	necessarily	be	needed;	however,	
cost-effectiveness	 analyses	 would	 be	 required,	 as	 less	 frequent	 mass	 campaigns	
could	lead	to	large	cost	savings.	
During	the	2025-2050	vaccination	period,	most	new	TB	cases	were	attributable	to	
reactivation	 disease,	 many	 of	 which	 were	 likely	 infected	 before	 introduction	 of	
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vaccine.	Hence,	 the	 incidence	 rate	 reduction	achieved	by	P&PI	vaccines	was	most	
sensitive	 to	 vaccine	 efficacy	 for	 prevention	 of	 disease,	 with	 limited	 gains	 from	
increases	 in	 efficacy	 against	 infection.	 Although	 there	 was	 value	 in	 efficacy	 for	
prevention	of	infection,	in	this	setting	greater	population-level	gains	were	achieved	
by	 improving	 vaccine	 efficacy	 for	 preventing	 development	 of	 disease.	 Therefore,	
development	 strategies	 for	 China	 and	 similar	 epidemics	 should	 aim	 to	 explore	
disease	outcomes	in	trials,	and	accelerate	development	of	candidate	vaccines	with	at	
least	some	anticipated	protection	against	disease.		
The	greatest	achievable	impact	with	the	vaccines	explored	reduced	incidence	rates	
in	 2050	 by	 79%	 (77-81%)	 compared	 to	 the	 no	 new	 vaccine	 baseline,	 reaching	 an	
incidence	rate	of	7	(UR:	6-8)	per	100,000	population	and	averting	11.6	million	(UR:	
10.2-12.6m)	 cases	 and	 270,000	 (UR:	 145,000-483,000)	 deaths	 by	 2050.	 This	 is	 a	
sizeable	burden	of	disease	averted,	and	would	be	a	significant	contribution	towards	
the	WHO	elimination	goal	(incidence	of	1	case	per	million	population	by	2050),37	as	
part	 of	 a	 package	 of	 TB	 control	 interventions.	 In	 contrast,	 two	 and	 three	 year	
durations	of	protection	with	10-yearly	mass	campaigns	would	deliver	less	than	20%	
incidence	rate	reduction,	and	if	coupled	with	low	vaccine	efficacies	(20%),	two-year	
duration	vaccines	would	avert	a	more	modest	1.0	million	(UR:	0.8-1.1m)	cases	and	
21,000	(UR:	11,000-38,000)	deaths	over	the	26	year	period.	Maximising	the	incidence	
rate	 reduction	 and	 cases	 averted	 should	 therefore	 be	 the	 strategic	 goal,	 but	 in	 a	
challenging	 development	 environment,	 identifying	 the	 minimum	 acceptable	
incidence	 rate	 reduction	 can	 inform	 vaccine	 characteristics	 in	 the	 TPP	 minimum	
profile,	and	hopefully	be	a	step	towards	more	efficacious	vaccines	in	the	future.		
Once	the	minimum	acceptable	incidence	rate	reduction	in	2050	has	been	chosen	by	
stakeholders,	 the	 appropriate	 section	 of	 Table	 3.4	 could	 be	 used	 within	 a	 target	
product	profile	or	preferred	product	characteristic	 table.	The	durations	to	achieve	
the	 absolute	 minimum	 impact	 and	 the	 duration	 above	 which	 minimal	 additional	
epidemiological	 gains	 could	 be	 achieved	 with	 10-yearly	 mass	 campaigns	 were	
identified	as	five	years	and	10	years	protection,	respectively,	and	are	therefore	the	
two	durations	reported.	For	these	two	durations	and	for	each	level	of	incidence	rate	
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reduction,	 the	median	 and	 range	 of	 vaccine	 efficacy	 estimates	 for	 prevention	 of	
infection	and	for	prevention	of	disease	were	estimated.	The	median	values	provide	
the	 set	 of	 characteristics	 that	 together	would	 likely	 provide	 the	 required	 level	 of	
protection	(e.g.	A	P&PI	vaccine	with	40%	VE-POD,	60%	VE-POI	and	5	years	duration	
of	protection	was	estimated	to	be	likely	to	provide	20-29%	IRR).		
Estimated	ranges	around	the	medians	reflect	the	characteristics	potentially	capable	
of	 delivering	 the	 required	 impact.	 These	 are	 wide	 and	must	 be	 interpreted	 with	
caution	 because	 the	 vaccine	 efficacy	 for	 prevention	 of	 infection	 and	 disease	 to	
provide	a	given	level	of	impact	are	correlated	(Table	3.4).	To	explore	an	example,	if	
an	IRR	of	20-29%	was	required	and	a	clinical	trial	conducted	with	a	vaccine	of	five	
years	duration	of	protection	with	only	infection	or	disease	as	an	endpoint,	either	type	
of	vaccine	could	potentially	deliver	this	level	of	impact	and	a	single-endpoint	study	
could	be	appropriate.	Though	it	should	be	noted	that	a	POI-only	vaccine	would	need	
to	have	a	vaccine	efficacy	of	90%-100%,	whereas	a	POD-only	vaccine	could	achieve	
this	impact	with	40-60%	vaccine	efficacy.	If	conducting	a	trial	only	measuring	VE-POI,	
there	 is	 a	 risk	 that	 a	 potentially	 suitable	 candidate	 could	 be	 discarded	 if	 VE-POD	
remained	unknown	and	VE-POI	were	 to	 fall	 below	 this	 high	 stage-gate	 threshold.	
Therefore,	in	China	trials	should	either	focus	on	VE-POD	endpoints,	or	include	both	
VE-POI	and	VE-POD	endpoints.	If	a	longer	duration	of	protection	were	expected	with	
a	 given	 vaccine,	 or	 both	 endpoints	 were	 measured	 and	 protection	 in	 both	 were	
anticipated,	lower	vaccine	efficacies	could	provide	sufficient	impact,	and	therefore	
studies	should	be	powered	to	measure	these	lower	efficacies.		
Target	 Product	 Profiles	 may	 be	 used	 for	 informing	 both	 clinical	 trial	 design	 and	
pipeline	 stage	 gating.	 Within	 the	 bounds	 of	 feasibility,	 clinical	 trials	 should	 be	
powered	 to	 detect	 the	 lowest	 vaccine	 efficacy	 that	 would	 provide	 sufficient	
population	level	impact.	Therefore,	TPP	vaccine	efficacies	can	inform	trial	endpoints	
and	sample	size.	 If	a	POI-	or	POD-alone	vaccine	would	be	 insufficient	to	reach	the	
target	impact,	both	endpoints	should	be	included	in	clinical	trials.		
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In	terms	of	stage	gating	after	a	study,	a	similar	approach	can	be	taken.	Once	clinical	
trial	data	are	available	to	provide	information	on	the	characteristics	of	a	new	vaccine,	
the	detailed	heat	maps	(e.g.	Figure	3.11)	can	allow	estimation	of	the	likely	impact	of	
a	 given	 vaccine.	 The	 estimated	 impact	 can	 be	 benchmarked	 against	 a	 minimum	
acceptable	 impact	 agreed	prospectively	by	 relevant	 stakeholders.	 If	 only	one	 trial	
endpoint	is	available	(i.e.	only	one	of	infection	or	disease),	it	may	be	preferable	to	
stage	gate	assuming	the	stringent	 ‘worst	case’	of	zero	vaccine	efficacy	against	the	
unmeasured	endpoint	to	give	confidence	to	developers	that	at	 least	the	minimum	
incidence	rate	 reduction	could	be	achieved	with	 that	vaccine,	potentially	higher	 if	
there	were	efficacy	against	the	unmeasured	outcome.	
Although	the	aim	of	this	research	was	not	to	rank	characteristics	against	one	another,	
the	incremental	benefit	from	a	percentage	increase	in	VE-POD	is	much	greater	than	
the	 same	 improvement	 in	 VE-POI.	 Therefore,	 in	 this	 epidemiological	 setting,	
prioritisation	 of	 P&PI	 candidates	 with	 potential	 for	 prevention	 of	 disease	 activity	
would	be	rational.		
A	 similar	 number	 of	 cases	were	 averted	with	 100%	 vaccine	 efficacy	 against	 both	
infection	and	disease	with	two	years	duration	of	protection,	as	was	estimated	with	
20%	vaccine	efficacy	against	each	and	10	years	duration	of	protection.	Therefore,	it	
is	 possible	 to	 compensate	 for	 lower	 vaccine	 efficacies	 with	 higher	 durations	 of	
protection	and	vice	versa,	but	would	require	potentially	large	compensatory	changes.	
The	additional	gains	from	an	additional	year	of	protection	from	a	vaccine	tend	to	be	
large	with	 higher	 efficacy	 vaccines,	 so	 exploring	more	 in-depth	what	 the	 relative	
benefits	of	longer	durations	compared	to	increasing	vaccine	efficacies	may	also	be	
informative	if	such	a	technical	trade-off	were	to	arise.	
Although	it	is	hoped	that	a	vaccine	effective	both	pre-	and	post-infection	(P&PI)	will	
be	developed	to	maximise	impact,	some	pipeline	candidates	may	only	be	effective	in	
one	of	these	populations.	It	would	make	only	a	small	difference	to	potential	incidence	
rate	reduction	by	2050	in	China	if	a	10	year	duration	post-infection	(PSI)	vaccine	were	
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developed	as	opposed	to	a	P&PI	vaccine	(IRR	71%	(UR:	70-71%)	versus	79%	(UR:	77-
81%),	respectively).	However,	a	pre-infection	(PRI)	vaccine	would	provide	much	less	
impact,	with	the	highest	achievable	incidence	rate	reduction	in	2050	as	little	as	27%	
(UR:	23-34%).	Although	the	P&PI	vaccine	was	a	combination	of	the	mechanisms	of	
protection	 from	 PSI	 and	 PRI	 vaccines,	 it	 is	 clear	 that	most	 impact	 from	 the	 P&PI	
vaccine	came	from	protection	against	disease	in	those	already	infected,	which	was	
consistent	with	baseline	 epidemiological	model	 outcomes	demonstrating	 that	 the	
majority	of	cases	in	China	were	reactivation	disease.	A	post-infection	vaccine	should	
be	 developed	 following	 a	 similar	 prevention	 of	 disease-focussed	 strategy	 as	 P&PI	
vaccines.	The	pre-infection	vaccine	was	almost	equally	sensitive	to	efficacy	against	
infection	 or	 disease,	 therefore	 clinical	 trials	 could	 benefit	 from	 including	 both	
endpoints	to	gauge	the	full	potential	of	such	vaccines.	
Incidence	rate	reductions	in	2050	were	the	primary	outcome	of	interest	in	this	study.	
However,	 several	 secondary	 outcomes	 helped	 provide	 a	 broader	 picture	 of	 the	
impact	of	the	vaccine	profiles.	Estimated	mortality	rate	reductions	were	similar	to	
the	 incidence	 rate	 reductions,	 with	 the	 exception	 of	 durations	 of	 five	 years	 and	
below,	in	which	mortality	rate	reductions	were	larger.	This	is	a	function	of	timing	of	
the	 last	 mass	 campaign	 (2045)	 before	 outcome	 measurement	 in	 2050.	 Shorter	
vaccines	(£5	years)	wane	before	the	end	of	2050,	causing	an	incidence	rate	rebound;	
whereas	the	mortality	rebound	occurs	after	a	lag,	given	that	deaths	occur	some	time	
after	the	development	of	disease.	For	seven	years	protection	and	above,	a	slightly	
higher	incidence	rate	reduction	than	mortality	rate	reduction	is	observed,	likely	due	
to	 the	 fact	 that	 an	 individual	 can	be	protected	 from	 recurring	 incident	 cases,	 but	
death	can	only	be	avoided	once.	A	similar	pattern	was	observed	when	comparing	
incidence	 rate	 reductions	 in	2035	 to	2050.	Mass	 vaccination	occurred	 in	2035,	 so	
unlike	2050	none	of	the	vaccines	had	waned	in	2035	(not	shown).		
Given	 the	 incidence	 rate	 reduction	 is	 sensitive	 to	 the	 relative	 timing	 of	 the	 last	
vaccination	 and	 the	 outcome	measurement,	 the	 number	 of	 cases	 averted	 by	 the	
different	profiles	may	also	be	of	interest	for	decision	making.	The	number	of	cases	
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and	deaths	averted	for	all	of	the	profiles	are	demonstrated	in	heat	maps	in	Figure	
3.13	and	Figure	3.14	and	 range	 from	around	1.0	million	 (UR:	0.8-1.1m)	cases	and	
21,000	 (UR:	 11,000-38,000)	 deaths	up	 to	 11.6	million	 (UR:	 10.2-12.6m)	 cases	 and	
270,000	(UR:	145,000-483,000)	deaths	during	the	2025-2050	vaccination	period.		
Discussion	with	stakeholders	suggested	that	shorter	five-year	spacing	between	mass	
campaigns	 could	 be	 feasible	 in	 some	 settings.28	 Reducing	 the	 frequency	 of	 mass	
campaigns	 from	 10-yearly	 to	 5-yearly	 more	 than	 doubled	 the	 incidence	 rate	
reduction	achieved	by	2	year	protection	vaccines,	and	also	improved	the	incidence	
rate	 reductions	 achieved	 by	 the	 3-7	 year	 protection	 vaccines.	 Conducting	 mass	
campaigns	 this	 frequently	 over	 the	 long	 term	 could	 potentially	 prove	 incredibly	
costly,	and	a	challenge	to	sustain	momentum	in	the	campaigns,	especially	as	burden	
of	 disease	 declines.	 However,	 annual	mass	 campaigns	 of	 1-29	 year	 olds	with	 the	
Menafrivac	vaccine	achieved	very	high	coverages	year	on	year.33	Therefore,	if	a	short	
duration	vaccine	were	developed	and	cost-effectiveness	analyses	were	 to	 suggest	
that	5-yearly	mass	campaigns	were	cost	effective,	there	may	be	value	in	considering	
more	frequent	mass	campaigns.	
3.5.2 Research	in	context	of	existing	literature	
As	discussed	in	Chapter	2,	this	research	need	was	 identified	as	no	existing	models	
had	 comprehensively	 explored	 the	 influence	 of	 vaccine	 characteristics	 on	
epidemiological	impact.	Such	research	is	needed	to	help	maximise	vaccine	impact	by	
informing	 Target	 Product	 Profile	 ‘ideal’	 characteristics,	 and	 ensuring	 at	 least	 a	
minimum	required	 level	of	 impact	by	helping	 inform	 ‘minimum’	characteristics.	 In	
addition,	 only	 two	 mathematical	 models	 had	 explored	 vaccine	 impact	 with	 very	
limited	 vaccine	profiles	 in	 China,	 yet	 this	 is	 a	 high	priority	 country	 given	 the	high	
burden	of	disease	and	the	existence	of	a	candidate	in	phase	III	trials.		
The	results	of	this	research	support	the	existing	literature,8	suggesting	that	efficacy	
for	prevention	of	disease	is	likely	to	provide	greatest	impact	and	more	rapidly	than	
prevention	of	 infection	vaccines.	The	 literature	to-date	was	divided	as	 to	whether	
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vaccines	 effective	 pre-infection	 or	 post-infection	would	 provide	 greatest	 impact.8	
Results	of	the	China	sub-model	in	Dye	(2013)	indicated	that	post-infection	vaccines	
delivered	to	latent	individuals	would	provide	greatest	protection,	but	as	discussed	in	
Chapter	2,	were	interpreted	with	caution	given	few	model	or	vaccine	details	were	
available.	 In	 the	 China	 model	 presented	 in	 this	 chapter,	 results	 supported	 the	
conclusions	 of	 the	 Dye	 study,	 as	 vaccines	 effective	 post-infection	 very	 clearly	
provided	greatest	epidemiological	impact.	This	was	due	to	the	large	and	increasing	
proportion	of	cases	arising	from	reactivation	of	latent	infection.		
Research	preceding	this	work	by	Knight	et	al.	explored	the	impact	of	adolescent/adult	
vaccination.1	Results	were	reported	at	the	global	and	income	level,	but	was	calibrated	
to	overall	TB	incidence	and	mortality	by	country	in	2009	and	the	population	size	in	
2009	 and	 2050.	 The	mass	 vaccination	 coverage	 assumption	 for	 China	 (73%)	 was	
similar	 to	 the	assumption	 in	our	model,	but	 routine	coverage	was	assumed	much	
higher,	 at	 99%	 routine	 coverage	 of	 neonates	 or	 10	 year	 olds.	 The	 upper-middle	
income	country	(UMIC)	group,	which	included	China,	experienced	a	42.4%	(UR:	30.8-
54.9%)	reduction	in	number	of	cases	2024-50	with	introduction	of	a	60%	efficacious	
P&PI,	all-or-nothing	prevention	of	disease	vaccine	delivered	to	adolescents/adults.	In	
my	study,	I	report	percentage	reduction	in	incidence	rates,	as	opposed	to	number	of	
cases,	but	results	for	the	most	similar	vaccine	are	within	the	same	region	of	impact	
(53.3%;	 UR:	 50.6-56.1).	 In	 the	 Knight	 study,	 approximately	 8	 million	 cases	 were	
averted	 across	 all	 UMICs	with	 this	 vaccine,	 and	 in	 this	 research	 an	 estimated	 7.5	
million	were	averted	in	China	alone.	
Two	new	studies	have	been	published	since	this	research	was	conducted.	The	first	
explored	the	impact	of	new	TB	vaccines	in	China	during	2018-2035,38	and	the	second	
was	 a	 global	 model	 exploring	 the	 importance	 of	 age-specificities	 in	 TB	 vaccine	
modelling.39		
The	Liu	study	compared	neonatal	vaccination	to	neonatal	plus	periodic	mass	all-age	
vaccination	 (‘mixed	 vaccination’)	 in	 China.38	 The	 mass	 revaccination	 frequencies	
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explored	were	mostly	shorter	(3-6	years)	than	were	considered	feasible	in	my	study	
(5-10	years).	Mass	campaign	coverages	were	 lower	 (10-40%)	 in	 the	Liu	 study,	but	
were	 coupled	 with	 very	 high	 routine	 neonatal	 coverage	 (70-95%),	 and	 optimistic	
vaccine	 characteristics	 (100%	 lifetime	 efficacy	 against	 infection)	 and	 timing	 of	
introduction	(2018).	Although	the	neonatal	campaigns	delivered	minimal	impact,	the	
mixed	vaccination	campaigns	initiated	in	2018	were	able	to	achieve	the	2035	WHO	
goal	 of	 an	 incidence	 rate	 of	 less	 than	 10	 cases	 per	million	 population.	 The	 100%	
efficacious	POI	vaccine	in	this	chapter	achieved	only	a	27%	(UR:	23-33%)	reduction	
compared	 to	 the	 no	 vaccine	 scenario	 by	 2035,	 but	 the	 comparatively	 greater	
incidence	reduction	in	the	Liu	study	was	due	to	the	very	optimistic	implementation,	
efficacy,	and	duration	of	protection	assumptions.	In	addition,	the	lack	of	relapse	after	
recovery	 from	 disease	 in	 the	 Liu	 model	 likely	 underestimates	 future	 burden	 of	
disease	(see	section	4.3.6.9).	
The	Arregui	model	compared	neonatal	to	adolescent	vaccination	(15	year	olds).39	The	
vaccine	modelled	was	a	POI-only	vaccine	and	allowed	development	of	disease,	 so	
behaved	as	a	 ‘leaky’	vaccine.	As	will	be	discussed	 in	more	depth	 in	Chapter	4,	the	
results	 of	 the	 Arregui	 model	 demonstrate	 the	 importance	 of	 age-structured	
models,39	including	demographic	structure	and	heterogeneous	contact	patterns	by	
age,	therefore	supporting	the	decision	taken	to	create	such	a	highly	age	structured	
model	in	this	research.	This	age	structure	is	particularly	important	for	investigation	
of	vaccine	age	targeting	to	adolescents	compared	to	older	adults	in	Chapter	4	of	this	
thesis.	
3.5.3 Study	Strengths	
This	is	the	first	study	to	provide	an	in-depth	exploration	of	the	impact	of	such	a	wide	
range	of	vaccine	efficacies,	durations	of	protection,	and	vaccination	populations	(pre-	
and	post-infection).	It	is	also	the	first	to	explore	TB	vaccine	efficacies	against	infection	
and	disease	 in	 combination,	 and	 the	 first	China	model	 to	explore	a	more	 realistic	
array	of	vaccine	characteristics.	Such	a	comprehensive	exploration	of	characteristics	
provides	a	unique	data	set	to	identify	the	characteristics	and	vaccination	populations	
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required	to	maximise	vaccine	impact,	and	also	to	identify	the	characteristics	required	
to	achieve	a	minimum	acceptable	 level	of	 impact	 to	 inform	TB	vaccine	TPPs,	help	
inform	 clinical	 trial	 design	 (e.g.	 sample	 size	 and	 endpoints)	 and	 selection	 of	
recruitment	populations.	As	more	clinical	trial	data	become	available,	model	outputs	
can	be	used	to	predict	future	impact	of	pipeline	vaccines.	
Age-specificities	of	the	model	are	discussed	in	more	depth	in	Chapter	4,	but	it	is	worth	
mentioning	that	the	model	is	highly	reflective	of	the	age	structure	of	the	population	
and	 of	 the	 TB	 epidemic	 in	 China.	 Particularly	 important	 in	 developing	 such	 age	
structured	 projections	 were	 the	 calibration	 to	 age-stratified	 demographic	 and	
epidemiological	data,	through	age	structure	in	the	modelled	parameters,	 including	
age-wise	 contact	 patterns.	 At	 time	 of	 development,	 this	 was	 the	 first	 TB	 vaccine	
model	 to	 incorporate	heterogeneous	mixing	patterns	by	age.	A	 recent	publication	
has	 also	 incorporated	mixing	 patterns,	 but	 used	 European	 data	 for	 global	mixing	
patterns,39	whereas	 in	 this	model	 I	 improve	on	 this	by	using	contact	pattern	data	
specific	to	China.15		
3.5.4 Study	Limitations	
There	 were	 several	 limitations	 to	 this	 study,	 most	 of	 which	 relate	 to	 model	
assumptions	discussed	elsewhere,	but	are	mentioned	again	below.			
The	model	is	calibrated	to	a	series	of	age-stratified	country-level	data.	The	mortality	
rate	 estimates	 for	 China	 are	 relatively	 low	 given	 the	 disease	 rates,	 therefore	 to	
achieve	a	model	fit,	wide	mortality	rate	confidence	interval	targets	for	calibration	and	
a	relatively	low	case	fatality	rate	were	assumed.	This	should	have	minimal	impact	on	
the	 percentage	 mortality	 rate	 reduction,	 but	 means	 estimates	 of	 the	 number	 of	
deaths	averted	is	likely	an	underestimate.	
The	model	 assumes	geographically	homogenous	TB	epidemiology	 in	China,	 yet	 as	
highlighted	by	Gao	et	al.	this	is	known	not	to	be	the	reality.	At	this	stage	in	vaccine	
development,	 the	 regional	 level	 of	 granularity	 is	 not	 required	 for	 vaccine	
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development	 decision-making	 and	 was	 therefore	 not	 required	 from	 this	 model.	
However,	 once	 a	 vaccine	 is	 available,	 regional	 tailoring	 of	 this	 model	 could	 be	
valuable	for	evidence-informed	decision	making	for	implementation	at	the	regional	
level.		
In	terms	of	the	model	parameters,	it	was	assumed	that	the	rates	of	progression	to	
active	 TB	 remained	 constant	 throughout	 the	 study	 period.	 However,	 given	
socioeconomic	 improvements	 over	 time,	 this	 approach	 might	 underestimate	 the	
progression	rates	in	the	earlier	years	and	overestimate	them	in	to	the	future.		
In	 the	 current	 model	 structure,	 when	 recovered	 populations	 are	 reinfected	 they	
either	 develop	 primary	 disease	 or	 return	 to	 the	 latent	 state.	 Although	 this	 is	 an	
acceptable	assumption,	remaining	in	the	recovered	state	instead	of	returning	to	the	
latent	state	could	be	a	possible	alternative	assumption.	Given	the	reactivation	rates	
in	 recovered	 populations	 are	 generally	 assumed	 higher,	 this	 would	 likely	 lead	 to	
higher	 projected	 TB	 reactivation	 and	 burden	 estimates,	 therefore	 increasing	 the	
importance	of	vaccines	for	preventing	infected	populations	against	development	of	
disease.	
Case	detection	and	successful	treatment	was	assumed	to	occur	in	one	time	step,	and	
lead	 to	 entering	 the	 recovered	 state.	 Given	 the	majority	 of	 cases	 on	 appropriate	
treatment	 are	 thought	 to	 become	 non-infectious	 by	 two	 weeks	 on	 treatment,	
compared	 to	 the	 six-month	 time	 step	 of	 the	 model,	 this	 was	 considered	 an	
appropriate	assumption.	However,	those	not	detected	and	successfully	treated	enter	
the	prevalent	state,	and	unless	transitioning	from	non-infectious	to	infectious	TB,	do	
not	experience	another	opportunity	for	treatment.	Such	details	of	the	care	cascade	
are	beyond	the	scope	of	this	research	question,	but	could	be	approached	in	further	
work,	especially	if	MDR	TB	were	to	become	a	focus	of	the	research	questions.		
There	 are	 many	 unknowns	 in	 the	 implementation	 of	 these	 vaccines,	 therefore	
standardised	assumptions	with	regards	to	delivery	parameters	such	as	coverage,	age	
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of	vaccination	and	frequency	of	mass	vaccination	have	been	made.	It	is	unlikely	that	
all	 adults	 would	 be	 vaccinated	 in	 mass	 campaigns,	 as	 some	 tailoring	 by	 local	
epidemiology	would	be	likely.	However,	the	all-age	mass	campaigns	were	selected	to	
ensure	coverage	of	the	epidemiological	peak(s),	therefore	if	adolescent	and/or	adult	
targeting	were	conducted	based	upon	robust	evidence	of	the	epidemiological	peak,	
it	would	be	expected	 that	 the	overarching	 conclusions	presented	here	would	 still	
hold.	A	second	frequency	of	mass	vaccination	is	considered	in	the	scenario	analysis,	
but	others	may	be	possible	once	more	information	about	a	new	candidate’s	duration	
of	 protection	 and	 efficacy	 is	 known.	 As	 demonstrated	 in	 the	 scenario	 analysis,	
frequency	 of	 mass	 vaccination	 can	 have	 a	 substantial	 impact	 on	 the	 achievable	
population-level	impact	of	shorter	duration	vaccines.	
Modelled	 estimates	 of	 the	 median	 vaccine	 efficacy	 assumed	 10-yearly	 mass	
campaigns,	 and	 were	 made	 for	 the	 duration	 allowing	 the	 minimum	 acceptable	
impact	(5	years	protection)	and	the	duration	above	which	minimal	epidemiological	
gains	 were	 made	 (10	 years).	 However,	 if	 more	 frequent	 mass	 campaigns	 were	
considered	beneficial	and	affordable,	lower	vaccine	efficacies	could	be	acceptable,	as	
was	demonstrated	in	the	scenario	analysis.	Also,	if	a	higher	minimum	level	of	impact	
were	 required,	a	higher	duration	of	protection	may	be	 required	 for	 calculation	of	
vaccine	efficacy	medians.	This	could	be	explored	in	an	additional	analysis	if	needed.	
The	time	horizon	of	vaccine	implementation	may	be	important	for	model	outcomes.	
As	discussed	in	the	systematic	review	of	TB	vaccine	models	(Chapter	2),8	longer	time	
horizons	 can	 potentially	 influence	 the	 relative	 impact	 of	 pre-	 and	 post-infection	
vaccines,	 as	 even	 though	 post-infection	 vaccines	may	 have	 greater	 initial	 impact,	
impact	with	pre-infection	vaccines	increases	with	longer	time	horizons.		
The	results	presented	here	are	representative	of	the	Chinese	epidemic,	which	is	an	
epidemic	driven	by	reactivation	disease	in	an	ageing	population	that	has	experienced	
high	historical	exposure.	These	results	may	be	generalisable	to	other	similar	settings,	
such	as	other	high	burden	ageing	epidemics	(e.g.	Thailand,	Russia),	but	it	should	be	
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noted	that	the	relative	impact	of	different	characteristics	is	likely	to	differ	in	other	
epidemiological	scenarios,	and	will	be	investigated	in	the	planned	continuation	of	this	
work	exploring	vaccine	impact	in	India	and	South	Africa.	
3.5.5 Implications	for	vaccine	development	and	policy	
This	 research	 highlights	 the	 need	 for	 careful	 consideration	 of	 the	 criteria	 for	 key	
vaccine	 characteristics	 such	 as	 duration	 of	 protection	 (keeping	 feasible	
implementation	 in	 mind),	 and	 vaccine	 efficacy	 against	 infection	 or	 disease	 when	
developing	TB	vaccine	Target	Product	Profile	and	Clinical	Development	Plans.	
For	 development	 strategists,	 such	 as	 BMGF,	 WHO,	 cross-product	 bodies	 and	
developers,	 a	 key	 implication	 of	 this	 research	 is	 the	 importance	 of	 efficacy	 for	
prevention	of	disease	for	maximising	impact	on	disease	burden	in	China	during	2025-
2050.	 Although	 there	 was	 some	 value	 in	 prevention	 of	 infection,	 vaccine	
development	 strategies	 for	 China	 and	 similar	 epidemics	 should	 aim	 to	 accelerate	
development	of	candidate	vaccines	with	at	least	some	anticipated	protection	against	
disease.	
There	are	several	implications	of	these	results	for	clinical	trial,	clinical	development	
plan	and	stage	gate	design,	relevant	to	development	strategists	and	clinical	triallists.	
Some	higher	 levels	of	 incidence	 rate	 reduction	were	only	achievable	with	at	 least	
some	vaccine	efficacy	against	disease.	Therefore,	an	infection	outcome	would	not	be	
sufficient	to	guarantee	these	higher	levels	of	impact.	If	high	levels	of	incidence	rate	
reduction	are	 required	 for	 stage	gating,	disease	outcomes	 should	be	measured	 in	
clinical	trials,	or	preferably	both	infection	and	disease	outcomes.	The	vaccine	efficacy	
required	for	a	“go”	decision	when	stage	gating	will	most	likely	be	higher	if	only	one	
outcome	is	measured	in	a	clinical	trial	(i.e.	infection	or	disease),	as	if	both	outcomes	
are	measured	a	non-zero	efficacy	 in	the	second	outcome	can	reduce	the	required	
efficacy	in	the	first.		
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To	achieve	an	absolute	minimum	incidence	rate	reduction	of	20-29%,	at	least	5	years	
protection	will	be	required	if	mass	campaigns	are	every	10	years.	Therefore,	clinical	
trials	should	be	designed	to	provide	data	on	duration	of	protection	beyond	the	usual	
2-3	years	of	 a	phase	 IIB	 trial.	 For	example,	phase	 II	 clinical	 trials	 could	 include	an	
extended	 immunological	 or	 infection/disease	 outcome	 follow-up	 in	 a	 subset	 of	
participants.	Alternatively,	if	longer-term	follow	up	data	are	unavailable	at	licensure,	
or	the	duration	of	protection	of	a	product	is	known	to	be	short,	the	results	of	this	
model	have	implications	for	decisions	by	country-level	decision	makers,	as	planning	
for	 more	 frequent	 revaccination	 campaigns	 will	 be	 critical	 to	 ensure	 the	 desired	
population	level	impact	is	achieved.		
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3.6 Supplementary	materials:	Chapter	3	
3.6.1 Additional	methods:	Model	equations		
The	 series	 of	 difference	 equations	 comprising	 the	 vaccinated	 and	 unvaccinated	
model	strata	are	provided.	The	first	set	of	equations	is	valid	for	all	time	steps	except	
that	at	the	start	of	the	year.	The	second	section	provides	equations	for	the	first	time	
step	of	the	year,	and	includes	ageing,	vaccination	and	vaccine	waning.	
The	equations	 for	 the	 five	M.tb	 sub-populations	 (uninfected	 (susceptible),	 latently	
infected,	infectious	active	disease,	non-infectious	active	disease,	and	recovered)	in	
year	k,	time	step	i	and	age	j	are	provided.	The	size	of	the	time	step	is	dt,	which	in	this	
research	was	selected	as	0.5	years	as	a	balance	between	sufficient	granularity	and	
computing	time/capacity.	The	time	step	in	the	model	is	given	by	i = #$(&'()'	+,()).' + 1	
for	the	first	time	step	of	the	year	and	i = #$(&'()'	+,()).' + 2	for	the	second	time	step	
of	the	year.		
New-borns	(births)	in	year	k	(B[k])	entered	the	population	as	uninfected	at	the	start	
of	 the	 year.	 Life	 span	 was	 limited	 to	 no	 more	 than	 100	 years.	 Following	 the	
methodology	 of	 Schenzle	 (1984),40	 ageing	 was	 implemented	 in	 the	 model	 on	 an	
annual	basis	by	transitioning	the	population	in	a	given	sub-population	of	age	j,	to	the	
same	sub-population	of	age	j+1	at	the	very	end	of	each	year.	
For	the	baseline	scenario	of	no	vaccination,	23, 25, 26 	and	d	were	set	to	zero.	In	the	
vaccine	scenarios,	vaccination	was	delivered	by	setting	the	relevant	theta	to	a	non-
zero	value	equal	to	vaccine	coverage	for	the	appropriate	age	groups	during	the	first	
time	step	of	each	vaccination	year.	
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Transmission	
7 8, 9 = :;<= : >, ? @ A 8, ? + AB 8, 9C 8, ?DEFDGHIDEJ 	
Where	 C 8, ? = 	 K 8, 9 + L 8, 9 + A 8, 9 + MA 8, 9 + N 8, 9 + KB 8, 9 +OEOPQROEOPSFLB 8, 9 + AB 8, 9 + MAT 8, 9 + NB 8, 9 .	
nygrp	was	the	number	of	contact	age	groups,	m	was	the	age	group	of	the	individual	
exposed	 to	 infection	 (including	 age	 j),	 y	was	 age	 group	 of	 contacts,	:[>, ?] 	was	
number	of	respiratory	contacts	of	age	group	m	with	contacts	of	age	group	y,	:;<=	
was	the	calibration	factor	for	model	fitting,	@	was	the	probability	of	transmission	per	
respiratory	 contact	 between	 an	 infectious	 active	 case	 and	 a	 susceptible	 person	
(which	is	later	scaled	for	protection	afforded	by	latent	infection),	and	jmin	and	jmax	
were	the	lower	and	upper	bounds	of	age	classes	within	a	contact	age	group	(y).	
Ageing	was	implemented	using	the	method	of	Schenzle	(1984).40	In	the	first	time	step	
(i)	of	any	given	year,	the	updated	values	for	populations	of	age	j	were	functions	of	
those	aged	one	year	younger	(j-1)	in	the	previous	time	step	(i-1).		
CDR[k,j]	was	the	case	detection	rate	(proportion)	for	year	k	in	age	j,	and	CoT[k]	was	
the	proportion	of	detected	cases	that	were	treated	successfully	in	a	given	year.	
Vaccination	 2 	and	waning	of	protection	(d)	were	assumed	to	occur	in	the	first	time	
step	of	a	given	year.	 In	the	middle	of	 the	year,	 the	only	transitions	 for	vaccinated	
populations	were	between	states	within	the	vaccinated	stratum.	As	the	vaccine	was	
modelled	 as	 ‘leaky’,	 all	 those	 receiving	 vaccine	 were	 moved	 to	 the	 vaccinated	
stratum,	thus	2Q[9, W]	was	equal	to	percentage	coverage	for	age	group	j	of	infection	
state	a	in	year	k.	Here,	X[8, 9]	is	the	risk	of	ending	vaccine	protection	at	time	step	i	
and	age	j.	The	vaccinated	terms	are	not	multiplied	by	dt	as	they	only	occur	at	set	time	
steps	in	the	year.		
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The	parameters	affected	by	vaccination	depended	upon	the	vaccine	type.	Prevention	
of	infection	vaccines	with	vaccine	efficacy	effI	reduced	infection	rates	(7)	by	1-effI,	
and	 prevention	 of	 disease	 efficacy	 (effD)	 reduced	 the	 parameters	 for	
reactivation/relapse	from	latency	and	recovered	(v	and	r)	and	proportion	developing	
primary	active	disease	(p)	by	1-effD.	For	vaccines	only	efficacious	when	delivered	pre-
infection	 (PRI),	25	and	26	were	 zero.	 For	 vaccines	 only	 efficacious	when	 delivered	
post-infection	(PSI),	23	was	zero,	therefore	KB 	remained	at	zero.	For	those	vaccines	
efficacious	both	pre-	and	post-infection,	the	vaccine	was	delivered	to	all	groups	that	
did	 not	 have	 active	 disease	 (i.e.	 non-zero	 and	 equal	 numbers	 for	23, 25	and	26 ).	
Transitions	 between	 the	 vaccinated	 and	unvaccinated	 active	 disease	 classes	were	
unidirectional,	only	occurring	upon	waning	of	protection.	
Time	steps	NOT	the	first	time	step	of	the	year	
Unvaccinated	(non-first	time	step)	
Susceptibles	
K 8, 9 	= 	K 8 − 1, 9 −	(] 9 + 7 8 − 1, 9 )K 8 − 1, 9 X^	
Latent	
L 8, 9 	= 	L 8 − 1, 9 + 7 8 − 1, 9 1 − _[9] K 8 − 1, 9 + `N 8 − 1, 9 X^−	 a 9 + 7 8 − 1, 9 _ 9 ` + ][9] L 8 − 1, 9 X^	
New	infectious	active	TB	cases	
bcd_A 8, 9 = 	7 8 − 1, 9 _ 9 f 9 K 8 − 1, 9 + `L 8 − 1, 9 + `N 8 − 1, 9 X^+ 	a 9 f 9 L 8 − 1, 9 X^ + g 9 f 9 N 8 − 1, 9 X^ + dMA 8 − 1, 9 X^	
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New	non-infectious	active	TB	cases	
bcd_MA 8, 9 = 	7 8 − 1, 9 _ 9 (1− f 9 ) K 8 − 1, 9 + `L 8 − 1, 9 + `N 8 − 1, 9 X^ + 	a 9 (1− f 9 )L 8 − 1, 9 X^ + g 9 (1 − f 9 )N 8 − 1, 9 X^	
Infectious	active	TB	cases	
A 8, 9 = A 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W] bcd_A 8, 9−	 b 9 + ] 9 + ]8[9] A 8 − 1, 9 X^	
Non-infectious	active	TB	cases	
MA 8, 9 = MA 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MA 8, 9−	 b 9 + ] 9 + ]b8 9 + d MA 8 − 1, 9 X^	
Recovered	
N 8, 9 = N 8 − 1, 9 + 	b 9 A 8 − 1, 9 + MA 8 − 1, 9 X^+	 hiN[W, 9]×hkC[W] bcd_A 8, 9 + c×bcd_MA 8, 9−	 g 9 + 7 8 − 1, 9 ` + ][9] N 8 − 1, 9 X^	
	
Vaccinated	(non-first	time	step)	
Vaccinated	susceptibles	
KB 8, 9 	= 	 KB 8 − 1, 9 −	 ] 9 + (1 − cffA 7 8 − 1, 9 )KB 8 − 1, 9 X^	
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Vaccinated	latent	
LB 8, 9 	= 	 LB 8 − 1, 9+ 1 − cffA 7 8 − 1, 9 1 − 1 − cffi _[9] KB 8 − 1, 9+ `NB 8 − 1, 9 X^−	 1 − cffi a 9 + 1 − cffA 7 8 − 1, 9 × 1 − cffi _ 9 `+ ][9] LB 8 − 1, 9 X^	
New	vaccinated	infectious	active	TB	cases	
bcd_AB 8, 9 = 	 1 − cffA 7 8 − 1, 9 1 − cffi _ 9 f 9 KB 8 − 1, 9+ `LB 8 − 1, 9 + `NB 8 − 1, 9 X^+	 1 − cffi a 9 f 9 LB 8 − 1, 9 X^+ 1 − cffi g 9 f 9 NB 8 − 1, 9 X^ + dMAB 8 − 1, 9 X^	
New	vaccinated	non-infectious	active	TB	cases	
bcd_MAB 8, 9 = 	 1 − cffA 7 8 − 1, 9 1 − cffi _ 9 (1− f 9 ) KB 8 − 1, 9 + `LB 8 − 1, 9 + `NB 8 − 1, 9 X^+	 1 − cffi a 9 (1 − f 9 )LB 8 − 1, 9 X^ + 1 − cffD g 9 (1− f 9 )NB 8 − 1, 9 X^	
Vaccinated	infectious	active	TB	cases	
AB 8, 9 = AB 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W] bcd_AB 8, 9−	 b 9 + ] 9 + ]8[9] AB 8 − 1, 9 X^	
Vaccinated	non-infectious	active	TB	cases	
MAB 8, 9 = MAB 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MAB 8, 9−	 b 9 + ] 9 + ]b8 9 + d MAB 8 − 1, 9 X^	
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Vaccinated	Recovered	
NB 8, 9 = NB 8 − 1, 9 + 	b 9 AB 8 − 1, 9 + MAB 8 − 1, 9 X^+	 hiN[W, 9]×hkC[W] bcd_AB 8, 9 + c×bcd_MAB 8, 9−	 1 − cffi g 9 + 1 − cffA 7 8 − 1, 9 ` + ][9] NB 8 − 1, 9 X^	
	
First	time	step	of	the	year	(ageing	and	vaccine	delivery/waning)	
Unvaccinated	(first	time	step	of	the	year)	
Susceptibles	
If	j=1:	K 8, 1 = m	
If	j≠1:	
K 8, 9 	= 	K 8 − 1, 9 − 1 − ] 9 − 1 + 7 8 − 1, 9 − 1 K 8 − 1, 9 X^− 23 W, 9 K 8 − 1, 9 − 1 + X[W, 9] 1 − 23 W, 9 )KB 8 − 1, 9 − 1 	
Latent	
L 8, 9 	= L 8 − 1, 9 − 1+ 	7 8 − 1, 9 − 1 1 − _ 9 − 1 K 8 − 1, 9 − 1 + `N 8 − 1, 9 X^− (a 9 − 1 + 7 8 − 1, 9 − 1 _ 9 − 1 ` + ] 9 − 1 )L 8 − 1, 9 − 1 X^− 25 W, 9 L 8 − 1, 9 − 1 + X[W, 9] 1 − 25 W, 9 )LB 8 − 1, 9 − 1 	
New	infectious	active	TB	cases	
bcd_A 8, 9 = 	7 8 − 1, 9 − 1 _ 9 − 1 f 9 − 1 K 8 − 1, 9 − 1 + `L 8 − 1, 9 − 1+ `N 8 − 1, 9 − 1 X^ + 	a 9 − 1 f 9 − 1 L 8 − 1, 9 − 1 X^+ g 9 − 1 f 9 − 1 N 8 − 1, 9 − 1 X^ + dMA 8 − 1, 9 − 1 X^	
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New	non-infectious	active	TB	cases	
bcd_MA[8, 9] = 	7 8 − 1, 9 − 1 _ 9 − 1 (1− f 9 − 1 ) K 8 − 1, 9 − 1 + `L 8 − 1, 9 − 1 + `N 8 − 1, 9 − 1 X^+ 	a 9 − 1 (1 − f 9 − 1 )L 8 − 1, 9 − 1 X^ + g 9 − 1 (1− f 9 − 1 )N 8 − 1, 9 − 1 X^	
Infectious	active	TB	cases	
A 8, 9 = A 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W] bcd_A 8, 9−	 b 9 − 1 + ] 9 − 1 + ]8[9 − 1] A 8 − 1, 9 − 1 X^+ X[W, 9]AB 8 − 1, 9 − 1 	
Non-infectious	active	TB	cases	
MA 8, 9 = MA 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MA 8, 9−	 b 9 − 1 + ] 9 − 1 + ]b8 9 − 1 + d MA 8 − 1, 9 − 1 X^+ X[W, 9]MAB 8 − 1, 9 − 1 	
Recovered	
N 8, 9 = N 8 − 1, 9 − 1 + 	b 9 − 1 A 8 − 1, 9 − 1 + MA 8 − 1, 9 − 1 X^+	 hiN[W, 9]×hkC[W] bcd_A 8, 9 + c×bcd_MA 8, 9−	 g 9 − 1 + 7 8 − 1, 9 − 1 ` + ] 9 − 1 N 8 − 1, 9 − 1 X^− 26 W, 9 N 8 − 1, 9 − 1 + X[W, 9] 1 − 26 W, 9 )NB 8 − 1, 9 − 1 	
Vaccinated	(first	time	step	of	the	year)	
Vaccinated	susceptibles	
KB 8, 9 	= 	 KB 8 − 1, 9 − 1−	 ] 9 − 1 + (1 − cffA 7 8 − 1, 9 − 1 )KB 8 − 1, 9 − 1 X^	+ 23 W, 9 K 8 − 1, 9 − 1 − X[W, 9] 1 − 23 W, 9 KB 8 − 1, 9 − 1 	
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Vaccinated	latent	
LB 8, 9 	= 	 LB 8 − 1, 9 − 1+ 1 − cffA 7 8 − 1, 9 − 1 1 − 1 − cffi _[9− 1] KB 8 − 1, 9 − 1 + `NB 8 − 1, 9 − 1 X^−	 1 − cffi a 9 − 1+ 1 − cffA 7 8 − 1, 9 − 1 )× 1 − cffi _ 9 − 1 ` + ][9 − 1] LB 8− 1, 9 − 1 X^ + 25 W, 9 L 8 − 1, 9 − 1− X[W, 9] 1 − 25 W, 9 )LB 8 − 1, 9 − 1 	
New	vaccinated	infectious	active	TB	cases	
bcd_AB 8, 9 = 	 1 − cffA 7 8 − 1, 9 − 1 1 − cffi _ 9 − 1 f 9− 1 KB 8 − 1, 9 − 1 + `LB 8 − 1, 9 − 1 + `NB 8 − 1, 9 − 1 X^+	 1 − cffi a 9 − 1 f 9 − 1 LB 8 − 1, 9 − 1 X^+ 1 − cffi g 9 − 1 f 9 − 1 NB 8 − 1, 9 − 1 X^+ dMAB 8 − 1, 9 − 1 X^	
New	vaccinated	non-infectious	active	TB	cases	
bcd_MAB 8, 9 = 	 1 − cffA 7 8 − 1, 9 − 1 1 − cffi _ 9 − 1 (1− f 9 − 1 ) KB 8 − 1, 9 − 1 + `LB 8 − 1, 9 − 1+ `NB 8 − 1, 9 − 1 X^ +	 1 − cffi a 9 − 1 (1− f 9 − 1 )LB 8 − 1, 9 − 1 X^ + 1 − cffi g 9 − 1 (1− f 9 − 1 )NB 8 − 1, 9 − 1 X^	
Vaccinated	infectious	active	TB	cases	
AB 8, 9 = AB 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W] bcd_AB 8, 9−	 b 9 − 1 + ] 9 − 1 + ]8 9 − 1 AB 8 − 1, 9 − 1 X^− X[W, 9]AB 8 − 1, 9 − 1 	
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Vaccinated	non-infectious	active	TB	cases	
MAB 8, 9 = MAB 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MAB 8, 9−	 b 9 − 1 + ] 9 − 1 + ]b8 9 − 1 + d MAB 8 − 1, 9 − 1 X^− X[W, 9]MAB 8 − 1, 9 − 1 	
Vaccinated	recovered	
NB 8, 9 = NB 8 − 1, 9 − 1 + 	b 9 − 1 AB 8 − 1, 9 − 1 + MAB 8 − 1, 9 − 1 X^+	 hiN[W, 9]×hkC[W] bcd_AB 8, 9 + c×bcd_MAB 8, 9−	 1 − cffi g 9 − 1 + 1 − cffA 7 8 − 1, 9 − 1 `+ ] 9 − 1 NB 8 − 1, 9 − 1 X^ + 26 W, 9 N 8 − 1, 9 − 1− X[W, 9] 1 − 26 W, 9 )NB 8 − 1, 9 − 1 	
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3.6.2 Additional	Methods:	Justification	of	parameters	and	calibration	data	
Justification	 of	 selection	 and	 sources	 for	 natural	 history,	 demographic,	 social	 and	
control	parameters	are	provided	in	this	section.	
3.6.2.1 Natural	history	(biological)	parameters	
Natural	history	parameter	prior	ranges	sampled	from	in	the	calibration	process	and	
the	 calibrated	 posterior	 ranges	 are	 summarised	 in	 Table	 3.7.	 Natural	 history	
parameters	were	assessed	for	age	variance	based	upon	the	literature	and	biological	
plausibility,	as	described	below.	
Parameters	considered	invariant	by	age	or	with	insufficient	data	demonstrating	age	
variability	were	probability	of	transmission	per	infectious	contact	(z),	protection	from	
active	 disease	 due	 to	 latent	 infection	 (x)	 and	 conversion	 from	 non-infectious	 to	
infectious	 active	 case	 (w).	 These	were	modelled	with	 the	 same	 value	 for	 all	 ages	
based	on	estimates	from	the	literature.	The	ranges	sampled	from	during	calibration	
were	in-line	with	values	applied	in	Knight	et	al.	and	historical	literature.1,13,41		
However,	 age-related	 differences	 in	 immunity,	 such	 as	 immune	 immaturity	 in	
children	and	immunosenescence	and	co-morbidities	 in	the	elderly,	are	believed	to	
influence	the	course	of	infection	and	disease.42,43	Therefore,	to	improve	the	modelled	
epidemiology,	parameters	with	an	epidemiological	or	biological	basis	for	age-based	
differences	 were	 calibrated	 separately	 for	 each	 age	 group.	 These	 included	 the	
proportion	 progressing	 directly	 to	 active	 disease	 (p),	 proportion	 developing	
infectious	disease	(f),	risk	of	reactivation	of	latent	infection	or	relapse	of	recovered	
disease	 (v	 and	 r),	 risk	 of	 natural	 cure	 from	 active	 disease	 (n)	 and	 an	 age-wise	
calibration	 factor	 for	 TB	 mortality	 rate	 (uiscale).	 The	 age	 groups	 with	 calibrated	
parameters	were	children	(0-14	years),	adolescents	and	adults	(15-64	years)	and	the	
elderly	(≥65	years).		
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Where	 available,	 parameter	 ranges	 for	 calibration	 were	 based	 upon	 available	
literature	 (see	 references	 in	 Table	 3.7).	 However,	 little	 literature	 exists	 to	 inform	
parameters	for	older	adults	and	the	elderly,43	and	no	previous	models	were	identified	
with	age-specific	parameters	for	these	age	groups.	Based	upon	published	literature	
and	expert	opinion	comparing	the	impact	on	immune	responses	of	HIV	versus	ageing,	
it	was	assumed	that	HIV-positive	parameter	ranges	were	an	appropriate	proxy	for	
the	 upper	 bound	 of	 immunosenescence	 in	 old	 age	 (Richard	 Aspinall,	 oral	
communication,	 5th	 June	2015).44	When	HIV-positive	 ranges	did	not	overlap	with	
HIV-negative	adult	parameters,	the	lower	bound	of	HIV-positive	ranges	were	taken	
(v	and	r),	and	where	overlap	occurred	the	upper	range	of	HIV-positive	parameters	
were	used	(p,	 f	and	n).	Therefore,	the	ranges	for	calibration	of	elderly	parameters	
encompassed	the	HIV-negative	adult	parameters	up	to	either	the	least	extreme	or	all	
values	 of	 the	 HIV-positive	 parameters	 (see	 Table	 3.7).	 Immune	 senescence	 is	 a	
gradual	 process,	 therefore	 to	 smooth	 the	 transition	 between	 adult	 and	 elderly	
parameters	for	v,	r,	and	n,	55-64	year	olds	were	programmed	to	take	the	mean	of	the	
15-54	years	and	elderly	calibrated	values.		
In	model	 calibration,	 the	 age-specific	 values	 for	 a	 given	parameter	were	 sampled	
independently.	Where	data	or	biological	plausibility	were	suggestive	of	an	age-wise	
relationship	between	parameters,	constraints	were	set	to	ensure	only	parameter	sets	
adhering	 to	 those	 relationships	were	 retained.	 For	 example,	 given	 TB	mortality	 is	
higher	 at	 the	 age	 extremes,43	 parameter	 sets	were	 only	 retained	 if	 the	 child	 and	
elderly	TB	mortality	calibration	factors	(uiscaleC	and	uiscaleE)	were	greater	than	or	
equal	to	the	adult	parameter	(uiscaleA).		
The	 model	 parameter	 determining	 the	 distribution	 between	 infectious	 and	 non-
infectious	TB	(f)	was	constrained	so	that	the	proportion	of	infectious	disease	in	the	
elderly	was	equal	to	or	less	than	the	adult	parameter.	This	is	based	upon	literature	
suggesting	that	although	approximately	75%	of	elderly	cases	manifest	as	pulmonary	
disease,45	 many	 present	 atypically	 with	 minimal	 pulmonary	 symptoms.45,46	 In	
addition,	 an	 increasing	 proportion	 of	 extrapulmonary	 disease	 is	 observed	 with	
increasing	age	in	this	population.43,47		
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The	 proportion	 of	 the	 population	 directly	 developing	 primary	 disease	 (p)	 and	
reactivation/relapse	 disease	 (v	 and	 r)	 may	 be	 higher	 in	 the	 elderly	 due	 to	
immunosenescence	weakening	the	immune	system’s	ability	to	control	infection.46,47	
Reactivation	has	been	demonstrated	to	occur	decades	after	infection,	therefore	even	
historical	 latent	 infection	can	reactivate.48	An	epidemiological	model	exploring	the	
incubation	 period	 between	 infection	 and	 disease	 demonstrated	 that	 incubation	
periods	became	shorter	with	age	at	infection,49,50	supporting	the	assumption	that	the	
risk	of	primary	progression	to	disease	is	likely	higher	in	older	age	groups.	Therefore	a	
constraint	was	 included	to	ensure	the	elderly	parameter	was	at	 least	equal	to	the	
adult	parameter.	Conversely,	natural	cure	(n)	was	considered	potentially	less	likely	in	
elderly	populations,	so	parameter	sets	with	equal	or	lower	natural	cure	in	the	elderly	
were	retained.	Details	of	these	constraints	can	be	found	in	Table	3.7.	
Two	 fitting	 factors	 (rmortTB	 and	 uiscale)	 were	 employed	 for	 calibration	 of	 TB	
mortality	in	infectious	and	non-infectious	disease	(ui	and	uni).	First	TB	mortality	was	
scaled	 by	 calibration	 factor	 rmortTB	 (increasing	mortality	 if	 rmortTB	 greater	 than	
zero,	and	reduced	if	less	than	zero),	then	scaled	by	age	with	age-specific	calibration	
factors	for	children,	adults	and	the	elderly	(uiscaleC,	uiscaleA,	and	uiscaleE).	
3.6.2.2 Demographic	parameters	
The	population	size	at	model	initiation,	and	birth	and	death	rates	over	time	form	the	
basis	 for	 the	 demographic	 structure	 of	 the	modelled	 population.	 The	model	 was	
initiated	 in	1900,	with	 initiation	population	 size	 (p0)	 set	 as	part	of	 the	 calibration	
process	(see	3.6.3.1).	The	‘burn	in’	period	(1900-1999)	ahead	of	the	period	of	interest	
(2000-2050)	 ensured	 the	populations	 in	 the	 calibration	 (2000-2010)	 and	outcome	
(2025-2050)	 periods	 had	 appropriate	 levels	 of	 historical	 exposure	 to	 produce	
relevant	age-wise	rates	of	infection	and	disease.		
Demographic	data	were	obtained	 from	the	UN	population	division	2012	revision.4	
The	 initial	 model	 birth	 rate	 was	 calculated	 by	 dividing	 UN	 average	 annual	 birth	
estimates	for	1975-1980	by	the	UN	reported	1980	population	of	China.4	The	initial	
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birth	 rate	was	 implemented	 from	 initiation	 to	1989.	To	account	 for	 the	 impact	of	
China’s	 one-child	 policy,	 a	 lower	 birth	 rate	 (based	 upon	 2010	 estimates)	 was	
implemented	from	1990-2009.	Although	the	one-child	policy	was	introduced	in	1979,	
data	 indicate	policy	 implementation	was	not	 instantaneous,	as	birth	 rates	did	not	
begin	to	decline	until	1989/1990,	therefore	the	lower	birth	rates	were	implemented	
in	 1990	 as	 opposed	 to	 1979.51	 From	 2010	 onwards,	 modelled	 birth	 rates	 were	
estimated	annually	using	UN	fertility	and	population	estimates/predictions.4	In	the	
model,	number	of	births	each	year	was	estimated	by	applying	birth	rates	as	described	
above	to	modelled	population	size.	
The	all-cause	mortality	was	calculated	in	the	model	by	year	of	age	and	calendar	year.	
This	was	modelled	by	using	UN	life	expectancy	data	for	China	to	calculate	annual	risk	
of	death	by	age	[1/(life	expectancy	at	a	given	age)],	for	1950,	2000,	and	annually	from	
2010-2050,	during	which	the	rate	is	constant	in	5-year	steps,	but	varies	by	age.4	To	
fit	mortality	by	age	and	over	time,	it	was	necessary	to	have	steps	in	mortality	rates	
to	reflect	historical	changes	in	mortality	in	China.	Background	mortality	was	higher	
historically	 due	 to	 social	 and	 healthcare	 determinants,	 so	 in	 the	 years	 preceding	
2000,	mortality	estimates	calculated	from	UN	population	data	for	1950	were	used,	
as	those	who	were	elderly	 in	the	calibration	period	would	have	been	born	around	
this	time,	so	reflected	their	historical	life	expectancy.	From	2000-2009,	the	mortality	
estimates	 for	 2000	 were	 used,	 then	 from	 2010	 to	 2050	 the	 modelled	 mortality	
tracked	the	UN	reported	data	and	predictions.4	
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Table	3.7:	Natural	history	and	demographic	parameters	(tables	adapted	from	Knight	et	al.1)	
Parameter	 Symbol	 Description	 Prior	proposal	range	and	constraints	 References	 Parameter	 range	
observed	 in	 1000	 model	
fits	
Births	 and	
all-cause	
death	 B[k]	 Number	 of	 births	 in	year	k	
Birth	rate	calculated	from	UN	fertility	and	
population	 estimates	 and	 applied	 to	
modelled	population.	1980s	birth	rate	pre-
1990,	 2010	 value	 1990-2009,	 and	 tracks	
annual	UN	data	from	2010	onwards.	
UN	 Population	
Division	 (revision	
2012)4	
n/a	
u[j]	
Background	 (all-
cause)	 death	 risk	 at	
age	j	
u[j]	=	1/LE[j]	
	
Death	 rate	 calculated	 from	 UN	 life	
expectancy	estimates	by	age	for	China	and	
applied	 to	 modelled	 population.	 1950s	
birth	rate	pre-2000,	2000	value	2000-2009,	
and	tracks	annual	UN	data	and	predictions	
from	2010	onwards.	
UN	 Population	
Division	 data	 (2012	
revision)	4	
n/a	
rmort*	 Calibration	factor	for	all-cause	mortality	
Calibrated	at	single	value	to	match	population	size	by	age	group	in	
2010	and	2050.	
Range:	-1	to	1	
If	(rmort	<	0	):	u[j]=(1+rmort)	u[j]		
If	(rmort	≥0):	u[j]=(1-u[j])rmort	+	u[j]		
-0.6	
Transmission	
λ[i,j]	
M.tb	 transmission	
risk	 (force	 of	
infection)	 in	 time	
step	i	for	age	j	
	
Calculated	in	the	model:	! ", $ = &'() &[+, ,]. / ", , + /1 ", ,2[", ,]3453678349  
 
n/a	
	174	
ηcal	
Scaling	 and	
calibration	factor	for	
daily	 number	 of	
respiratory	contacts		
Scales	 respiratory	 contacts	 to	 annual	 number	 of	 contacts	 and	
calibrates	to	TB	incidence	
Calibration	range:	0-5	(range	based	upon	preliminary	modelling)	
1.85-2.82	
η[m,y]		
Daily	 number	 of	
respiratory	 contacts	
by	 age	 group	m	 and	
contacts	in	age	group	
y	
Calibrated	by	ηcal	to	match	TB	incidence		
Initial	values	and	mixing	patterns	 taken	 from	Read	et	al.	2014,15	
made	symmetrical	to	account	for	reporting	bias.15	
n/a	
z	
Probability	 of	
transmission	 per	
respiratory	 contact	
between	 an	
infectious	 and	
uninfected	individual	
Fixed	value	from	literature:	0.1	 Dye	et	al	200852	
Abu	 Raddad	 et	 al	
2009	41	
Knight	et	al	20141	
0.1	
Progression	
to	 active	
disease	
p[j]	
Proportion	of	(re-)	
infected	Uninfected,	
Latents	or	
Recovereds	directly	
developing	active	TB	
(fast/	primary	
disease),	by	year	of	
age	
p[	j	<	15]	=	0.01-0.06	
p[	j		≥	15,	<65]	=	0.08	–	0.2	
p[	j		≥	65]	=	0.08-0.36	(adult	and	HIV-
positive	range)	
	
Constraint:	Parameter	 set	only	 retained	 if	
elderly	 parameter	 selected	 was	 greater	
than	or	equal	to	adult	parameter.	
A	Dye	et	al	199813,*	
Knight	et	al	20141	
Abu	 Raddad	 et	 al	
2009	41,**	
Dye	et	al	200852	
	
p[	j	<	15]	=	0.014-	0.030	
p[	j	≥15,	<65]	=	0.14-0.2	
p[	j	≥65]	=	0.21-	0.36	
x	
	
Protection	 from	 re-
infection	 or	
developing	active	TB	
due	to	being	latently	
infected	 or	
(1-x)	is	the	value	for	the	level	of	protection	
afforded		
Range:	0.25	–	0.41	
	
Vynnycky	 and	 Fine	
1997	53	
Abu	 Raddad	 et	 al	
2009	41	
Dye	et	al	200852	
Gomes	et	al	200754	
	
	
0.25-0.36	
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recovered	 from	
infection	
v[j]	
Risk	 of	 reactivation	
in	 latently	 infected	
population			
v	[	j<15]	=	0.0001	-	0.0003		
v	[j³15,	j<65]	=	0.0001	-	0.0003		
v[	 j≥65]	=	0.0001	 -	 0.04	 (adult,	 and	up	 to	
lower	bound	of	HIV-positives)	
	
Constraint:	Parameter	 set	only	 retained	 if	
elderly	 parameter	 selected	 was	 greater	
than	or	equal	to	adult	parameter.	
Dye	et	al	199813	
Gomes	et	al	200754	
Schulzer	et	al	199255	
Knight	et	al	20141	
Schaaf	et	al	201043	
	
	
v[	j	<15]	=	0.00010-
0.00019	
v	[j³15	&	j<65]	=	0.00018	-	
0.00028		
v[	j	55-64]	=	0.00020-
0.00194	
v[	j		≥	65]	=	0.00020	-	
0.00369	
Infectious	TB	
f[j]		
Proportion	 of	 new	
active	 cases	 directly	
becoming	 infectious,	
by	age	
f[j	<	15]	=	0-0.15	
f[j	≥	15,	<65]	=	0.25-0.75		
f[	j		≥	65]	=		0.19-0.75	(point	estimate	from	
elderly	 study,	 range	 from	 adult	 and	 HIV-
positive	ranges)	
	
Constraint:	Parameter	 set	only	 retained	 if	
adult	parameter	selected	was	greater	than	
or	equal	to	elderly	parameter.	
Abu	 Raddad	 et	 al	
200941	
Dye	et	al	200852	
Yokishawa	 et	 al	
199245	
Marion	et	al	200946	
Rajagopalan	 and	
Yoshikawa	200047	
Schaaf	et	al	201043	
f[j<15]=	0.10-0.15	
f[j	≥	15,	<65]	=	0.66-0.75	
f[	j		≥	65]	=		0.61-0.75	
w	
Risk	 of	 converting	
from	 non-infectious	
to	 infectious	 active	
case	
0.007	–	0.02	 Dye	et	al	199813	
Ferebee	et	al	197056	
	
0.009-0.018	
TB	mortality	
ui;	
Death	 risk	 for	
infectious	 untreated	
TB,	varies	by	age		
	0.6	
Calibrated	to	TB	mortality	by	rmortTB	and	
uiscale	(see	below)	
Tiemersma	 et	 al	
201157	
	
/	
uni	
Death	 risk	 for	 non-
infectious	 untreated	
TB,	varies	by	age	
0.21	
Calibrated	to	TB	mortality	by	rmortTB	and	
uiscale	(see	below)	
Tiemersma	 et	 al	
201157	
	
/	
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rmortT
B*	
Calibration	factor	for	
ui	and	uni	
Sampled	to	calibrate	ui	and	uni	to	TB	mortality.	
Range	sampled:	-1	to	1	
	
If	(rmortTB	<	0	):	uia=(1+rmortTB)ui	,	unia=(1+rmortTB)uni		
If	(rmortTB	≥0):	uia=(1-ui)rmortTB	+	ui	,	unia=(1-uni)rmortTB	+	uni	
-0.96	to	-0.75		
uiscale	 Calibration	 factor	 to	vary	ui	and	uni	by	age	
uiscale	[j	<	15]	=	0-2	
uiscale	[j	≥	15,	<65]	=	0-2	
uiscale	[	j		≥	65]	=	0-2		
Where	uib=	uiscale*uia	
	
Constraint:	 Parameter	 set	 only	 retained	 if	 child	 and	 elderly	
parameters	 selected	 were	 greater	 than	 or	 equal	 to	 adult	
parameter.43	
uiscale	[j	<	15]	=	0.98-2.00	
uiscale	[j	≥	15,	<65]	=	0.10-
1.0	
uiscale	[	j		≥	65]	=	0.18-1.56	
Natural	 cure	
and	relapse	
n	
Annual	 risk	 of	
natural	 cure	 for	 TB	
cases,	varies	by	age	
n[j<55]	=	0.1	–	0.25	
n[	j		55-64]	=	(n[j<55]	+	n[	j		≥	65])/2	
n[	j		≥	65]	=	0.1	–	0.25	
	
Constraint:	Parameter	 set	only	 retained	 if	
adult	parameter	selected	was	greater	than	
or	equal	to	elderly	parameter.	
Abu	 Raddad	 et	 al	
200941	
Dye	et	al	200852	
	
n[j<55]	=	0.16-0.24	
n[	j		55-64]	=	0.13-0.18	
n[	j		≥	65]	=	0.10-0.15	
r	
Annual	 risk	 of	
relapse	 from	
recovered	 to	 active	
TB,	varies	by	age	
r[j	<15]	=	0.005-0.015		
r[j	≥	15,	<55]	=	0.005-0.015		
r[j	≥	55,	<65]	=	(r[j<55]	+	r[j	≥	65])/2	
r[	j		≥	65]	=	0.005-0.2	(adult,	and	up	to	lower	
bound	of	HIV-positives)	
Gomes	et	al	200458	
Knight	et	al	20141	
Schaaf	et	al	201043	
	
r[j	<15]	=	0.005-0.010		
r[j	≥	15,	<55]	=	0.005-0.007		
r[j	≥	55,	<65]	=	0.005-0.015	
r[	j		≥	65]	=	0.005-0.025	
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3.6.2.3 Social	mixing	parameters	
Heterogeneous	age-specific	social	mixing	patterns	were	incorporated	into	the	model.	
Previous	 TB	 vaccine	models	 have	 assumed	 homogenous	 random	mixing	 patterns	
within	 modelled	 populations,1,41,52,59	 but	 such	 homogenous	 mixing	 does	 not	
appropriately	 represent	 the	 reality	 of	 age-assortativity	 in	 contact	 patterns.	 One	
recently	published	model	included	age-assortativity	in	contacts,	applying	European	
contact	data	to	global	populations.39	However,	age	structure	and	cultural	factors	in	
the	surveyed	population	affect	generalisability	of	contact	patterns.	In	this	model,	 I	
applied	China-specific	age-wise	contact	patterns	 from	the	Read	et	al.	 study	to	the	
modelled	population	in	China	to	appropriately	represent	the	likelihood	of	a	contact	
event	occurring.15	
The	Read	 study	estimated	 the	 total	 and	average	daily	number	of	 contacts	by	age	
strata	(0-5,	6-19,	20-64	and	≥	65years)	from	contact	diaries,	in	a	study	enrolling	1821	
participants	 from	 southern	 China.15	 Contacts	 were	 defined	 as	 face-to-face	
conversation	 or	 skin-on-skin	 touch,	 so	 are	 broadly	 representative	 of	 the	 type	 of	
contact	relevant	to	M.tb	 transmission.15	The	study	demonstrated	heterogeneity	 in	
the	average	number	of	contacts	between	age	groups,	in	particular	that	the	largest	
number	of	contacts	tended	to	be	within	the	participant’s	age	group	or	with	the	20-
64	 years	 age	 group	 (Figure	 3.22,	 left).15	 Importantly,	 the	 total	 number	 of	 daily	
contacts	 was	 lowest	 for	 the	 elderly	 population.	 The	 clear	 differences	 in	 absolute	
number	of	contacts	made	by	each	age	group	and	the	age	assortativity	in	the	contacts	
made	provided	a	clear	rationale	for	incorporating	age-specific	contact	patterns	in	this	
model.		
The	heterogeneous	mixing	pattern	from	this	study	was	incorporated	in	the	model	in	
the	term	! ", $ .	This	is	a	matrix	of	the	average	number	of	contacts	per	person	per	
day	between	an	individual	in	the	participant	group	(m)	and	individuals	in	a	contact	
age	group	(y)	(cym)	(Figure	3.22).	In	the	calibration	process,	this	matrix	is	multiplied	
by	 a	 scaling	 factor	 (ncal).	 Reporting	or	 participation	biases	 in	 the	 study	produced	
asymmetry	in	the	number	of	contacts	between	pairs	of	age	groups	in	the	reported	
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contact	matrix	 (Figure	3.22,	 left).15	 Symmetry	was	achieved	using	 the	methods	of	
Baguelin	 et	 al.,60	 by	 estimating	 the	 total	 number	 of	 contacts	 from	 all	 subjects	 in	
participant	age	group	m	with	contact	age	group	y,	and	for	the	age	groups	reversed,	
taking	an	average	of	the	two,	and	converting	back	to	a	contact	rate	by	dividing	the	
number	of	 contacts	by	 the	 size	of	 the	participant	age	group	 (equation	below	and	
Figure	3.22,	right):	
%&'	 = *+ (-&' ∗ /') +	(-'& ∗ /&) /'				
where	-&'	is	average	number	of	contacts	of	participants	in	group	m	with	people	in	
group	y,	-'&	is		average	number	of	contacts	of	participants	in	group	y	with	people	in	
group	m,	 and	/' 	and	/&	are	 the	 number	 of	 participants	 in	 age	 group	 m	 and	 y,	
respectively.60			
In	the	model,	this	contact	matrix	is	then	multiplied	by	the	probability	of	transmission	
occurring	upon	a	respiratory	contact	between	an	infectious	and	uninfected	(z)	and	
by	 the	 proportion	 of	 the	 contact	 population	 that	 are	 infected	 2 3,45[3,4] .	 These	 are	
summed	over	the	contact	age	groups	to	give	Mtb	transmission	risk	(force	of	infection)	
in	 time	 step	 i	 for	 age	 j	 (λ[i,j]).	 As	 described	 in	 section	 3.3.3,	 the	 matrix	 is	 also	
multiplied	by	a	scaling	factor	(ncal)	in	the	fitting	process	to	calibrate	the	total	number	
of	contacts	to	the	epidemiological	data.		
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Figure	3.22:	Average	number	of	reported	contacts	per	day	(left,	Read	et	al.	2014.15)	and	average	
number	of	contacts	per	person	in	the	participant	age	group	per	day	following	matrix	averaging	to	
ensure	symmetric	total	numbers	of	contacts	(right)	
	
3.6.2.4 Existing	TB	Control	measure	parameters	
The	existing	control	measure	parameters	are	summarised	in	Table	3.8.		
BCG	coverage	was	assumed	to	remain	at	current	levels	as	existing	coverage	is	high	
and	stable,	therefore	was	not	explicitly	modelled,	as	the	impact	of	BCG	is	intrinsic	to	
the	calibration	data.		
Data	from	China	and	some	other	countries	have	 indicated	that	the	case	detection	
rate	 (CDR)	 may	 be	 lower	 in	 elderly	 populations	 than	 adults,	 due	 to	 diagnostic	
difficulties	and	reduced	access	to	care.61	Age-wise	differences	were	reflected	in	the	
model	by	exploring	age-specific	CDR	calibration	factors	for	<55	years	and	the	elderly,	
with	 parameter	 sets	 retained	 only	 if	 adult	 CDR	was	 at	 least	 equal	 to	 the	 elderly	
parameter.	An	older	adult	calibration	factor	was	calculated	as	the	mean	of	the	adult	
and	 elderly	 factors.	 These	 older	 adult	 parameters	 were	 to	 allow	 a	more	 gradual	
parameter	transition	in	to	old	age.		
Although	case	detection	estimates	 fluctuated	over	 time,	 the	data	 suggest	a	 large,	
rapid	 increase	 from	35%	to	74%	between	2002	and	2005.17	WHO	 ‘case	detection’	
requires	diagnosis	and	reporting,	whereas	in	the	model	it	only	represents	diagnosis;	
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therefore,	the	low	early	estimates	of	case	detection	and	the	sudden	rapid	rise	were	
likely	an	artificially	rapid	jump	reflecting	a	more	steady	(2000-2010),	but	still	large,	
increase	in	diagnosis	ratios	due	to	scale	up	of	TB	control	efforts,	coupled	with	a	very	
rapid	improvement	in	reporting.	Therefore,	the	WHO	China	CDR	data	for	1990-2012	
were	used	as	the	basis	for	developing	a	generalised	logistic	function	to	reflect	a	rapid	
but	 steady	 increase	 in	 CDR	 over	 this	 period,	 and	 a	 much	 slower	 but	 continued	
improvement	(up	to	a	 limit	of	100%)	in	detection	beyond	this.	As	described	in	the	
calibration	section	(3.6.3),	this	CDR	was	then	calibrated	to	epidemiological	data	by	
age-specific	scaling	factors	(CDRscale)	for	‘children,	adolescents	and	adults’,	and	the	
elderly,	with	55-64	year	olds	as	the	average	of	younger	adults	and	the	elderly	value.	
The	value	of	the	scaled	CDR	was	capped	to	ensure	scaling	could	not	 increase	CDR	
beyond	100%.	A	scaling	factor	(e)	for	the	CDR	was	included	to	account	for	the	relative	
case	 detection	 of	 bacteriologically	 negative	 and	 extrapulmonary	 TB	 disease	
compared	to	bacteriologically	positive	disease.	
WHO	reported	treatment	success	rates	were	employed	between	1994	and	2011,	and	
the	1994	and	2011	rates	held	constant	before	and	after	this	period,	respectively.16	
Although	the	lack	of	future	improvement	could	be	considered	somewhat	pessimistic,	
given	the	high	 levels	of	treatment	success	 (95%)	reported	 in	recent	years,16,17	and	
that	 only	 3.6%	of	 the	 197	 countries	 studied	 in	 Knight	 et	 al.	 report	 a	 higher	 2011	
treatment	 success	 rate	 than	 China,1,16	 there	 remains	 minimal	 opportunity	 for	
improving	existing	control	measures,	therefore	this	was	considered	a	likely	scenario.	
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Table	3.8:	Control	measure	parameters	
Parameter	 Symbol	 Description	 Prior	proposal	range	and	constraints	 References	 Parameter	range	observed	in	1000	fits	
Case	
detection	
CDR[k]	
Case	 Detection	 Ratio	
(proportion	 of	 new	
active	 TB	 cases	
detected	 and	 started	
on	treatment)	year	k	
2012	baseline:	89%	
	
CDR	data	for	1990-2012	were	used	as	the	
basis	for	developing	a	generalised	logistic	
function	 to	 reflect	 a	 rapid	 but	 steady	
increase	in	CDR	over	this	period.		
WHO	 TB	 burden	
estimates	17	
/	
CDRscale	 Calibration	 factor	 for	CDR,	varies	by	age	
Calibrated	to	match	TB	prevalence,	mortality	and	incidence.		
	
Range	sampled:	-0.5	to	2	independently	for	<55year	olds	and	≥65	
year	olds.	55-64	year	olds	took	the	mean	of	the	older	and	younger	
sampled	values.		
	
Constraint:	Parameter	set	only	retained	if	adult	calibration	factor	
selected	was	greater	than	or	equal	to	elderly	parameter.43	
CDR[k]=CDRscale*CDR[k]	
CDRscale[j<55]	=	0.33-0.51	
		
CDRscale[j	 ≥	 55,	 <65]	 =	
0.09	–	0.28	
	
CDRscale[j	 	≥	65]	=	 -0.19	 -	
0.10	
e	
Relative	 case	
detection	rate	of	non-
infectious	cases	
0.4	–	0.8	 Assumed	14	 0.58-0.80	
Treatment	
CoT[k]	
Treatment	 success	
proportion	 (cured	 or	
complete	 treatment)	
in	year	k	
2011	baseline:	95%	
	
WHO	data	1994-2011,	then	constant	CoT	
from	2011	onwards	
WHO	 treatment	
outcomes	16	
n/a	
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3.6.3 Additional	Methods:	Calibration	methodology	
A	 two-stage	 calibration	 process	 was	 employed,	 with	 the	 first	 stage	 a	 manual	
calibration	to	age-stratified	UN	population	projections	for	2010	and	2050,18	and	the	
second	 stage	 an	 adaptive	 rejection	 ABC	 MCMC-based	 method	 using	 a	 modified	
easyABC	package	to	calibrate	to	18	country-specific	epidemiological	data	ranges.	
3.6.3.1 	Demographic	calibration		
Demographic	data,	 including	age-stratified	population	size	estimates	 for	2010	and	
2050,	were	obtained	from	the	UN	population	division	2012	revision	(Table	3.9).4	The	
model	 was	 adjusted	 to	 align	 with	 the	 overall	 population	 size	 and	 four	 age	
stratifications	(0-14	years,	15-54	years,	55-64	years	and	³65	years)	at	these	two	time	
points.	Uncertainty	ranges	were	only	available	for	0-14	years	and	15-54	years,	as	UN	
population	 estimates	 explore	 uncertainty	 in	 fertility	 assumptions,	 which	 do	 not	
impact	older	age	groups	over	this	time	frame.5		
Table	3.9:	Demographic	calibration	targets	for	China	
Calibration	Factor	 Year	
Age	
(years)	
Estimate	
Lower	
bound	
Upper	
bound	
Population	size	
(thousands)4	
2010	
All	 1,359,822	 n/a	 n/a	
0-14	 246,707	 n/a	 n/a	
15-54	 863,710	 n/a	 n/a	
55-64	 135,859	 n/a	 n/a	
65+	 113,546	 n/a	 n/a	
2050	
All	 1,384,976	 1,208,829	 1,579,558	
0-14	 204,187	 124,968	 300,552	
15-54	 623,982	 527,054	 722,200	
55-64	 225,492	 n/a	 n/a	
65+	 331,315	 n/a	 n/a	
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Calibration	of	modelled	demography	to	the	above	targets	was	achieved	by	manual	
adjustment	 of	 the	 population	 size	 at	model	 initiation	 (p0)	 and	 a	 fitting	 factor	 for	
mortality	 rates	 (rmort).	 The	 fitted	 values,	 which	 gave	 the	 best	 overall	 fit	 to	 the	
selected	calibration	data	were	1,267,142	million	 for	p0	and	 -0.6	 for	 rmort.	Model	
demographic	fits	are	shown	in	Figure	3.7.	
3.6.3.2 Epidemiological	calibration	targets	
Estimates	 and	 confidence	 intervals	 around	 age-stratified	 prevalence	 of	
bacteriologically-positive	 pulmonary	 TB	 disease	 were	 obtained	 from	 national	
prevalence	surveys	conducted	in	2000	and	2010,	reported	in	Wang	et	al.	 (2014).19	
Data	 from	 the	 1990	 survey	 were	 not	 used,	 as	 the	 diagnostic	 protocol	 was	 less	
sensitive,	and	age-stratified	data	were	not	reported.	Although	all-TB	prevalence	rates	
were	 available,	 clinically	 diagnosed	 TB	 included	 in	 these	 estimates	 was	 likely	 an	
overestimate	of	true	prevalence	due	to	over	diagnosis	based	on	clinical	signs,	and	did	
not	align	well	with	the	disease	states	in	the	model.	Therefore,	calibration	was	to	the	
biologically-positive	 prevalence	 data,	 as	 these	 most	 closely	 represented	 the	
infectious	disease	state	in	the	model	(I).	
Disease	Surveillance	Point	data,	considered	nationally	representative,	were	used	to	
estimate	mortality	 rates	 by	 age.21	 Published	 adjusted	mortality	 estimates	 did	 not	
align	with	the	age	bands	required	for	calibration,	therefore	age	groups	were	brought	
together	using	published	crude	data	to	estimate	unadjusted	rates.	In	the	published	
analyses	the	adjusted	estimates	were	adjusted	twice,	first	using	methods	for	complex	
sampling	surveys,	and	second	for	under-reporting	of	mortality.	These	adjustments	
were	not	reproducible	with	the	available	data	and	methodological	information,	but	
uncertainty	 ranges	 for	 calibration	were	 based	 upon	 estimates	 of	 under	 reporting	
from	other	 data	 sources.	 Causes	 of	misclassification	 of	 TB	 deaths	 include	HIV	 co-
infection	and	malnourishment,	and	occur	more	frequently	in	deaths	at	home	or	in	
rural	 areas.	Wang	 et	 al.	 and	 Yang	 et	 al.	 estimated	 TB	mortality	mis-classification	
(underestimation)	 in	 China,	 particularly	 due	 to	 miscoding	 as	 pneumonia,62	 at	
Chapter	3:	Epidemiological	impact	of	TB	vaccine	characteristics												 					184 
approximately	50%.63,64	Therefore	the	upper	range	of	the	calibration	ranges	was	set	
at	 50%	 higher	 than	 the	 unadjusted	 point	 estimates,	 which	 encompassed	 the	
published	adjusted	estimates.	Although	misclassification	of	non-cases	as	cases	is	less	
common,	it	does	occur,	so	symmetric	uncertainty	ranges	around	the	point	estimate	
were	assumed.	
Country-level	TB	incidence	stratified	by	age	is	not	currently	reported	by	the	WHO,	
therefore	 age-specific	 notification	 rates	 of	 all	 TB	 (including	 smear	 positive,	 smear	
negative,	 and	 extra-pulmonary	 TB)	were	 employed	 for	model	 fitting.20	Up	 to	 20%	
over-reporting	 of	 notifications	may	 occur	 due	 to	 the	 use	 of	 clinical	 algorithms	 as	
opposed	 to	 biological	 testing	 for	 diagnosis.	 Up	 to	 20%	 under-reporting	 was	
estimated,	 as	 it	 was	 assumed	 that	 the	 reported	 data	 only	 captured	 public	 (CDC)	
notifications,	which	constitute	80%	of	cases,	and	also	cases	that	are	asymptomatic	or	
do	 not	 exhibit	 standard	 symptoms	 may	 be	 missed.65,66	 Therefore,	 confidence	
intervals	 for	 calibration	 were	 +/-20%	 of	 the	 WHO-reported	 notification	 point	
estimates.17	
To	ensure	an	appropriate	case	detection	rate	in	the	fitting	process,	the	model	was	
also	 calibrated	 to	 the	 all-age	 TB	 incidence	 rate	 in	 2010	 obtained	 from	 the	WHO	
database.17	WHO	incidence	rates	and	ranges	are	retrospectively	updated	each	year,	
therefore	ranges	fitted	to	are	those	for	2010,	but	accessed	in	July	2016.	
Prevalence	of	infection	surveys	using	TST	and	Quantiferon	(QFN)	tests	in	four	rural	
sites	in	China	provide	age-stratified	estimates	of	latent	tuberculosis	infection	(LTBI)	
prevalence.22	However	these	data	were	only	used	for	comparison,	not	for	calibration,	
as	there	was	some	uncertainty	in	generalisability	of	the	four	study	sites	to	the	whole	
of	China.	In	addition,	without	a	gold	standard	test	for	comparison,	the	sensitivity	and	
specificity	of	TST	and	QFN	tests	are	not	fully	understood.67	Given	the	modelled	latent	
infection	captures	all	infected	individuals,	it	is	unknown	the	extent	to	which	the	study	
data	would	need	to	be	adjusted	to	align	with	the	modelled	population.	
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3.6.3.3 Epidemiological	calibration		
Calibration	to	the	18	China-specific	epidemiological	data	points	was	achieved	using	
an	 adaptive	 rejection	 ABC	 MCMC-based	 method	 using	 a	 modified	 easyABC	
package.23,24	
The	parameter	space	in	this	model	was	highly	multi-dimensional	(24	natural	history	
and	case	management	parameters),	therefore	un-seeded	MCMC	would	likely	have	
required	infeasible	numbers	or	lengths	of	MCMC	chains	to	identify	suitable	regions	
of	the	parameter	space.	Therefore,	the	adapted	package	was	employed	to	allow	for	
provision	of	seed	parameter	estimates	to	initiate	the	MCMC	chains.23		
To	identify	a	series	of	suitable	seed	estimates,	a	maximum	likelihood-based	approach	
was	 implemented.	 One	 million	 parameter	 sets	 were	 randomly	 selected	 from	
literature-informed	 prior	 ranges	 and	 run	 through	 the	 ‘no	 new	 vaccine’	 baseline	
model.	Such	a	large	number	of	parameter	sets	ensured	thorough	exploration	of	the	
parameter	space.	Variances	were	estimated	for	the	calibration	data,	assuming	the	
data	 were	 normally	 distributed.	 For	 each	 of	 the	million	model	 outputs,	 the	 joint	
likelihood	function	for	observing	the	calibration	data	given	the	model	outputs	was	
calculated	to	assess	goodness	of	fit	of	each.	The	twenty	highest	likelihood	runs	were	
selected	as	seeds	for	the	adaptive	rejection	ABC	MCMC-based	calibration.		
In	the	adaptive	rejection	ABC	MCMC-based	calibration,	the	aim	was	to	fit	within	the	
calibration	 ranges	 of	 all	 18	 epidemiological	 data	 points	 (Table	 3.10).	
Acceptance/rejection	 criteria	 in	 the	 MCMC	 chains	 were	 based	 upon	 a	 sufficient	
number	(ranging	13-18,	see	adaptive	fitting	below)	of	epidemiological	model	outputs	
falling	within	the	calibration	ranges.	Adaptive	fitting	was	employed,	 increasing	the	
acceptance	criterion	during	a	series	of	ABC	MCMC	chain	sets	from	13	to	18	data	point	
fits,	to	ultimately	identify	parameter	space	fitting	all	18	data	points	(‘fully	fitted’).68	
In	each	set	of	chains,	between	five	and	twenty	of	the	highest	fits	of	the	previous	set	
were	used	as	seeds	for	the	subsequent	set	of	chains,	and	the	acceptance	criterion	
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incrementally	 increased	as	the	fit	 improved.	Once	parameter	sets	providing	a	fully	
fitted	model	 had	 been	 identified	 using	 this	method,	 five	were	 selected	 randomly	
using	the	runif	command	as	seeds	for	five	200,000-run	ABC-MCMC	chains.	2152	full	
fits	were	obtained	from	these	final	million	ABC	MCMC	runs,	of	which	one	thousand	
were	randomly	selected	using	runif.	As	an	adaptive	ABC-MCMC	was	implemented,	
MCMC	chains	were	not	contiguous,	therefore	removal	of	initial	burn-in	period	from	
the	final	chains	was	not	required.	This	was	checked	by	comparing	outputs	from	the	
first	and	second	half	of	the	chains,	which	confirmed	similarity	throughout	the	chains.	
The	selected	1000	parameter	sets	were	used	to	estimate	the	median	and	uncertainty	
ranges	of	the	model.	
Table	3.10:	Epidemiological	calibration	targets	for	China	
Calibration	Factor	 Year	 Age	(years)	 Estimate	
Lower	
bound	
Upper	
bound	
All	TB	notification	rate	
(/100,000/yr)20	
2010	
All	 63.9	 51.1	 76.7	
0-14	 2.7	 2.2	 3.2	
15-54	 64.6	 51.7	 77.5	
55-64	 104.4	 83.5	 125.2	
65+	 143.1	 114.5	 171.7	
TB	Mortality	Rate	
(/100,000/yr)21	
2010	
All	 3.37	 1.69	 5.06	
0-14	 0.29	 0.15	 0.44	
15-59	 1.91	 0.96	 2.87	
60+	 15.69	 7.85	 23.54	
Microbiologically-positive	
pulmonary	TB	prevalence	
rate	
(/100,000/yr)19	
2000	
³15	 178	 163	 195	
15-29	 92	 72	 116	
30-59	 155	 126	 189	
60+	 596	 510	 698	
2010	
³15	 116	 101	 132	
15-29	 59	 40	 86	
30-59	 99	 77	 129	
60+	 346	 294	 407	
All	age	TB	incidence	rate	
(/100,000/yr)17	 2010	 All	age	 78	 72	 83	
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3.6.4 Additional	Methods:	Vaccine	Parameters	
Vaccine	introduction	was	implemented	in	2025,	as	this	was	considered	the	earliest	
likely	date	of	 implementation	of	 a	new	vaccine.	Modelled	 characteristics	of	novel	
vaccines	have	previously	been	categorised	within	four	dimensions:	the	host	infection	
status	 required	 for	 efficacy,	 the	 effect	 type,	 vaccine	 efficacy,	 and	 duration	 of	
protection.8	An	additional	characteristic	is	whether	the	modelled	vaccine	efficacy	is	
‘all-or-nothing’	or	‘leaky’.	Implementation	parameters	included	timing	of	vaccination,	
ages	vaccinated	and	coverage.	
3.6.4.1 Host	infection	status	
Previous	exposure	of	the	immune	system	may	impact	the	immune	response	to	the	
vaccine	antigen.	Therefore,	 the	efficacy	of	 a	 given	 candidate	may	be	 reliant	upon	
whether	the	vaccinated	individual	is	M.tb-naïve,	currently	latently	infected	or	ever-
infected.	Therefore,	four	infection	status	combinations	were	modelled	(Table	3.11).	
Pre-infection	vaccines	were	assumed	to	prevent	development	of	active	disease	only	
in	never-infected	 individuals	 (!" > 0, !& = 0, !( = 0).	 Post-infection	 (PSI)	 vaccines	
were	assumed	efficacious	when	delivered	to	either	latently	infected	populations	or	
those	who	 had	 recovered	 from	 active	 disease	 (!" = 0, !& > 0, !( > 0).	 A	 vaccine	
effective	pre-	and	post	infection	(P&PI),	producing	immunity	in	all	except	those	with	
active	 disease	 (!" > 0, !& > 0, !( > 0 ),	 was	 modelled	 to	 estimate	 the	 greatest	
preventative	 vaccine	 impact	 given	 the	 efficacy	 and	 other	 vaccine	 parameters.		
Therapeutic	 vaccines	 were	 not	 explored	 in	 this	 study,	 so	 none	 were	 considered	
effective	in	the	populations	with	active	disease.	
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Table	3.11:	Host	infection	statuses	in	which	each	vaccine	type	is	effective	
Vaccine	
Never	infected	
(S)	
Latently	
infected	(L)	
Active	Disease	
(I	or	NI)	
Recovered	from	
disease	(R)	
PRI	 Yes	 No	 No	 No	
PSI	 No	 Yes	 No	 Yes	
P&PI	 Yes	 Yes	 No	 Yes	
	
3.6.4.2 Effect	type	and	vaccine	efficacy	
As	described	in	the	main	text	and	model	equations,	prevention	of	infection	vaccines	
reduced	 the	 infection	 parameter,	 and	 prevention	 of	 disease	 vaccine	 reduced	 the	
parameters	 for	 development	 of	 disease	 (proportion	 developing	 primary	 active	
disease,	 and	 risk	 of	 reactivation	 from	 latent	 and	 recovered	 classes).	 Modelled	
vaccines	 did	 not	 affect	 infectiousness	 of	 disease,	 severity	 of	 disease,	 case	 fatality	
ratio,	likelihood	of	natural	cure,	or	case	detection.	
As	 the	 research	question	 aimed	 to	 explore	 the	 impact	 of	 a	 comprehensive	 set	 of	
vaccine	efficacies,	the	full	range	of	vaccine	efficacies	from	0%	to	100%,	in	10%	steps,	
were	 explored	 for	 both	 prevention	 of	 infection	 and	 prevention	 of	 disease	 and	 in	
combination	with	each	other.	
3.6.4.3 Vaccine	Duration	and	Waning	of	Protection	
Modelled	durations	were	2,	3,	5,	7,	10,	15,	20,	25	years	and	lifelong.	The	minimum	
expected	duration	of	protection	anticipated	from	clinical	trials	is	two	years.	Although	
it	is	unlikely	that	data	on	immune	responses	of	any	longer	than	five	years	would	be	
known	at	registration,	given	BCG	is	known	to	protect	for	at	least	10	years,	potentially	
longer,69	 it	 is	possible	that	these	 longer	durations	of	protection	would	be	possible	
with	 new	 vaccines.	Vaccination	 is	modelled	 as	 ‘take’,	 and	waning	 assumed	 to	 be	
exact.	No	Immunosenescent	waning	is	assumed.		
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3.6.4.4 Leaky	versus	all-or-nothing	vaccine	
The	 model	 that	 the	 basic	 structure	 was	 developed	 from	modelled	 all-or-nothing	
prevention	 of	 disease	 vaccines,1	 meaning	 that	 the	 proportion	 moved	 to	 the	
vaccinated	 stratum	was	vaccine	efficacy	 scaled	by	 coverage	 (‘effective	 coverage’),	
with	 the	 vaccinated	 stratum	 100%	 protected	 against	 disease.	 The	 different	
assumption	modeled	here	was	of	 ‘leaky’	vaccine	efficacy,	 in	which	 the	proportion	
moved	 to	 the	 vaccinated	 stratum	 equals	 coverage,	 and	 the	 vaccinated	 stratum	
receive	partial	protection	against	infection	and/or	disease.		
Prevention	of	infection	vaccine	efficacy	(effI)	was	applied	to	the	infection	parameter	
(l)	by	multiplying	it	by	(1-effI),	and	prevention	of	disease	efficacy	(effD)	reduced	the	
proportion	developing	primary	active	disease	(p),	and	risk	of	reactivation	from	the	
latent	 (v)	and	recovered	classes	 (r).	 In	 this	 leaky	protection	model,	 the	vaccinated	
population	 can	 develop	 infection	 and	 disease,	 just	 with	 a	 lower	 risk	 than	 the	
unvaccinated	population.		
There	were	two	main	reasons	for	choosing	leaky	vaccine	efficacy.	Firstly,	Ragonnet	
(2015)	has	demonstrated	that	models	vaccinating	with	all-or-nothing	vaccines	tend	
to	 have	 greater	 impact	 than	 leaky	 vaccines.70	 Therefore,	 to	 ensure	 conservative	
estimates	in	this	model,	which	is	important	when	estimating	the	potential	achievable	
impact	 of	 a	 vaccine,	 a	 leaky	 vaccine	 was	 more	 appropriate.70	 Secondly,	 from	 a	
technical	 perspective,	 all-or-nothing	 vaccination	 could	 not	 be	 used	 to	 model	 a	
vaccine	with	simultaneous	efficacy	against	infection	and	disease,	as	is	the	research	
question	 here.	 To	 model	 these	 activities	 concurrently	 would	 require	 either	 1)	
separate	vaccine	strata	for	POI	and	POD	efficacy,	which	was	considered	an	unrealistic	
scenario	as	it	requires	populations	to	experience	either	protection	against	infection	
or	disease,	or	2)	the	two	efficacy	types	combined	in	to	one	vaccine	stratum,	but	this	
would	 not	 be	 representative	 of	 both	 types	 of	 efficacy,	 which	 is	 integral	 to	 the	
research	question	and	therefore	required.		
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3.6.4.5 Vaccine	implementation	and	coverage	
Timing	and	ages	for	routine	and	mass	vaccination	are	explained	in	detail	in	the	main	
text.	In	brief,	annual	routine	vaccination	at	9	years	was	based	upon	using	the	HPV	
vaccination	 platform,	 mass	 vaccination	 of	 adolescents	 and	 adults	 was	 to	 ensure	
coverage	 of	 the	 epidemiological	 peak,	 and	 10-yearly	 mass	 campaigns	 were	
considered	the	most	feasible	scenario	by	stakeholders.	
Coverage	of	routine	vaccination	of	9	year	olds	was	a	conservative	assumption	(80%).	
This	was	based	upon	a	combination	of	gross	secondary	school	enrolment	ratio	from	
China	(94.3%)	taking	 in	to	account	vaccination	coverage	of	those	attending	school	
would	not	be	100%,	and	the	HPV	coverage	achieved	for	9	year	olds	in	South	Africa	
(87%).30,31	 Coverage	 of	 mass	 vaccination	 was	 modelled	 at	 70%,	 based	 upon	
Menafrivac	 data	 and	 influenza	 vaccination	 in	 China.34,35	 Experience	 from	 serial	
vaccination	suggests	approximately	a	10%	drop	 in	coverage	between	doses,32	and	
Menafrivac	campaigns	in	sub	Saharan	Africa	achieved	coverages	of	70-98%	of	1-29	
year	olds.33	However,	given	the	broader	age	range	for	vaccination	in	this	model,	and	
that	 routine	 elderly	 influenza	 vaccination	 in	 China	 only	 reaches	 coverages	 of	 36-
49%,34,35	the	lower	end	of	the	Menafrivac	coverage	was	considered	an	appropriate	
assumption	(70%).	
3.6.5 Additional	Methods:	Selection	of	outcome	measures	
In	 recent	modelling	 to	 inform	TB	antimicrobial	 TPPs,	 given	 there	was	an	effective	
standard	 of	 care,	 the	 research	 aimed	 to	 focus	 on	 improving	 one	 or	 two	 priority	
characteristics	that	would	provide	the	most	impact.71	Without	an	existing	vaccine	for	
adolescent/adult	tuberculosis,	such	prioritization	is	of	less	relevance.	Instead,	based	
upon	stakeholder	consultation,	my	research	aimed	to	more	broadly	inform	targets	
for	the	overall	efficacy	and	duration	profile	of	the	vaccine	required	to	achieve	given	
levels	of	population-level	impact.	
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	The	primary	outcome	measure	of	impact	selected	was	incidence	rate	reduction	in	
2050	compared	to	the	no	new	vaccine	baseline.	To	inform	the	TPP	characteristics,	
estimates	 of	 the	 values	 of	 the	 duration	 and	 vaccine	 efficacies	 for	 prevention	 of	
infection	and	disease	characteristics	required	to	achieve	pre-defined	levels	of	impact	
were	 required.	 Given	 the	 interdependence	 of	 these	 three	 characteristics,	 two	
durations	of	protection	were	identified	(see	3.3.5),	and	median	values	and	ranges	for	
the	prevention	of	 infection	and	disease	characteristics	required	to	achieve	a	given	
population-level	 reduction	 in	 TB	 incidence	 rate	 in	 2050	 were	 estimated.	 More	
importantly,	the	heatmaps	demonstrating	population	level	reduction	in	TB	incidence	
rate	compared	to	no	new	vaccine	baseline	in	2050	for	all	evaluated	values	of	VE-POI,	
VE-POD	and	duration	of	protection	outputs	should	be	referred	to	in	TPPs.	
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Summary	of	Chapter	4	
	
The	objective	of	chapter	4	(objective	3)	was	to	investigate	the	impact	of	age-targeted	
vaccination	programmes	to	adolescents	versus	older	adults	on	population-level	TB	
epidemiology.		
In	this	chapter,	I	further	adapted	the	calibrated	China	model	developed	in	chapter	3	
to	 explore	 age	 targeting	 of	 new	 TB	 vaccines.	 This	 chapter	 reports	 the	 results	 of	
exploring	the	impact	of	vaccination	of	adolescents	(15-19	years)	versus	older	adults	
(60-64	years)	with	new	TB	vaccines.	A	subset	of	vaccines,	selected	based	upon	the	
results	of	the	modelling	in	chapter	3,	were	explored	in	this	chapter.	The	contributions	
of	 the	 authors	 to	 this	 work	 are	 described	 in	 the	 paper	 cover	 sheet.	 This	 work	 is	
reported	as	research	paper	2,	currently	under	review	at	the	Lancet	Global	Health.		
Citation	(paper	2):	Harris	RC,	Sumner	T,	Knight	GM,	Evans	T,	Cardenas	V,	Chen	C,	and	
White	 RG.	New	 tuberculosis	 vaccines	 –	 the	 impact	 of	 age	 targeted	 vaccination	 in	
China	and	implications	for	vaccine	development.	Under	review	
Earlier	 iterations	 of	 this	 work	 were	 submitted	 to	 Aeras	 as	 a	 report,	 and	 were	
presented	 at	 the	 TB	 Vaccine	 4th	 Global	 Forum	 (21st	 April	 2015)	 and	 the	 Union	
Conference	for	Lung	health	(6th	December	2015).	
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CHAPTER	4 Age	targeting	of	new	TB	vaccines	in	China	
4.1 Introduction	
4.1.1 Background	
Modelling	studies	have	demonstrated	that	routine	vaccination	of	adolescents	and/or	
periodic	mass	vaccination	of	adults	provides	much	greater	impact	more	rapidly	than	
routine	 vaccination	 of	 neonates.2-5	 Adolescent/adult	 vaccination	 has	 also	 been	
demonstrated	to	be	more	cost	effective,	as	vaccines	with	as	low	as	20%	efficacy	and	
5	years	duration	of	protection	demonstrated	a	cost	effective	price,	whereas	neonatal	
vaccines	were	only	found	to	have	a	cost	effective	price	at	much	higher	efficacies	and	
durations.2		
Accordingly,	 vaccine	 implementation	 in	 Chapter	 3	 was	 modelled	 as	 routine	
vaccination	of	9	year	olds	alongside	HPV	vaccination,	with	periodic	mass	vaccination	
of	adolescents/adults.	This	takes	advantage	of	a	 likely	future	vaccination	platform,	
and	 helps	 maximise	 absolute	 impact	 through	 mass	 vaccinations.	 However,	 the	
resources	required	to	conduct	such	mass	campaigns,	especially	the	more	frequent	
scenarios,	would	be	substantial.	Therefore,	age-targeting	of	routine	vaccination	could	
help	ensure	a	balance	between	maximisation	of	vaccine	impact	and	efficient	use	of	
resources.		
In	Chapter	3,	the	baseline	epidemiological	model	demonstrated	a	very	clear	shift	in	
the	 age	 distribution	 of	 TB	 in	 China	 between	 2000	 and	 2050.	 In	 2000,	most	 cases	
occurred	in	the	15-64	year	old	age	group	(75.8%;	UR:	71.3-81.0);	whereas	by	2050,	
74.5%	(UR:	70.2-78.6)	were	estimated	to	occur	in	the	elderly	(≥65	years	old).	This	was	
concurrent	 with	 a	 transition	 from	 a	 new-infection-driven	 to	 a	 reactivation-driven	
epidemic.	This	is	indicative	of	the	potential	importance	of	older	adult	age	groups	in	
efforts	to	maximise	future	impact	of	new	TB	vaccines.		
Given	these	results,	a	clear	research	need	was	identified	to	investigate	whether	the	
current	 focus	 on	 targeting	 routine	 vaccination	 to	 adolescents	 or	 an	 possible	
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alternative	targeting	strategy	focused	on	older	adults	could	potentially	help	maximise	
impact.	No	existing	research	explores	the	impact	of	vaccinating	older	adults	or	the	
elderly	against	TB,	therefore	this	is	the	first	of	its	kind	for	TB	vaccines.6	
Older	adults	are	a	population	almost	entirely	excluded	from	current	clinical	trials.	The	
M72-AS01E	vaccine	candidate	in	phase	IIB	trials	recruits	only	18-50	year	olds,7	and	
the	DAR-901	candidate	is	currently	in	trials	in	13-15	year	olds.8	The	only	candidate	
recruiting	up	to	64	year	olds	is	the	M.vaccae	candidate	in	phase	III	trials	in	China,9	
and	 there	 are	 no	 candidates	 recruiting	 the	 elderly.	 Older	 age	 groups	 tend	 to	 be	
excluded	due	to	uncertainty	with	regards	to	safety	and	immunogenicity.	However,	
the	robust	efficacy	achieved	zoster	vaccines	in	older	adults	and	the	elderly	provides	
precedent	 for	 considering	 TB	 vaccine	 development	 in	 older	 age	 groups.10,11	
Therefore,	 results	 of	 this	 study	 are	 of	 importance	 for	 informing	 recruitment	
populations	 for	 future	 trials	 and,	 if	 found	 to	 be	 efficacious	 in	 these	 age	 groups,	
implementation	strategies	once	a	candidate	is	registered.		
In	this	chapter,	I	further	developed	the	model	reported	in	Chapter	3,	to	explore	the	
relative	impact	of	vaccinating	adolescents	versus	older	adults	in	China.	
4.1.2 Aims	and	objectives	
This	Chapter	contributes	towards	the	first	aim	of	the	thesis	and	objective	3:	
Aim	 1:	 Generate	 mathematical	 models	 of	 age-stratified	 demography	 and	 TB	
epidemiology	 to	 explore	 the	 population-level	 epidemiological	 impact	 of	 vaccine	
characteristics	and	 implementation	strategies	 for	potential	new	TB	vaccines,	using	
China	as	a	case	study.	
Objective	3:	Using	the	calibrated	model	of	the	TB	epidemic	in	China	and	main	vaccine	
characteristics	 (objective	 2),	 investigate	 the	 impact	 of	 age-targeted	 vaccination	
programmes	to	adolescents	versus	older	adults	on	population-level	TB	epidemiology.	
Chapter	4:	Age	targeting	of	new	TB	vaccines		 	201	
4.1.3 Overview	of	modelled	vaccine	characteristics	
Detailed	 methods	 are	 presented	 in	 the	 relevant	 sections	 of	 the	 manuscript	 and	
supplementary	materials.	A	brief	summary	follows	of	the	key	vaccine	characteristics	
chosen	based	upon	the	results	of	Chapter	3,	and	the	main	differences	compared	to	
Chapter	3	(Table	4.1).	
To	 explore	 age	 targeting,	 in	 the	 following	 research	 adolescent	 vaccines	 were	
routinely	delivered	to	15	year	olds,	and	older	adult	vaccines	to	60	year	olds,	with	a	
one-off	3-year	mass	campaign	of	ages	16-19	and	61-64	year	olds.	Selection	of	these	
vaccination	 ages	 took	 into	 consideration	 the	 high	 burden	 age	 groups	 observed	 in	
Chapter	 3,	 logistical	 feasibility	 of	 delivery,	 the	 adolescent	 age	 group	 of	 current	
strategic	 focus,	 and	 safety	 considerations	 for	 the	older	 age	group.	 To	explore	 the	
impact	 of	 implementation	 success,	 both	 30%	 and	 70%	 vaccination	 coverage	 was	
explored.	
In	Chapter	3	it	was	demonstrated	that	prevention	of	disease	vaccines	will	be	needed	
to	maximise	the	future	impact	of	new	TB	vaccines	in	China.	Therefore,	in	this	chapter	
the	 model	 was	 adapted	 to	 focus	 on	 prevention	 of	 disease	 vaccination	 as	 ‘all-or-
nothing’	protection.		
Vaccines	effective	post-infection	were	shown	to	deliver	greatest	impact	in	China	over	
the	time	horizon	explored,	but	given	that	the	prevalence	of	infection	was	estimated	
to	be	substantially	higher	in	older	age	groups,	in	this	chapter	I	continue	to	model	pre-
infection,	post	infection	and	pre-	and	post-infection	vaccines,	so	as	not	to	bias	the	
results	towards	older	adult	vaccination.	 In	Chapter	3,	post-infection	vaccines	were	
assumed	 to	 provide	 efficacy	 both	 in	 latency	 and	 in	 populations	 recovered	 from	
disease.	However,	it	is	possible	that	post-infection	vaccines	would	be	registered	for	
use	only	in	latency,	so	the	relative	impact	of	these	two	types	of	post-infection	vaccine	
was	explored	in	this	study.		
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Based	upon	results	from	Chapter	3,	I	decided	to	explore	a	subset	of	vaccine	efficacies	
of	 40%,	 60%	 and	 80%.	 These	 were	 anticipated	 to	 be	 technically	 feasible,	 and	 in	
Chapter	3	were	estimated	to	achieve	40-49%	up	to	60-69%	incidence	rate	reduction	
in	2050	 if	delivered	as	a	P&PI	POD	vaccine	with	10	years	protection	and	10-yearly	
mass	vaccination	campaigns.		
In	this	chapter,	duration	of	protection	was	limited	to	10	and	20	years.	Based	upon	
expert	 opinion,	 these	were	 considered	 a	 likely	 and	 an	 optimistic	 scenario	 for	 the	
duration	 of	 protection,	 and	 allowed	 exploration	 of	 the	 impact	 of	 targeted	
vaccination.	In	Chapter	3,	waning	occurred	exactly	at	the	duration	of	protection	for	
all	individuals	and	was	not	altered	by	the	age	of	the	vaccinated	individual.	This	was	
improved	 to	more	 closely	 reflect	biological	 variation	 in	 this	 chapter,	 by	modelling	
waning	at	the	population	level	as	normally	distributed	around	the	mean	duration	of	
protection,	with	a	 standard	deviation	of	10%	of	 the	mean.	 Secondly,	 in	older	 age	
groups	it	is	biologically	plausible	that	immunosenescence	could	lead	to	more	rapid	
waning	 of	 protection.	 To	 avoid	 bias	 towards	 older	 adult	 vaccination,	
immunosenescent	waning	was	represented	by	accelerated	waning	in	the	population	
aged	 ≥65	 years.	 In	 the	main	 analysis	 this	 was	 assumed	 at	 2%	 per	 year,	 but	 was	
explored	for	0-5%	in	sensitivity	analyses.	
A	summary	of	the	comparisons	between	the	vaccines	modelled	in	chapters	3	and	4	is	
provided	in	(Table	4.1),	and	further	detail	is	provided	in	the	manuscript	in	section	4.2.	
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Table	4.1:	Summary	of	differences	in	vaccine	characteristics	between	the	model	developed	in	
Chapter	3	compared	to	Chapter	4.	
Vaccine	characteristic	
Vaccines	modelled	
in	Chapter	3	
Vaccines	modelled	
in	this	chapter	(Chapter	4)	
Routine	vaccination	
age	 9	year	olds	 15	or	60	year	olds	
Mass	vaccination	age	 ≥10	years	old	 16-19	or	61-64	year	olds	
Mass	frequency	
Every	10	years	(or	duraton	of	
protection	if	longer),	
starting	in	2025	
One-off,	
during	2025-2027	
Coverage	routine/mass	 80%	/	70%	 30%	or	70%	/	30%	or	70%	
Effect	type		 POI&D	 POD-only	
Host	infection	status	
required	for	efficacy	
P&PI,	PRI,	PSI-L&R	 P&PI,	PRI,	PSI-L&R,	PSI-L	
Vaccine	efficacy	 0-100%	 40-80%	
Take	or	degree	efficacy	 Leaky	(‘degree’)	 All-or-nothing	(‘take’)	
Duration	of	protection	 2	years	to	lifelong	 10	or	20	years	
Waning	 All	wane	at	exactly	duration	of	protection.	
Normally	distributed	around	
mean	(s.d.	1	or	2	years).	Elderly	
immunoscenescent	waning	2%.	
	
Chapter	4:	Age	targeting	of	new	TB	vaccines		 	204	
4.2 Research	Paper	2:	New	tuberculosis	vaccines	–	the	impact	of	age	
targeted	vaccination	in	China	and	implications	for	vaccine	
development	
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Paper	 2:	 New	 tuberculosis	 vaccines	 –	 the	 impact	 of	 age	 targeted	 vaccination	 in	
China	and	implications	for	vaccine	development	
Authors:	 Rebecca	 C.	 Harris,	 Tom	 Sumner,	 Gwenan	 M.	 Knight,	 Tom	 Evans,	 Vicky	
Cardenas,	Chen	Chen,	and	Richard	G	White.	
Author	 contributions:	 All	 authors	 contributed	 to	 development	 of	 the	 research	
question.	The	research	methodology	was	developed	by	myself	with	input	from	Prof.	
Richard	 White,	 Dr	 Tom	 Sumner	 and	 Dr	 Gwenan	 Knight.	 I	 collected	 the	 data	 for	
parameterisation	 and	 calibration	of	 the	model	 from	 secondary	 sources.	 The	basic	
structure	of	the	model	was	based	upon	a	model	developed	by	Dr	Gwenan	Knight,	but	
I	substantially	modified	the	model	with	guidance	from	Prof.	Richard	White,	Dr	Tom	
Sumner	 and	 Dr	 Gwenan	 Knight,	 including	 development	 of	 age	 structure	 and	
parameterisation,	 calibration	 to	 age	 stratified	 epidemiological	 (prevalence,	
notifications,	 mortality	 and	 incidence)	 and	 demographic	 calibration	 targets,	 age	
targeted	 vaccination	 and	 immunosenescence,	 incorporation	 of	 social	 mixing	
patterns,	and	development	of	model	outcomes	(e.g.	incidence	rate	reduction,	NNV)	
amongst	other	developments.	I	carried	out	the	model	calibration,	with	guidance	from	
Dr	Tom	Sumner.	Interpretation	of	results	were	my	own	and	I	wrote	the	first	draft	of	
the	 manuscript	 and	 incorporated	 co-author	 feedback	 manuscript.	 All	 authors	
reviewed	manuscript	drafts	and	approved	the	final	manuscript.	
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New	tuberculosis	vaccines	–	the	impact	of	age	targeted	
vaccination	in	China	and	implications	for	vaccine	development	
Authors:	Rebecca	C.	Harris,a,*	Tom	Sumner,a	Gwenan	M.	Knight,b	Tom	Evans,c,d	Vicky	
Cardenas,c,e	Chen	Chen,f,g	and	Richard	G	White.a		
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Abstract	
Background:	Tuberculosis	is	the	leading	single-pathogen	cause	of	death	worldwide,	
with	China	the	third	largest	contributor	to	global	tuberculosis	incidence.	New	tools,	
such	 as	 new	 vaccines,	 are	 needed	 to	 meet	 WHO	 tuberculosis	 goals.	 Current	
tuberculosis	vaccine	development	strategies	mostly	target	infants	or	adolescents,	but	
given	China’s	ageing	epidemic,	vaccinating	older	ages	may	be	important.	We	explored	
the	potential	impact	of	new	tuberculosis	vaccines	in	China,	targeted	to	adolescents	
(15-19	 years)	 or	 older	 adults	 (60-64	 years)	 and	 varying	 vaccine	 characteristics,	 to	
inform	strategic	vaccine	development.	
Methods:	A	Mycobacterium	tuberculosis	transmission	model	was	calibrated	to	age-
stratified	 demographic	 and	 epidemiological	 data	 from	 China.	 Vaccine	
implementation	(age	targeting	and	coverage)	and	characteristics	(efficacy,	duration	
of	 protection,	 and	 host	 infection	 status	 required	 for	 efficacy)	 were	 explored.	
Outcomes	included	incidence	and	mortality	rate	reduction	in	2050	compared	to	no	
new	vaccine,	and	number	needed	to	vaccinate	per	case	averted.	
Findings:	By	2050,	results	suggest	that	74·5%	(uncertainty	range	(UR):	70·2-78·6)	of	
incident	tuberculosis	cases	in	China	would	occur	in	the	elderly	(≥65	years),	and	75·1%	
(UR:	66·8-80·7)	would	be	due	to	reactivation,	rather	than	recent	transmission.	The	
vaccine	profiles	explored	averted	up	to	3·0million	cases	over	2025-2050.	All	vaccine	
profiles	 delivered	 to	 older	 adults	 had	 higher	 population-level	 impact,	 and	 lower	
number	 needed	 to	 vaccinate	 per	 case	 or	 death	 averted,	 than	 if	 delivered	 to	
adolescents.	 Vaccinating	 older	 adults	 with	 post-infection	 vaccines	 provided	
substantially	 greater	 impact	 than	 pre-infection	 vaccines.	 Results	 were	 robust	 to	
sensitivity	analysis.	
Interpretation:	Adolescent-targeted	tuberculosis	vaccines,	the	focus	of	many	current	
development	plans,	would	have	low	impact	in	ageing,	reactivation-driven	epidemics	
like	China.	Instead,	an	efficacious	post-infection	vaccine	delivered	to	older	adults	will	
be	critical	to	maximise	population-level	impact	in	this	setting,	and	would	provide	a	
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crucial	contribution	towards	achieving	WHO	goals.	Older	adults	should	be	included	
in	tuberculosis	vaccine	clinical	development	and	implementation	planning.		
Funding:	Aeras	and	UK	MRC	
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Research	in	context	panel	
Evidence	 before	 this	 study:	 A	 recently	 published	 systematic	 review	 of	 the	
tuberculosis	(TB)	vaccine	epidemiological	modelling	literature	(Harris	et	al,	2016)	was	
updated	for	articles	published	up	to	19th	July	2017.	The	published	literature	suggests	
that	targeting	new	vaccines	to	adolescents	would	have	greater	 impact	than	 infant	
vaccination,	however	no	previous	research	has	explored	the	potential	impact	of	new	
TB	vaccines	targeted	to	older	adults	or	the	elderly.	Two	studies	exploring	the	impact	
of	new	TB	vaccines	in	China	compared	vaccination	at	birth	to	mass	vaccination,	and	
suggested	that	post-infection	mass	vaccination	may	be	important	for	elimination	in	
China.	However,	critically,	age	specificity	in	demographic	and	epidemic	dynamics	in	
China	has	not	been	addressed	in	vaccine	models.		
Added	value	of	this	study:	Our	research	is	the	first	to	explore	the	potential	impact	of	
new	 TB	 vaccines	 targeted	 to	 older	 adults,	 and	 to	 compare	 this	 approach	 to	 the	
current	 strategic	 focus	 on	 adolescent	 vaccination.	 This	 data-driven	 model	 is	
calibrated	to	age-stratified	data	from	the	WHO,	UN	population	division,	and	empirical	
studies	 for	 demographics,	 prevalence,	mortality,	 notification	 and	 incidence	 rates,	
including	capturing	temporal	trends,	and	incorporates	empirical	data	on	non-random	
age	mixing.	This	study	is	the	first	to	show	that	older	adult	vaccination	with	new	TB	
vaccines	 is	 likely	 to	be	critical	 to	maximising	 impact	 in	settings	such	as	China,	and	
strengthens	the	conclusions	from	previous	studies	suggesting	that	vaccines	effective	
post-infection	will	be	needed	in	China.	
Implications	of	all	the	available	evidence:	Although	adolescent	vaccination	may	be	
a	suitable	global-level	strategy,	important	differences	in	country-level	epidemiology	
and	demography	may	cause	adolescent-targeted	TB	vaccines	to	have	low	impact	in	
ageing,	 reactivation-driven	 TB	 epidemics	 such	 as	 in	 China.	 In	 these	 settings,	 an	
efficacious	post-infection	vaccine	delivered	to	older	adults	will	be	critical	to	maximise	
population-level	 impact.	 Older	 adults	 should	 be	 included	 in	 TB	 vaccine	 clinical	
development	and	implementation	planning.		 	
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Background	
Despite	 progress	 in	 tuberculosis	 (TB)	 prevention	 and	 care	 during	 the	 last	 two	
decades,12	 China	 remains	 the	 third	 largest	 contributor	 to	 global	 TB	 incidence,	
accounting	for	918,000	(788,000-1,060,000)	new	cases	 in	2015.13	 Increasing	public	
sector	investment	in	TB	care	has	contributed	to	case	detection	rates	reaching	87%	
and	treatment	success	of	95%.12,13	Given	the	substantial	achievements	in	scale-up	of	
existing	TB	care	and	prevention	options,	mathematical	modelling	suggests	that	gains	
possible	 from	 further	 investment	 in	 existing	 tools	 alone	 are	 unlikely	 to	 reach	 the	
World	 Health	 Organization	 (WHO)	 2025,	 2035	 and	 2050	 TB	 goals	 in	 China.14-18	
Innovative	 tools,	 such	 as	 new	 TB	 vaccines,	 have	 been	 shown	 to	 be	 essential	 to	
achieving	these	targets.14-17		
Recent	years	have	seen	increasingly	rapid	advances	in	the	development	of	new	TB	
vaccines,	with	thirteen	candidates	in	clinical	trials,	including	four	in	phase	IIB/III.19	TB	
vaccine	target	product	profiles	(TPPs)	outline	the	desired	vaccine	characteristics	and	
recipient	populations	for	new	vaccines,	and	clinical	development	plans	provide	the	
pathway	to	achieving	these	criteria.	Mathematical	modelling	provides	a	systematic	
framework	 to	 explore	 the	 potential	 future	 impact	 of	 vaccine	 characteristics	 and	
implementation	 strategies	 to	 inform	TPP	development.	 Impact	 achieved	 varies	by	
epidemiological	 and	demographic	 setting,5,6	 therefore	 country-specific	models	 are	
needed	for	appropriate	vaccine	selection	and	implementation	planning	such	as	age	
targeting.	A	prophylactic	TB	vaccine	candidate	is	in	Phase	III	clinical	trials	in	China	at	
time	of	writing,9	 therefore	modelling	 to	elucidate	 the	potential	 impact	of	new	TB	
vaccines	and	implementation	strategies	in	China	is	urgently	needed.	
Traditional	vaccine	development	pathways	 focussed	on	 infant	vaccination,	 though	
recently	the	field	has	experienced	a	paradigm	shift	towards	adolescents	and	adults,20	
supported	by	insights	from	mathematical	modelling.2,5	However,	older	adult	(60-64	
years)	 and	 elderly	 (≥65	 years)	 populations	 remain	 neglected	 in	 TB	 vaccine	
development	 pathways,	 despite	 several	 developed	 and	 developing	 countries	
experiencing	high	TB	disease	burden	in	older	age	groups.21	Given	the	dramatic	and	
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on-going	population	ageing	in	China,22	and	elevated	prevalence	of	latent	infection	in	
older	populations,1	a	shift	in	burden	to	older	age	groups	could	be	expected.		
The	modelling	literature	for	TB	vaccines	has	recently	been	systematically	reviewed.6	
Although	studies	have	explored	vaccination	of	infants	compared	to	adolescents	or	all	
ages,	no	model	explores	the	potential	impact	of	new	TB	vaccines	for	older	adults	or	
the	elderly.6	Dynamics	of	 TB	disease	and	demographics	are	 intimately	 linked,	 and	
influence	the	impact	of	age-targeted	interventions.5	Only	two	studies	have	modelled	
new	 TB	 vaccines	 in	 China,4,23	 and	 neither	 accounted	 for	 age	 specificities	 in	
epidemiology	or	demographics.	Further,	in	these	studies,	vaccination	was	either	at	
birth	or	all-ages,	and	vaccine	characteristics	modelled	were	unclear	or	unrealistic	(e.g.	
100%	 vaccine	 efficacy).4,23	 Although	 not	 exploring	 vaccines,	 a	 modelling	 study	 in	
China	 showed	 that	 existing	 TB	 interventions	 alone	 would	 not	 reach	 WHO	 2035	
targets,	 whereas	 development	 of	 preventative	 therapy	 for	 the	 elderly	 could	 be	
“transformational”.16		
In	this	paper,	we	aimed	to	estimate	future	trends	in	TB	epidemiology,	and	the	impact	
of	new	TB	vaccines	in	China	by	varying	implementation	strategies	(age-targeting	and	
coverage)	 and	 vaccine	 characteristics	 (efficacy,	 duration	 of	 protection,	 and	 host	
infection	status	required	for	efficacy).	
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Methods		
Model	structure	and	calibration	
An	age-stratified	population-level	compartmental	deterministic	transmission	model	
calibrated	 to	 China’s	 TB	 epidemic	 was	 developed	 in	 R,24	 based	 upon	 the	 model	
developed	by	Knight	et	al.	(2014).2	A	summary	follows.	See	supplementary	materials	
for	full	details.	
The	 model	 represents	 five	 infection	 states:	 uninfected,	 latent	 infection,	
bacteriologically-positive	 active	 TB	 disease,	 bacteriologically-negative	 active	 TB	
disease,	 and	 recovered	 from	 active	 TB	 disease	 populations.	 Transitions	 between	
states	 represent	 acquisition	 of	 infection,	 development	 of	 primary,	 reactivation	 or	
relapse	disease,	effective	detection	and	treatment,	or	natural	cure	(Supplementary	
Figure	S1).	Births	enter	the	uninfected	state,	all-cause	mortality	occurs	in	all	states,	
and	TB	mortality	occurs	 in	active	disease	states.	Uninfected,	 latent	and	recovered	
states	 comprised	 both	 unvaccinated	 and	 vaccinated	 strata.	 Age	 was	 modelled	 in	
single	 years	 from	0-100.	Main	 age	 categories	 for	 parameters	 and	outcomes	were	
children	 (0-14	 years),	 adolescents	 and	 adults	 (15-64	 years),	 and	 the	 elderly	 (≥65	
years).	Age	categories	for	vaccine	implementation	were	adolescents	(15-19	years)	or	
older	adults	(60-64	years).		
Age-stratified	natural	history	parameter	prior	ranges,	summarised	in	Supplementary	
Table	 S1,	were	 identified	based	upon	available	data.	HIV	has	been	 identified	as	 a	
proxy	for	elderly	immunosenescence,25	therefore	for	parameters	without	available	
elderly	data,	priors	were	based	upon	data	from	HIV	populations.	Temporal	evolution	
of	 the	 age	 distribution	 of	 infection	 and	 disease	 was	 captured	 historically	 and	
prospectively	by	calibration	to	age-stratified	epidemiological	and	demographic	data	
using	 age-specific	 natural	 history	 parameters	 and	 contact	 patterns.	 To	 provide	 a	
more	 gradual	 older-age	 transition	 in	 reactivation,	 relapse,	 natural	 cure	 and	 case	
detection	parameters,	55-64	year	old	parameters	were	estimated	as	the	mean	of	the	
adult	and	elderly	calibrated	values.	Heterogeneity	in	age-wise	contact	patterns	were	
based	upon	data	 from	a	 study	 in	 Southern	China.26	 Treatment	 success	was	based	
upon	historical	data,	and	assumed	to	plateau	beyond	2011	due	to	high	success	rates	
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achieved	(95%).27	Case	detection	followed	a	generalised	logistic	function	based	upon	
WHO	1990-2010	data.28	BCG	delivery	was	assumed	to	remain	constant,	so	was	not	
explicitly	modelled.	
A	 two-stage	 calibration	 process	 was	 employed,	 with	 the	 first	 stage	 a	 manual	
calibration	to	UN	2010	and	2050	age-stratified	demographic	data	and	projections,29	
and	 the	 second	 stage	 an	 adaptive	 rejection	 Approximate	 Bayesian	 Computation-
Markov	Chain	Monte	Carlo	 (ABC-MCMC)-based	method	using	a	modified	easyABC	
package	to	calibrate	to	historical	epidemiological	data	(see	Supplementary	Section	
4.3.3	for	details).30,31	To	provide	the	temporal	and	age-stratified	granularity	required,	
the	 model	 was	 calibrated	 to	 18	 epidemiological	 data	 ranges:	 China’s	
bacteriologically-positive	prevalence	rates	(≥15,	15-29,	30-59	and	≥60	years)	in	2000	
and	2010,12	2010	notification	rates	(all-age,	0-14,	15-54,	55-64,	and	≥65	years),32	2010	
mortality	 rates	 (all-age,	 0-14,	 15-59	 and	 ≥60	 years),33	 and	 2010	 all-age	 incidence	
rate.28	After	ranking	by	 likelihood,	the	20	highest	from	one	million	parameter	sets	
randomly	selected	from	uniform	priors	were	used	as	seeds	for	the	adaptive	rejection	
ABC-MCMC.	 Sequential	 parallel	 ABC-MCMC	 chains	 were	 employed,	 seeding	 with	
acceptances	from	the	previous	chains	and	adapting	the	rejection	criterion	until	a	full	
model	fit	to	all	18	data	ranges	was	achieved.	Results	and	uncertainty	ranges	were	
based	on	one	thousand	parameter	sets	randomly	selected	from	the	acceptances	in	
the	final	set	of	ABC-MCMC	runs.	
Epidemiological	outcomes	
Epidemiological	 outcomes	were	 calculated	annually	 for	 2000-2050	 in	 the	baseline	
(‘no	new	vaccine’)	scenario.	Contribution	by	age	group	to	annual	incident	cases	was	
calculated	as	the	proportion	of	total	incident	cases	arising	from	a	given	age	group.	
The	proportion	of	incident	disease	due	to	new	transmission	versus	reactivation	was	
estimated	annually.	The	population	attributable	fraction	(PAF)	of	each	age	group	to	
annual	 M.tb	 infections	 was	 estimated	 using	 methods	 described	 previously.34	
Prevalence	 of	 latent	 infection	was	 estimated	 by	 age,	 for	 comparison	 to	 empirical	
data.1	
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Vaccine	characteristics	and	implementation	
Two	implementation	characteristics	(age	targeting	and	coverage)	and	three	vaccine	
characteristics	 (vaccine	 efficacy,	 host	 infection	 status	 required	 for	 efficacy,	 and	
duration	of	protection)	were	varied,	exploring	96	vaccination	scenarios	in	total.		
Two	age	targeting	scenarios	were	explored:	vaccination	of	adolescents	(15-19	year	
olds)	and	of	older	adults	(60-64	year	olds).	Vaccination	was	implemented	2025-2050.	
Routine	vaccination	was	provided	annually	throughout	this	period	to	15	or	60	year	
olds.	Initial	catch-up	campaigns	were	performed	in	2025-2027	for	16-19	year	olds	or	
61-64	year	olds.		
Routine	vaccine	coverage	of	30%	and	70%	of	the	target	populations	was	explored.	
Only	those	with	active	disease	were	excluded	from	vaccination.	Annual	coverage	for	
catch-up	campaigns	was	assumed	to	be	a	third	of	the	routine	coverage.	We	assumed	
no	latent	infection	screening	prior	to	vaccination,	but	each	vaccine	was	only	effective	
in	 the	specified	host	 infection	status	groups.	Therefore,	 the	proportion	effectively	
immunised	in	a	given	year	was	the	product	of	coverage	in	hosts	with	the	specified	
infection	status,	and	vaccine	efficacy.		
Vaccine	 efficacy	 (VE)	 was	 modelled	 as	 40%,	 60%	 and	 80%	 protective	 against	
development	of	TB	disease	 (‘prevention	of	disease’).	Vaccination	was	modelled	as	
‘take’	(all-or-nothing)	protection.	Vaccine	protection	in	four	host	infection	statuses	
was	 explored:	 1)	 uninfected	 individuals	 (pre-infection:	 PRI),	 2)	 latently	 infected	
individuals	(post-infection,	latency-only:	PSI-L),	3)	individuals	either	latently	infected	
or	 recovered	 from	active	disease	 (post-infection:	PSI-L&R),	or	4)	 individuals	either	
uninfected,	 latently	 infected,	 or	 recovered	 from	 active	 disease	 (pre-	 and	 post-
infection:	P&PI).		
The	rate	of	vaccine	waning	was	set	so	that	the	duration	of	vaccine	protection	was	
normally	distributed	with	a	mean	of	10	or	20	years	and	a	standard	deviation	of	1	or	
2	years,	respectively.	Waning	returned	the	population	to	the	equivalent	unvaccinated	
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state.	 To	 account	 for	 immunosenescence,	 an	 additional	 2%	 annual	 waning	 was	
assumed	 for	 elderly	 populations,	 and	 was	 varied	 between	 0-5%	 in	 sensitivity	
analyses.	
All	 combinations	 of	 these	 characteristics	 and	 implementation	 strategies	 were	
explored.	 For	 reporting	of	 some	outcomes,	 an	 ‘intermediate’	 vaccination	 scenario	
was	defined	as	60%	VE,	10-year	protection	and	70%	coverage.		
Vaccine	impact	outcomes	
Primary	outcomes	were	the	percentage	incidence	rate	reduction	and	mortality	rate	
reduction	in	each	vaccination	scenario	compared	to	the	no	new	vaccine	baseline	in	
2050.	Secondary	outcomes	were	cumulative	number	of	TB	cases	or	deaths	averted	
2025-2050	compared	to	baseline,	and	the	cumulative	number	needed	to	vaccinate	
(NNV)	per	case	or	death	averted	2025-2050.	These	outcomes	were	compared	by	age	
targeting	and	other	vaccine	characteristics.	
Role	of	the	funding	source 
The	 study	 sponsor	 (Aeras),	 a	 non-profit	 Product	 Development	 Partnership,	
contributed	 to	 development	 of	 the	 research	 question,	 and	 commented	 on	
manuscript	drafts.		
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Results	
Baseline	(no	new	vaccine)	scenario	
The	model	fitted	overall	and	age-stratified	data	for	demography	and	TB	prevalence,	
notification,	incidence	and	mortality	rates	(Figure	1A	and	Supplementary	Figures	S3-
8).	
Modelled	all-age	infection	prevalence	was	15·7%	(UR:	12·8-18·7)	in	2013,	increasing	
almost	linearly	from	1·3%	(UR:	1·0-1·6)	in	5-9	year	olds,	to	37·0%	(UR:	31·1-42·6)	in	
≥70	 year	olds	 (Supplementary	 Figure	 S10).	Although	not	 calibrated	 to	 these	data,	
modelled	 age-stratified	 infection	 prevalence	 aligned	 closely	 with	 published	
Quantiferon	data.1	At	vaccine	introduction,	2·2%	(UR:	1·7-2·8)	of	15-19	year	olds	and	
25·3%	 (UR:	 20·5-30·2)	 of	 60-64	 year	 olds	 were	 latently	 infected	 (Supplementary	
Figure	S11).	
Between	2000	and	2050,	a	substantial	shift	was	projected	in	the	age	distribution	of	
incident	TB	cases,	from	75·8%	(UR:	71·3-81·0)	in	adolescents	and	adults	(15-64	years)	
in	2000,	 to	74·5%	 (UR:	70·2-78·6)	 in	 the	elderly	 (≥65	years)	 in	2050	 (Figure	1B).	A	
concurrent	age	 shift	was	observed	 in	 the	 source	of	new	 infections	 (Figure	1C	and	
Supplementary	 Section	 4.3.5.1).	 Over	 the	 same	 period,	 the	 model	 predicted	 a	
transition	from	a	recent-infection-driven,	to	a	reactivation-driven	epidemic.	Between	
2000	and	2025,	the	estimated	proportion	of	incident	disease	due	to	reactivation	rose	
from	28·6%	(UR:	21·9-32·5)	to	60·1%	(UR:	51·1-64·9).	By	2050,	75·1%	(UR:	66·8-80·7)	
of	all	incident	disease	cases	were	estimated	to	derive	from	reactivation	(Figure	1D),	
though	the	proportion	due	to	reactivation	was	lower	in	15-19	year	olds	(6·1%;	4·8-
7·8%)	than	in	60-64	year	olds	(78·1%;	UR:	71·8-81·8%).	
In	 the	 baseline	 scenario,	 the	 all-age	 TB	 disease	 incidence	 rate	 was	 projected	 to	
decline	from	56·2/100,000	population/year	(UR:	51·4-60·0)	in	2025	to	33·7/100,000	
population/year	 (UR:	 27·6-38·8)	 in	 2050,	 and	 the	mortality	 rate	 from	2·0/100,000	
population/year	 (UR:	 1·2-3·4)	 to	 1·1/100,000	 population/year	 (UR:	 0·6-2·2)	
(Supplementary	Figures	S5-6).		
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Epidemiological	impact	of	new	TB	vaccines	
Vaccine	impact,	in	terms	of	incidence	rate	reduction	in	2050	compared	to	the	no	new	
vaccine	baseline	in	2050,	varied	by	age	targeting,	host	infection	status	required	for	
efficacy,	vaccine	efficacy,	coverage	and	duration	of	protection	(Figure	2).		
All	 vaccine	 profiles	 explored	 provided	 greater	 population-level	 impact	 when	
delivered	to	older	adults	than	adolescents	(Figure	2).	The	relative	differences	were	
demonstrated	 by	 the	 ‘intermediate’	 vaccine	 profile	 (Table	 1),	 where	 the	 median	
population	level	incidence	rate	reduction	by	older	adult	vaccination	ranged	from	1.9-	
to	 157.5-times	 greater	 than	 observed	with	 adolescent	 vaccination,	 depending	 on	
host	 infection	status	required	for	efficacy.	For	the	same	 intermediate	profiles,	 the	
estimated	median	cumulative	number	needed	to	vaccinate	(NNV)	per	case	averted	
2025-2050	for	older	adult	vaccination	were	0.011	to	0.796	times	the	NNV	estimates	
for	adolescent	vaccination.		
The	relative	impact	of	pre-	versus	post-infection	vaccines	varied	by	vaccination	age	
(Figure	2).	For	older	adult	vaccination,	the	predicted	impact,	from	lowest	to	highest,	
was:	 vaccines	 effective	 pre-infection	 (PRI),	 post-infection	 in	 latency	 (PSI-L),	 post	
infection	in	individuals	either	latently	infected	or	recovered	from	active	disease	(PSI-
L&R),	 and	 pre-	 and	 post-infection	 (P&PI).	 Vaccination	 of	 older	 adults	 with	 post-
infection	 vaccines	 provided	 greater	 impact	 and	 required	 vaccination	 of	 fewer	
individuals	per	case	averted	than	pre-infection	vaccines	(Figure	2	and	Supplementary	
Table	S4).	For	adolescent	vaccination,	although	greatest	impact	was	also	with	P&PI	
vaccines,	pre-infection	vaccines	were	predicted	to	have	greater	impact	than	the	two	
post-infection	(PSI-L	and	PSI-L&R)	vaccines.		
The	 relative	 incidence	 rate	 reduction	 by	 older	 adult	 compared	 to	 adolescent	
vaccination	was	 smallest	with	 pre-infection	 vaccines	 (‘intermediate’	 vaccine	 older	
adult:adolescent	 ratio	1·9;	UR:	1·5-2·6),	and	greatest	with	post-infection	 (PSI-L&R)	
vaccines	(ratio	157·5;	UR:	119·3-225·6).	
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Inducing	 vaccine	 protection	 in	 both	 latent	 and	 recovered	 populations	 (PSI-L&R)	
provided	markedly	greater	 impact	 than	protection	only	 in	 latency	 (PSI-L)	 (Figure	2	
and	 Supplementary	 Figure	 14).	 This	 was	 especially	 important	 in	 older	 adult	
populations,	 where	 latency-only	 vaccines	 (PSI-L)	 provided	 44%	 (UR:	 20-89%)	 less	
impact	than	PSI-L&R	vaccines	(Figure	2).		
As	expected,	 increased	vaccine	efficacy,	duration	of	protection	or	 coverage	 led	 to	
greater	incidence	rate	reductions	(Figure	2).	The	cumulative	NNV	per	case	or	death	
averted	 2025-2050	 declined	 with	 increasing	 vaccine	 efficacy	 and	 duration	 of	
protection,	as	additional	benefit	was	gained	without	delivery	of	additional	vaccines	
(Supplementary	Tables	S7-8).	Although	raising	coverage	substantially	increased	cases	
averted,	many	more	vaccine	doses	were	required,	so	cumulative	NNV	was	found	to	
increase	 slightly	 at	 higher	 coverages.	 The	 same	 patterns	 of	 vaccine	 impact	 were	
observed	for	mortality	as	for	incidence.		
Of	the	vaccine	profiles	and	implementation	strategies	explored,	the	most	effective	
was	the	vaccine	effective	P&PI	with	80%	VE,	20-year	protection	and	70%	coverage.	
Delivered	to	older	adults	this	vaccine	averted	3·0	million	(UR:	2·5-3·5m)	cases	2025-
2050,	whereas	when	delivered	to	adolescents	only	502,000	(UR:	431,000-591,000)	
cases	 were	 averted	 (Figure	 2	 and	 Supplementary	 Table	 S4).	 The	 lowest	 impact	
vaccines	explored	averted	as	few	as	2,000	cases	during	2025-2050.	
	Immunosenescent	 waning	 assumptions	 had	 minimal	 impact	 on	 the	 primary	
outcome.	Increasing	annual	immunosenescent	waning	from	2%	to	5%	reduced	the	
“intermediate”	vaccine	 incidence	rate	reduction	from	13·8%	to	12·9%.	Conversely,	
assuming	no	immunosenescence	increased	this	estimate	to	14·4%.	
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Discussion	
During	2025-2050,	all	vaccine	profiles	explored	in	China	provided	higher	population-
level	impact	on	cases	or	deaths,	and	lower	cumulative	number	needed	to	vaccinate	
per	 case	 or	 death	 averted,	 when	 delivered	 to	 older	 adults	 (60-64	 years)	 than	
adolescents	 (15-19	 years).	 With	 the	 most	 effective	 vaccine	 profile	 and	 coverage	
explored,	up	to	3·0	million	cases	were	averted	between	2025-2050.	By	2050,	the	no	
new	vaccine	baseline	results	suggest	that	around	75·1%	of	incident	TB	cases	would	
be	 due	 to	 reactivation	 of	 existing	 infections	 rather	 than	 recent	 transmission,	 and	
74·5%	of	incident	cases	would	occur	in	the	elderly	(≥65	years).	Vaccination	of	older	
adults	with	post-infection	vaccines	provided	much	greater	impact	than	pre-infection	
vaccines.	Adolescent	vaccination	was	found	to	provide	limited	impact	on	China’s	TB	
epidemic	2025-2050.		
In	 the	 no	 new	 vaccine	 baseline,	 transition	 from	 an	 adult,	 transmission-driven	
epidemic	to	an	elderly,	reactivation-driven	epidemic	was	predicted	to	occur	before	a	
new	vaccine	is	likely	to	be	launched,	as	a	result	of	population	ageing	concurrent	with	
reduced	transmission	due	to	improved	TB	diagnosis,	care	and	prevention.	
Even	 though	 immunosenescence	 disadvantaged	 older	 adult	 vaccination,	 targeting	
older	 adults	 consistently	 provided	 greater	 epidemiological	 impact	 than	 targeting	
adolescents,	regardless	of	the	vaccine	characteristics	explored.	Although	older	adult	
campaigns	 delivered	 more	 vaccines	 than	 adolescent	 campaigns	 for	 the	 same	
coverage	due	 to	 the	 larger	population	 size,	number	needed	 to	vaccinate	per	 case	
averted	was	lower,	often	considerably,	than	for	adolescent	vaccination,	suggesting	
cost	effectiveness	calculations	may	also	support	older	adult	vaccination	strategies.	
Even	if	 lower	coverage	was	assumed	for	older	adult	campaigns	(30%)	than	school-
based	adolescent	campaigns	(70%),	vaccines	targeted	to	older	adults	would	still	be	
likely	 to	 provide	 at	 least	 equivalent,	 if	 not	 greater,	 impact	 than	 adolescent	
vaccination.	
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The	 relative	 impact	 of	 pre-infection	 versus	 post-infection	 vaccines	 varied	 in	
adolescent	and	older	adult	populations.	Vaccination	of	older	adults	achieved	higher	
population-level	 impact	 with	 post-infection	 vaccines,	 whereas	 higher	 impact	 was	
achieved	 in	 adolescents	 by	 pre-infection	 vaccines;	 explained	 by	 the	 substantially	
higher	prevalence	of	latent	infection	in	older	adults.	Pre-infection	vaccines	provided	
similarly	 low	 population-level	 impact	 whether	 vaccinating	 adolescents	 or	 older	
adults.	Post-infection	vaccines	delivered	to	older	adults	will	be	central	to	achieving	
the	highest	possible	impact.	However,	post-infection	vaccines	would	have	negligible	
impact	if	delivered	to	adolescents.	Post-infection	vaccines	effective	in	both	latent	and	
recovered	populations	provided	greater	impact	than	latency-only,	particularly	when	
delivered	 to	 older	 adults,	 indicating	 vaccines	 also	 effective	 against	 relapse	 after	
recovery	 from	 active	 disease	 could	 have	 important	 additional	 value.	 Vaccines	
effective	both	pre-and	post-infection	provided	greatest	impact	in	both	age	groups,	
and	would	be	the	ideal	candidate	for	development,	but	at	a	minimum	a	post-infection	
vaccine	suitable	for	older	adult	vaccination	should	be	developed	for	TB	prevention	in	
China	if	highest	population	level	impact	before	2050	is	the	primary	goal.	
Of	the	vaccine	profiles	and	delivery	strategies	explored,	an	up	to	32%	reduction	in	TB	
incidence	rate	could	be	achieved	in	2050,	which	would	be	a	substantial	contribution	
towards	 WHO	 2050	 goals.	 Even	 greater	 impact	 could	 be	 achieved	 with	 less	
conservative	 delivery	 strategies	 (e.g.	 one	 off	mass	 vaccination	 to	 all	 adults),	 or	 if	
higher	efficacy	or	duration	of	protection	were	achieved.	Our	model	demonstrates	
that	 an	 appropriately	 designed	 and	 delivered	 new	 TB	 vaccine	 could	 provide	 a	
substantial	contribution	to	TB	prevention	in	China.	
Limitations	
There	is	a	notable	data	gap	with	regards	to	elderly	TB	natural	history	parameters.	We	
represented	 this	 uncertainty	 by	 sampling	 from	 elderly	 parameter	 priors	 spanning	
HIV-negative	 and	 HIV-positive	 adult	 ranges	 in	 the	 calibration	 process.	 Given	
population	 ageing,	 the	 assumption	 that	 the	 contact	 matrix	 remained	 constant	
throughout	the	study	period	may	provide	conservative	impact	estimates.	The	vaccine	
was	 assumed	 to	 provide	 “all-or-nothing”	 protection,	 but	 the	 alternative	 “leaky”	
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assumption	could	reduce	impact	estimates.35	Due	to	high	current	treatment	success	
and	case	detection	estimates,	these	were	assumed	to	plateau.	 If	 improvements	 in	
current	 care	 measures	 were	 achieved,	 or	 better	 diagnostics	 or	 treatments	
introduced,	the	impact	achieved	by	vaccines	could	potentially	be	reduced.	However,	
this	 would	 not	 affect	 conclusions	 with	 respect	 to	 age	 targeting	 unless	 such	 an	
intervention	varied	in	effectiveness	by	age.	
Impact	was	evaluated	up	to	2050	to	align	with	the	WHO	2050	elimination	goal,	so	
results	are	specific	to	2025-2050.	Full	benefit	of	vaccines	delivered	pre-2050	would	
extend	 beyond	 2050,	 therefore	 relative	 vaccine	 impact	 may	 change	 over	 longer	
horizons.6	 Better	 vaccines	 (e.g.	 lifelong	 protection)	 or	 coverage	 could	 improve	
impact,23	 but	 were	 not	 considered	 likely	 scenarios	 by	 experts.	 Infant	 vaccination	
could	be	explored,	but	 impact	would	be	very	 low	over	this	time	horizon	given	the	
declining	 force	 of	 infection	 in	 China.2,5	 To	 answer	 the	 research	 question,	 we	
deliberately	restricted	mass	campaigns	to	narrow	age	ranges	(15-19	and	60-64	years).	
If	 a	 new	 efficacious	 vaccine	 became	 available,	 broader	 campaigns	 could	 be	
implemented	to	increase	overall	impact,	but	would	not	affect	our	overall	conclusions.		
Value	of	this	research		
This	research	is	the	first	to	explore	the	potential	impact	of	new	TB	vaccines	targeted	
to	older	age	groups,	and	 to	provide	a	comparison	of	 this	approach	 to	 the	current	
strategic	 focus	 on	 adolescent	 vaccination.20	 This	 required	 age-specific	 model	
parameterization	and	calibration,	and	is	the	first	China	TB	model	to	calibrate	to	age-
stratified	mortality	 and	 notification	 rates	 and	 include	 data-informed	 non-random	
mixing	 by	 age.	 Our	 results	 are	 consistent	 with	 the	 conclusions	 of	 the	 Dye	 study	
regarding	the	importance	of	post-infection	vaccines	in	China,23	but	provide	a	critical	
clarification:	that	population-level	impact	with	such	vaccines	is	contingent	on	delivery	
to	 older	 age	 groups.	 These	 results	 build	 on	 the	 Huynh	 study	 demonstrating	 the	
importance	of	controlling	elderly	reactivation	disease.16	Our	results	extend	previous	
work	which	suggested	that	adolescent/adult	campaigns	would	have	a	greater	impact	
than	 infant	vaccination,2,4,5	as	we	develop	the	argument	 further	by	demonstrating	
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that	in	ageing	epidemics,	most	impact	could	be	achieved	by	targeting	older	adults,	
potentially	minimising	the	resources	required	per	case	averted.	
Policy	impact	
Adolescent-targeted	vaccines,	the	focus	of	current	development	plans,	would	have	
low	impact	in	ageing,	reactivation-driven	TB	epidemics	like	China.	In	these	settings,	
an	 efficacious	 post-infection	 vaccine	 delivered	 to	 older	 adults	 will	 be	 critical	 to	
maximise	population-level	impact	and	would	provide	a	crucial	contribution	towards	
achieving	 the	WHO	2050	 TB	 goals.	Older	 adults	 should	 be	 included	 in	 TB	 vaccine	
clinical	development	and	implementation	planning.		
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Figures	and	Tables	
A	 B	
	 	
Figure	1:	(A)	Predicted	(lines)	and	empirical	data	(points)	for	microbiologically-positive	TB	prevalence	in	≥15	year	olds	(black),	15-29	year	olds	(red),	30-59	year	olds	(yellow)	and	≥60	
year	olds	(green),	calibrated	to	survey-estimated	2000	and	2010	microbiologically-positive	pulmonary	TB	prevalence	rates.12	Ranges	due	to	uncertainty	in	natural	history	parameters	
identified	in	the	calibration	process	are	shown	by	shaded	ribbons.	For	other	calibration	see	Supplementary	Section	4.3.3.	(B)	Predicted	percentage	of	annual	incident	TB	cases	by	age	and	
calendar	year	in	the	baseline	(no	new	vaccine)	scenario.	Ranges	represent	the	uncertainty	across	the	1000	model	fits	around	the	proportion	of	incident	cases	in	a	given	age	group.	
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C	 D	
	 	
Figure	1:	(C)	Predicted	population	attributable	fraction	of	each	age	group	to	new	M.tb	infections,	by	calendar	year.	Lines	represent	median	estimates	for	0-4	year	olds	(red),	5-19	year	olds	
(yellow),	20-64	years	(blue)	and	65	years	and	above	(green).	Ranges	due	to	uncertainty	in	natural	history	parameters	are	shown	by	shaded	ribbons.	M.tb:	Mycobacterium	tuberculosis.	(D)	
Predicted	proportion	of	all	annual	incident	disease	cases	due	to	recent	infection	(red)	versus	reactivation	(black),	by	calendar	year.	Ranges	due	to	uncertainty	in	natural	history	parameters	
are	shown	by	shaded	ribbons.	
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Figure	2:	Predicted	population	level	impact	on	TB	incidence	rate	in	2050	compared	to	the	no	new	vaccine	scenario,	by	host	infection	status	required	for	efficacy,	age	
targeting,	vaccine	efficacy,	coverage	and	duration	of	protection.	Vaccination	was	implemented	in	2025-2050,	with	adolescent	vaccination	delivered	routinely	to	15	year	olds	
and	a	3-year	catch	up	campaign	in	16-19	year	olds	2025-2027,	and	older	adult	vaccination	delivered	routinely	to	60	year	olds	with	a	3-year	catch	up	campaign	in	61-64	year	
olds	2025-2027.	Cov:	vaccine	coverage,	VE:	Vaccine	Efficacy.	 	
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Table	1:	Predicted	population	level	impacts	of	the	‘intermediate’	vaccine	profile	(60%	vaccine	efficacy,	10	years	protection	and	70%	coverage),	by	host	infection	status	
required	for	efficacy	and	age	targeting.	Ratios	presented	are	of	older	adult:adolescent	values.	NNV	=	Number	needed	to	vaccinate	
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4.3 Paper	2	supplementary	appendix	
The	supplementary	appendix	to	research	paper	2	is	included	in	this	section.	As	this	
model	was	 a	 further	 development	 of	 the	model	 described	 in	 Chapter	 3,	 to	 avoid	
excessive	repetition	of	methods	and	baseline	model	fitting	results,	sections	from	the	
paper	 supplement	 that	 repeat	methodology	 or	 results	 described	 previously	 have	
been	replaced	with	signposting	to	the	relevant	sections	in	Chapter	3.		
4.3.1 Model	structure	
An	 age-structured,	 compartmental,	 deterministic	 transmission	 model	 (Figure	 S1)	
described	by	a	series	of	difference	equations	 (section	4.3.2)	was	developed	based	
upon	the	epidemiological	model	described	in	Chapter	3.	The	narrative	description	of	
TB	natural	history	represented	by	the	unvaccinated	stratum	can	therefore	be	found	
in	Chapter	3	section	3.3.		
In	this	study,	the	vaccine	was	modelled	as	all-or-nothing	protection,	as	opposed	to	
leaky/degree	 protection,	 thus	 did	 not	 permit	 development	 of	 disease	 in	 the	
vaccinated	population.	As	a	consequence,	the	transitions	between	the	unvaccinated	
and	vaccinated	strata	differ	from	Chapter	3.	Therefore,	the	full	set	of	equations	for	
both	strata	are	provided	in	section	4.3.2	below.	The	new	model	vaccine	structure	in	
this	study	is	described	below.	
Vaccination	was	incorporated	into	the	model	through	a	distinct	vaccinated	stratum,	
consisting	 of	 uninfected	 (S),	 latently	 infected	 (L)	 and	 recovered	 after	 disease	 (R)	
states	(Figure	S1b).	Therapeutic	vaccination	was	not	considered,	so	transition	from	
unvaccinated	to	vaccinated	strata	was	only	possible	for	the	uninfected,	 latent	and	
recovered	populations,	at	rate	!", !$	and	!),	respectively.	Theta	was	equivalent	to	
vaccine	coverage	(cov)	multiplied	by	vaccine	efficacy	(VE)	in	the	given	age	group	and	
year.	Protection	was	modelled	as	all-or-nothing,	therefore	unsuccessfully	vaccinated	
individuals	(1-VE)	remained	in	the	unvaccinated	stratum,	and	successfully	vaccinated	
individuals	(VE)	were	transferred	to	the	vaccinated	stratum.	Vaccines	were	modelled	
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as	protective	against	disease,	meaning	vaccinated	individuals	could	become	infected,	
but	were	completely	protected	against	development	of	disease.	Individuals	departed	
the	vaccinated	stratum	either	through	all-cause	mortality	(u)	or	reaching	the	end	of	
the	duration	of	protection	and	returning	to	the	unvaccinated	stratum	(d).	
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A)	
	
B)		
	
Figure	S1:	Model	structure	A)	unvaccinated	stratum,	and	B)	vaccinated	stratum,	adapted	from	
Knight	et	al.	20142	
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4.3.2 Model	equations	
Difference	equations	describing	the	model	populations	in	year	k,	time	step	i	and	age	
j	are	provided	below.	The	size	of	 time	step	(dt),	was	set	 to	0.5	years	as	a	balance	
between	 sufficient	 granularity	 and	 computing	 time/capacity.	 The	 time	 step	 in	 the	
model	 is	 given	by	* = ,-(/0120	3412)60 + 1	for	 the	 first	 time	 step	of	 the	 year	 and	* =,-(/0120	3412)60 + 2	for	the	second	time	step	of	the	year.		
The	first	set	of	equations	is	valid	for	all	time	steps	except	that	at	the	start	of	each	
year.	The	second	section	provides	equations	for	the	first	time	step	of	each	year,	and	
includes	ageing,	vaccination	and	vaccine	waning.	
Births	and	ageing	
Births	entered	the	population	as	uninfected	at	the	start	of	each	year.	Life	expectancy	
was	 data-informed,	 but	 limited	 to	 no	 more	 than	 100	 years.	 Following	 the	
methodology	 of	 Schenzle	 (1984),36	 ageing	 was	 implemented	 in	 the	 model	 on	 an	
annual	basis	by	transitioning	the	population	in	a	given	sub-population	of	age	j,	to	the	
same	sub-population	of	age	j+1	at	the	end	of	each	year.	
Transmission	 : *, ; = <=>? <[A, B]D E *, BF[*, B]3GH3I2J3GK  
where	F *, B = L *, ; + M *, ; + E *, ; + NE *, ; + O *, ;+LP *, ; + MP *, ; + OP *, ;QGQR1SQGQRTH 	and	nygrp	was	
the	number	of	contact	age	groups,	m	was	the	age	group	of	the	individual	exposed	to	
infection	 (including	 age	 j),	 y	was	 age	 group	 of	 contacts,	<[A, B] 	was	 number	 of	
respiratory	 contacts	 of	 age	 group	m	 with	 contacts	 of	 age	 group	 y,	<=>? 	was	 the	
calibration	 factor	 for	 model	 fitting,	 D 	was	 the	 probability	 of	 transmission	 per	
respiratory	contact	between	an	infectious	active	case	and	a	uninfected	person	(which	
is	later	scaled	for	protection	afforded	by	latent	infection),	and	jmin	and	jmax	were	
the	lower	and	upper	bounds	of	age	classes	within	a	contact	age	group	(y).	
	Chapter	4:	Age	targeting	of	new	TB	vaccines	 234	
Vaccination	
Vaccination	(!)	and	waning	of	protection	(d)	were	assumed	to	occur	in	the	first	time	
step	of	a	given	year.	As	vaccine	protects	only	against	disease,	those	in	the	vaccinated	
stratum	could	become	infected	during	all	time	steps.	
Detection	and	treatment	
CDR[k,j]	was	the	case	detection	rate	(proportion)	for	year	k	in	age	j,	and	CoT[k]	was	
the	proportion	of	detected	cases	that	were	treated	successfully	in	a	given	year.	
	
Equations	for	time	steps	NOT	the	first	time	step	of	the	year	
Unvaccinated		
Uninfected	(Susceptible)	L *, ; = 	L * − 1, ; − V ; + : * − 1, ; L * − 1, ; WX	
Latent	M *, ; = M * − 1, ; + : * − 1, ; 1 − Y ; (L * − 1, ; + ZO * − 1, ; )WX	− [ ; + : * − 1, ; Y[;]Z + V[;] M * − 1, ; )WX	
New	infectious	active	TB	cases	\]^_E *, ; = : * − 1, ; Y ; ` ; L * − 1, ; + ZM * − 1, ; + 	ZO * − 1, ; WX	+	[ ; ` ; M * − 1, ; WX + 	a ; ` ; O * − 1, ; WX + ^NE * − 1, ; WX	
New	non-infectious	active	TB	cases	\]^_NE *, ; = : * − 1, ; Y[;] 1 − `[;] L * − 1, ; + ZM * − 1, ;+ 	ZO * − 1, ; WX	+	[ ; 1 − `[;] M * − 1, ; WX + a ; (1 − `[;])O * − 1, ; WX	
Infectious	active	TB	cases	E *, ; = E * − 1, ; + 1 − bcO d, ; ×bfF d \]^_E *, ; 	− \ ; + V ; + VT[;] E * − 1, ; WX	
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Non-infectious	active	TB	cases	NE *, ; = NE * − 1, ; + 1 − ]	×bcO d, ; ×bfF d \]^_NE *, ; 	
	 − \ ; + V[;] + VHT[;] + ^ NE * − 1, ; WX	
Recovered	O *, ; = O * − 1, ; + \ ; E * − 1, ; + NE * − 1, ; WX	+(bcO d, ; ×bfF d ) \]^_E *, ; + ]	\]^_NE *, ; 	−(a ; + : * − 1, ; Z + V[;])O[* − 1, ;]WX	
Vaccinated		
Vaccinated	uninfected	(susceptible)	LP *, ; = LP * − 1, ; − :[* − 1, ;]LP * − 1, ; WX	
	−V[;]LP * − 1, ; WX	
Vaccinated	latent	MP *, ; = MP * − 1, ; + : * − 1, ; (LP * − 1, ; + ZOP * − 1, ; )WX	
	 −V[;]MP * − 1, ; WX	
Vaccinated	recovered	OP *, ; = OP * − 1, ; − Z:[* − 1, ;]OP * − 1, ; WX	
	 −V[;]OP * − 1, ; WX	
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First	time	step	of	the	year	(ageing	and	vaccine	delivery/waning)	
Unvaccinated		
Uninfected	(susceptible)	
If	j=1:	L *, 1 = g	
If	j≠1:	L *, ; = 	L * − 1, ; − 1 − V ; − 1 + : * − 1, ; − 1 L * − 1, ; − 1 WX	
	 −!" d, ; L * − 1, ; − 1 	+W d, ; 1 − !" d, ; LP * − 1, ; − 1 	
Latent	M *, ; = M * − 1, ; − 1 + : * − 1, ; − 1 1 − Y ; − 1 (L * − 1, ; − 1+ ZO * − 1, ; − 1 )WX	− [ ; − 1 + : * − 1, ; − 1 Y[; − 1]Z + V[; − 1] M * − 1, ; − 1 )WX	−!$ d, ; M * − 1, ; − 1 		+W d, ; 1 − !$ d, ; MP * − 1, ; − 1 	
New	infectious	active	TB	cases	\]^_E *, ; = : * − 1, ; − 1 Y ; − 1 ` ; − 1 L * − 1, ; − 1 + ZM * − 1, ; − 1+ 	ZO * − 1, ; − 1 WX	+	[ ; − 1 ` ; − 1 M * − 1, ; − 1 WX	+	a ; − 1 ` ; − 1 O * − 1, ; − 1 WX + ^NE * − 1, ; − 1 WX		
New	non-infectious	active	TB	cases	\]^_NE *, ; = : * − 1, ; − 1 Y ; − 1 1 − `[; − 1] L * − 1, ; − 1+ ZM * − 1, ; − 1 + 	ZO * − 1, ; − 1 WX	+	[ ; − 1 1 − `[; − 1] M * − 1, ; − 1 WX + a ; − 1 (1 − `[;− 1])O * − 1, ; − 1 WX	
Infectious	active	TB	cases	E *, ; = E * − 1, ; − 1 + 1 − bcO d, ; ×bfF d \]^_E *, ; 	
	 − \ ; − 1 + V ; − 1 + VT[; − 1] E * − 1, ; − 1 WX	
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Non-infectious	active	TB	cases	NE *, ; = NE * − 1, ; − 1 + 1 − ]	×bcO d, ; ×bfF d \]^_NE *, ; 	
	 − \ ; − 1 + V[; − 1] + VHT[; − 1] + ^ NE * − 1, ; − 1 WX	
Recovered	O *, ; = O * − 1, ; − 1 + \ ; − 1 E * − 1, ; − 1 + NE * − 1, ; − 1 WX	+(bcO d, ; ×bfF d ) \]^h T,Q + ]	×	\]^_NE *, ; WX	−(a ; − 1 + : * − 1, ; − 1 Z + V[; − 1])O[* − 1, ; − 1]WX	−!) d, ; O * − 1, ; − 1 		+W d, ; 1 − !) d, ; OP * − 1, ; − 1 	
Vaccinated			
Vaccinated	uninfected	(susceptible)	LP *, ; = LP * − 1, ; − 1 + !" d, ; L * − 1, ; − 1 	
	 −(:[* − 1, ; − 1]+	V[; − 1])LP * − 1, ; − 1 WX	
	 −W[d, ;] 1 − !" d, ; LP * − 1, ; − 1 	
Vaccinated	latent		MP *, ; = MP * − 1, ; − 1 + !$ d, ; M * − 1, ; − 1 	+	: * − 1, ; − 1 (LP * − 1, ; − 1 + ZOP * − 1, ; − 1 )WX	
	 −	V[; − 1]MP * − 1, ; − 1 WX − W[d, ;] 1 − !$ d, ; MP * − 1, ; − 1 	
Vaccinated	recovered	OP *, ; = OP * − 1, ; − 1 + !) d, ; O * − 1, ; − 1 − Z:[* − 1, ;− 1]OP * − 1, ; − 1 WX	
	 −V[; − 1]OP * − 1, ; − 1 WX − W[d, ;] 1 − !) d, ; OP * − 1, ; − 1 		 	
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4.3.3 Model	parameters,	data	sources	and	calibration	
Justification	 of	 selection	 and	 sources	 for	 natural	 history,	 demographic,	 social	 and	
control	parameters	have	been	described	previously	in	Chapter	3.	
Natural	 history	 parameter	 range	 justifications	 are	 summarised	 in	 Chapter	 3,	 and	
natural	history	parameter	prior	ranges,	referred	to	as	Supplementary	Table	S1	in	the	
manuscript,	 are	 described	 in	 the	 same	 section.	 Demographic	 parameters	 are	
described	in	Chapter	3,	as	are	data	to	inform	heterogeneous	social	mixing	patterns	
by	 age	 and	existing	 control	measures.	As	 the	 focus	of	 this	 research	question	was	
related	 to	 age-targeted	 vaccination,	 the	 age	 stratification	 in	 natural	 history	
parameters,	 social	 mixing	 patterns,	 control	 measures	 and	 demographics	 was	 the	
most	important	element	of	the	design	and	calibration	of	this	model.	
As	described	in	full	in	Chapter	3,	a	two-stage	calibration	process	was	employed,	with	
the	first	stage	a	manual	calibration	to	age-stratified	UN	population	projections	for	
2010	 and	 2050,29	 and	 the	 second	 stage	 an	 adaptive	 rejection	 ABC	MCMC-based	
method	 using	 a	 modified	 easyABC	 package	 to	 calibrate	 to	 18	 China-specific	
epidemiological	data	ranges.	To	represent	age-structured	TB	epidemiology	in	China,	
the	 model	 was	 calibrated	 to	 eighteen	 epidemiological	 data	 points	 and	 their	
confidence	 or	 uncertainty	 intervals,	 representing	 four	 outcomes	 in	 2010	
(bacteriologically	positive	prevalence,	mortality,	notifications	and	incidence)	for	all-
ages	and/or	age-stratified	epidemiological	outcomes.	To	capture	 temporal	 trends,	
prevalence	was	calibrated	to	data	from	both	2000	and	2010.	Supplementary	Figures	
S3-S8	referred	to	in	paper	2	for	demonstrating	the	model	fit	can	be	found	in	Chapter	
3,	section	3.4.1,	figures	3.3-3.8.	
4.3.4 Vaccine	implementation	and	characteristics	
To	answer	the	research	question	exploring	the	impact	of	vaccine	age	targeting,	the	
vaccine	implementation	scenarios	modelled	in	this	chapter	differ	from	those	in	the	
previous	 work.	 Vaccine	 implementation	 assumptions	 include	 age	 targeting	 of	
vaccination,	 year	 of	 implementation	 and	 coverage.	 The	 subset	 of	 vaccine	
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characteristics	 modelled	 was	 informed	 by	 the	 results	 presented	 in	 Chapter	 3.	
Modelled	 vaccine	 characteristics	 included	 the	 host	 infection	 status	 required	 for	
efficacy,	 the	 effect	 type,	 vaccine	 efficacy,	 and	 duration	 of	 protection.	 These	 are	
summarised	in	Table	S3	and	described	below.	The	absolute	impact	of	vaccines	with	
these	characteristics,	as	well	as	the	relative	impact	by	age	targeting	was	explored.	
4.3.4.1 Implementation:	Age	targeting	of	vaccination	programmes	
The	target	populations	explored	in	this	research	were	adolescents	(15-19	year	olds)	
and	older	adults	(60-64	year	olds).	Adolescent	vaccination	was	routinely	delivered	to	
15	year	olds	annually	from	2025	to	2050,	and	a	catch	up	campaign	for	16-19	year	olds	
was	 implemented	 2025-2027.	 The	 equivalent	 older	 adult	 campaign	 vaccinated	 60	
year	olds	routinely,	and	61-64	year	olds	in	the	3-year	catch	up	campaign.	
Adolescent	 vaccination	 was	 of	 interest	 given	 many	 current	 clinical	 trials,	 target	
product	profiles	and	vaccine	development	strategies	focus	on	vaccination	in	this	age	
group.	 Previous	 modelling	 has	 shown	 that	 vaccinating	 adolescents	 and/or	 adults	
would	provide	greater	and	more	 cost	effective	 impact	 than	vaccinating	 in	 infancy	
over	the	2024/25-2050	time	horizon.2,5	In	many	countries	a	rapid	increase	in	TB	rates	
occurs	during	adolescence,	therefore	vaccination	of	this	age	group	would	hopefully	
provide	protection	during	 the	period	during	which	 infection	and	disease	 rates	are	
known	to	be	high.	With	a	lifelong	protective	vaccine,	vaccination	of	adolescents	could	
eventually	 be	 age	 de-escalated	 in	 to	 infancy,	 but	 given	 the	 immediate	 need	 for	
protection	 in	 adolescence	 and	 adulthood,	 and	 the	 consideration	 that	 lifelong	
protection	is	unlikely	with	early	candidates,	vaccination	of	adolescents	would	provide	
greater	impact	more	rapidly	than	infant	vaccination.	Vaccination	of	15-19	year	olds	
would	allow	delivery	of	vaccination	through	school-based	platforms.	
Vaccination	of	older	adults	was	explored	due	to	the	ageing	population	structure	in	
China	and	high	prevalence	of	M.tb	infection	observed	in	older	age	groups	in	empirical	
studies.1,22	 The	 decision	 to	 vaccinate	 specifically	 60-64	 year	 olds	 took	 in	 to	
consideration	 immunosenescence,	 safety,	and	 the	age	group	 for	which	protection	
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was	required.	Due	to	the	high	burden	of	disease	in	the	elderly,	this	population	would	
ideally	be	protected	by	new	vaccines,	but	due	to	safety	and	immunogenicity	concerns	
with	 regards	 to	 vaccination	 of	 elderly	 populations,37	 delivery	 to	 older	 adults	 was	
considered	a	more	feasible	approach	for	protecting	older	age	groups.	
Since	lifelong	protection	is	considered	unlikely,	vaccinating	as	late	as	possible	without	
entering	the	main	onset	of	immunosenescence	was	considered	the	best	approach,	
as	vaccination	before	 immunosenescence	 increases	 the	 likelihood	of	a	 robust	and	
sustained	immune	response	to	vaccines	(Richard	Aspinall,	oral	communication,	5th	
June	2015).	This	 is	 supported	by	results	of	Zostavax	 trials	against	herpes	zoster	 in	
older	adults,	where	vaccine	efficacy	 in	60-69	year	olds	(64%,	95%	CI:	56-71%)	was	
similar	to	50-59	year	olds	(70%,	95%	CI:	54-81%),	but	much	higher	than	in	70-79	year	
olds	 (41%,	 95%	 CI:	 28-52%)	 and	 ≥80	 years	 (18%,	 95%	 CI:	 -29	 to	 48%).38	
Immunosenescence	 is	a	gradual	process	and	varies	between	 individuals,	 therefore	
there	is	no	specific	age	that	is	certain	to	precede	immune	deterioration.	However,	
based	upon	expert	opinion	and	the	Zostavax	data,	vaccination	at	the	age	of	60	would	
precede	the	onset	of	immunosenescence	in	most	individuals	(Richard	Aspinall,	oral	
communication,	 5th	 June	 2015).38	 Therefore,	 vaccination	 of	 60-64	 year	 olds	 was	
explored	as	a	possible	alternative	target	population	for	new	TB	vaccines	in	China.		
4.3.4.2 Implementation:	Timing	and	coverage	
Vaccine	was	assumed	to	be	widely	 introduced	 in	2025.	At	 time	of	writing,	several	
candidates	were	due	to	complete	phase	IIB/III	clinical	trials	in	2017/2018;	therefore	
if	any	of	these	vaccines	were	successful,	vaccine	could	be	implemented	by	2025.			
Vaccination	coverage	of	30%	and	70%	of	the	target	populations	were	explored.	Scale	
up	was	assumed	to	be	 immediate	 in	 routine	vaccination	 (15	or	60	year	olds),	and	
catch	up	campaigns	in	16-19	year	olds	or	61-64	year	olds	were	assumed	to	occur	over	
a	 period	 of	 three	 years	 from	 introduction,	 with	 a	 third	 of	 the	 desired	 coverage	
achieved	in	each	year	(e.g.	30%	coverage	assumes	10%	per	year	for	3	years).		
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The	higher	coverage	assumption	(70%)	was	based	upon	school	attendance	levels,	a	
vaccine	 acceptance	 study	 in	 China,	 and	 coverage	 achieved	 with	 HPV	 vaccines	
delivered	in	schools	in	South	Africa.	The	gross	secondary	school	enrolment	ratio	in	
China	 is	 94.3%,	 and	 the	 HPV	 coverage	 achieved	 in	 9	 year	 olds	 in	 South	 Africa	 is	
87%.39,40	It	was	anticipated	that	some	adolescents	would	be	missed	due	to	absence	
on	vaccination	days,	and	attendance	up	to	the	age	of	19	would	likely	be	lower	than	
this,	so	70%	coverage	was	deemed	a	reasonable	expectation	of	adolescent	coverage.	
A	 qualitative	 study	 of	 acceptance	 of	 hypothetical	 adult	 hepatitis	 B	 vaccination	
indicated	a	55-72%	acceptance	rate	if	the	vaccine	were	offered	free	of	charge	with	0-
100	Yuan	compensation	towards	indirect	costs.41	Therefore,	70%	coverage	appears	
feasible	in	older	adults	given	the	upper	end	of	the	range	from	the	qualitative	study	
and	would	be	likely	in	adolescents	given	school	attendance	is	high.		
Influenza	vaccination	rates	were	considered	a	suitable	proxy	for	potential	older	adult	
TB	coverage	as	influenza	vaccination	is	provided	free	of	charge	to	citizens	³60years	
in	government-run	hospitals.	Studies	of	self-reported	coverage	in	the	elderly	indicate	
vaccine	coverage	of	36-49%	in	the	2008-2011	period.42-44	These	data	were	collected	
during	 the	 2009	 H1N1	 pandemic,	 so	 may	 represent	 higher	 than	 usual	 coverage.	
Although	it	is	hoped	that	acceptance	and	coverage	of	TB	vaccines	would	be	higher	
than	this,	30%	coverage	was	deemed	a	suitable	pessimistic	assumption	to	explore	
the	lower	bounds	of	possible	coverage.	
4.3.4.3 Characteristics:	Host	infection	status	for	efficacy	
Previous	exposure	of	the	immune	system	may	impact	the	immune	response	to	the	
vaccine	antigen.	Previous	exposure	has	been	found	to	reduce	the	efficacy	of	BCG,45	
whereas	 for	 some	 viral	 vectored	 MV85A	 vaccines	 immune	 priming	 by	 previous	
exposure	was	found	to	 improve	the	antigen-specific	 immune	response.	Therefore,	
the	 efficacy	 of	 a	 given	 candidate	 may	 be	 reliant	 upon	 whether	 the	 vaccinated	
individual	 is	M.tb-naïve,	 currently	 latently	 infected	 or	 ever-infected.	 Clinical	 trials	
tend	to	enrol	either	uninfected	46	or	infected	7,47	populations,	assessed	by	IGRA	or	
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PPD,	 depending	 upon	 the	 anticipated	 pre-requisites	 for	 an	 immune	 response	
according	to	the	antigens	included	in	the	vaccine.		
Four	infection	status	combinations	were	modelled	(Table	S2).	Pre-infection	vaccines	
were	 assumed	 to	 prevent	 development	 of	 active	 disease	 only	 in	 never-infected	
individuals	(!" > 0, !$ = 0, !) = 0).	Two	types	of	post-infection	(PSI)	vaccines	were	
modelled,	the	first	(PSI-L)	was	only	effective	in	those	currently	latently	infected	with	
M.tb	 (!" = 0, !$ > 0, !) = 0 ),	 including	 those	 who	 had	 recovered	 but	 were	 re-
infected	 and	 enter	 the	 latent	 state.	 	 The	 second	 (PSI-L&R)	 was	 efficacious	 when	
delivered	to	either	latently	infected	populations	or	those	who	had	recovered	from	
active	 disease	 (!" = 0, !$ > 0, !) > 0).	 Finally,	 a	 vaccine	 effective	 pre-	 and	 post	
infection	 (P&PI),	producing	 immunity	 in	all	except	 those	with	active	disease	 (!" >0, !$ > 0, !) > 0),	was	modelled.		
Therapeutic	vaccines	were	not	explored	in	this	study,	so	no	vaccines	were	effective	
in	populations	with	active	disease.	
Table	S2:	Host	infection	status	for	vaccine	efficacy	
Vaccine	 Never	infected	(S)	
Latently	
infected	(L)	
Active	Disease	
(I	or	NI)	
Recovered	
from	disease	
(R)	
PRI	 Yes	 No	 No	 No	
PSI-L	 No	 Yes	 No	 No	
PSI-L&R	 No	 Yes	 No	 Yes	
P&PI	 Yes	 Yes	 No	 Yes	
	
4.3.4.4 Characteristics:	Effect	type	
Vaccines	 with	 a	 prevention	 of	 disease	 (POD)	 effect	 type	 were	 modelled.	 This	
protection	 was	 modelled	 as	 ‘all-or-nothing’,	 meaning	 that	 vaccinated	 individuals	
were	either	completely	protected	against	disease	or	received	no	protection,	and	that	
the	distribution	between	these	two	subsets	was	equal	to	vaccine	efficacy.	Therefore,	
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upon	vaccination	of	a	population,	the	effectively	vaccinated	proportion	transitioned	
to	the	vaccinated	stratum	and	received	complete	protection	against	development	of	
disease,	 whereas	 those	 in	 whom	 the	 vaccine	 was	 not	 effective	 remained	 in	 the	
unvaccinated	stratum	and	remained	fully	susceptible	to	development	of	disease.		
As	vaccine	did	not	protect	against	infection,	in	the	vaccinated	class	it	was	still	possible	
to	become	infected	or	reinfected	and	move	to	the	vaccinated	latent	class.		Prevention	
of	disease	was	modelled	as	opposed	to	prevention	of	infection	efficacy,	as	literature	
suggests	that	prevention	of	disease	vaccines	generally	provide	greater	impact	than	
prevention	of	 infection	vaccines	 in	adolescent	and	adult	populations.6	 In	addition,	
most	late-stage	vaccines	are	currently	being	measured	against	disease	endpoints	as	
opposed	to	infection	endpoints.7		
4.3.4.5 Characteristics:	Efficacy		
Vaccine	 efficacies	 of	 40%,	 60%	and	80%	were	modelled.	Although	examples	 exist	
exploring	the	extremes	of	vaccine	efficacy	(17.6-100%),	the	majority	of	TB	vaccine	
models	in	the	literature	explore	a	VE	range	of	40-80%.6	Given	current	challenges	in	
developing	 a	 highly	 effective	 TB	 vaccine,	 the	 upper	 bound	 of	 vaccine	 efficacy	
considered	technically	feasible	was	80%.		
Although	 interesting	 to	understand	 the	 lower	 limit	of	 vaccine	efficacy	 required	 to	
achieve	minimum	required	levels	of	 impact	 in	Chapter	3,	this	was	not	the	primary	
focus	of	this	research	question.	In	Chapter	3,	a	40%	to	80%	efficacy	POD	P&PI	vaccine	
providing	10	years	protection	achieved	a	substantial	epidemiological	impact	of	40-
49%	up	to	60-69%	incidence	rate	reduction.	Also	of	importance	is	that	detection	of	
vaccine	efficacy	as	low	as	20%	would	necessitate	potentially	unfeasibly	large	clinical	
trials	to	accrue	sufficient	disease	endpoints.	Therefore,	a	lower	bound	of	40%	vaccine	
efficacy	was	selected.		
When	effective	 in	multiple	population	groups	 (e.g.	 latent	and	 recovered),	efficacy	
was	assumed	to	be	the	same	in	all	groups.		
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In	the	model,	coverage	and	efficacy	were	multiplied	to	calculate	effective	coverage	
(theta),	which	is	the	proportion	of	those	in	a	given	model	state	that	are	moved	to	the	
equivalent	vaccinated	state	at	the	beginning	of	each	vaccination	year.		
4.3.4.6 Characteristics:	Duration	of	protection	and	waning	
Mean	duration	of	protection	was	assumed	10	or	20	years.	The	majority	of	models	in	
the	 literature	 assumed	 10	 year	 or	 lifelong	 immunity.6	 Based	 upon	 expert	
consultation,	 lifelong	 immunity	 was	 considered	 unlikely	 with	 early	 candidates,	
therefore	10	and	20	years	of	protection	were	modelled.	
A	 sigmoid-shaped	 waning	 profile	 was	 assumed,	 therefore	 waning	 was	 normally	
distributed	around	a	mean	of	10	or	20	years	protection	with	a	standard	deviation	of	
1	 or	 2	 years,	 respectively.	 Waning	 was	 exact,	 meaning	 that	 those	 individuals	
experiencing	 waning	 leave	 the	 vaccinated	 category	 and	 return	 to	 the	 equivalent	
unvaccinated	state.		
In	 addition	 to	 this	 basic	 waning,	 it	 was	 assumed	 that	 immunosenescent	 waning	
occurs	in	the	elderly	(≥65	years)	due	to	ageing-induced	deterioration	of	the	immune	
system.	Based	upon	expert	consultation,	immunosenescent	waning	was	assumed	to	
be	2%	per	year	in	addition	to	basic	waning,	starting	from	when	an	individual	reaches	
65	years	old	(Richard	Aspinall,	oral	communication,	5th	June	2015).	However,	there	
were	few	data	to	inform	this	assumption,	therefore	in	sensitivity	analyses	0%	and	5%	
immunosenescent	waning	were	also	explored,	based	upon	expert	opinion	and	results	
from	Zoster	vaccine	studies	in	the	elderly.11,38	Additional	discussion	on	this	issue	can	
be	found	in	Appendix	B.	
.	
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Table	S3:	Vaccine	parameters	
Parameter	 Symbol	 Description	 Detail	 References	 Parameter		
Vaccine	
implement
ation	and	
characteris
tics	
c[k,j]	
Coverage	 of	 vaccine	
for	 those	 aged	 j	 in	
year	k	
	
Annual	 routine	 vaccination	 of	 30%	 and	 70%	
explored,	 age	 targeted	 to	 15	 or	 60	 year	 olds.	 In	
addition,	three-year	catch	up	campaign	for	16-19	
year	olds	or	61-64	year	olds,	with	above	coverages	
distributed	 over	 period	 of	 campaign	 (i.e.	 30%	
would	be	10%	coverage	of	the	age	group	in	each	
of	the	3	years	of	the	campaign)	
Secondary	school	
attendance,	
qualitative	
studies,	&	self-
reported	
influenza	vaccine	
coverage.39-44	
30%	and	70%	
VEa	
Vaccine	 efficacy	 for	
preventing	 active	 TB	
disease	
40%,	60%,	80%	 Assumed	 40%,	60%,	80%	
	"#, "%, "& 		
[k,j]	
	
Proportion	of	
Uninfected,	Latent	
or	Recovered	aged	j	
moving	to	vaccine	
strata	in	year	k		
Equal	 to	 coverage	multiplied	by	vaccine	efficacy.	
Where	 a	 is	 the	 population	 vaccinated	 (i.e.	
Uninfecteds,	Latents	or	Recovereds):	
	"'	[k,j]	=	c[k,j]	×	VEa	
Assumed	 PRI	("#),		
PSI-L	("%),		
PSI-L&R	("%, "&),	
P&PI	("#, "%, "&)	
D	
Duration	 of	 vaccine	
efficacy	
Average	waning	 of	 protection	 at	 10	 or	 20	 years,	
normally	 distributed	 around	 the	 mean	 with	
standard	 deviation	 of	 1	 or	 2	 years,	 respectively.	
Elderly	(³65	years)	immunosenescence	2%/year.	
Assumed	 10	or	20yrs.	2%/year	
elderly	 senescence,	
varied	 0-5%	 in	
sensitivity	analyses.	
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4.3.5 Additional	methods	for	calculating	outcomes	
4.3.5.1 Population	Attributable	Fraction	(PAF)	
The	population	attributable	fractions	(PAFs)	of	each	age	group	to	the	annual	number	
of	Mtb	 infections	in	2000,	2025	and	2050	were	calculated	in	the	baseline	scenario	
using	methods	described	previously	in	Orroth	et	al.34	The	age	groups	explored	were	
defined	by	the	four	age	groups	in	the	contact	matrix	(0-4,	5-19,	20-64,	≥65	years).		
The	model	 was	 first	 run	 allowing	 transmission	 from	 all	 infected	 populations	 as	 a	
baseline.	It	was	then	re-run	four	times	for	each	year	of	interest,	blocking	transmission	
from	 infected	 individuals	 in	 one	 age	 group	 per	 run	 by	 reducing	 the	 infectious	
individuals	 in	 that	 age	 group	 to	 zero.	 The	 total	 number	 of	 new	 infections	 was	
estimated	in	the	year	of	interest	for	each	of	these	runs.	The	percentage	reduction	in	
new	infections	compared	to	the	baseline	was	calculated,	giving	an	estimate	of	the	
PAF,	 indicating	 the	 contribution	 of	 that	 age	 group	 to	 M.tb	 transmission	 in	 the	
population	as	a	whole.		
4.3.5.2 Cumulative	Number	Needed	to	Vaccinate	
As	this	is	a	dynamic	transmission	model	and	the	NNV	is	calculated	over	an	extended	
period	 of	 time	 (2025-2050)	 as	 opposed	 to	 annually,	 the	 reported	measure	 is	 the	
cumulative	NNV	per	case	or	death	averted	for	the	period	2025-2050.	It	is	calculated	
by	dividing	 the	 total	number	of	vaccines	delivered	during	 that	period	by	 the	 total	
number	of	cases	or	deaths	averted	during	the	same	period.	Programmatically,	this	
measure	 could	 be	 seen	 as	 an	 indicator	 of	 impact	 achieved	 per	 vaccine	 resource	
expended,	therefore	minimising	the	NNV	is	desirable.		
4.3.6 Additional	results	and	discussion	
4.3.6.1 Epidemiological	 outcomes:	 Burden	 of	 disease	 and	 contribution	 to	
transmission	in	vaccinated	age	groups	
At	time	of	vaccine	introduction	(2025),	1·5%	(UR:	1·3-1·7)	of	cases	occurred	in	the	15-
19	 year-old	 target	 group	 for	 adolescent	 vaccination,	 whereas	 8·4%	 (UR:	 7·9-8·8)	
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occurred	in	the	60-64	year	old	age	group	targeted	for	older	adult	vaccination.	Routine	
vaccination	of	15	or	60	year	olds	with	a	vaccine	of	10-years	duration	of	protection	
would	protect	15-24	or	60-69	year-olds.	By	2050,	1·8%	(UR:	1·5-2·3)	and	21%	(UR:	20-
22)	of	cases	were	projected	 to	occur	 in	 the	15-24	and	60-69	year-old	age	groups,	
respectively.	 This	 highlights	 the	 potentially	 avoidable	 burden	 of	 disease,	 which	 is	
clearly	higher	in	the	older	age	group.	
Figure	1C	 in	 the	main	article	demonstrates	 the	population	attributable	 fraction	of	
each	age	group	towards	new	infections	over	time	 in	the	no	new	vaccine	baseline.	
These	results	suggest	a	transition	from	adult-dominated	transmission	in	2000	(74%	
from	20-64	year	olds;	UR:	72-75)	to	elderly-driven	transmission	in	2050	(57%	from	65	
year	olds	and	above;	UR:	51-65).	Minimal	transmission	originated	from	children	or	
adolescents.	 Transmission	 from	 children	 and	 adolescents	 aged	 5-19	 years	 old	
declined	from	0·8%	(UR:	0·7-0·9%)	in	2025	to	0·4%	(UR:	0·4-0·5)	in	2050.	This	suggests	
that	 the	potential	 indirect	effects	of	an	adolescent	vaccine	would	be	minimal	and	
declining	over	the	vaccination	period.		
The	contribution	of	the	20-64	year	old	group,	which	includes	the	vaccination	age	for	
older	adults	also	declined	during	this	period.	However,	older	adult	vaccination	with	
10	or	20	years	protection	extends	into	the	elderly	years,	and	the	contribution	of	the	
elderly	 to	 transmission	 increased	 from	39·9%	 (UR:35·5-46·8)	 in	 2025	 to	 57·2	 (UR:	
51·4-65·1%)	in	2050.	Therefore,	a	vaccine	in	this	age	group	could	have	a	substantial	
indirect	effect	by	reducing	the	number	of	cases	in,	and	therefore	transmission	from,	
this	elderly	age	group.	
4.3.6.2 Epidemiological	 outcomes:	 Age-wise	 proportion	 of	 disease	 arising	 from	
reactivation	versus	new	infection	
Overall	distribution	of	annual	incident	disease	originating	from	new	infections	versus	
reactivation	disease	is	shown	in	Figure	1D	in	the	main	article.	A	transition	from	new-
infection	driven	to	a	reactivation	driven	epidemic	was	estimated	to	occur	between	
2014	and	2024.	By	2050,	74·4%	(UR:73·7-75·8)	of	 incident	cases	were	reactivation	
disease.		
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In	 those	 below	 55	 years	 of	 age,	 the	majority	 of	 incident	 TB	 disease	 cases	 in	 the	
population	were	consistently	caused	by	new	infections	over	2000-2050	(Figure	S9).	
Historically,	this	was	also	the	case	in	older	age	groups.	However,	for	55-64	year	olds,	
the	model	suggests	that	a	switch	from	new	infections	towards	reactivation	disease	
occurred	in	2002/2003	(UR:	<2000	to	2011).	In	the	elderly,	it	appears	the	switch	to	
reactivation	driven	disease	occurred	before	2000,	but	uncertainty	ranges	suggest	the	
transition	could	have	been	as	late	as	2006	(Figure	S9).	In	this	elderly	group,	the	model	
suggests	 that	 reactivation	 disease	 could	 constitute	 84.3%	 (UR:	 76.4-89.9%)	 of	 all	
annual	incident	cases	in	2050.		
The	scale	up	of	existing	control	measures	has	reduced	burden	of	disease	mostly	by	
reducing	transmission.	The	increasing	contribution	of	the	elderly	to	overall	TB	disease	
burden	 during	 the	 2000-2050	 period	 (main	 article,	 Figure	 1B)	 combined	with	 the	
growing	contribution	of	reactivation	disease	in	this	age	group,	can	account	for	the	
transition	from	new-infection-driven	to	a	reactivation-driven	epidemic	in	China	over	
the	modelled	time	frame.		
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A	 B	
	 	
C	 D	
	 	
Figure	S9:	Proportion	of	annual	new	active	cases	emerging	from	new	infections	(red)	versus	
reactivation	of	existing	infection	(black)	from	2000-2050	in	age	group	A.	0-14	year	olds,	B.15-54	
year	olds,	C.	55-64	year	olds,	and	D.	≥65	years	old.	Lines	are	median	values	and	shaded	areas	
represent	uncertainty	ranges.	
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4.3.6.3 Epidemiological	outcomes:	Prevalence	of	LTBI	by	age	
The	model	was	 not	 calibrated	 to	 the	 Gao	 et	 al.	 prevalence	 of	 infection	 data,1	 as	
although	the	four	locations	selected	for	the	study	were	considered	representative	of	
the	social	and	epidemiological	diversity	across	China,	the	study	did	not	use	random	
selection	of	 sites	or	participants	 from	a	nationally-representative	 sampling	 frame;	
therefore	the	generalisability	to	our	country-level	model	was	uncertain.		
A	 comparison	 to	 these	 data,	 however,	 found	 that	 the	 modelled	 age-stratified	
prevalence	 of	 infection	matched	 the	 published	Quantiferon	 (QFN)	 data	 very	well	
(Figure	S10).	In	our	model,	the	overall	prevalence	of	infection	was	15.3%	(UR:	13.8-
17.0%),	ranging	from	1.3%	(1.2-1.4%)	in	children	aged	5-9	years,	up	to	36.9%	(32.9-
40.3%)	 in	 ≥70	 years	 old.	 In	 the	 Gao	 study,	 prevalence	 of	 infection	 measured	 by	
Quantiferon	was	19%,	ranging	from	3%	in	children	5-9	years	to	32%	in	≥70	years	old.	
The	model	appeared	to	slightly	overestimate	infection	prevalence	in	the	>70	years	
group,	 but	 data	 suggest	 that	 QFN	 and	 TST	 tests	 are	 slightly	 less	 sensitive	 in	 the	
elderly.48	TST-estimated	prevalence	was	higher	than	QFN	estimates	for	all	except	one	
age	 group	 due	 to	 lower	 test	 specificity.	 Alignment	 of	 model	 outcomes	 with	 the	
empirical	Quantiferon	data	set	speaks	to	the	validity	of	this	epidemiological	model.	
Prevalence	 of	 latent	 TB	 at	 vaccine	 introduction	 in	 2025	 showed	 a	 similar	 age	
distribution	to	2013	(Figure	S11),	but	a	slightly	lower	overall	prevalence	of	13·6%	(UR:	
11·0-16·4%)	due	 to	declining	 transmission	 rates.	Prevalence	of	 infection	was	1·8%	
(UR:	 1·4-2·2%)	 in	 10-19	 year	 olds,	which	 includes	 the	 adolescent	 15-19	 years	 age	
group	receiving	the	vaccine,	and	26·6%	(UR:	21·6-31·6%)	in	60-69	year	olds,	which	
includes	the	older	adult	60-64	year	old	vaccinated	group.	Prevalence	of	infection	is	
much	 higher	 in	 the	 older	 adult	 group,	 meaning	 that	 a	 greater	 proportion	 of	 the	
population	receiving	a	post-infection	vaccine	would	be	effectively	immunised	in	the	
older	adult	than	the	adolescent	age	group.	Conversely,	a	greater	proportion	of	the	
adolescent	population	would	be	effectively	immunised	with	a	pre-infection	vaccine,	
but	 the	 risk	of	developing	disease	 in	 the	uninfected	population	 is	obviously	much	
lower	than	the	infected	population.	
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Figure	S11:	Age-stratified	latent	TB	infection	prevalence	in	2025,	modelled	outcomes.	Grey	bars	
and	error	bars	denote	modelled	median	estimates	and	uncertainty	ranges.	
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Figure	S10:	Age-stratified	latent	TB	infection	prevalence	in	2013,	modelled	and	empirical	data.	Grey	
bars	and	error	bars	denote	modelled	median	estimates	and	uncertainty	ranges.	Empirical	data	from	
Gao	et	al.	(2013)	are	TST	prevalence	(blue	circles)	and	Quantiferon	(red	diamonds).1	
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4.3.6.4 Vaccination	 outcomes:	 Comparison	 of	 post-infection	 vaccine	 effect	 types	
(PSI-L	vs	PSI-L&R)	
Two	types	of	post-infection	(PSI)	vaccine	were	compared:	a	vaccine	effective	only	in	
latent	 populations	 (PSI-L)	 and	 a	 vaccine	 effective	 in	 both	 latent	 and	 recovered	
populations	(PSI-L&R).	Results	in	the	main	article	(Figure	2)	demonstrate	a	substantial	
increase	in	impact	by	protecting	the	recovered	population	in	addition	to	the	latently	
infected	population.	However,	there	was	large	variability	in	the	amount	of	additional	
impact	that	could	be	gained	by	protecting	the	recovered	population	as	a	result	of	
uncertainty	in	estimates	of	the	impact	of	the	latency-only	vaccine	(PSI-L).	
Whereas	 uncertainty	 ranges	 on	 the	 PSI-L&R	 results	 were	 relatively	 narrow,	
uncertainty	 ranges	 on	 latency-only	 vaccines	 were	 wide.	 This	 was	 a	 result	 of	 the	
calibration	process.	Calibration	targets	allowed	a	relatively	precise	estimation	of	total	
reactivation	disease	(from	both	latent	and	recovered	combined),	but	did	not	permit	
precise	calibration	of	disease	originating	from	the	latently	infected	population	alone.	
As	discussed	in	more	detail	below,	this	led	to	wide	uncertainty	in	the	proportion	of	
the	TB	burden	contributed	by	the	latently	infected	population,	and	therefore	wide	
intervals	for	the	latency-only	post	infection	vaccines.	
As	shown	in	Figure	1B	in	the	main	text,	during	the	2025-2050	vaccination	period,	the	
majority	 of	 disease	 originated	 from	 the	 older	 adult	 and	 elderly	 population,	 and	
supplementary	Figure	S9	C&D	demonstrate	that	this	population	experience	mostly	
reactivation	disease.	However,	as	can	be	seen	in	Figure	S12,	the	proportion	of	this	
reactivation	disease	coming	from	latent	versus	recovered	populations	showed	wide	
variation	between	the	1000	fitted	model	runs,	especially	in	the	elderly	age	group.	
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The	 proportion	 of	 disease	 from	 latent	 versus	 recovered	 populations	 in	 2050	was	
inversely	associated	(Figure	S13A).		
A	 B	
	 	
Figure	S13:	A)	The	proportion	of	reactivation	disease	from	latent	and	recovered	populations	for	
1000	model	fits	in	2050	and	B)	Association	between	risk	of	reactivation	from	the	latent	elderly	
population	(velderly)	and	risk	of	reactivation	from	the	recovered	elderly	population	(relderly)	in	
1000	model	fits.	
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Figure	S12:	Origin	of	annual	incident	cases	in	A)	15-54	year	olds	and	B)	the	elderly.	Proportion	of	all	
annual	incident	cases	originating	from	new	infections	(red)	or	reactivation	(black).	Reactivation	
disease	is	further	broken	down	to	show	reactivation	cases	originating	from	the	latent	population	
(yellow)	or	recovered	population	(blue)	
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All	parameters	from	the	1000	model	fits	were	plotted	against	the	ratio	of	reactivation	
disease	from	latent:recovered	populations	to	identify	the	drivers	of	this	balance	(not	
shown).	Only	two	parameters	were	found	to	be	associated	with	this	ratio:	the	rate	of	
reactivation	from	latency	in	the	elderly	(velderly)	and	the	rate	of	reactivation	from	
the	recovered	class	in	the	elderly	(relderly).		
As	 the	 model	 was	 fitted	 to	 age-wise	 notification	 and	 prevalence	 rates,	 and	 the	
majority	of	elderly	disease	was	reactivation	disease,	these	reactivation	parameters	
were	 the	main	drivers	 for	 fitting	 to	 the	burden	of	disease	 in	 the	elderly.	 The	 two	
parameters	were	inversely	associated	(Figure	S13B),	as	the	model	produced	a	good	
fit	to	the	elderly	burden	of	disease	data	if	a	high	value	for	one	of	these	parameters	
was	compensated	for	by	a	low	value	in	the	other	parameter.	Therefore,	a	narrow	fit	
to	overall	burden	of	disease	was	achieved,	but	with	a	wide	range	of	possible	values	
for	 these	 two	mutually	 compensatory	parameters	and	 therefore	wide	uncertainty	
ranges	around	the	proportion	coming	from	latency	or	recovered	populations.	Given	
the	 burden	 of	 disease	 originating	 from	 the	 latent	 population	 was	 so	 varied,	 the	
achievable	impact	with	a	latency-only	post	infection	vaccine	(PSI-L)	was	also	highly	
variable	within	the	1000	model	fits.	
A	better	understanding	of	the	contribution	of	recurrence	versus	latent	reactivation	
would	be	required	for	calibration	to	fully	understand	the	potential	impact	of	a	PSI-L	
vaccine,	which	may	be	important,	as	some	TB	vaccine	clinical	trials	are	recruiting	only	
latently	infected	participants	and	excluding	those	with	previous	history	of	TB.7	
Wide	 uncertainty	 ranges	were	 observed	 in	 both	 adolescent	 and	 older	 adult	 PSI-L	
vaccine	 scenarios.	However,	 uncertainty	was	proportionally	 greater	 in	 older	 adult	
vaccination	due	to	the	larger	burden	of	reactivation	disease	in	older	age	groups	and	
the	broader	priors	for	older	adult	and	elderly	reactivation	parameters.	In	addition,	
the	 contribution	 of	 reactivation	 from	 the	 recovered	 population	 in	 adolescents	 is	
limited	 by	 the	 small	 proportion	 of	 the	 population	 experiencing	 TB	 disease	 by	
adolescence.	
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Regardless	of	the	uncertainties	in	the	PSI-L	vaccine	impact,	PSI-L&R	vaccines	provided	
consistently	 substantially	 higher	 impact,	 indicating	 that	 in	 vaccine	development	 it	
may	be	important	to	explore	whether	a	vaccine	is	safe	and	effective	in	both	those	
latently	infected	and	recovered	from	disease.	
The	 wide	 intervals	 on	 the	 PSI-L	 results	 also	 affect	 the	 comparison	 with	 the	 pre-
infection	vaccines.	Although	median	 impact	estimates	were	much	higher	 for	post-
infection	 latency-only	 than	 pre-infection	 vaccines,	 overlap	 of	 estimate	 ranges	
indicated	some	uncertainty	as	to	the	difference	in	impact	between	these	vaccines.	
For	 example,	 the	 latency-only	 post-infection	 vaccine	 with	 “intermediate”	 profile	
provided	 to	 older	 adults	 reduced	 2050	 incidence	 rates	 by	 6·1%	 (UR:	 1·3-8·7%)	
compared	 to	 baseline,	 indicating	 some	 uncertainty	 as	 to	 whether	 a	 latency-only	
vaccine	would	have	greater	impact	than	the	equivalent	pre-infection	vaccine	(3·3%,	
UR:2·3-5·3%).	
4.3.6.5 Vaccination	 outcomes:	 Reduction	 in	 2050	 TB	 mortality	 rate	 in	 vaccine	
scenarios	compared	to	the	no	new	vaccine	baseline	
The	reduction	in	population-level	TB	mortality	rate	in	2050	compared	to	the	no	new	
vaccine	 scenario	was	estimated	by	host	 infection	 status	 required	 for	efficacy,	 age	
targeting,	vaccine	efficacy,	coverage	and	duration	of	protection	(Figure	S14).	Overall,	
trends	observed	were	reflective	of	those	observed	for	incidence	rates	(Figure	2,	main	
article).		
In	all	vaccination	scenarios,	in	absolute	terms	more	cases	were	averted	than	deaths.	
Logically	this	follows,	given	at	least	one	case	must	be	averted	to	avoid	a	death,	and	
the	vaccines	were	assumed	not	to	affect	disease	severity.		
At	a	population	level,	adolescent	vaccination	yields	a	greater	percentage	reduction	
in	 incidence	 rate	 than	 the	 percentage	 reduction	 in	 mortality	 rate,	 whereas	 the	
opposite	was	observed	in	older	adult	vaccination.	This	is	a	function	of	the	relative	TB	
mortality	 rate	 in	 the	 population	 directly	 protected	 by	 the	 vaccine.	 The	 model	 is	
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parameterised	 such	 that	TB	death	 rates	 in	 the	elderly	 (≥65	years)	 are	equal	 to	or	
higher	than	in	adolescents	and	adults.	As	older	adult	vaccines	providing	10	or	20	years	
duration	of	protection	protect	up	to	the	age	of	69	or	79	years,	respectively,	higher	
case	 fatality	 rates	 in	 the	elderly	period	 (≥65	years)	meant	 that	more	deaths	were	
avoided	 per	 case	 averted	 through	 older	 adult	 vaccination	 than	 adolescent	
vaccination,	as	most	cases	averted	 in	adolescent	vaccination	were	 in	younger	age	
groups	experiencing	lower	case	fatality	rates.	Consequently,	older	adult	vaccination	
lowers	the	average	population-level	CFR,	whereas	adolescent	vaccination	increases	
the	average	population-level	CFR.		
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Figure	S14:	Reduction	in	population	level	TB	mortality	rate	in	2050	compared	to	the	no	new	vaccine	scenario,	by	host	infection	status	required	for	efficacy,	age	
targeting,	vaccine	efficacy,	coverage	and	duration	of	protection.	Vaccination	was	implemented	in	2025-2050,	with	adolescent	vaccination	delivered	routinely	to	15	year	
olds	and	a	3-year	catch	up	campaign	in	16-19	year	olds	2025-2027,	and	older	adult	vaccination	delivered	routinely	to	60	year	olds	with	a	3-year	catch	up	campaign	in	61-64	
year	olds	2025-2027.	Cov:	vaccine	coverage,	VE:	Vaccine	Efficacy,	Dur:	Average	duration	of	vaccine	protection.	
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4.3.6.6 Vaccination	outcomes:	Cumulative	number	needed	to	vaccinate	(NNV)	per	
case	or	death	averted	2025-2050	
The	cumulative	number	of	vaccines	delivered	2025-2050	and	cumulative	cases	and	
deaths	 averted	 compared	 to	 the	 no	 new	 vaccine	 baseline	 during	 the	 same	 time	
period	were	estimated.	These	were	used	to	calculate	the	cumulative	number	needed	
to	vaccinate	per	case	averted	(Table	S4)	and	cumulative	number	needed	to	vaccinate	
per	death	averted	(Table	S5)	over	the	2025-2050	period.	
Due	 to	 the	 demographic	 structure	 of	 the	 population,	 vaccination	 of	 older	 adults	
required	more	doses	than	the	equivalent	coverage	in	adolescents	(e.g.	70%	coverage	
required	approximately	378	million	older	adult	vaccines	or	317	million	adolescent	
vaccines	2025-2050).	Given	the	main	demographic	parameters	were	fixed	in	the	first	
stage	 of	 the	 fitting	 process,	 uncertainty	 ranges	 are	 representative	 of	 the	 small	
differences	in	population	size	as	a	result	of	variation	in	TB	natural	history	parameters.	
The	cumulative	number	of	cases	and	deaths	averted	by	adolescent	vaccination	2025-
2050	ranged	from	2000	(UR:	2,000-3,000)	to	502,000	(UR:	431,000-591,000)	cases	
(Table	S4),	and	30	(UR:	10-60)	up	to	5,220	(2,760-8,690)	deaths	(Table	S5).	In	older	
adult	vaccination	campaigns,	many	more	cases	and	deaths	were	anticipated	to	be	
averted,	 estimated	 at	 110,000	 (UR:	 85,000-151,000)	 to	 3.0	million	 (UR:	 2.5-3.5m)	
cases	and	2,790	(1,400-6,410)	to	73,730	(37,700-146,410)	deaths	through	older	adult	
vaccination	campaigns.		
The	 lowest	 achievable	 cumulative	 NNVs	 per	 case	 averted	 2025-2050	 with	 the	
adolescent	and	older	adult	vaccines	explored	were	590	(501-688)	and	120	(103-141),	
respectively,	reaching	as	high	as	59,070	(43,503-77,369)	to	1,505	(1,104-1,944)	with	
the	 least	 effective	 vaccines	 explored.	 Cumulative	 NNV	 per	 death	 averted	 for	
adolescent	 vaccination	 ranged	 from	48,826	 (37,877-71,140)	 to	 3.8m	 (3.1m-6.3m),	
and	older	adult	NNVs	ranged	from	5,464	(4,249-6,190)	to	65,575	(53,816-75,898).		
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For	the	highest	impact	P&PI	vaccines,	adolescent	campaigns	required	5.3	times	the	
number	 of	 vaccinated	 individuals	 to	 avert	 one	 case	 compared	 to	 older	 adult	
vaccination	 (Table	 1,	 main	 article).	 The	 impact	 of	 adolescent	 versus	 older	 adult	
vaccination	differed	most	for	PSI-L&R	vaccines;	for	the	‘intermediate’	vaccine	profile,	
91	times	more	adolescents	would	need	to	be	vaccinated	than	older	adults	to	avert	
the	 same	 number	 of	 cases,	 and	 200	 times	 more	 adolescents	 would	 need	 to	 be	
vaccinated	 to	 avert	 the	 same	number	of	deaths.	 The	most	 similar	 impact	profiles	
were	pre-infection	vaccines,	for	which	only	1.3	and	2.7	times	more	adolescent	than	
older	adult	vaccines	were	needed	per	case	or	death	averted,	 respectively,	 for	 the	
‘intermediate’	vaccine	profile.	
Although	a	larger	number	of	vaccines	were	delivered	in	older	adult	campaigns	than	
equivalent	adolescent	campaigns,	many	more	cases	and	deaths	were	averted,	thus	
the	number	needed	to	vaccinate	per	case	or	death	averted	was	lower	with	older	adult	
vaccination.	 Given	 substantially	 fewer	 vaccines	 are	 required	 per	 case	 or	 death	
averted	 for	 older	 adult	 vaccination,	 assuming	 the	 number	 and	 size	 of	 doses	 for	
protection	 is	 the	 same	 as	 for	 adolescents,	 the	 impact	 per	 vaccine	 dose	would	 be	
higher	 with	 older	 adult	 vaccination.	 To	 confirm	 whether	 older	 adult	 vaccination	
would	be	more	cost	effective	would	require	full	cost	effectiveness	analyses,	as	such	
differences	could	be	offset	by	costs	of	delivery.		The	cost	of	school-based	adolescent	
delivery	is	likely	to	be	lower	than	older	adult	platforms,	though	influenza	vaccines	are	
delivered	in	China	at	60	years	old,	so	delivery	alongside	influenza	vaccines	could	be	a	
low-cost	option	if	coverage	could	be	improved.	
Cumulative	number	needed	to	vaccinate	per	case	or	death	averted	2025-2050	was	
found	to	be	marginally	higher	with	70%	coverage	than	30%	coverage.	Although	more	
cases	are	averted	by	increased	coverage,	this	is	suggestive	that	the	large	increase	in	
number	of	vaccines	required	is	not	outweighed	or	even	matched	by	the	additional	
cases	averted	by	increasing	coverage.		For	example,	increasing	coverage	of	the	older	
adult	‘intermediate’	P&PI	vaccine	from	30%	to	70%	increased	the	number	of	cases	
averted	 from	 0·73	 million	 to	 1·64	 million,	 but	 increased	 the	 number	 of	 vaccines	
required	from	162	million	to	378	million,	so	NNV	over	2025-50	was	found	to	increase	
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marginally	from	223	(192-261)	to	230	(UR:	199-269)	with	this	increase	in	coverage	
(Table	S4).	
The	 increase	 in	NNV	with	higher	coverage	 levels	was	due	to	a	combination	of	 the	
vaccination	time	horizon	and	the	changing	disease	burden	over	that	period.	Higher	
coverage	 reduces	disease	 rates	more	 rapidly	 initially	 after	 introduction,	 so	over	 a	
short	 horizon	 the	 large	 additional	 number	 of	 vaccines	 for	 higher	 coverage	 averts	
many	more	cases.	However,	in	the	latter	part	of	the	vaccination	period,	the	higher	
coverage	 levels	 had	 already	 brought	 down	 burden	 of	 disease	 to	 such	 levels	 that	
although	 the	 proportion	 of	 cases	 averted	 in	 the	 70%	 coverage	 scenario	 was	 still	
higher,	there	were	fewer	cases	remaining	to	be	averted	than	in	the	30%	coverage	
scenario.	Therefore,	in	later	years,	large	volumes	of	additional	vaccine	were	provided	
for	limited	additional	epidemiological	gain	in	the	70%	coverage	scenario.	Over	these	
longer	 periods	 the	 cumulative	 number	 of	 vaccines	 delivered	 for	 70%	 coverage	 is	
much	 higher	 than	with	 30%	 coverage,	 but	 because	 the	 incremental	 gain	 is	much	
lower	in	the	later	years	while	the	same	high	level	of	vaccination	is	maintained,	the	
cumulative	 NNV	 over	 this	 period	 is	 higher	 with	 70%	 coverage	 than	 with	 30%	
coverage.	 Therefore,	 although	NNV	 is	marginally	 higher	with	 the	 higher	 coverage	
level	 explored,	 higher	 absolute	 reductions	 in	 disease	 burden	 were	 achieved	 and	
disease	reduction	targets	could	be	met	much	faster	with	higher	coverage	levels,	so	is	
likely	to	still	be	considered	programmatically	favourable.	
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Table	S4:	Cumulative	number	needed	to	vaccinate	per	case	averted	2025-2050	
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479	(410-568)	 663		(558-773)	
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80	
10	
317,139	
(316,955-
317,287)	
10	(8-14)	 30,568		(22,508-40,058)	
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(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-
L&R	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,916	
(135,838-
135,980)	
4	(3-5)	 38,771		(29,534-50,337)	
20	
135,916	
(135,838-
135,980)	
6	(4-7)	 23,774		(18,156-30,782)	
60	
10	
135,917	
(135,838-
135,980)	
5	(4-7)	 26,042		(19,838-33,813)	
20	
135,917	
(135,838-
135,980)	
9	(7-11)	 15,987		(12,210-20,701)	
80	
10	
135,917	
(135,838-
135,980)	
7	(5-9)	 19,679		(14,990-25,551)	
20	
135,917	
(135,838-
135,980)	
11	(9-15)	 12,094	(9,237-15,661)	
70	
40	
10	
317,139	
(316,955-
317,287)	
8	(6-11)	 39,554		(30,129-51,359)	
20	
317,139	
(316,955-
317,287)	
13	(10-17)	 24,327		(18,581-31,503)	
60	
10	
317,139	
(316,955-
317,287)	
12	(9-16)	 26,831		(20,437-34,840)	
20	
317,139	
(316,955-
317,287)	
19	(15-25)	 16,547		(12,638-21,429)	
80	
10	
317,139	
(316,955-
317,287)	
15	(12-20)	 20,471		(15,592-26,585)	
20	
317,139	
(316,955-
317,287)	
25	(19-33)	 12,660	(9,669-16,396)	
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ra
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-
L&R	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
380		
(305-431)	 426	(375-532)	
20	
162,162	
(161,417-
162,746)	
547		
(432-625)	 297	(259-376)	
60	
10	
162,162	
(161,417-
162,746)	
567		
(455-643)	 286	(252-357)	
20	
162,162	
(161,418-
162,746)	
815		
(643-931)	 199	(174-252)	
80	
10	
162,163	
(161,418-
162,746)	
752		
(603-853)	 216	(190-269)	
20	
162,163	
(161,418-
162,746)	
1,079		
(852-1,233)	 150	(131-190)	
70	
40	
10	
378,380	
(376,642-
379,741)	
874		
(700-992)	 433	(381-541)	
20	
378,380	
(376,642-
379,741)	
1,254		
(990-1,432)	 302	(264-383)	
60	
10	
378,381	
(376,644-
379,743)	
1,295		
(1,037-1,469)	 292	(257-365)	
20	
378,381	
(376,644-
379,743)	
1,852		
(1,461-2,117)	 204	(179-259)	
80	
10	
378,382	
(376,645-
379,744)	
1,704		
(1,364-1,935)	 222	(195-278)	
20	
378,383	
(376,646-
379,744)	
2,432		
(1,919-2,781)	 156	(136-197)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(uncertainty	
range)	
P&PI	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,917		
(135,838-
135,980)	
78	(68-92)	 1,743		(1,485-2,013)	
20	
135,917		
(135,838-
135,980)	
118	(102-139)	 1,149		(976-1,339)	
60	
10	
135,917	
(135,838-
135,980)	
116	(100-136)	 1,174		(1,001-1,356)	
20	
135,917	
(135,838-
135,980)	
175	(150-206)	 776		(659-905)	
80	
10	
135,917	
(135,838-
135,980)	
153	(132-179)	 890		(758-1,028)	
20	
135,917	
(135,838-
135,980)	
230	(198-271)	 590		(501-688)	
70	
40	
10	
317,139	
(316,955-
317,287)	
177	(153-208)	 1,792		(1,527-2,070)	
20	
317,139	
(316,955-
317,287)	
266	(229-314)	 1,190		(1,011-1,388)	
60	
10	
317,139	
(316,955-
317,287)	
259	(224-304)	 1,223		(1,043-1,414)	
20	
317,139	
(316,955-
317,287)	
388	(333-456)	 818		(695-954)	
80	
10	
317,139	
(316,956-
317,288)	
338	(292-396)	 939		(801-1,086)	
20	
317,139	
(316,956-
317,288)	
502	(431-591)	 632		(537-737)	
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y	
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ra
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n	
Individuals	
Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
P&PI	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
489		
(418-566)	
332		
(286-387)	
20	
162,162	
(161,417-
162,746)	
693		
(585-807)	
234		
(200-277)	
60	
10	
162,163	
(161,418-
162,746)	
727		
(622-841)	
223		
(192-261)	
20	
162,163	
(161,418-
162,746)	
1,028		
(868-1,196)	
158		
(135-187)	
80	
10	
162,163	
(161,418-
162,746)	
962		
(822-1,111)	
169		
(146-197)	
20	
162,163	
(161,418-
162,746)	
1,355		
(1,145-1,576)	
120		
(103-141)	
70	
40	
10	
378,381	
(376,643-
379,742)	
1,116		
(954-1,289)	
339		
(293-396)	
20	
378,381	
(376,643-
379,742)	
1,571		
(1,327-1,824)	
241		
(207-285)	
60	
10	
378,382	
(376,645-
379,744)	
1,643		
(1,403-1,893)	
230		
(199-269)	
20	
378,383	
(376,645-
379,744)	
2,300		
(1,944-2,663)	
164		
(142-194)	
80	
10	
378,384	
(376,647-
379,745)	
2,150		
(1,837-2,473)	
176		
(153-206)	
20	
378,384	
(376,648-
379,746)	
2,995		
(2,532-3,459)	
126		
(109-149)	
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Table	S5:	Cumulative	number	needed	to	vaccinate	per	death	averted	2025-2050	
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	(%
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in
e	
Ef
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y	
(%
)	
Du
ra
tio
n	
Individuals	
Vaccinated	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Death	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(uncertainty	
range)	
PRI	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,917	
(135,838-
135,980)	
0.85		
(0.45-1.40)	
140,995	
(108,261-201,462)	
20	
135,917	
(135,838-
135,980)	
1.18		
(0.62-1.97)	
102,019	
(77,815-145,567)	
60	
10	
135,917	
(135,838-
135,980)	
1.26		
(0.67-2.08)	
95,446	
(73,282-136,383)	
20	
135,917	
(135,838-
135,980)	
1.74		
(0.92-2.91)	
69,254	
(52,823-98,818)	
80	
10	
135,917	
(135,838-
135,980)	
1.66		
(0.89-2.74)	
72,682	
(55,800-103,857)	
20	
135,917	
(135,838-
135,980)	
2.29		
(1.21-3.83)	
52,880	
(40,334-75,456)	
70	
40	
10	
317,139	
(316,955-
317,287)	
1.92		
(1.03-3.17)	
146,838		
(112,726-209,823)	
20	
317,139	
(316,955-
317,287)	
2.65		
(1.39-4.43)	
107,023	
(81,630-152,716)	
60	
10	
317,139	
(316,955-
317,287)	
2.81		
(1.51-4.64)	
101,379	
(77,813-144,867)	
20	
317,139	
(316,955-
317,287)	
3.85		
(2.03-6.44)	
74,340	
(56,700-106,081)	
80	
10	
317,139	
(316,956-
317,288)	
3.65		
(1.96-6.04)	
78,703	
(60,397-112,465)	
20	
317,139	
(316,956-
317,288)	
4.98		
(2.62-8.34)	
58,048	
(44,272-82,833)	
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ra
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n	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	range)	
PRI	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
2.79		
(1.40-6.41)	
64,045	
(52,494-74,077)	
20	
162,162	
(161,417-
162,745)	
3.66		
(1.76-8.71)	
50,007	
(40,335-56,999)	
60	
10	
162,162	
(161,417-
162,745)	
4.14		
(2.08-9.51)	
43,078	
(35,326-49,839)	
20	
162,162	
(161,417-
162,745)	
5.43		
(2.61-12.90)	
33,721	
(27,189-38,416)	
80	
10	
162,162	
(161,417-
162,745)	
5.47		
(2.75-12.54)	
32,596	
(26,742-37,721)	
20	
162,162	
(161,417-
162,745)	
7.15		
(3.44-16.98)	
25,580	
(20,617-29,126)	
70	
40	
10	
378,378	
(376,639-
379,739)	
6.34		
(3.19-14.53)	
65,575	
(53,816-75,898)	
20	
378,378	
(376,639-
379,739)	
8.29		
(3.98-19.64)	
51,546	
(41,536-58,671)	
60	
10	
378,378	
(376,640-
379,740)	
9.31		
(4.69-21.27)	
44,613	
(36,654-51,666)	
20	
378,378	
(376,640-
379,740)	
12.13		
(5.83-28.61)	
35,270	
(28,397-40,097)	
80	
10	
378,379	
(376,640-
379,740)	
12.15	
(6.13-27.69)	
34,136	
(28,076-39,554)	
20	
378,379	
(376,640-
379,740)	
15.78	
(7.59-37.07)	
27,132	
(21,832-30,816)	
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ra
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	range)	
PSI-L	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,916	
(135,838-
135,980)	
0.03	
(0.01-0.06)	
3,706,285	
(2,958,178-
6,096,566)	
20	
135,916	
(135,838-
135,980)	
0.04	
(0.02-0.08)	
2,462,677	
(1,965,549-
4,056,801)	
60	
10	
135,916	
(135,838-
135,980)	
0.04	
(0.02-0.09)	
2,500,691	
(1,996,083-
4,113,801)	
20	
135,916	
(135,838-
135,980)	
0.06	
(0.03-0.13)	
1,663,455	
(1,327,628-
2,740,425)	
80	
10	
135,916	
(135,838-
135,980)	
0.05	
(0.03-0.11)	
1,898,161	
(1,515,252-
3,122,865)	
20	
135,916	
(135,838-
135,980)	
0.08	
(0.04-0.17)	
1,264,068	
(1,008,846-
2,082,613)	
70	
40	
10	
317,139	
(316,955-
317,287)	
0.06	
(0.03-0.13)	
3,826,806	
(3,054,996-
6,296,245)	
20	
317,139	
(316,955-
317,287)	
0.09	
(0.05-0.19)	
2,550,356	
(2,035,391-
4,202,038)	
60	
10	
317,139	
(316,955-
317,287)	
0.09	
(0.05-0.20)	
2,623,571	
(2,094,819-
4,317,445)	
20	
317,139	
(316,955-
317,287)	
0.13	
(0.07-0.28)	
1,753,138	
(1,399,062-
2,889,019)	
80	
10	
317,139	
(316,955-
317,287)	
0.12	
(0.06-0.26)	
2,023,385	
(1,615,897-
3,330,456)	
20	
317,139	
(316,955-
317,287)	
0.17	
(0.09-0.37)	
1,355,760	
(1,081,876-
2,234,576)	
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ra
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-L	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
4.60	
(0.65-13.31)	
45,342	
(37,100-79,890)	
20	
162,162	
(161,417-
162,745)	
6.34	
(0.85-19.17)	
32,516	
(27,191-59,563)	
60	
10	
162,162	
(161,417-
162,745)	
6.85	
(0.97-19.83)	
30,446	
(24,908-53,646)	
20	
162,162	
(161,417-
162,745)	
9.44	
(1.27-28.51)	
21,857	
(18,274-40,037)	
80	
10	
162,162	
(161,417-
162,745)	
9.08	
(1.28-26.25)	
22,999	
(18,812-40,524)	
20	
162,162	
(161,417-
162,745)	
12.48	
(1.68-37.71)	
16,528	
(13,815-30,275)	
70	
40	
10	
378,378	
(376,641-
379,740)	
10.54	
(1.49-30.48)	
46,217	
(37,799-81,436)	
20	
378,378	
(376,641-
379,740)	
14.49	
(1.95-43.76)	
33,237	
(27,778-60,881)	
60	
10	
378,378	
(376,642-
379,740)	
15.55	
(2.19-44.98)	
31,324	
(25,609-55,197)	
20	
378,379	
(376,642-
379,740)	
21.33	
(2.87-64.41)	
22,582	
(18,864-41,362)	
80	
10	
378,379	
(376,643-
379,741)	
20.41	
(2.88-59.01)	
23,879	
(19,515-42,079)	
20	
378,379	
(376,644-
379,741)	
27.92	
(3.76-84.29)	
17,257	
(14,408-31,607)	
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ra
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-
L&R	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,916	
(135,838-
135,980)	
0.04		
(0.02-0.09)	
1,953,107	
(1,814,214-
3,607,241)	
20	
135,916	
(135,838-
135,980)	
0.06		
(0.03-0.13)	
1,264,352	
(1,173,728-
2,346,808)	
60	
10	
135,917	
(135,838-
135,980)	
0.06		
(0.03-0.13)	
1,317,972	
(1,224,238-
2,434,448)	
20	
135,917	
(135,838-
135,980)	
0.09		
(0.05-0.19)	
854,077	
(792,859-
1,585,394)	
80	
10	
135,917	
(135,838-
135,980)	
0.08		
(0.04-0.17)	
1,000,553	
(929,387-
1,848,334)	
20	
135,917	
(135,838-
135,980)	
0.12		
(0.06-0.25)	
649,058	
(602,536-
1,204,912)	
70	
40	
10	
317,139	
(316,955-
317,287)	
0.09		
(0.05-0.20)	
2,017,371	
(1,873,873-
3,726,978)	
20	
317,139	
(316,955-
317,287)	
0.14		
(0.07-0.29)	
1,309,585	
(1,215,717-
2,431,232)	
60	
10	
317,139	
(316,955-
317,287)	
0.14		
(0.07-0.29)	
1,383,557	
(1,285,122-
2,556,696)	
20	
317,139	
(316,955-
317,287)	
0.20		
(0.10-0.42)	
900,378	
(835,840-
1,671,837)	
80	
10	
317,139	
(316,955-
317,287)	
0.18		
(0.09-0.38)	
1,067,459	
(991,497-
1,973,094)	
20	
317,139	
(316,955-
317,287)	
0.26		
(0.13-0.55)	
696,435	
(646,515-
1,293,391)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-
L&R	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
9.83		
(4.83-19.37)	
19,036	
(14,653-21,122)	
20	
162,162	
(161,417-
162,746)	
13.70		
(6.59-27.68)	
13,582		
(10,382-15,247)	
60	
10	
162,162	
(161,417-
162,746)	
14.64		
(7.20-28.85)	
12,785	
(9,841-14,183)	
20	
162,162	
(161,418-
162,746)	
20.38		
(9.80-41.18)	
9,131	
(6,980-10,249)	
80	
10	
162,163	
(161,418-
162,746)	
19.38		
(9.53-38.19)	
9,659	
(7,435-10,713)	
20	
162,163	
(161,418-
162,746)	
26.95		
(12.96-54.45)	
6,906	
(5,279-7,750)	
70	
40	
10	
378,380	
(376,642-
379,741)	
22.50		
(11.06-44.34)	
19,413	
(14,943-21,528)	
20	
378,380	
(376,642-
379,741)	
31.27		
(15.03-63.19)	
13,890	
(10,617-15,585)	
60	
10	
378,381	
(376,644-
379,743)	
33.21		
(16.32-65.42)	
13,164	
(10,132-14,590)	
20	
378,381	
(376,644-
379,743)	
46.03		
(22.11-93.00)	
9,441	
(7,216-10,589)	
80	
10	
378,382	
(376,645-
379,744)	
43.57		
(21.40-85.83)	
10,040	
(7,727-11,122)	
20	
378,383	
(376,646-
379,744)	
60.22		
(28.93-121.71)	
7,218	
(5,517-8,092)	
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Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	range)	
P&PI	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,917	
(135,838-
135,980)	
0.89		
(0.48-1.47)	
131,098		
(102,232-190,927)	
20	
135,917	
(135,838-
135,980)	
1.23		
(0.65-2.05)	
94,158	
(73,049-137,194)	
60	
10	
135,917	
(135,838-
135,980)	
1.31		
(0.71-2.18)	
88,762	
(69,211-129,270)	
20	
135,917	
(135,838-
135,980)	
1.83		
(0.97-3.04)	
63,931		
(49,596-93,150)	
80	
10	
135,917	
(135,838-
135,980)	
1.73		
(0.93-2.88)	
67,604	
(52,708-98,455)	
20	
135,917	
(135,838-
135,980)	
2.40		
(1.27-3.99)	
48,826	
(37,877-71,140)	
70	
40	
10	
317,139	
(316,955-
317,287)	
2.00		
(1.08-3.33)	
136,595		
(106,491-198,928)	
20	
317,139	
(316,955-
317,287)	
2.78		
(1.47-4.62)	
98,833	
(76,667-143,998)	
60	
10	
317,139	
(316,955-
317,287)	
2.93		
(1.58-4.87)	
94,346	
(73,535-137,392)	
20	
317,139	
(316,955-
317,287)	
4.04		
(2.14-6.72)	
68,685	
(53,275-100,065)	
80	
10	
317,139	
(316,956-
317,288)	
3.81		
(2.06-6.34)	
73,274	
(57,096-106,698)	
20	
317,139	
(316,956-
317,288)	
5.22		
(2.76-8.69)	
53,659	
(41,615-78,168)	
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Ol
de
r	A
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30	
40	
10	
162,162	
(161,417-
162,746)	
12.57		
(6.56-24.13)	
14,698	
(11,502-16,502)	
20	
162,162	
(161,417-
162,746)	
17.17		
(8.74-34.06)	
10,671	
(8,303-12,097)	
60	
10	
162,163	
(161,418-
162,746)	
18.68		
(9.75-35.85)	
9,897	
(7,743-11,107)	
20	
162,163	
(161,418-
162,746)	
25.47		
(12.97-50.51)	
7,199	
(5,600-8,159)	
80	
10	
162,163	
(161,418-
162,746)	
24.66		
(12.88-47.35)	
7,496	
(5,864-8,410)	
20	
162,163	
(161,418-
162,746)	
33.58		
(17.10-66.59)	
5,464	
(4,249-6,190)	
70	
40	
10	
378,381	
(376,643-
379,742)	
28.59		
(14.93-54.90)	
15,091	
(11,804-16,927)	
20	
378,381	
(376,643-
379,742)	
38.89		
(19.81-77.10)	
11,013	
(8,564-12,474)	
60	
10	
378,382	
(376,645-
379,744)	
41.94		
(21.92-80.58)	
10,292	
(8,048-11,534)	
20	
378,383	
(376,645-
379,744)	
56.80		
(28.98-112.67)	
7,544	
(5,863-8,538)	
80	
10	
378,384	
(376,647-
379,745)	
54.71		
(28.63-105.18)	
7,893	
(6,170-8,838)	
20	
378,384	
(376,648-
379,746)	
73.73		
(37.70-146.41)	
5,810	
(4,514-6,571)	
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4.3.6.7 Vaccination	outcomes:	Vaccine	efficacy	by	age	
Vaccine	efficacy	was	 assumed	 to	be	 invariable	by	 age	of	 administration.	 This	was	
considered	acceptable	given	the	age	of	routine	older	adult	vaccination	(60	years)	was	
selected	to	precede	the	main	onset	of	immunosenescence,49	and	given	that	zoster	
vaccine	 trials	 have	 provided	 proof	 of	 concept	 for	 achieving	 robust	 efficacy	 and	
immunogenicity	 in	 older	 age	 groups.11	 However,	 to	 account	 for	 possible	
immunosenescence,	an	additional	2%	waning	per	year	(0-5%	in	sensitivity	analyses)	
was	assumed	from	the	age	of	65	years.		
Given	the	higher	proportion	of	co-morbidities	in	older	adults	than	adolescents,	and	
the	 experience	with	 elderly	 vaccination	 against	 influenza,50	 vaccine	 efficacy	 could	
conceivably	be	lower	in	this	older	population.	Therefore,	an	exploration	of	whether	
the	 conclusions	would	 be	 robust	 to	 reduced	 vaccine	 efficacy	 in	 older	 age	 groups	
follows.	
Although	the	absolute	worst	case	scenario	would	be	a	complete	lack	of	efficacy	in	
older	adults,	this	seems	an	unlikely	scenario	for	the	population	of	60	year	olds.	For	
influenza	vaccination,	70-90%	efficacy	has	been	observed	in	adults	and	17-53%	in	the	
elderly.50	Using	this	as	a	basis	for	a	differential	of	efficacy,	adolescents	were	assumed	
to	experience	80%	vaccine	efficacy,	and	older	adults	towards	the	higher	end	of	the	
elderly	influenza	vaccine	efficacy	(40%	efficacy)	given	older	adults	are	younger	than	
the	elderly.	The	longer	vaccine	duration	(20	years)	was	assumed	for	adolescents,	and	
for	 older	 adults	 10	 years	 was	 assumed,	 with	 the	 added	 disadvantage	 of	
immunosenescence	from	the	age	of	65	years.	Coverage	was	also	assumed	as	70%	in	
adolescents,	and	only	30%	for	older	adults.	These	constituted	 the	 ‘high’	and	 ‘low’	
scenarios	for	adolescents	and	older	adults,	respectively	(Table	S6).	
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Table	S6:	Comparison	of	impact	of	adolescent	vaccination	‘high’	scenario	(80%	VE,	70%	coverage,	
20	years	protection)	versus	older	adult	‘low’	scenario	(40%	VE,	30%	coverage,	10	years	protection).	
NNV:	Number	needed	to	vaccinate	
Vaccine	
mechanism	
Age	group	
vaccinated	
(scenario)	
Cases	averted	2025-
2050,	Thousands	
(Uncertainty	range)	
Cumulative	NNV	per	
case	averted	2025-2050		
(Uncertainty	range)	
PRI	 Adolescent	
(high)	
479		
(410-568)	
663		
(558-773)	
Older	adult	
(low)	
110		
(85-151)	
1,473	
(1,077-1,907)	
PSI-L	 Adolescent	
(high)	
17		
(13-22)	
19,142		
(14,101-24,974)	
Older	adult	
(low)	
193		
(39-317)	
838		
(511-4,212)	
PSI-L&R	 Adolescent	
(high)	
25		
(19-33)	
12,660	
(9,669-16,396)	
Older	adult	
(low)	
380		
(305-431)	
426		
(375-532)	
P&PI	 Adolescent	
(high)	
502		
(431-591)	
632		
(537-737)	
Older	adult	
(low)	
489		
(418-566)	
332		
(286-387)	
	
Comparing	 the	 adolescent	 ‘high’	 to	 older	 adult	 ‘low’	 vaccine	 and	 coverage,	 older	
adult	 vaccination	 averted	 more	 cases	 and	 required	 fewer	 vaccinations	 per	 case	
averted	for	both	post-infection	vaccines.	Therefore,	even	if	trials	were	to	show	that	
a	 post-infection	 vaccine	 were	 much	 less	 efficacious	 and	 durable	 and	 anticipated	
achievable	coverage	were	much	lower	in	older	adults	than	adolescents,	older	adult	
vaccination	would	 likely	 still	 provide	 greater	 impact	 than	 vaccinating	 adolescents.	
Therefore,	for	vaccines	with	the	potential	for	post-infection	efficacy,	ensuring	trials	
are	designed	to	examine	safety	and	efficacy	in	these	older	age	groups	is	essential.	
When	 comparing	 identical	 vaccine	 efficacies	 and	durations,	 pre-infection	 vaccines	
provided	greater	impact	with	older	adult	vaccination,	though	the	age-wise	difference	
is	 much	 smaller	 than	 was	 observed	 post-infection	 vaccines.	 Therefore,	 when	
comparison	was	made	between	the	‘high’	adolescent	and	‘low’	older	adult	vaccine	
scenario,	 results	 suggested	 that	 the	 adolescent	 vaccine	may	 provide	 substantially	
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higher	impact,	avoiding	more	than	four	times	the	number	of	cases,	with	an	NNV	of	
less	than	half	the	older	adult	estimate.		
To	explore	 this	 further,	 sensitivity	 to	 reductions	 in	 individual	characteristics	 in	 the	
older	 adult	 vaccination	 scenario	was	 estimated	 for	 the	median	 estimate	 of	 cases	
averted.	Coverage	was	the	biggest	influencing	factor,	as	the	median	estimate	of	cases	
averted	by	older	adult	vaccination	reduced	by	23%	by	halving	efficacy	to	40%,	25%	
by	halving	duration	of	protection	to	10	years,	and	by	55%	by	reducing	coverage	from	
30%	to	70%.	The	reduction	in	duration	or	efficacy	was	insufficient	to	bring	the	median	
cases	averted	by	older	adult	vaccination	below	the	adolescent	vaccination	estimate.	
The	impact	of	reduced	coverage	in	older	adults	was	sufficient	for	the	number	of	cases	
averted	by	this	strategy	to	fall	below	the	adolescent	vaccination	strategy	with	higher	
coverage,	 though	 the	 NNV	 per	 case	 averted	 was	 still	 lower	 with	 older	 adult	
vaccination.	 If	 both	 coverage	 and	 efficacy	 were	 reduced	 simultaneously	 in	 older	
adults,	adolescent	vaccination	became	preferable.	Therefore,	if	clinical	trials	were	to	
demonstrate	 substantially	 lower	 efficacy	 and/or	 duration	 of	 protection	 in	 older	
adults,	or	feasibility	assessments	were	suggestive	of	low	coverage	in	this	older	age	
group,	further	modelling	would	be	required	to	assess	whether	adolescent	vaccination	
or	 another	 approach	 to	 vaccination	 might	 be	 preferable.	 Understanding	 vaccine	
characteristics	across	age	groups	will	be	important	to	inform	data-driven	vaccination	
strategies	with	a	pre-infection	vaccine.		
For	a	vaccine	efficacious	pre-	and	post-infection,	the	median	number	of	cases	averted	
for	the	‘high’	adolescent	vaccine	scenario	was	marginally	higher	than	the	‘low’	older	
adult	vaccine,	but	with	largely	overlapping	uncertainty	ranges	(Table	S6).	The	‘high’	
scenario	 (70%	 coverage)	 in	 adolescents	 required	 almost	 double	 the	 number	 of	
vaccines	 needed	 for	 30%	 coverage	 of	 older	 adults,	 therefore	 the	 NNV	 per	 case	
averted	was	much	lower	for	older	adult	vaccination.	Therefore,	with	a	P&PI	vaccine,	
even	with	 the	 pessimistic	 assumption	 of	 halving	 vaccine	 efficacy	 and	 duration	 of	
protection	 for	older	adults	 compared	 to	adolescent	vaccination,	assuming	vaccine	
waning	of	2%	due	 to	 immunosenescence	after	 the	age	of	65	years,	and	assuming	
much	 lower	 coverage	 (30%	 instead	 of	 70%),	 older	 adult	 vaccination	 would	 still	
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provide	a	 similar	 level	of	 impact	 to	adolescent	vaccination,	and	would	be	a	much	
more	efficient	use	of	resources	as	would	require	almost	half	the	number	of	vaccines	
to	achieve	that	impact.		
The	key	recommendation	from	earlier	in	this	chapter	was	the	need	for	inclusion	of	
older	adults	 in	clinical	 trials,	 to	 investigate	efficacy	and	allow	for	 the	possibility	of	
registration	in	this	epidemiologically	important	age	group.	This	additional	discussion	
further	 strengthens	 this	 recommendation.	 For	 post-infection	 or	 pre-	 and	 post-
infection	 vaccines,	 older	 adult	 vaccination	 would	 be	 recommended	 even	 with	
substantially	lower	efficacy	or	duration	than	observed	in	adolescents.	Therefore,	data	
to	support	registration	in	this	population	will	be	vital.	For	pre-infection-only	vaccines,	
age-stratified	estimates	of	efficacy	will	be	important	for	designing	impact-maximising	
implementation	strategies,	as	the	preference	for	vaccinating	older	adults	could	be	
diminished	or	negated	if	efficacy,	duration	or	coverage	were	substantially	lower	than	
in	adolescents.	
4.3.6.8 Comparison	of	results	to	Chapter	3	
In	 Chapter	 3	 the	 research	 question	 focussed	 on	 exploring	 the	 impact	 of	 vaccine	
characteristics,	keeping	implementation	static	as	routine	vaccination	of	9	year	olds	
alongside	periodic	mass	vaccination	of	≥10	year	olds.	Implementation	scenarios	(age	
and	coverage)	and	the	relative	 impact	of	vaccine	characteristics	with	different	age	
targeting	were	explored	in	this	chapter.		
Although	differences	exist	between	the	two	models,	the	most	comparable	vaccines	
were	the	10-year	protection	and	60%	efficacy	against	disease	effective	pre-	and	post-
infection	scenarios,	with	coverage	of	80%	in	chapter	3	and	70%	in	this	chapter.	With	
this	vaccine,	routine	plus	mass	vaccination	in	Chapter	3	reduced	2050	incidence	rates	
by	 53.3%	 (UR:	 50.6-56.1%),	 averting	 7.5	 million	 cases	 2025-50	 (UR:	 7.0-8.1).	 The	
adolescent	vaccination	policy	in	this	chapter	reduced	2050	incidence	rates	by	1.8%	
(UR:	1.5-2.4%),	averting	0.26	million	cases	(UR:	0.22-0.30)	during	2025-50,	and	the	
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older	adult	 vaccination	policy	 reduced	 incidence	 rates	by	13.8%	 (UR:	12.9-15.2%),	
averting	1.64	million	cases	(UR:	1.40-1.89).		
Although	the	mass	versus	age-targeted	implementation	scenarios	are	compared,	age	
of	 vaccination	 was	 not	 the	 only	 contributory	 factor	 to	 impact	 differences.	 For	
example,	 routine	 coverage	 was	 10%	 higher	 in	 Chapter	 3,	 and	 protection	 was	
modelled	 as	 all-or-nothing	 instead	 of	 ‘leaky’	 in	 this	 chapter.	 Therefore,	 although	
results	provide	a	comparison	of	 targeted	versus	mass	campaigns,	 these	additional	
distinctions	must	be	considered.			
From	 a	 country	 decision-maker	 perspective,	 both	 epidemiological	 impact	 and	 the	
resources	required	are	important	considerations,	as	discussed	earlier	in	this	chapter.	
Although	number	of	vaccines	delivered	was	not	estimated	in	Chapter	3,	based	upon	
modelled	population	size	an	approximate	estimate	of	the	number	required	for	the	
three	10-yearly	mass	vaccination	campaigns	with	70%	coverage	of	10-100	year	olds	
could	be	made	(approximately	2.6	billion).	The	three	mass	campaigns	alone	(i.e.	not	
accounting	for	routine	vaccination	of	9	year-olds)	would	require	more	than	six	times	
the	 number	 of	 vaccines	 delivered	 in	 any	 of	 the	 70%	 coverage	 scenarios	 in	 this	
chapter,	which	would	also	have	implications	for	the	number	needed	to	vaccinate	per	
case	averted.		
Feasibility	of	mass	vaccination	described	in	Chapter	3	would	rely	on	the	viability	and	
practicality	 of	 such	 large-scale	 production.	 China	 is	 the	 world’s	 largest	 vaccine	
producer,	manufacturing	in	total	more	than	one	billion	vaccine	doses	per	annum,51	
so	 country-level	 capacity	would	 be	 anticipated	 to	 be	 able	 to	meet	 such	 demand.	
Achievability	 also	 relies	 on	 TB	 remaining	 a	 public	 health	priority	 in	 China	 and	 the	
availability	of	funding	for	vaccine	production	and	delivery.	
Assuming	these	do	not	become	limiting	issues,	broad	mass	vaccination	of	adolescents	
and	 adults	 would	 bring	 about	 a	 bigger	 reduction	 in	 2050	 incidence	 rates	 than	
targeted	campaigns	of	15	or	60	year	olds,	therefore	would	be	the	ideal	scenario	to	
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maximise	 vaccine	 impact	 if	 resources	 were	 not	 limited.	 However,	 the	 supply,	
logistical	and	cost	implications	of	vaccinating	the	entire	population	aged	≥10	years	
every	decade,	in	addition	to	routine	vaccination	of	9	year	olds,	would	be	substantial.	
Therefore,	 although	 the	 results	 of	 Chapter	 3	 support	 such	 wide-scope	 mass	
campaigns	 where	 feasible,	 the	 results	 of	 this	 chapter	 demonstrate	 that	 targeted	
routine	 vaccination	 of	 older	 adults	 could	 help	 maximise	 impact	 if	 resources	 are	
limited.	Therefore,	investigating	efficacy	in	this	older	adult	population	is	essential	in	
clinical	trials.	
4.3.6.9 Additional	discussion	of	context	
Previous	 mathematical	 modelling	 research	 has	 demonstrated	 that	 vaccination	 of	
adolescents,	or	adolescents	and	adults,	would	be	expected	to	provide	greater	impact	
and	cost	effectiveness	than	neonatal	vaccination.2,4,5	Neonatal	vaccination	with	new	
TB	vaccines	has	been	predicted	 to	provide	 limited	 impact	 in	China,	even	with	 the	
optimistic	assumption	of	100%	efficacy	against	infection	with	lifelong	protection	and	
95%	coverage,4	 therefore	vaccination	of	 infants	was	not	explored	 in	this	 research.	
Discussion	of	the	results	of	this	study	in	context	are	found	in	the	main	manuscript	in	
this	chapter,	but	some	additional	comparisons	with	the	two	most	recent	and	relevant	
studies	are	provided	below.	
The	Liu	study	comprised	a	TB	model	calibrated	to	China’s	TB	notifications,	comparing	
neonatal	 vaccination	 to	 neonatal	 plus	 periodic	 mass	 all-age	 vaccination	 (‘mixed	
vaccination’).	Over	a	17-year	time	frame,	7.63x108	doses	were	delivered	in	the	key	
mixed	vaccination	 scenario.4	 In	 this	 chapter,	 the	number	of	 vaccines	 ranged	1.36-
3.78x108,	but	were	delivered	to	a	narrower	age	group	and	over	a	longer	time	frame	
(26	years).	In	the	Liu	study,	the	time	to	achieving	the	2035	WHO	goal	was	halved,	yet	
the	 number	 of	 vaccinations	 delivered	 did	 not	 double,	 by	 implementing	 the	 25%	
coverage	‘mixed’	vaccination	strategy	compared	to	neonatal	vaccination.	Therefore,	
mass	 or	 adult	 campaigns	 appear	 to	 deliver	 more	 impact	 per	 vaccination	 than	
neonatal	vaccination.	However,	 the	number	needed	to	vaccinate	per	case	averted	
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was	 not	 estimated,	 therefore	 direct	 comparisons	 cannot	 be	 made	 with	 the	
vaccination	scenarios	presented	in	this	thesis.	
The	Liu	model	was	calibrated	to	China’s	new	TB	notification	data	for	2004-2014,	with	
a	good	fit	to	temporal	trends	achieved.	Due	to	specifically	fitting	to	these	annual	data,	
the	Liu	model	may	more	closely	track	year-on-year	notifications	than	the	research	
presented	in	these	two	chapters,	but	this	comes	at	the	cost	of	having	not	calibrated	
to	detailed	age	and	epidemiological	data	(mortality,	incidence	and	prevalence),	which	
is	essential	to	more	accurately	reflect	the	natural	history	and	transmission	dynamics.	
Such	age-relevant	dynamics	were	essential	to	the	age	targeting	research	question	in	
this	 chapter,	 and	 were	 achieved	 in	 my	 research	 through	 significant	 age-specific	
structure,	parameterisation	and	calibration.		
Empirical	studies	have	demonstrated	the	importance	of	recurrent	TB,	with	one	study	
in	 China	 indicating	 that	 populations	 recovered	 from	 a	 previous	 TB	 episode	
experienced	disease	rates	of	more	than	18	times	the	observed	rate	 in	the	general	
population.52	Modelling	recurrence	is	an	important	natural	history	transition,	and	in	
my	 research	 accounted	 for	 approximately	 20-70%	 of	 all	 reactivation	 disease.	 The	
range	 on	 this	 estimate	 is	wide	 due	 to	 the	 lack	 of	 appropriate	 calibration	 data	 to	
apportion	 cases	 between	progression	 from	 latent	 and	 recovered	populations,	 but	
even	 the	 lower	 end	 of	 the	 modelled	 estimate	 of	 recurrence	 demonstrates	 an	
important	contribution.	Vaccine	protection	of	the	population	recovered	from	disease	
provided	 substantial	 additional	 impact	 beyond	 that	 achievable	 by	 protecting	 only	
latent	 populations.	 In	 the	 Liu	 et	 al.	 study,	 recurrent	 disease	 was	 not	 modelled.4	
Therefore,	 to	calibrate	to	notification	data,	 transmission	or	progression	to	disease	
rates	may	have	been	overestimated,	and	 the	 future	burden	of	TB	may	have	been	
underestimated	 without	 the	 contribution	 of	 recurrence.	 If	 transmission	 was	
overestimated,	the	estimated	impact	of	such	a	prevention	of	infection	vaccine	may	
be	too	high,	and	predictions	of	achieving	2035	goals	would	be	optimistic.	Inclusion	of	
the	 recovered	 population	 is	 clearly	 important	 for	 predicting	 the	 future	 of	 China’s	
epidemic	and	potential	impact	of	future	vaccines,	thus	the	inclusion	of	relapse	and	
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reinfection	 following	 recovery	 is	 an	 important	 element	of	 the	 research	presented	
here.	
Another	 recently	 published	 TB	 vaccine	 study	 (Arregui	 et	 al.,	 2017),5	 explored	 the	
influence	of	age	specificity	in	model	parameterisation	and	fitting	on	the	estimated	
impact	 of	 future	 TB	 vaccines.	 Similar	 to	 the	 Liu	 study,	 a	 prevention	 of	 infection	
vaccine	with	relatively	optimistic	vaccine	assumptions	was	modelled,	including	80%	
vaccine	efficacy	with	lifelong	protection	and	100%	coverage	of	the	target	population.		
Vaccination	of	15	year	olds	in	the	Arregui	study	was	somewhat	comparable	to	the	
80%	efficacy	vaccine	with	20-year	protection	delivered	to	adolescents	in	the	study	in	
this	 chapter,	 though	 it	 should	 be	 noted	 that	 the	 Arregui	 vaccine	was	 for	 lifelong	
prevention	of	 infection	and	the	model	was	regional	as	opposed	to	China-specific.5	
Although	not	explicitly	stated	in	the	publication,	it	is	assumed	that	China	was	included	
in	the	Western	Pacific	Region	(WPR),	as	defined	by	WHO.53	In	the	Arregui	study,	this	
vaccine	was	estimated	to	avert	approximately	2.3	million	cases	 in	the	WPR	during	
2025-2050	 (extracted	 from	 Figure	 S16),5	 and	 the	 similar	 adolescent	 vaccination	
scenario	in	this	thesis	averted	0.5	million	(UR:	0.4-0.6m)	cases	in	China	over	the	same	
period.	Due	to	model	and	vaccine	differences,	 this	comparison	 is	 interpreted	with	
caution.		
Interestingly,	 in	 the	 Arregui	 WPR	 model,	 sensitivity	 analyses	 removing	 the	 age	
specificity	in	the	demography	and	epidemiology	of	the	model	increased	the	number	
of	cases	averted	by	adolescent	vaccination.5	Therefore,	without	age-specificity	in	the	
model,	 the	 impact	 of	 adolescent	 vaccines	 and	 the	 difference	 between	 infant	 and	
adolescent	vaccines	was	overestimated.	In	the	light	of	results	presented	in	Chapters	
3	 and	 4	 of	 this	 thesis,	 it	 is	 hypothesised	 that	 this	 difference	 derives	 from	 over-
allocation	of	cases	and	transmission	to	younger	age	groups	by	heterogeneous	contact	
patterns.	This	was	supported	by	commentary	 in	 the	Arregui	publication	 indicating	
that	the	eldest	age	groups	were	the	most	impacted	by	the	inclusion	of	heterogeneous	
contact	patterns.5	
	Chapter	4:	Age	targeting	of	new	TB	vaccines	 285	
In	the	model	presented	in	this	thesis,	and	in	the	Arregui	‘complete’	model,5	fitting	to	
age-stratified	 data	 and	 contact	 patterns	 ensured	 that	 the	 distribution	 of	 disease	
burden	was	reflective	of	age-structured	epidemiology	and	demography.	Importantly,	
in	 the	model	 presented	 here,	 such	 age-structured	models	 are	 valuable	 for	 more	
accurately	 estimating	 the	 future	 burden	 of	 disease,	 the	 impact	 of	 age-targeted	
vaccination,	and	most	importantly	for	identifying	the	ages	that	should	be	targeted	to	
provide	the	greatest	population-level	impact.	
In	 both	 the	 Arregui	 model	 and	 this	 thesis,	 reactivation	 rates	 were	 higher	 in	 the	
recovered	state	than	the	latent	state.	In	Arregui	et	al.,	re-infection	leading	to	slow	
progression	therefore	remains	in	the	recovered	state	so	progression	is	reflective	of	
the	population’s	disease	history5	In	the	model	presented	in	this	thesis,	re-infection	
leading	to	slow	progression	enters	the	latent	state.	Therefore,	the	natural	history	of	
reinfection	 in	 recovered	 populations	 could	 be	 improved	 in	 future	 work.	 Such	 a	
change	would	not	be	expected	to	alter	the	direction	of	impact	or	conclusions	of	this	
research.	It	would	be	anticipated	to	marginally	increase	the	number	and	proportion	
of	cases	arising	from	the	recovered	population,	which	would	be	likely	to	increase	the	
absolute	 estimates	 of	 vaccine	 impact,	 strengthen	 the	 conclusion	 that	 older	 adult	
vaccination	 with	 post-infection	 vaccines	 would	 provide	 greater	 impact	 than	
adolescent	 vaccination,	 and	 the	 PSI-L&R	 vaccine	would	 have	 even	 greater	 impact	
compared	to	PSI-L	vaccines.		
Several	limitations	observed	in	the	Arregui	study	that	are	important	for	exploring	age-
targeting	were	avoided	in	the	research	in	this	thesis.5	For	example,	the	Arregui	study	
modelled	5-year	age	steps	up	to	70	years	old.5	Yet,	in	this	study,	I	estimated	that	38%	
of	all	active	cases	in	2025	occurred	in	the	population	≥70	years;	therefore	it	was	vital	
to	explicitly	model	the	burden	and	transmission	from	these	oldest	age	groups	and	
explore	vaccines	protecting	older	ages.	Therefore,	I	modelled	1-year	age	steps	up	to	
100	 years	 of	 age,	 and	 explored	 vaccines	 delivered	 to	 older	 adults	 capable	 of	
protecting	into	the	elderly	period.	
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Although	 contact	 patterns	were	 not	 the	most	 influential	 age-related	 factor,	 their	
inclusion	 has	 been	demonstrated	 to	 change	 vaccine	 impact	 estimates.5	Given	 the	
greatest	change	was	observed	in	older	age	groups	when	switching	from	homogenous	
to	 heterogeneous	 contact	 patterns,5	 data-informed	 contact	 patterns	 were	 clearly	
important	for	the	research	question	in	this	chapter.	 In	the	Arregui	study,	Polymod	
data	from	eight	European	countries	was	applied	to	the	five	modelled	regions,	and	the	
influence	of	setting-specific	demography	was	managed	by	scaling	the	contact	matrix	
to	regional	demographic	estimates.5	However,	this	does	not	account	for	differences	
at	 the	 country	 level,	 nor	 does	 it	 account	 for	 the	 influence	 of	 social	 and	 cultural	
aspects.	 Therefore,	 using	 country-specific	 data,	 as	 was	 the	 case	 in	 the	 study	
presented	 in	 this	 thesis,	 ensured	 contact	 patterns	 were	 representative	 of	 the	
modelled	population.	
The	Arregui	study	demonstrated	that	epidemiological,	demographic	and	social	age	
dependencies	 substantially	 changed	 vaccine	 impact	 estimates,	 supporting	 the	
importance	of	the	substantial	age	structure	and	calibration	in	the	model	presented	
in	this	thesis.	The	Arregui	study	explored	just	one	vaccine	profile	targeted	to	infants	
or	 adolescents,	 whereas	 this	 thesis	 provides	 the	 research	 needed	 to	 inform	 TPP	
decision	 making	 through	 an	 in-depth	 exploration	 of	 vaccine	 profiles	 and	
consideration	of	vaccination	of	older	adult	populations.	
4.4 Conclusion	
The	 research	 presented	 in	 this	 chapter	 investigated	 the	 impact	 of	 age-targeted	
vaccination	 programmes	 on	 population-level	 TB	 epidemiology	 (objective	 3).	 The	
results	 clearly	 demonstrated	 that,	 with	 all	 vaccine	 characteristics	 explored,	 older	
adult	vaccination	delivered	greater	impact	than	adolescent	vaccination.	Older	adult	
vaccination	 delivered	 larger	 reductions	 in	 2050	 TB	 incidence	 rates,	 averted	more	
cases	and	deaths,	and	required	fewer	vaccinations	per	case	averted	than	adolescent	
vaccination;	demonstrating	that	older	adult	vaccination	is	likely	to	maximise	impact	
and	prove	a	more	efficient	use	of	 resources.	Previous	research	has	recommended	
adolescent/adult	 over	 infant	 vaccination	 to	 maximise	 impact.2,4,5	 This	 research	
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develops	 this	 argument	 for	 vaccinating	 adolescent/adult	 age	 groups	 further	 by	
demonstrating	that	in	ageing	epidemics,	most	impact	could	be	achieved	by	targeting	
older	adults,	potentially	minimising	the	resources	required	per	case	averted.	
The	relative	impact	of	adolescent	versus	older	adult	vaccination	schedules	differed	
between	pre-infection	and	post-infection	vaccines.	Post-infection	vaccines	provided	
substantial	impact	in	older	adults,	whereas	impact	was	negligible	when	this	vaccine	
was	 delivered	 to	 adolescents.	 Although	 pre-infection	 vaccines	 provided	 relatively	
similar	 levels	 of	 impact	 when	 vaccinating	 either	 age	 group,	 the	 impact	 was	
substantially	lower	than	that	achievable	with	vaccination	of	older	adults	with	a	post-
infection	vaccine.	In	this	setting,	a	vaccine	efficacious	post-infection	or	pre-	and	post-
infection	 delivered	 to	 older	 adults	 will	 be	 critical	 to	 maximise	 population-level	
impact.	 Previous	 research	 was	 suggestive	 of	 this	 importance	 of	 post-infection	
vaccines	for	reducing	the	burden	of	disease	in	China,23	and	is	supported	by	the	results	
of	Chapter	3	and	the	older	adult	vaccination	campaign	in	this	chapter.	However,	if	
delivered	to	adolescents,	post-infection	vaccines	would	provide	much	lower	impact	
than	 pre-infection	 vaccines.	 Therefore,	 the	 research	 presented	 here	 provides	 a	
critical	 clarification:	 that	 maximising	 population-level	 impact	 with	 post-infection	
vaccines	is	contingent	on	delivery	to	older	age	groups.	
When	 planning	 vaccination	 programmes,	 there	may	 be	 other	 considerations	 that	
would	 influence	 the	 decision	 regarding	 age	 of	 vaccination,	 such	 as	 the	 resources	
required	 or	 the	 accessibility	 of	 the	 populations.	 School-based	 platforms	 would	
provide	relatively	easy	access	to	adolescents,	whereas	strengthening	the	 influenza	
vaccine	platform	for	vaccination	of	60	year	olds	may	require	more	investment	and	
may	 achieve	 lower	 coverages.	 However,	 almost	 all	 vaccines	 delivered	 higher	
population-level	impact	with	older	adult	vaccination	even	when	comparing	as	little	
as	30%	coverage	of	older	adults	to	70%	coverage	of	adolescents.	Therefore,	even	with	
reduced	coverage,	older	adult	vaccination	would	be	the	preferred	vaccination	age.	
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More	vaccines	were	delivered	in	the	older	adult	campaigns,	but	the	number	needed	
to	 vaccinate	 (NNV)	 per	 case	 averted	was	 consistently	 lower	 than	 for	 adolescents,	
demonstrating	 that	 the	 increased	 impact	 far	 outweighs	 the	 additional	 vaccines	
required.	NNV	is	a	useful	measure	of	the	balance	between	resource	use	and	benefit,	
and	by	this	measure	clearly	demonstrates	that	older	adult	vaccination	remains	the	
most	 efficient	 use	 of	 resources	 as	 well	 as	 providing	 greatest	 impact.	 However,	
differences	may	exist	in	the	costs	of	vaccine	delivery	between	these	two	age	groups	
and	the	age	of	averted	cases	 is	not	taken	 into	consideration	 in	the	NNV	measure.	
Therefore,	 future	work	could	develop	more	detailed	health	economic	analyses,	by	
incorporation	of	more	detailed	costings	of	vaccine	and	delivery,	and	by	estimating	
quality	adjusted	life	years	gained	by	vaccination.	
When	compared	to	the	results	of	Chapter	3,	as	would	be	expected,	 the	 impact	of	
routine	targeted	vaccination	was	less	than	that	achieved	by	broad	mass	vaccination.	
However,	the	results	of	this	chapter	demonstrate	that	it	is	essential	that	older	adult	
age	groups	are	included	in	whichever	vaccination	campaign	is	conducted.	If	resources	
are	limited,	targeted	vaccination	of	older	adults	may	help	maximise	the	achievable	
impact.	
Previous	literature	has	focussed	on	infant,	adolescent	or	mass	vaccination,	therefore	
this	study	 is	 the	first	 to	show	that	older	adult	vaccination	with	new	TB	vaccines	 is	
likely	to	be	critical	for	maximising	impact	in	settings	such	as	China,	and	strengthens	
the	 conclusions	 from	 previous	 studies	 suggesting	 that	 vaccines	 effective	 post-
infection	 will	 be	 needed	 in	 this	 setting.	 In	 terms	 of	 modelling	 methodology,	 age	
specificity	in	demographic	and	epidemic	dynamics	has	not	previously	been	addressed	
in	China	vaccine	models,	therefore	research	 in	this	thesis	 is	the	first	to	apply	such	
age-specific	methodology.	This	research	is	one	of	only	two	TB	models	to	incorporate	
heterogeneous	 social	 contact	 patterns,5	 and	 the	 only	 TB	model	 to	 apply	 country-
specific	contact	patterns	to	a	model	of	that	country.	
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There	are	several	limitations	of	this	work,	discussed	throughout	the	chapter.	These	
included	 the	 dearth	 of	 elderly	 natural	 history	 data,	 the	 assumption	 that	 contact	
patterns	 do	 not	 change	 over	 time	 and	 that	 no	 new	 interventions	 would	 be	
introduced.	 These	 could	 be	 explored	 in	 further	 epidemiological	 and	 modelling	
research.	Relative	 impact	of	vaccines	could	change	over	 longer	 time	horizons,	but	
model	uncertainty	would	become	too	large	much	beyond	2050.	This	research	does	
not	explore	all	possible	routine	vaccination	ages	as	those	modelled	were	considered	
appropriate	given	the	anticipated	future	epidemiology	and	the	existence	of	platforms	
for	vaccine	delivery.	Once	a	vaccine	is	available	and	the	characteristics	are	known,	
modelling	 could	 be	 used	 to	 further	 optimise	 the	 older	 adult	 vaccination	 age,	 and	
explore	different	mass	campaign	options.	
This	 research	 clearly	 demonstrates	 the	 importance	 of	 including	 older	 adults	 in	
vaccine	implementation	plans.	With	the	exception	of	influenza	and	zoster	vaccines,	
the	majority	of	routine	vaccines	are	delivered	at	young	ages.	Therefore,	older	adult	
platforms	may	need	to	be	developed	or	strengthened	for	delivery	of	vaccines	to	older	
age	groups.	To	allow	on-label	use	 following	vaccine	 registration,	older	age	groups	
need	to	be	included	in	clinical	trials,	ideally	from	phase	IIB,	but	at	a	minimum	by	phase	
III,	 to	ensure	 that	 sufficient	participants	have	been	exposed	 to	 the	 investigational	
product	 to	demonstrate	safety	and	 immunogenicity	 to	the	regulators.	Clinical	 trial	
outcomes	should	ideally	be	disease	endpoints.	Studies	would	ideally	enrol	both	pre-	
and	 post-infection	 populations	 of	 sufficient	 sample	 size	 to	 allow	 stratification	 of	
efficacy	estimates	by	infection	status.	However,	the	required	sample	size	would	likely	
be	 infeasible,	 so	 at	 a	minimum	 trials	 should	 recruit	 post-infection	 populations	 to	
demonstrate	 safety,	 and	 potentially	 conduct	 stratified	 analyses	 as	 secondary	
outcomes.	
4.5 Overall	conclusions	from	modelling	research	(Aim	1)	
The	first	aim	of	this	thesis	was	to	“generate	mathematical	models	of	age-stratified	
demography	and	TB	epidemiology	 to	explore	 the	population-level	epidemiological	
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impact	of	vaccine	characteristics	and	implementation	strategies	for	potential	new	TB	
vaccines,	using	China	as	a	case	study”.		
In	Chapter	2,	I	presented	a	comprehensive	summary	of	the	existing	new	TB	vaccine	
modelling	literature	to	identify	available	literature	and	research	gaps	for	informing	
vaccine	development.	This	study	confirmed	that	modelling	had	not	comprehensively	
explored	the	impact	of	combinations	of	efficacy	for	prevention	of	infection	and/or	
disease,	 efficacy	 pre-	 and/or	 post-infection	 and	 duration	 of	 protection,	which	 are	
needed	 to	 inform	 vaccine	 Target	 Product	 Profiles.	 Several	 studies	 compared	
prevention	 of	 infection	 to	 prevention	 of	 disease	 vaccines,	 and	 consistently	 found	
prevention	of	disease	vaccines	to	provide	greater	impact	and	more	rapidly;	however,	
results	were	confounded	by	simultaneous	changes	 to	vaccine	delivery,	 so	 findings	
were	 interpreted	with	 caution.	 Additionally,	 studies	 exploring	 vaccines	 efficacious	
against	both	infection	and	disease	did	not	explore	varying	the	relative	efficacy	against	
infection	and	disease.	The	available	 literature	was	divided	as	 to	whether	vaccines	
effective	pre-	or	post-infection	would	provide	greatest	impact,	without	clarity	as	to	
the	underlying	causes	of	the	differences	in	results.	In	addition,	no	models	explored	
the	potential	impact	of	vaccinating	older	adults,	a	possible	vaccination	population	of	
interest	in	ageing	populations	such	as	China.	The	TB	vaccine	modelling	literature	for	
China	explored	a	very	limited	subset	of	vaccines	with	minimal	age	structure	in	the	
modelled	populations.	This	 lack	of	 in-depth	modelling	of	new	TB	vaccines	 in	China	
was	 a	 significant	 gap	 in	 the	 literature	 given	 its	 priority	 as	 a	 high	 burden	 country,	
ageing	population,	and	upcoming	phase	III	TB	vaccine	clinical	trial	results.	
These	research	gaps	were	addressed	in	Chapters	3	and	4,	 in	which	I	developed	an	
M.tb	 transmission	 model	 calibrated	 to	 age-stratified	 demographic	 and	
epidemiological	data	from	China,	and	applied	this	model	as	a	case	study	to	explore	
the	absolute	and	relative	epidemiological	impact	of	different	vaccine	characteristics	
and	 implementation	 strategies	 identified	 as	 research	 gaps	 in	 Chapter	 2.	 Results	
suggest	 that,	 in	 this	 setting,	 efficacy	 for	 prevention	 of	 disease	would	 provide	 the	
greatest	 contribution	 towards	 impact.	 The	majority	 of	 the	 achievable	 impact	was	
through	post-infection	protection	of	those	latently	infected	or	recovered	from	active	
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disease.	At	least	5	years	duration	of	protection	was	predicted	as	necessary	to	achieve	
a	minimum	of	20-29%	reduction	in	incidence	rate	compared	to	the	no	new	vaccine	
baseline	 in	 2050.	 The	 median	 characteristics	 for	 efficacy	 against	 infection	 and	
disease,	and	duration	of	protection	were	estimated	to	inform	the	minimum	and	ideal	
characteristics	in	TB	vaccine	target	product	profiles.		
The	 results	 of	 the	 second	 modelling	 study	 exploring	 vaccine	 implementation	
indicated	 that	 current	 development	 plans	 focussing	 on	 adolescents	 may	 have	
minimal	impact	on	the	burden	of	TB	in	China.	Even	at	much	lower	coverage,	older	
adult	 vaccination	 provided	 greater	 population-level	 impact	 than	 vaccination	 of	
adolescents.	Developing	vaccines	for	older	adults	to	protect	through	to	old	age	will	
be	imperative	for	the	future	of	TB	control	in	this	setting.	In	particular,	a	vaccine	able	
to	protect	older	adult	populations	already	latently	infected	will	be	key	for	maximising	
population-level	impact	in	ageing,	reactivation-driven	tuberculosis	epidemics	similar	
to	China.		
The	results	presented	are	specific	to	China,	but	may	also	be	generalisable	to	several	
other	 high	 TB	 burden	 countries	 with	 ageing	 epidemics,	 and	 as	 China	 is	 the	 third	
largest	contributor	to	global	TB	incidence,	measures	to	maximise	TB	control	in	China	
will	be	of	global	importance.	
In	summary,	this	research	demonstrates	an	important	potential	contribution	of	new	
TB	vaccines	towards	WHO	2050	goals	of	TB	elimination	in	China,	but	has	important	
implications	 for	 current	 vaccine	 development	 strategy	 and	 planning	 vaccine	
platforms	for	implementation.	These	include	the	need	for	development	and	testing	
of	 candidates	 to	 explore	 efficacy	 against	 disease,	 particularly	 in	 post-infection	
populations,	 the	 inclusion	 of	 older	 adults	 in	 clinical	 trials,	 and	 planning	 delivery	
strategies	for	this	age	group.	These	recommendations	advocate	for	the	importance	
of	 including	 the	 above	 endpoints	 and	 populations	 in	 TB	 vaccine	 development,	
particularly	 those	currently	neglected	 in	many	development	strategies;	but	should	
not	be	 interpreted	as	 requiring	 the	exclusion	of	 infection	endpoints,	pre-infection	
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populations,	 or	 younger	 trial	 populations,	 as	 they	 may	 provide	 some	 additional	
benefit	if	sufficient	resources	are	available	to	include	them.		
Target	 product	 profiles,	 ideally	 informed	 by	mathematical	modelling	 as	 described	
above,	are	 translated	 in	 to	clinical	development	plans	 (CDPs)	designed	 to	develop	
appropriate	 candidates	 ready	 for	 delivery	 to	 identified	 target	 populations.	 As	
highlighted	 in	 the	 TB	 vaccine	 Blueprint’s	 second	 epidemiological	 research	 need,	
designing	clinical	trials	and	selecting	trial	sites	and	recruitment	populations	requires	
appropriate	epidemiological	data.		
As	has	been	discussed	in	the	literature,	there	is	a	dearth	of	trial-ready	research	sites	
with	 known	 sufficient	 TB	 burden	 for	 vaccine	 trials.54	 Country	 and	 regional	 level	
programmatic	 tuberculosis	 data,	 and	 prevalence	 surveys	 where	 available,	 can	 be	
used	 to	 identify	 regions	 experiencing	 a	 trial-suitable	 burden	of	 disease.	However,	
data	of	greater	granularity	and	specific	to	communities	where	recruitment	is	planned	
is	needed,	to	calculate	a	sample	size	that	is	a	data-informed	balance	of	minimising	
costs	and	the	number	of	participants	exposed	to	the	investigational	product,	against	
minimising	risk	of	failure	due	to	insufficient	endpoints.	Such	data	can	also	help	direct	
recruitment	 through	 identification	 of	 geographical	 hotspots	 in	 the	 intended	
recruitment	populations	(e.g.	HIV-negative	populations	or	specific	age	groups).		Given	
the	lack	of	sufficiently	granular	available	data,	and	the	expense	of	large	prospective	
prevalence	 or	 incidence	 studies,	 new	 methods	 are	 required	 to	 acquire	 the	 data	
needed	for	design	of	TB	vaccine	efficacy	trials	in	low-income,	high-burden	settings.	
The	development	and	evaluation	of	a	novel	tool	to	meet	this	research	need	for	TB	
vaccine	development	is	described	in	Chapter	5.	
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Summary	of	Chapter	5	
	
This	chapter	reports	the	development	and	evaluation	results	 (objective	4)	of	ePAL	
(electronic	PArticipant	Locator),	a	novel,	low	cost,	rapidly	implementable	and	easy	to	
use	 app	 for	 spatial	mapping	 of	 the	 place	 of	 residence	 of	 TB	 cases	 registering	 for	
treatment	in	Blantyre,	Malawi.	The	development	and	evaluation	results	are	reported	
as	research	paper	3,	which	is	in	preparation	for	submission.	Preliminary	findings	of	
this	work	were	presented	at	 the	2016	TSRU	conference.	The	results	of	12	months	
data	collection	by	NTP	TB	officers	using	ePAL	in	Blantyre,	Malawi	are	summarised	in	
this	chapter.	This	includes	spatial	heatmaps	(objective	4c)	of	all	TB,	and	demographic	
and	clinical	subgroups	relevant	to	TB	trial	recruitment	populations	or	outcomes.		
Citation	 (paper	 3):	Harris	 RC,	 Kaswaswa	K,	 Choko	AT,	Molineux	A,	MacPherson	P,	
Webb	 E,	 Shonga	 W,	 Mapunga	 J,	 Matchaya	 M,	 White	 RG*,	 and	 Corbett	 EL*.	
Development	 and	 evaluation	 of	 novel	 software	 to	 identify	 place	 of	 residence	 for	
clinic-based	 TB	patients	 in	Blantyre,	Malawi.	 (proposed	authors,	 author	 order	 and	
title.	In	review	with	co-authors.	*Joint	senior	authors)		
This	chapter	fulfilled	objective	4	of	the	thesis:	
a)	 Develop	 and	 implement	 a	 novel,	 low	 resource,	 rapidly	 implementable	 and	
easy	 to	 use	 app	 for	 spatial	 mapping	 of	 the	 place	 of	 residence	 of	 TB	 cases	
registering	for	treatment	in	Blantyre,	Malawi.	
b)	 Evaluate	the	accuracy	of	patient	coordinates	measured	via	the	app	compared	
to	the	gold	standard	of	measurements	taken	using	GPS	at	the	patient’s	place	of	
residence.	
c)	 Based	upon	place	of	residence	collected	using	the	app,	generate	spatial	maps	
of	disease	numbers	and	rates	 in	populations	potentially	relevant	for	TB	vaccine	
trial	recruitment.	
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CHAPTER	5 Informing	clinical	trial	design	-	the	electronic	
PArticipant	Locator	(ePAL)	app	for	spatial	mapping	of	TB	
registrations	
5.1 Introduction	
Translation	 of	 tuberculosis	 (TB)	 vaccine	 Target	 Product	 Profiles	 (TPPs)	 into	
implementable	clinical	trials	requires	local	epidemiological	data	to	inform	trial	design	
and	 recruitment.	 Available	 prevalence	 and	 incidence	 studies,	 and	 country-	 and	
regionally-aggregated	 National	 Tuberculosis	 Programme	 (NTP)	 data	 can	 assist	
shortlisting	of	sites	with	sufficiently	high	TB	rates	to	conduct	a	clinical	trial.	However,	
as	 highlighted	by	 the	 TB	Vaccine	Blueprint	 epidemiological	 research	needs	 (Box	1	
Chapter	 1),	 following	 these	 preliminary	 regional-level	 assessments,	 local	 data	
stratified	 by	 likely	 recruitment	 characteristics	 and	 trial	 outcomes	 are	 required.	
Surprisingly	few	trial-ready	research	sites	have	sufficiently	granular	data	available	to	
inform	identification	of	high	TB	risk	recruitment	populations	and	to	assist	estimation	
of	 sample	 sizes	 that	 balance	 cost	 and	 risk.1	 Appropriate	 epidemiological	 data	 are	
essential	to	ensure	that	sufficient	participants	are	recruited	in	to	the	study	to	accrue	
an	adequate	number	of	endpoints	over	a	reasonable	timeframe.	
The	 mathematical	 modelling	 research	 in	 Chapters	 3	 and	 4	 demonstrated	 the	
importance	of	prevention	of	disease	vaccines	for	maximising	new	TB	vaccine	impact.	
It	was	recommended	that	late-phase	clinical	trials	should	focus	on	disease	endpoints,	
therefore	TB	disease	incidence	data	are	required	to	inform	trial	design.	In	China,	older	
adults	 were	 identified	 as	 an	 age	 group	 of	 interest	 for	 vaccine	 implementation	
targeting.	 This	 may	 vary	 by	 epidemiological	 setting,	 but	 knowledge	 of	 burden	 of	
disease	 and	 identification	 of	 geographical	 disease	 hotspots	 by	 age	 could	 support	
development	of	studies	in	a	given	setting.	Efficacy	trials	often	exclude	HIV-positive	
individuals,	 so	 identifying	 where	 high	 burden	 of	 disease	 exists	 in	 HIV-negative	
populations	is	also	important	for	trial	design	and	recruitment.	
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Prospective	prevalence	and	incidence	studies	are	the	gold	standard	to	inform	these	
trial	design	aspects.	Where	available,	such	data	are	the	gold	standard	for	informing	
trial	design.	However,	existing	studies	may	become	very	rapidly	outdated,	and	the	
cost	and	time	implications	of	prospectively	initiating	these	studies	ahead	of	phase	IIB	
and	phase	III	trials	would	be	substantial,	especially	given	that	these	late	phase	trials	
require	involvement	of	multiple	research	sites	(e.g.	eight	recruitment	centres	across	
three	 countries	 in	 the	 M72	 phase	 IIB	 trial).2	 Therefore,	 inexpensive	 and	 rapidly	
implementable	alternative	methods	are	needed	to	collect	sufficient	data	to	design	
late-phase	clinical	trials.	
Existing	 alternatives	 and	 their	 strengths	 and	 limitations	 are	 discussed	 in	 detail	 in	
Chapter	 2.	 Health	 and	 demographic	 surveillance	 sites	 can	 provide	 high	 quality,	
granular	data,	but	there	are	a	limited	number	of	these	sites,	which	are	not	necessarily	
in	high	TB	burden	locations	and	would	be	prohibitively	expensive	to	set	up	solely	for	
the	purpose	of	TB	vaccine	clinical	trials.	NTP	data	are	readily	available,	but	publicly	
available	summaries	are	generally	aggregated	at	the	district	or	regional	level.	Data	
can	 be	 extracted	 from	 NTP	 records	 to	 achieve	 clinic-level	 granularity,	 but	 clinic	
catchment	areas	may	be	large	(e.g.	100,000	population	in	India)	and	many	areas	of	
high	 TB	 burden	 are	 in	 low-income,	 urban	 settings	 that	may	 be	missing	municipal	
address	 systems.3	Although	a	 verbal	 description	of	 place	of	 residence	 is	 generally	
captured	in	NTP	records,	these	may	prove	insufficient	to	identify	the	patient’s	area	
of	residence	in	practice.4		
Conducting	home	visits	for	GPS	coordinate	collection	for	patients	recruited	at	NTP	
clinics	could	provide	the	required	geospatial	information.		This	could	be	conducted	
by	 travelling	 directly	 home	with	 the	 patient,	 or	 recruiting	 them	 at	 the	 clinic	 and	
arranging	 a	 later	 follow	 up	 visit	 at	 the	 home.	 However,	 the	 former	 requires	
substantial	 human	 resourcing	 and	 logistics,	 whereas	 the	 latter	 may	 experience	
substantial	 loss	 to	 follow	 up	 given	 the	 challenges	 of	 contacting	 and	 finding	 the	
participants.		
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To	 remove	 the	 need	 for	 home	 visits	 in	 an	 HIV	 testing	 cluster-randomised	 trial	 in	
Malawi,	 a	 map	 book	 system	 for	 clinic-based	 capture	 of	 cluster	 residency	 was	
developed.4,5	The	map	book	consisted	of	a	series	of	paper	maps	marked	with	points	
of	 interest	 (POIs)	 and	 the	 cluster	 boundaries	 from	 the	 parent	 study	 to	 allow	
identification	 of	 study	 cluster.	 An	 evaluation	 of	 the	 tool	 in	 40	 participants	 by	
conducting	 home	 visits	 to	 collect	 GPS	 coordinates	 demonstrated	 excellent	 study	
cluster	agreement	(97.5%).4		This	tool	provided	proof	of	concept	for	the	use	of	point-
of-interest	annotated	maps	for	remote	identification	of	place	of	residence.	The	map	
book	format,	however,	does	not	provide	the	resolution	required	for	designing	new	
individual-level	trials,	and	long-term	sustainability	would	also	benefit	from	a	switch	
to	electronic	based	data	collection.		The	concept	was	therefore	employed	as	the	basis	
for	 the	design	of	a	new	tool,	an	electronic	 tablet-based	application	 (app)	 to	more	
accurately	identify	a	patient’s	place	of	residence	when	registering	for	TB	treatment.	
The	map	book	was	developed	in	Blantyre,	Malawi,	an	urban,	high	TB	burden	setting,	
lacking	 the	municipal	address	 system	needed	 for	 identification	of	patient	place	of	
residence.	Malawi	has	one	of	the	top-20	fastest	growing	urban	populations	globally,6	
with	 an	 absolute	 increase	 of	 approximately	 4%	 per	 year.6	 In	 Blantyre	 city,	 the	
population	density	has	increased	from	1,514	per	square	kilometre	in	1987	to	3,006	
per	square	kilometre	in	the	last	census	in	2008.7	Overcrowding	and	poor	ventilation	
may	contribute	to	TB	transmission	in	high	density	urban	slums.8		
Blantyre’s	high	TB	burden,	rapid	urbanisation,	and	lack	of	addresses	for	geolocating	
TB	 cases	 provided	 the	 ideal	 setting	 for	 development	 and	 implementation	 of	 an	
electronic	 clinic-based	 spatial	mapping	 tool	 for	 TB	 patients.	 It	 was	 hoped	 that	 in	
addition	to	supporting	existing	studies	in	the	site,	it	could	gather	appropriate	data	in	
the	hope	of	conducting	TB	vaccine	trials	in	this	setting	in	the	future.			
In	this	chapter	 I	present	the	development,	 implementation	and	evaluation	of	a	TB	
spatial	 mapping	 app	 in	 Blantyre,	 Malawi,	 with	 the	 aim	 of	 mapping	 the	 place	 of	
residence	 of	 populations	 experiencing	 disease	 outcomes	 relevant	 to	 TB	 vaccine	
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clinical	trials.	Based	upon	place	of	residence	collected	using	the	app,	I	present	maps	
of	trial-relevant	outcomes	in	potential	recruitment	populations	for	TB	vaccine	trials.	
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5.2 Paper	3:	Development	and	evaluation	of	novel	software	to	
identify	place	of	residence	for	clinic-based	tuberculosis	patients	
in	Blantyre,	Malawi	
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Abstract	
Background:	In	many	low-income,	urban	settings	with	high	tuberculosis	(TB)	burden,	
the	absence	of	municipal	address	systems	poses	a	significant	obstacle	to	clinical	trial	
design,	patient	follow	up,	and	targeting	of	public	health	interventions.	We	developed	
and	evaluated	software	for	use	by	Blantyre	District	Health	Office	(DHO),	Malawi,	to	
remotely	capture	place	of	residence	for	registering	tuberculosis	patients.				
Methods:	 High-resolution	 satellite	 maps	 were	 annotated	 with	 points	 of	 interest	
(POIs)	captured	by	community	health	workers	and	loaded	onto	electronic	tablets	for	
use	with	 a	 bespoke	 ‘electronic	 PArticipant	 Locator’	 application	 (ePAL	 app;	 Tripod	
Software,	 Salford)	 combining	 touch-screen	 Global	 Positioning	 System	 (GPS)	
coordinate	capture	with	an	electronic	tuberculosis	register.	Following	training,	ePAL	
was	 used	 by	 tuberculosis	 officers	 from	 11	 primary	 care	 clinics	 for	 collection	 of	
demographics,	 health	 status	 and	 coordinates	of	place	of	 residence	 for	 consenting	
adults	 (≥18	 years)	 initiating	 TB	 treatment.	 Case	 capture	 and	 data	 quality	 were	
monitored	 against	 DHO	 registers.	 Accuracy	 of	 ePAL-recorded	 co-ordinates	 was	
evaluated	against	GPS	coordinates	obtained	at	the	place	of	residence.	
Findings:	Community	health	workers	defined	3,243	POIs.	Over	12	months	from	12th	
February	2015,	1,899	TB	patients	(98.7%	participation)	were	registered	using	ePAL.	
Case-capture	 increased	 from	61%	 to	 95%	 from	months	 1	 to	 12	of	 the	 study.	GPS	
coordinates	captured	at	evaluation	home-visits	with	121	participants	were	median	
84	metres	(IQR:	35-317	metres)	from	those	captured	through	ePAL.	Advantages	of	
the	ePAL	system	included	real-time	availability	of	high-resolution	spatial	data,	and	
ease	of	use	by	DHO	staff.	ePAL	continues	to	be	used	as	part	of	routine	TB	registration	
in	September	2017,	supported	by	monthly	DHO	meetings.	
Interpretation:	ePAL	enabled	sustainable	and	reasonably	accurate	capture	of	place	
of	 residence	of	patients	presenting	at	TB	clinics	 in	areas	 lacking	 formal	addresses.	
Data	 generated	 by	 ePAL	 could	 have	 both	 clinical	 trial	 and	 programmatic	 utility,	
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through	facilitating	patient	follow	up	and	informing	spatially	targeted	public	health	
interventions	and	clinical	trials.	With	local	annotation,	ePAL	is	readily	adaptable	for	
spatiotemporal	mapping	and	home	tracing	in	other	settings.		
Funding:	UK	Medical	Research	Council	and	Wellcome	Trust.	
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Article	
Background	
Tuberculosis	 (TB)	was	 the	 cause	of	death	of	 1.8	million	people,	 including	400,000	
people	living	with	HIV	(PLHIV)	in	2015.9	Despite	being	such	a	major	cause	of	death,	
the	high	costs	and	development	risks	associated	with	TB	prevention	studies,	such	as	
trials	of	new	TB	vaccines	or	complex	community-based	interventions,	are	prohibitive	
and	 rate-limiting.1	 This	 reflects	 the	 combination	 of	 the	 suboptimal	 and	 costly	
diagnostics,	 TB	 incidence	 and	 prevalence	 rates	 that	 even	 in	 high	 burden	 settings	
necessitate	large	sample	sizes,	and	a	prolonged	and	highly	variable	interval	between	
transmission	and	disease.1			
Robust	epidemiological	data	could	help	 identify	high	burden	populations	 to	direct	
trial	 recruitment,	assist	 sample	size	minimisation,	and	help	de-risk	 study	endpoint	
accrual.1	Public	health	programmes	could	also	benefit	from	such	data	for	design	and	
targeting	 of	 local	 TB	 prevention	 and	 care	 programmes.	 However,	 the	 prohibitive	
factors	affecting	clinical	trials	often	also	preclude	formal	prospective	cohort	studies	
to	 inform	clinical	 trial	 design	and	 site	 selection	ahead	of	 trial	 initiation.	 They	also	
mean	 that	 available	 disease	 burden	 estimates	 are	 prone	 to	 being	 incorrect,	 out-
dated,	or	not	available	for	otherwise	suitable	trial	sites.1,10		
National	Tuberculosis	Programmes	(NTPs)	collect	an	abundance	of	relevant	data,	but	
often	report	TB	disease	burden	as	data	aggregated	by	administrative	units	that	are	
either	too	large	(e.g.	districts)	or	poorly	defined	(e.g.	facility	catchment	areas)	to	fully	
inform	planning.	Methods	of	 recording	patient	place	of	 residence	 in	NTP	registers	
often	lack	the	clarity	and	reproducibility	required	to	support	disaggregation.4,10,11	
Africa	 and	Asia	 are	 urbanising	 rapidly	 (>1%	per	 year).6	 Inadequate	 town	 planning	
capacity	has	left	more	than	half	of	city	streets	in	sub	Saharan	Africa	without	a	formal	
address	 system,	 leaving	 residents	 to	 rely	 on	 imprecise	 and	 poorly-reproducible	
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landmark-based	directions	to	communicate	where	they	live.3,4	Poverty,	overcrowding	
and	poor	ventilation	in	urban,	high-density,	informal	settlements	may	contribute	to	
increased	risk	of	M.tb	transmission	and	TB	disease.8,12	This	confluence	of	urbanisation	
and	TB	risk	has	resulted	in	higher	tuberculosis	prevalence	in	urban	than	rural	areas	
at	the	global	level.12	For	example,	a	study	in	the	Philippines	estimated	the	TB	risk	in	
children	in	‘slum’	areas	was	nine	times	higher	than	in	‘non-slum’	areas.13	These	high	
burden	urban	areas	present	a	challenge	and	an	opportunity:	a	challenge	to	manage	
TB	control	effectively,	but	with	improved	data	could	present	an	opportunity	to	target	
public	health	interventions	and	clinical	trial	recruitment	to	high	burden	settings	to	
maximise	impact	and	reduce	cost.	
Research	 approaches	 outside	 of	 sites	 with	 pre-existing	 demographic	 health	
surveillance	systems	have	included	locally	drawn	street	maps,	and	home	visits,	which	
are	expensive	and	time	consuming.10	The	current	study	builds	on	a	demonstration	
study	in	2011,4,5	which	provided	proof	of	concept	for	the	clinic-based	use	of	maps	
annotated	with	points	of	 interest	 (POIs)	 for	 identification	of	place	of	 residence	 in	
urban	settings.	 In	this	study,	a	paper-based	“map	book”	was	used	by	DHO	staff	to	
assist	patients	in	identifying	whether	they	were	resident	in	one	of	28	research	study	
catchment	 areas	 (~1,300	 adults)	 in	 Blantyre,	 Malawi.4	 The	 study	 found	 excellent	
agreement	between	cluster-residency	defined	in	the	clinic	using	the	“map	book”	and	
cluster	residency	obtained	through	home-visits	(97.5%,	n=40).4		
The	 current	 study	 sought	 to	 broaden	 the	 utility	 of	 this	 tool	 beyond	 cluster	
randomised	studies	and	improve	sustainability,	by	seeking	to	digitise	the	system	and	
support	collection	of	specific	coordinates	of	the	place	of	residence.	Solutions	to	allow	
real-time	electronic	data	collection	and	improved	data	on	place	of	residence	as	part	
of	National	Tuberculosis	Programmes	could	provide	long-term	benefit	to	the	public	
health	 system	 through	 informing	 patient	 follow	 up,	 improving	 efficiency	 of	 data	
collection,	and	targeting	of	TB	control	programmes,10	and	generate	the	information	
required	to	select	clinical	trial	locations	and	populations	to	minimise	cost	and	risk.		
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Here	we	describe	the	development,	implementation	and	evaluation	of	the	accuracy	
of	 a	 novel	 electronic	 PArticipant	 Locator	 (ePAL)	 application	 for	 use	 on	 electronic	
tablets	for	collection	of	Global	Positioning	System	(GPS)	coordinates	of	the	place	of	
residence	of	TB	patients	registering	for	TB	treatment	in	urban	Blantyre,	Malawi.	The	
aim	was	to	provide	an	electronic	TB	register	that	could	support	long-term,	real-time	
capture	 of	 high-resolution	 spatial	 information	 as	 part	 of	 routine	 TB	 registration	
activities	in	urban	Blantyre,	Malawi.			
Methods	
Study	setting	and	design	
The	study	was	conducted	in	urban	Blantyre,	Malawi,	a	city	with	large	areas	of	high-
density	 informal	 residential	 settlements	 and	 an	 estimated	 population	 of	
approximately	750,000	in	2016.	All	11	TB	registration	centres	that	served	Blantyre	
City	participated	in	the	study,	including	two	public	and	three	private	hospitals,	and	
six	 local	 primary	 care	 centres.	 TB	 diagnosis,	 registration	 and	 care	 was	 provided	
exclusively	through	these	centres,	which	relied	on	paper-based	registers	with	brief	
recording	of	verbal	descriptions	given	by	patients	of	their	place	of	residence.	
The	study	was	conducted	prospectively	(see	appendix	A	for	protocol)	in	three	phases:	
1)	app	design,	2)	implementation	and	run-in,	and	3)	the	main	study	and	evaluation	
phase.	 The	 data	 reported	 here	 relates	 to	 the	 implementation,	 monitoring	 and	
evaluation	aspects	of	the	study.		
ePAL	App	Design	
The	ePAL	app	combined	an	electronic	case	report	form	(eCRF)	with	high	resolution	
satellite	maps	of	urban	Blantyre	 (approx.	area:	254km2)	and	community-identified	
points	 of	 interest	 (POIs)	 (Figure	 5.1).	When	 the	 location	 was	 selected	 via	 touch-
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screen,	it	was	converted	in-app	and	stored	as	the	corresponding	WGS84	(EPSG:	4326)	
coordinates.		
Maps	were	purchased	from	European	Space	Imaging.14		POIs	were	collected	by	study	
staff	and	Ministry	of	Health	(MoH)	Community	Health	Workers	(CHW).	 	Staff	used	
Garmin	eTrex	20	Global	Positioning	System	(GPS)	handsets	to	capture	POIs	that	were	
identified	by	CHWs	as	being	used	for	local	address-finding.	A	pilot	study	of	one	CHW	
area	informed	the	target	POI	density,	and	set	a	minimum	density	of	10	to	20	POIs,	
per	catchment	area.		
To	ensure	uninterrupted	ePAL	use	offline,	the	app,	maps	and	POIs	were	stored	on	the	
tablet	hard-drive.	TB	officers	used	 the	app	to	collect	participant	demographic	and	
health	information,	and	select	the	participant’s	place	of	residence	on	the	annotated	
maps.	 Following	 several	 iterations,	 features	 of	 the	 app	 to	 facilitate	 prompt	 and	
accurate	 identification	 of	 the	 place	 of	 residence	 included	 high	 resolution	 zoom,	
searchable	community-identified	POIs,	colour	coding	of	POIs	by	type	(e.g.	place	of	
worship,	shop),	and	a	drop-down	menu	of	city	wards.	
The	app	runs	on	Android	devices:	Asus	Google	Nexus	7-inch	or	9-inch	tablets	(2GB	
RAM,	 16GB	 eMMC)	 were	 used	 for	 the	 implementation	 study.	 	 Data	 entry	 was	
facilitated	through	use	of	simple	instructions	in	a	choice	of	English	or	Chichewa,	and	
large	 buttons	 for	 data	 entry.	 Verbal	 consent	 and	 checks	 against	 inclusion	 and	
exclusion	 criteria	were	 in-built.	 Sputum	 sample	 barcodes	were	 scanned	 using	 the	
tablet’s	camera	to	allow	linkage	to	subsequent	laboratory	results.		
Patient	data,	specimen	bar-code	and	GPS	coordinates	were	stored	under	encryption	
on	the	tablet,	and	uploaded	daily	by	the	TB	officers	via	the	2G/3G	mobile	network	
using	 comma	 delineated	 files.	 The	 central	 database	 was	 held	 on	 a	 server	 at	 the	
Malawi-Liverpool-Wellcome	Trust	clinical	research	site,	accessible	in	real-time	from	
any	location	via	a	password-protected	web	interface.	
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Implementation	and	run-in	period	
Following	 a	 one-day	 training	 session	 for	 all	 44	 TB	 officers	 and	 nurses	 working	 in	
Blantyre’s	TB	clinics,	implementation	of	the	ePAL	app	began	in	November	2014.	Each	
clinic	 received	 a	 password-protected	 and	 encrypted	 electronic	 tablet	 with	 ePAL	
installed.	The	study	commenced	with	a	10-week	run-in	period	preceding	the	main	
study.	During	the	run-in	period,	app	user	interface	improvements	were	incorporated	
based	upon	suggestions	gathered	at	regular	meetings	with	field	users.		
Main	study		
The	main	study	and	evaluation	period	began	on	12th	February	2015	and	ran	for	12	
months.	All	adult	patients	(³18	years	old)	registering	for	TB	treatment	in	any	of	the	
11	clinics	serving	Blantyre	city	were	 invited	to	participate	 in	 the	main	ePAL	study,	
regardless	of	place	of	residence.	For	those	providing	verbal	consent	to	participate,	
demographic,	clinical	information,	and	place	of	residence	were	collected	using	ePAL.		
Data	quality	monitoring	was	continuous	throughout	the	study.	Uploads	to	the	ePAL	
database	were	regularly	monitored	via	the	web	interface.	Any	unusual	gap	in	uploads	
triggered	 a	 call	 or	 visit	 by	 study	 staff.	 Clinics	 were	 visited	 monthly	 to	 check	 for	
hardware,	software	or	mobile	data	connectivity	issues.	During	this	visit,	the	number	
of	ePAL	uploads	was	checked	against	the	NTP	paper	registers,	and	seven	fields	(e.g.	
sex,	smear	status)	were	checked	against	the	NTP	register	for	a	random	10%	sample	
of	ePAL	records	(minimum	one	record	per	clinic)	selected	prospectively	using	Stata.	
Monitoring	data	were	collected	on	a	Nexus	5	tablet	using	Open	Data	Kit	(ODK).		
Monthly	meetings	were	held	with	TB	officers	 to	provide	a	 forum	for	collaborative	
troubleshooting	 hardware	 or	 software	 issues	 and	 feedback	 of	 clinic-level	 ePAL	
summary	reports,	including	data	quality	targets	such	as	case	capture	and	zoom	level.	
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Evaluation	cohort	
Recruitment	to	the	evaluation	cohort	was	limited	to	patients	who	reported	living	in	
one	 of	 three	 high-density	 neighbourhoods	 of	 Blantyre	 (Figure	 5.2),	 described	
elsewhere.5	Evaluation	in	these	settlements	tested	accuracy	in	the	highest	density,	
and	 therefore	most	 challenging,	 areas	 in	which	 to	 ascertain	 location	 of	 residence	
using	ePAL.	GPS	coordinates	collected	at	the	participant’s	place	of	residence	were	
used	 to	 evaluate	 the	 spatial	 accuracy	 of	 the	 ePAL-collected	 coordinates.	 A	 study	
research	assistant	was	guided	to	the	residence	by	the	participant,	and	collected	an	
averaged	waypoint	GPS	 coordinate	 location	using	Garmin	 eTrex	 20	handsets.	 The	
evaluation	cohort	consisted	of	patients	providing	written	(or	thumbprint)	informed	
consent	and	registered	in	ePAL	during	the	first	four	months	of	the	main	study.	Home	
visits	were	conducted	in	the	run-in	period	and	after	the	first	four	months	of	the	study	
for	monitoring	purposes.	
Statistical	analyses	
Statistical	analyses	were	conducted	 in	Stata	 (version	13.1)	and	R	 (version	3.3.1).15	
Descriptive	analyses	of	the	recruitment	population	for	the	main	study	were	reported	
for	 the	12	months	of	 the	study.	For	the	evaluation	cohort,	 the	 ‘spDists’	command	
within	the	‘sp’	R	package	was	used	to	calculate	the	distance	in	metres	between	the	
ePAL	 and	 evaluation	 GPS	 spatial	 point	 for	 each	 participant	 using	 the	 great	 circle	
distance	method	(WGS84	ellipsoid).	ePAL	accuracy	was	assessed	by	the	median	and	
interquartile	 range	 of	 the	 distances	 in	metres	 between	 the	 paired	 ePAL	 and	 GPS	
coordinates.		
The	cumulative	proportions	accurate	to	within	20m,	50m,	100m,	200m,	500m	and	
1000m	were	estimated	with	95%	confidence	intervals	(CI).	The	target	sample	size	for	
the	evaluation	cohort	was	196,	which	would	provide	5-7%	precision	when	estimating	
proportion	agreement	with	a	point	estimate	of	50-85%.		Time	between	date	of	ePAL	
record	 and	 date	 of	 evaluation	 data	 upload	 (latest	 possible	 follow	 up	 date)	 were	
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calculated.	Predictors	of	accuracy	and	missing	data	were	explored	using	Spearman’s	
correlation,	Kruskal-Wallis	rank	sum,	and	Chi-squared	tests,	as	appropriate.		
Ethical	considerations	
Ethics	approval	for	this	study	was	granted	by	the	research	ethics	committees	of	the	
University	 of	 Malawi	 College	 of	 Medicine	 (COMREC)	 and	 the	 London	 School	 of	
Hygiene	 and	 Tropical	Medicine	 (LEO).	 All	 participants	 in	 the	main	 study	 provided	
verbal	 informed	 consent,	 and	 participants	 in	 the	 evaluation	 cohort	 also	 provided	
written	or	witnessed	thumbprint	informed	consent.	
Results	
During	September	to	November	2014,	194	CHWs	in	Blantyre	 identified	3,243	POIs	
(mean	of	17	per	CHW)	following	community	engagement.	 In	the	ePAL	app,	962	of	
these	POIs	were	prioritised	to	be	visible	at	all	levels	of	map	zoom,	and	the	remainder	
visible	 only	 once	 further	 zoomed	 in,	 to	 avoid	 obscuring	 underlying	map	 features	
when	zoomed	out.	Feedback	from	TB	officers	was	used	to	improve	functionality	and	
ePAL	user	experience	during	two	months	of	pilot	data	capture	in	clinics.		
Study	population	
Flow	of	study	participants	is	shown	in	Figure	5.3.	For	12	months	from	12th	February	
2015,	overall	case	capture	with	ePAL	was	77%	of	the	patients	recorded	in	the	NTP	
register	(1,924/2,489),	with	capture	increasing	from	61%	to	95%	over	months	1	to	12,	
once	logistical	challenges	had	been	resolved	relating	to	weekend	registrations	and	
need	for	additional	electronic	 tablets	 in	 the	busiest	clinics.	1,899	 (98.7%)	of	1,924	
eligible	 adults	 agreed	 to	 participate,	 with	 the	main	 reasons	 for	 non-participation	
being	not	wishing	to	participate	in	research	(n=12),	time	pressure	(n=3),	not	wanting	
data	 recorded	 (n=1)	 or	 place	 of	 residence	 (n=1)	 captured	 electronically.	 Eight	
provided	no	reason	for	non-participation.		
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The	majority	of	registrations	occurred	in	the	two	public	hospitals	(50.7%,	n=962	in	
Queen	Elizabeth	Central	Hospital	[QECH]	and	13.6%	in	Mlambe	Hospital),	4.4%	(n=83)	
of	registrations	were	from	private	hospitals,	and	32%	from	six	primary	care	clinics.	
Thirty-four	TB	officers	collected	data	in	ePAL	over	this	period,	with	more	than	half	of	
all	records	collected	by	six	TB	officers.		
Participants	 were	 mostly	 male	 (n=1,167,	 61.4%),	 and	 mean	 age	 was	 37.9	 years.	
Sputum	smear	microscopy	results	were	available	for	56.9%	(n=1,080)	of	participants,	
of	 whom	 58.8%	 (n=636)	 were	 smear	 positive.	 Overall,	 43%	 of	 patients	 had	
microbiologically	 confirmed	 disease	 (microscopy,	 Xpert	 or	 culture)	 at	 time	 of	
registration	for	TB	care.	The	majority	were	classified	as	previously	untreated	‘new’	
TB	cases	(n=1,661,	87.5%),	with	5.6%	relapse,	6.3%	‘other’,	and	<1%	were	treatment	
failure	 or	 return	 after	 default.	 For	 those	 reporting	 cough,	median	duration	was	 4	
weeks	(IQR:	3-5	weeks).		
For	all	patients	registered	with	ePAL,	self-reported	residence	in	urban	Blantyre	was	
73%	(1,385/1,899),	with	19%	of	patients	residing	in	rural	Blantyre	(353/1,899),	and	
8%	out-of-District	(161/1,899).	A	total	of	1,240	participants	provided	coordinates	in	
ePAL	 (Figure	 5.3),	 of	 which	 1,229	 reported	 residence	 in	 urban	 Blantyre.	Monthly	
estimates	of	coordinate	capture	for	those	self-reporting	residency	in	Blantyre	ranged	
77%	 (95%	 CI:	 68-85%)	 to	 95%	 (95%	 CI:	 89-98%).	 Two	 percent	 of	 those	 reporting	
residence	 outside	 of	 urban	 Blantyre	 had	 ePAL	 coordinates	 falling	 within	 urban	
Blantyre	 boundaries.	 Of	 those	 missing	 coordinates	 (n=	 659),	 503	 were	 resident	
outside	of	urban	Blantyre,	and	156	reported	as	resident	in	Blantyre	but	were	missing	
coordinates.	
Of	the	1,240	participants	with	ePAL	coordinates,	514	(41%)	self-reported	residence	
in	 the	 evaluation	 neighbourhoods.	 Only	 13	 (3.4%)	 of	 these	 participants	 refused	
participation	in	an	evaluation	visit.	A	total	of	252	evaluation	visits	were	conducted,	
of	which	121	participants	were	recruited	in	to	ePAL	within	the	4	month	evaluation	
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period,	and	the	remainder	were	conducted	for	monitoring	purposes,	either	during	
the	run-in	period	(n=48)	or	after	the	evaluation	period	(n=83).	
Monitoring	
Ninety-six	percent	of	coordinates	were	collected	at	the	two	highest	resolution	zoom	
levels.	Monthly	capture	at	the	highest	zoom	level	ranged	from	38%	to	84%,	increasing	
over	time.	Monitoring	checks	of	seven	variables	for	131	patient	records	identified	a	
1.5%	error	 rate,	with	 79%	of	 errors	 relating	 to	 erroneous	 allocation	of	 gender.	 In	
addition	to	the	planned	checks,	minor	errors	were	reported	in	25	NTP	registration	
IDs.		
Evaluation	
In	the	four	month	evaluation	period,	171	participants	self-reporting	as	resident	in	the	
evaluation	 area	 provided	 written	 consent	 to	 participate.	 Follow	 up	 of	 these	
participants	with	 successful	 collection	 of	 GPS	 coordinate	 at	 the	 home	was	 70.8%	
(n=121).		
The	median	distance	between	the	ePAL-recorded	coordinates	of	place	of	residence	
and	the	GPS	reading	taken	at	the	evaluation	visit	for	these	121	patients	was	84	metres	
(Interquartile	 range	 (IQR):	 35m-317m).	 The	minimum	estimated	distance	was	4m,	
and	 the	greatest	was	11.6km,	with	 the	participant	having	GPS-recorded	 residency	
outside	of	 the	evaluation	 area.	Accuracy	 to	within	 50m	was	35.5%	 (95%	CI:	 27.0-
44.8%).	Accuracy	to	within	other	ranges	are	shown	in	Table	5.2.	
In	the	4-month	evaluation	period	of	the	study,	the	target	sample	size	of	196	home	
visits	was	not	reached.	With	a	reduced	sample	size	of	121,	the	study	was	powered	to	
give	precision	of	6.5%-9%.	Combining	the	evaluation	and	monitoring	visits	during	the	
12	months	of	the	study,	204	participants	were	followed	up.		
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In	the	evaluation	cohort,	median	distance	by	registration	centre	was	54m	(IQR:	24-
139m)	and	89m	(IQR:	36-219m)	in	the	two	primary	care	clinics,	88m	(IQR:	48-420m)	
at	QECH,	292m	(IQR:	135-951m)	at	Mlambe	hospital	and	16m	for	 the	one	patient	
recruited	at	Adventist	Hospital.	Kruskal-Wallis	rank	sum	tests	indicated	no	evidence	
of	 a	 difference	 in	 the	 evaluation	 distance	 distributions	 between	 health	 centres	
(p=0.11),	 although	 there	 was	 evidence	 of	 a	 difference	 between	 data	 collectors	
(p=0.03).	
Fourteen	percent	of	evaluation	visits	identified	a	place	of	residence	more	than	1km	
from	the	location	identified	in	ePAL.	Pearson’s	chi-squared	tests	were	conducted	to	
identify	characteristics	predictive	of	a	large	displacement	(>1km)	between	the	ePAL	
and	 evaluation	 GPS	 coordinates.	 None	 of	 20	 possible	 explanatory	 variables	 were	
significantly	 associated	 with	 large	 displacement,	 including	 study	 month.	 A	
Spearman’s	 rank	 test	 for	 correlation	 between	month	 and	 distance	was	 also	 non-
significant	(p=0.13).		
In	 the	 larger	monitoring	data	set	 for	 the	 full	12	months	of	 the	study,	a	significant	
relationship	 between	 large	 errors	 (>1km)	 and	 patient-level	 factors,	 notably	 HIV	
status,	raised	the	question	of	whether	some	patients	had	deliberately	misinformed	
TB	officers	about	the	true	location	of	their	household,	motivated	by	TB	and/or	HIV	
stigma.	 Informal	 interview	 during	 home	 visits	 identified	 various	 patient-level	
explanations,	for	instance	staying	with	relatives	for	diagnosis.		However,	these	data	
were	not	fully	systematically	captured.	
Median	 time	 lag	 between	 ePAL	 entry	 and	 evaluation	 data	 upload	 (latest	 possible	
follow	up	date)	was	26	days	(IQR:	14-37	days).	The	Spearman’s	correlation	between	
the	 evaluation	 distance	 and	 data	 collection	 lag	 estimate	 was	 0.12	 (p=0.17),	
suggesting	 negligible	 correlation	 between	 delays	 in	 follow	 up	 and	 discrepancy	
between	the	ePAL	and	GPS	measurements.	
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Chi-squared	tests	suggest	a	difference	in	availability	of	data	from	evaluation	visits	by	
TB	officer	(p=0.01)	and	number	of	people	in	household	(p=0.04).	Chi-squared	tests	
were	also	conducted	with	the	full	12-month	data	set,	in	which	the	significance	of	any	
differences	between	the	TB	officers	became	weak.	
Discussion	
The	main	findings	of	this	study,	in	which	a	novel	spatial	application,	ePAL	(electronic	
PArticipant	 Locator),	was	 developed,	 implemented	 and	 evaluated	 in	 collaboration	
with	the	National	TB	Programme	and	District	Health	Office	in	Blantyre,	Malawi,	was	
that	 this	 provided	 a	 rapidly	 implementable	 and	 sustainable	 approach	 to	 remote	
capture	of	place	of	residence	for	patients	with	no	formal	address	system.		
Monthly	 feedback	 meetings	 supported	 troubleshooting	 and	 near	 complete	 case-
capture	 within	 a	 few	 months	 of	 implementation.	 	 Real-time	 collection	 of	 GPS	
coordinates	was	sufficiently	accurate	for	most	patients	to	support	real-time	spatial	
analysis	of	disease	burden,	and	interventions	such	as	household	contact	screening.		
Home	visits	showed	substantial	errors	 in	household	 identification	 for	about	1	 in	7	
patients,	 however,	 reflecting	 issues	 such	 as	multiple	 places	 of	 residence,	 but	 also	
likely	deliberate	misidentification	by	some	patients.	Data	generated	by	ePAL	has	high	
potential	 research	 and	 programmatic	 utility,	 and	 could	 facilitate	 spatial	
epidemiology,	design	and	implementation	of	public	health	interventions	and	clinical	
trials,	and	patient	follow-up.		
Strengths	of	ePAL	for	collection	of	spatial	data	include	its	accuracy,	ease	of	use,	low	
cost,	integration	into	routine	NTP	data	collection	with	QAQC	processes	in	place,	real	
time	data	accessible	via	a	web	interface,	and	ability	to	function	offline	with	infrequent	
access	to	mobile	data	and	electricity.	A	key	feature	of	the	app	was	tailoring	of	content	
and	the	user	experience	through	stakeholder	involvement:	for	example,	community	
engagement	for	identification	of	locally-relevant	POIs	in	the	initial	development,	and	
ongoing	feedback	and	improvement	of	the	app	and	data	collection	through	regular	
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meetings	 with	 the	 TB	 officers.	 This	 may	 have	 also	 contributed	 to	 very	 high	
participation	rates.	The	app	interface	and	training	were	designed	for	ease	of	use	by	
individuals	without	experience	of	electronic	data	collection.	Error	rates	were	low	for	
single-entry	 electronic	 data	 capture.	 Implementation	 was	 rapid	 and	maintenance	
was	relatively	low	in	cost	and	staff	time.		
This	tool	can	be	adapted	for	use	in	different	settings,	with	the	main	investment	for	
introduction	 into	 new	 locations	 being	 purchase	 of	 high	 resolution	 satellite	 maps	
(~USD$	1,000	per	100	km2),	and	collection	of	local	points	of	interests	needed	to	fully	
annotate	the	map	and	make	it	more	readily	usable.	In	this	study	POI	capture	involved	
Ministry	of	Health	CHWs,	plus	study	staff	time	over	seven	weeks	of	POI	collection.		
One	 full	 time	 field	 staff	 member	 was	 employed	 for	 ongoing	 monitoring	 and	
evaluation	 visits,	 which	 is	 likely	 to	 be	 essential	 for	 maintaining	 as	 well	 as	
understanding	accuracy	and	case-capture.	Our	use	of	tablets	instead	of	computers	
kept	 hardware	 costs	 for	 electronic	 data	 capture	 low,	 and	 avoided	 reliance	 on	
unstable	sources	of	electricity	and	internet.	With	the	support	of	the	District	Health	
Office	 and	NTP,	most	 data	were	 collected	 routinely	 by	 TB	 officers	 during	 patient	
registration	activities.	TB	officers	 received	a	small	per	diem	for	attending	monthly	
feedback	meetings,	but	no	other	compensation.		One	staff	member	was	employed	to	
assist	data	collection	in	the	busiest	central	hospital.	
ePAL-based	 data	 collection	 was	 successfully	 incorporated	 in	 to	 the	 National	
Tuberculosis	Programme	through	this	integration	in	to	routine	patient	registration.	
Initial	 computer	 and	map	 literacy	was	 low	 for	 some	TB	officers,	with	many	never	
having	used	an	electronic	device	before,	but	with	one	full-day	training,	and	regular	
support	through	meetings	twice	per	month	(one	in	the	clinic	and	one	at	the	DHO),	
NTP	staff	were	able	to	easily	and	effectively	use	the	ePAL	app	for	collection	of	patient	
data	and	location	of	residence.	Initial	differences	between	TB	officer	in	terms	of	ePAL	
accuracy	 diminished	over	 time.	 Results	 of	 the	 study,	 including	 health	 centre-level	
reports,	were	provided	to	the	NTP	and	TB	officers	on	a	monthly	basis.	
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We	 estimate	median	 distance	 between	 the	 ePAL	 coordinates	 and	 GPS-measured	
coordinates	 to	 be	 84m	 (IQR:	 35-317m).	 The	 median	 would	 correspond	 to	
approximately	6	to	8	dwellings	from	the	patient’s	residence	 in	the	highest	density	
areas,	but	as	close	as	the	adjacent	structure	in	low-density	suburbs.	The	accuracy	of	
GPS	 measurements	 at	 the	 home	 was	 maximised	 by	 taking	 averaged	 waypoints,	
reducing	the	inherent	inaccuracy	of	measurement	to	a	few	metres,	although	this	will	
have	been	increased	by	cloud	cover,	rain,	and	proximity	to	buildings.		Home-visit	and	
ePAL	GPS	 readings	 used	 slightly	 different	 reference	 points	 (from	 the	 front	 of	 the	
building	 at	 home-visit,	 but	 centre	 of	 the	 building	 image	 on	 the	 satellite	 maps),	
introducing	 unavoidable	 ‘inaccuracy’	 even	when	 fully	 correct.	 The	 evaluation	was	
conducted	 in	 the	 highest	 density	 slum	 areas	 of	 the	 city	 and	 included	 patients	
registered	 in	clinics	remote	from	these	neighbourhoods,	with	no	obvious	effect	of	
proximity	from	the	clinic	(site	of	ePAL	capture)	on	accuracy.			
Evaluation	was	focused	on	patients	registering	in	the	first	4	months	of	the	study,	with	
smaller	numbers	 recruited	 for	on-going	quality	assurance	thereafter.	 	As	such,	we	
cannot	comment	on	accuracy	trends	over	time,	which	are	 likely	to	have	 improved	
with	increasing	user-familiarity	with	ePAL	and	periodic	improvements	to	the	software	
over	the	course	of	the	first	year.	Conducting	home	visits	was	more	time	consuming	
than	anticipated,	affecting	both	timeliness	and	final	numbers	followed	up.		There	was	
no	obvious	effect	of	longer	intervals	between	registration	and	home	visit	on	accuracy.		
A	displacement	of	>1km	was	recorded	between	the	ePAL	and	home	visit	coordinates	
for	14.0%	of	evaluation	participants.	Feedback	from	the	field	team	suggested	that	
such	 large	 differences	 were	 mostly	 due	 to	 relocation,	 for	 instance	 temporary	
residence	with	a	relative	to	seek	TB	care,	and	also	as	a	result	of	heavy	rainfalls	and	
flooding	 in	early	2015.	 	Over	the	 longer	study	period,	 large	displacement	was	also	
significantly	associated	with	HIV	status,	raising	deliberate	misidentification	because	
of	HIV	stigma	as	a	possible	cause.		
Limitations	
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The	 main	 limitation	 was	 the	 difficulty	 of	 conducting	 home	 visits	 in	 high	 density	
informal	settlement	areas,	which	followed	verbal	description	given	to	TB	officers	and	
recorded	in	the	paper	NTP	register	(the	standard	approach	before	ePAL).	Use	of	ePAL	
coordinates	 was	 avoided	 to	 prevent	 observer	 bias.	 	 Tracking	 down	 the	 correct	
households	 proved	 very	 time-consuming,	 leading	 to	 some	 long	 delays	 between	
registration	 and	 home	 visit	 (IQR:	 14-37,	 maximum	 182),	 and	 was	 completely	
unsuccessful	 in	 50	 (29.2%)	 of	 patients	 registering	 in	 the	 four-month	 evaluation	
period.	While	these	 issues	underscore	the	need	for	alternatives	such	as	ePAL,	 it	 is	
possible	that	incomplete	capture	may	have	biased	our	estimates	of	accuracy	if,	for	
instance,	deliberately	incorrect	information	had	been	provided	both	for	ePAL	and	the	
verbal	address.	A	more	systematic	classification	of	underlying	issues	resulting	in	large	
distance	errors,	ideally	including	qualitative	interviews	to	probe	for	HIV/TB	stigma	as	
well	as	to	identify	multiple	residencies,	would	have	provided	better	understanding	of	
the	cause	of	these	differences	and	extent	to	which	they	could	be	minimized.	ePAL	
case	capture	issues	early	in	the	study	were	rectified	by	provision	of	additional	support	
and	electronic	tablets	for	data	collection	in	the	QECH	hospital.	
Conclusion	
In	summary,	ePAL	provides	a	pragmatic	digital	tool	that	can	be	integrated	into	the	
National	Tuberculosis	Programme	to	collect	place	of	residence	for	patients	living	in	
settings	 without	 a	 municipal	 address	 system.	 These	 data	 provide	 broad	
programmatic	and	research	benefits,	 including	design	of	preventative	clinical	trials	
for	TB.	The	system	is	readily	adaptable	to	other	diseases,	and	can	be	implemented	in	
any	setting	where	satellite	maps	can	be	purchased	for	offline	use	and	annotated	with	
local	points	of	interest.			
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List	of	abbreviations	
App	 Application	
CHW	 Community	Health	Worker	
CI	 Confidence	intervals	
cRCT	 cluster	Randomised	Controlled	Trial	
DHO	 District	Health	Office	
eCRF	 electronic	Case	Report	Form	
ePAL	 electronic	PArticipant	Locator	
GPS	 Global	Positioning	System	
IQR	 Interquartile	range	
M.tb	 Mycobacterium	tuberculosis	
MoH	 Ministry	of	Health	
NTP	 National	Tuberculosis	Programme	
ODK	 Open	Data	Kit	
POI	 Point	of	Interest	
TB		 Tuberculosis	
UR	 Uncertainty	Range	
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Figures	and	Tables	
Figure	5.1:	Screen	shots	of	the	ePAL	annotated	
map	at	zoom	level	18	(top	left),	annotated	map	
at	zoom	level	19	(top	right),	and	an	ePAL	eCRF	
question	(bottom	left). 
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Figure	5.2:	Outline	of	study	processes	for	main	study	and	evaluation	cohort 
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Figure	5.3:	ePAL	participant	study	flow	
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Table	5.2:	Proportion	of	evaluation	participants	by	estimated	distance	between	ePAL	and	GPS	
measurement	
Distance	range	
(metres)	
Number	
within	
distance	
range	
Proportion	
within	
distance	
range		
(95%	CI)	
Cumulative	
number	
within	
distance	
Cumulative	
proportion	
within	
distance		
(95%	CI)	
0	≤	m	<	20	 16	 13.2%	(7.8-20.5)	 16	
13.2%	
(7.8-20.5)	
20	≤	m	<50	 27	 22.3%	(15.2-30.8)	 43	
35.5%	
(27.0-44.8)	
50	≤	m	<	100	 24	 19.8%	(13.1-28.0)	 67	
55.3%	
(46.0-64.4)	
100	≤	m	<	200	 18	 14.8%		(9.1-22.5)	 85	
70.2%	
(61.2-78.2)	
200	≤	m	<	500	 12	 9.9%	(5.2-16.7)	 97	
80.2%	
(71.9-86.9)	
500	≤	m	<	1000	 7	 5.8%	(2.4-11.6)	 104	
86.0%	
(78.5-91.6)	
1000	≤	m	 17	 14.0%	(8.4-21.5)	 121	
100.0%	
(97.0-100*)	
*	One-sided	97.5%	confidence	interval	
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5.3 Additional	methods	
5.3.1 Additional	ePAL	app	features	
Some	 additional	 app	 details	 and	 map	 features	 not	 discussed	 in	 section	 5.2	 are	
summarised	in	Table	5.3	below.	
Table	5.3:	Summary	of	additional	ePAL	app	features	
ePAL	 App	
Feature	
Function	 Description	
POI	control	 Button	 to	 turn	
POIs	on/off	
	
On	the	ePAL	maps,	pressing	the								button	turns	
the	 POI	 labels	 on	 and	 off.	 This	 is	 of	 use	 if	 a	
participant’s	 place	of	 residence	 lies	underneath	
one	of	the	POI	labels.	
Road	
controls	
Button	 to	 turn	
roads	 and	 area	
boundaries	
on/off	
	
On	 the	 ePAL	 maps,	 pressing	 the	 		 	 button	
turns	the	road	and	boundary	markings	on	and	off.		
Zoom	 Grid-based	
zooming	
	
Map	 zooming	 is	 grid-based	 using	 the	
buttons	(as	opposed	to	‘pinch’	action).	This	was	
selected	as	 the	most	straightforward	option	 for	
inexperienced	users.	
Zoom	traffic	
lights	
Indicate	
sufficient	 zoom	
level	
	
Although	proportion	 collecting	 coordinates	 at	 a	
high	 level	of	zoom	(at	 least	zoom	18)	was	good	
throughout	the	study,	to	encourage	collection	at	
zoom	19,	a	traffic	light	system	was	introduced	in	
early	2016.	The	 	symbol	 in	the	top	left	corner	
of	the	map	changes	to	 	at	zoom	19	(see	Figure	
5.4).	
Summary	
screen	
Allow	 check	 of	
collected	data		
The	final	screen	of	the	app	contains	a	summary	
of	all	of	the	collected	data,	allowing	the	TB	officer	
to	return	to	the	eCRF	if	any	data	are	incorrect	
Settings	
section	
Language	 and	
TB	 centre	
selection	
Language	can	be	switched	between	English	and	
Chichewa	 in	 the	 settings	 section	of	 the	app.	TB	
centre	is	selected	in	the	settings	to	allow	correct	
auto-generation	 of	 the	 ePAL	 participant	
reference	 (as	 this	 starts	 with	 the	 centre	 code).	
Initials	 of	 new	 data	 collectors	 to	 appear	 as	
options	 in-app	 can	 be	 added	 in	 the	 settings	
section.		
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Top	 left:	 ePAL	 map	 fully	 zoomed	 out	 (zoom	 12)	
demonstrating	POI	search	function.	Red	boundaries	
are	 wards,	 and	 the	 green	 boundary	 is	 the	 ePAL	
evaluation	area.	
	
Top	right:	ePAL	map	at	zoom	level	18.	Different	POI	
categories	are	represented	by	different	colours	(e.g.	
green	 =	 shop,	 blue	 =	 place	 of	 worship,	 purple	 =	
bridges	 and	 public	 structures,	 white	 =	 plots	 and	
other).	
	
Bottom	 left:	 ePAL	 map	 at	 full	 zoom	 (level	 19)	
demonstrating	 the	 high	 density	 of	 structures	 and	
high	coverage	of	POIs.	When	a	place	of	residence	is	
selected	by	the	user,	the	red	pointer	labelled	“Me”	
shows	 the	 selected	 location,	 and	 can	 be	moved	 if	
placed	incorrectly.	If	the	participant	doesn’t	live	in	
urban	Blantyre,	“not	on	map”	can	be	selected.	
	
	
Figure	5.4:	Screen	shots	of	ePAL	app	
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5.3.2 Pilot	of	POI	density	
In	the	paper-based	map	book	study,	an	average	of	9	POIs	(range:	3-13)	were	marked	
on	 maps	 of	 each	 cluster	 with	 a	 mean	 adult	 population	 of	 1,324.4	 Higher	 target	
resolution	in	the	ePAL	study	was	expected	to	require	a	higher	POI	density.	A	pilot	was	
conducted	with	‘map	book’-style	maps	to	identify	an	appropriate	POI	density	for	the	
ePAL	maps.		
Printed	maps	with	one	of	three	POI	densities	(10,	15	and	20	POIs	per	HSA	area)	were	
field	 tested.	 Eighteen	 randomly	 selected	 adults	 attending	 a	 market	 place	 in	 the	
annotated	area	were	invited	to	participate.	Those	verbally	consenting	to	participate	
were	 asked	 to	 identify	 and	 mark	 their	 place	 of	 residence	 on	 a	 printed	 map	 (six	
participants	for	each	POI	density),	then	accompanied	by	a	field	worker	to	their	place	
of	 residence	 for	 collection	 of	 GPS	 coordinates	 (Garmin	 eTrex	 20,	 Garmin	
International,	 Inc.,	Olathe,	Kansas).	The	paper-based	 location	and	GPS	coordinates	
were	compared	visually,	and	proximity	(yes/no)	agreed	by	consensus	between	two	
reviewers	(RH	and	WS).	All	participants	using	maps	with	20	POIs	were	assessed	to	
have	achieved	close	proximity,	whereas	only	4/6	of	participants	using	maps	with	10	
POIs	were	considered	to	have	achieved	close	proximity.	Therefore,	target	density	of	
20	POIs	(minimum	10)	per	HSA	area	was	set.	
POIs	were	collected	by	a	team	of	field	workers	between	23rd	September	and	14th	
November	2014	using	Garmin	eTrex	20	handsets	(Garmin	International,	Inc.,	Olathe,	
Kansas).	Additional	POIs	were	added	as	necessary	to	areas	identified	by	TB	officers.	
In	total,	ePAL	currently	contains	3,243	POIs,	averaging	17	per	HSA	area.	ePAL	POIs	
can	be	managed	via	the	web	interface,	allowing	future	POI	updates.	
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5.3.3 GPS	accuracy	
Inherent	 inaccuracies	 in	 GPS	 receivers	 and	 methods	 of	 GPS	 collection	 affect	 the	
accuracy	 of	 the	 gold	 standard	 GPS	 measurement	 used	 for	 comparison	 to	 ePAL	
coordinates.		
The	U.S.	government	guarantees	satellite	error	will	remain	below	7.8m,	and	in	May	
2016	was	estimated	as	below	0.7m	with	95%	probability.16	Inherent	error	in	Garmin	
receivers	 are	 estimated	 as	 “typically	 accurate	 to	 within	 10	meters”.17	 Combined,	
these	 two	 contribute	 to	 an	 overall	 GPS	 reader	 error	 of	 approximately	 10m.	
Environmental	 factors	 such	 as	 signal	 blockage	 by	 proximity	 to	 buildings	 and	
atmospheric	conditions	can	increase	this	error	further.	Given	many	of	the	evaluation	
visits	were	conducted	during	Malawi’s	wet	season,	atmospheric	conditions	are	likely	
to	have	unavoidably	affected	evaluation	visit	GPS	readings.	
Study	 design	 and	 standard	 operating	 procedures	 endeavoured	 to	minimise	 these	
errors.	Firstly,	to	maximise	accuracy	of	the	GPS	measurements,	waypoint	averaging	
was	employed.	This	functionality	takes	a	measurement	every	second	until	the	sample	
size	 is	 large	enough	 that	 the	estimate	of	 the	mean	remains	stable	with	additional	
sampling	 (defined	 on	 the	 handset	 as	 “100%	 confidence”).	 This	 process	 takes	 3-5	
minutes	 depending	 on	 the	 weather	 conditions	 and	 satellite	 position,	 but	 greatly	
improves	accuracy	compared	to	single	waypoint	measurement.	Secondly,	 to	avoid	
signal	blocking	by	buildings,	standard	operating	procedures	stipulated	measurement	
of	GPS	from	1m	in	front	of	the	main	dwelling	entrance.		
In	 the	clinic,	ePAL	users	 selected	 the	centre	of	 the	participant’s	dwelling	as	doors	
were	not	visible	on	the	maps.	Therefore,	 the	GPS	data	collection	method	ensured	
adequate	 signal	 strength,	but	 contributed	 to	a	 consistent	offset	of	 several	metres	
from	the	location	of	the	dwelling	if	correctly	identified	on	ePAL.	
The	 evaluation	 sub-study	was	 powered	 to	measure	 a	 proportion	 of	 85%	 of	 ePAL	
measurements,	with	a	lower	limit	of	the	95%	confidence	interval	of	80%,	within	20m	
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of	the	GPS	reading.	The	distance	was	based	upon	the	assumptions	of	10m	inaccuracy	
in	the	GPS	reading	plus	5m	inaccuracy	due	to	the	selection	of	the	centre	versus	the	
door	of	the	building,	allowing	for	only	5m	inaccuracy	in	the	selection	of	the	location	
in	 ePAL.	 Considering	 the	 limitations	 in	 both	 GPS	 measurement	 and	 use	 of	 ePAL	
experienced	once	in	the	field,	this	was	soon	identified	as	an	unrealistic	expectation.	
Given	the	environmental	conditions,	10m	was	likely	an	overestimate	of	the	accuracy	
of	the	GPS	reader.	The	sources	of	inaccuracy	from	the	practical	use	of	ePAL	were	also	
underestimated,	such	as	using	fingers	to	select	the	place	of	residence	could	introduce	
inaccuracy.	Therefore,	the	median	estimate	of	84m	between	the	evaluation	and	ePAL	
coordinates	was	considered	a	 success,	especially	when	considered	 in	context	 (see	
Figure	5.4).	To	note,	ePAL	is	now	being	used	with	stylus	screen	pens	to	allow	more	
accurate	selection	of	the	map	location.	
5.3.4 Additional	information	on	statistical	methods	
For	sustainability	of	ongoing	use	by	the	local	data	management	team,	data	cleaning	
and	 data	 analysis	 for	 monthly	 monitoring	 was	 conducted	 in	 Stata,	 version	 13.1	
(StataCorp	LP,	College	Station,	Texas).		
The	map	 tiles	 in	 the	 ePAL	 app	were	 converted	 to	 the	Google	 Earth	 (ESPG:	 3857)	
projection.	When	a	location	is	selected	on	the	screen,	the	application	programming	
interface	accounts	for	location	and	zoom	level	to	record	the	coordinates	in	WGS84	
(EPSG:	4326)	projection	in	the	ePAL	database	in	comma	separated	value	format.	The	
GPS	handsets	collected	data	in	the	WGS84	setting,	therefore	direct	calculation	of	the	
distance	between	the	spatial	points	collected	by	ePAL	in	the	clinic	and	by	the	Garmin	
handset	at	the	evaluation	visit	was	possible.	
Several	options	exist	for	calculating	the	distance	between	two	spatial	points	in	R.	To	
ensure	that	choice	of	package/command	did	not	significantly	affect	 the	estimated	
distance,	the	distance	between	the	GPS	and	the	ePAL	data	set	were	calculated	using	
the	 ‘raster’	 package	 ‘pointDistance’	 command,	 ‘geosphere’	 package	 ‘distm’	
command,	and	the	‘sp’	package	‘spDists’	command.	The	difference	between	these	
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methods	 of	 distance	 estimation	 did	 not	 exceed	 0.2%	 of	 the	 estimated	 distance,	
therefore	all	were	considered	suitable	methods.	The	spDists	calculates	the	distance	
between	the	two	points	using	Great	Circle	distance	(WGS84	ellipsoid)	and	provides	
convenient	to	use	outputs,	so	was	selected	for	use	in	this	study.	
5.4 Additional	monitoring	and	evaluation	results		
5.4.1 Monitoring	
Given	the	primary	aim	of	the	study	was	capture	of	patient	place	of	residence,	one	of	
the	 key	 monitoring	 aspects	 was	 appropriate	 capture	 of	 coordinates.	 The	 overall	
coordinate	capture	of	those	reporting	urban	Blantyre	residence	was	89%.	Monthly	
point	 estimates	 of	 the	 proportion	with	 available	 coordinates	 ranged	 77%	 to	 95%	
(Table	5.4).	Through	monitoring	and	feedback	to	the	TB	officers	at	monthly	meetings,	
coordinate	capture	was	maintained	at	high	levels.	
Limitations	 of	 this	 measurement	 should	 be	 recognised,	 as	 the	 ‘gold	 standard’	
measure	relies	on	participant	self-report	of	residency	in	urban	Blantyre.	Errors	in	self	
report	could	lead	to	over-	or	under-estimation	of	coordinate	capture.	
Comparison	of	case	capture	in	ePAL	to	the	NTP	register	was	an	important	monitoring	
measure	during	the	study.	NTP	records	provided	a	robust	denominator.	Monthly	case	
capture	for	the	study	and	continued	use	of	ePAL	are	presented	in	Figure	5.5.		 	
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Table	5.4:	Proportion	coordinate	capture	by	month	in	participants	reporting	residency	in	urban	
Blantyre	
Study	Month	
Proportion	of	urban	Blantyre	
residents	with	coordinates		
(95%	confidence	intervals)	
1	 81%	(72-88%)	
2	 87%	(79-93%)	
3	 77%	(68-85%)	
4	 93%	(86-97%)	
5	 92%	(85-96%)	
6	 94%	(87-98%)	
7	 95%	(89-98%)	
8	 93%	(86-97%)	
9	 91%	(84-96%)	
10	 84%	(75-91%)	
11	 86%	(78-92%)	
12	 91%	(84-96%)	
	
	
Figure	5.5:	Monthly	case	capture	with	ePAL	as	compared	to	NTP	registers	from	February	2015	to	
March	2017.	
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5.4.2 Evaluation	
The	main	evaluation	outcome	was	defined	as	distance	between	the	evaluation	and	
ePAL	 coordinates	 estimated	 in	 metres.	 Median	 distance	 between	 the	 ePAL	 and	
evaluation	coordinates	was	84m	(IQR:	35m-317m).	However,	as	a	quality	assurance	
measure,	the	latitude	offset	and	longitude	offset	between	ePAL	and	evaluation	visit	
coordinates	were	also	calculated	to	ensure	there	was	no	systematic	offset	 (Figure	
5.6).	There	is	no	visible	skew	in	the	data,	so	no	issue	was	identified.	
	
Figure	5.6:	Longitude	and	latitude	offset	(WGS84	degrees)	between	pairs	of	ePAL	and	evaluation	
coordinates		
	
Exact	 time	 between	 clinic	 registration	 and	 evaluation	 follow	 up	 visit	 was	 not	
recorded.	 However,	 date	 of	 upload	 of	 evaluation	 visit	 data	 was	 available,	 so	 lag	
between	 date	 of	 collection	 and	 latest	 possible	 follow	 up	 date	 was	 estimated.	 As	
discussed	in	section	5.2,	mean	lag	between	ePAL	entry	and	latest	possible	follow	up	
was	 26	 days	 (IQR:	 14-37	 days),	 ranging	 from	 2	 days	 to	 182	 days	 (Figure	 5.7).	
Spearman’s	 correlation	 between	 the	 evaluation	 distance	 and	 data	 collection	 lag	
estimate	was	0.12	(p=0.17),	suggesting	negligible	correlation.	
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Figure	 5.7:	 Comparison	 of	 time	 elapsed	 between	 ePAL	 registration	 and	 evaluation	 data	 upload	
('maximum	possible	lag',	days)	plotted	against	evaluation	distance	(metres).	
	
In	total,	204	evaluation	and	monitoring	visits	were	conducted	during	the	12	months	
of	the	main	study.	Evaluation/monitoring	results	by	month	are	presented	in	Figure	
5.8.	
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Figure	 5.8:	 Estimated	 distance	 between	 ePAL-	 and	 GPS-	 measured	 place	 of	 residence	 by	 study	
month.	To	allow	visualisation	of	the	data	trends,	the	y	axis	was	cropped	at	1500m.	A	small	number	of	
points	lay	above	this	cut	off:	Feb	2015	(n=3),	Mar	(n=2),	Apr	(n=3),	May	(n=3),	June	(n=3),	Aug	(n=2),	
Sept	(n=2),	Oct	(n=2),	Nov	(n=1).	
	
All	patients	reporting	residence	in	the	evaluation	area	during	the	first	4	months	of	
the	 study	were	 invited	 to	participate	 in	 the	evaluation	visit	 at	 the	home.	Consent	
rates	 for	evaluation	visits	were	very	high,	and	 if	100%	 follow	up	were	achievable,	
closer	 to	 the	 196	 needed	 for	 the	 evaluation	 cohort	 would	 have	 been	 achieved.	
However,	as	was	expected,	the	challenges	of	lack	of	addresses	and	incomplete	mobile	
phone	ownership	for	contacting	participants	led	to	loss	to	follow	up.	Due	to	these	
challenges,	the	time	per	evaluation	visit	was	much	greater	than	expected.		
Characteristics	 of	 participants	 with	 missing	 data	 have	 been	 described	 elsewhere	
section	5.2.	Characteristics	explored	were	suggestive	of	a	difference	in	missing	data	
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by	TB	officer,	though	this	appeared	diminish	with	only	evidence	of	a	difference	over	
the	12	month	period.	ePAL	data	were	not	used	to	assist	evaluation	visits,	so	did	not	
bias	the	results.	Theoretically,	an	association	could	exist	between	ability	to	describe	
place	of	 residence	and	both	ease	of	evaluation	 follow	up	and	of	 locating	place	of	
residence	in	ePAL.	Therefore,	those	located	for	evaluation	visits	could	be	those	with	
more	accurate	ePAL	 locations.	Data	were	not	available	to	test	 this	possible	risk	of	
bias,	but	given	evaluation	visits	could	be	arranged	by	meeting	at	a	well-known	point	
of	interest,	this	bias	is	considered	fairly	unlikely.	
The	12	months	of	the	study	was,	by	design,	initiated	at	the	same	time	as	the	launch	
of	the	searchable	POI	function	as	this	was	the	last	major	change	to	the	app.	However,	
it	took	some	time	for	the	TB	officers	to	uptake	and	become	comfortable	using	the	
POI	search	function.	Therefore,	in	the	early	phase	of	the	study,	some	TB	officers	were	
probably	not	using	the	full	functionality	of	the	tool.	The	POI	search	function	greatly	
increased	 the	 ease	 of	 finding	 the	 correct	 area	 on	 the	map.	 Therefore,	 evaluation	
should	have	perhaps	been	initiated	a	month	or	two	after	the	implementation	of	the	
app	update.	However,	this	most	likely	means	estimates	of	accuracy	are	conservative,	
as	the	POI	search	function	may	have	improved	the	user	experience.	
5.4.3 Study	continuation	
In	 moving	 forward	 with	 ePAL	 after	 the	 12-month	 study	 period,	 evaluation	
transitioned	to	monitoring	visits.	These	followed	the	same	format	as	evaluation	visits,	
but	were	conducted	for	5%	of	registrations	(at	 least	1	per	centre	per	month).	The	
written	 consent	 and	 evaluation	 questions	 were	 removed	 from	 the	 app	 as	 the	
evaluation	 period	 had	 finished.	A	 small	 number	 of	 key	 risk	 factor	 questions	were	
moved	into	the	case	report	form.		
Ethics	approval	has	been	sought	and	granted	for	de-escalating	the	enrolment	age	for	
ePAL	 data	 collection	 as	 part	 of	 the	 “Hit	 TB	 Hard”	 study	 to	 include	 children.	 For	
children	 aged	 <8	 years	 old,	 verbal	 consent	was	 sought	 from	 the	 guardian	 for	 the	
child’s	participation.	For	children	aged	8-17	years,	verbal	consent	was	sought	from	
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the	guardian	and	verbal	assent	procedures	were	put	in	place	for	the	participant.	The	
child	was	only	enrolled	if	both	patient	assent	and	guardian	consent	were	given.		
	
5.5 Spatial	mapping	with	ePAL	to	inform	clinical	trial	design	
5.5.1 Utility	of	ePAL	to	inform	design	of	prevention	of	disease	TB	vaccine	clinical	
trials	
ePAL	provides	a	low-cost,	rapidly	implementable	tool	that	can	be	employed	to	assess	
the	 spatial	 distribution	 and	 burden	 of	 disease	 in	 specific	 populations.	 There	 is	 a	
shortage	of	research	sites	with	both	clinical	trial	capacity	and	appropriate	available	
epidemiological	data.	As	described	previously,	spatiotemporal	data	can	help	inform	
identification	of	TB	disease	hotspots,	both	overall	in	the	population	and	in	potential	
subsets	for	trial	recruitment.	This	can	inform	data-driven	sample	size	calculations	to	
help	balance	the	minimisation	of	costs	against	risk	of	achieving	insufficient	endpoints.	
From	 a	 safety	 perspective,	 minimising	 the	 number	 exposed	 to	 investigational	
products	is	preferable,	and	from	an	ethical	perspective,	if	new	vaccines	are	effective,	
enrolling	those	populations	most	at	risk	improves	the	risk-benefit	of	participation.	
Without	an	alternative	source	of	epidemiological	data,	NTP	data	would	be	employed	
to	inform	sample	size	calculations.	However,	publicly	available	data	are	aggregated	
at	the	regional	or	district	level,18	and	do	not	differentiate	whether	patients	registering	
in	Blantyre	 are	 city	 residents.	 Results	of	 the	ePAL	 study	demonstrate	 that	 a	 large	
proportion	(27%,	n=	514)	of	those	registering	in	Blantyre	are	rural	Blantyre	or	out-of-
district	residents.	A	TB	vaccine	trial	with	a	sample	size	based	upon	NTP	data	would	
be	 substantially	 under-powered,	 as	 these	 non-residents	 would	 be	 included.	
Therefore,	even	the	most	basic	use	of	ePAL	to	identify	Blantyre	residents	would	be	
an	important	contribution	to	informing	appropriate	sample	size	calculations	for	new	
TB	vaccine	efficacy	studies.	A	simpler	questionnaire-based	approach	could	be	taken	
to	collecting	this	level	of	data,	but	there	are	many	additional	advantages	to	the	high	
resolution	data	ePAL	provides.	
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Figure	5.9:	All	TB	registrations	collected	using	ePAL	over	a	12	month	period	(February	2015-2016)	
provided	as	A)	individual	spatial	points	(blue	dots),	and	B)	notification	rates	estimated	by	census	
enumeration	area	(red	dots	are	health	centres)	
As	can	be	seen	 in	Figure	5.9A	above,	the	majority	of	 incident	TB	cases	 in	Blantyre	
were	focussed	in	central	and	central-west	areas	of	the	city.	This	high	concentration	
of	cases	 in	 these	areas	 is	 indicative	of	potential	 suitability	 for	 trial	 recruitment.	 In	
Figure	5.9B,	these	ePAL	registered	cases	are	combined	with	census	enumeration	area	
population	estimates	to	calculate	TB	notification	rates.7	This	provides	much	higher	
granularity	than	the	NTP-reported	data,	where	rates	are	reported	for	urban	Blantyre.	
Once	converted	to	rates,	even	though	the	areas	with	a	large	number	of	cases	were	
also	areas	of	high	population	density,	the	number	of	cases	in	this	area	was	so	high	
that	rates	remained	high,	indicating	that	this	could	be	a	suitable	population	for	TB	
vaccine	 trial	 recruitment.	 However,	 several	 additional	 areas	 are	 highlighted	 once	
rates	 as	 opposed	 to	 numbers	 of	 cases	 are	 considered.	 Several	 areas	 that	 did	 not	
appear	high	burden	when	considering	 the	point	processes	data	were	 identified	as	
having	high	notification	rates.	Given	clinical	trial	sample	sizes	are	based	upon	rates,	
these	areas	with	fewer	residents	but	high	numbers	of	reported	cases	could	be	ideal	
for	TB	vaccine	clinical	trials.		
For	ongoing	clinical	 trials,	 the	exact	definition	of	 ‘disease’	varies	between	studies,	
with	 some	measuring	effect	against	purely	microbiologically	 confirmed	endpoints,	
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and	others	 using	broader	 clinically-defined	endpoints.2,19	 The	 results	 in	 Figure	 5.9	
would	 most	 likely	 be	 directly	 relevant	 for	 studies	 measuring	 clinically	 defined	
endpoints.	Some	studies	limit	the	outcome	to	pulmonary	disease,	therefore	mapping	
exclusively	of	pulmonary	disease	may	be	more	 informative.	 Sixty	percent	of	 ePAL	
participants	 (1,135/1,899)	reported	pulmonary	disease,	which	 is	mapped	 in	Figure	
5.10	below.	785	participants	resident	 in	urban	Blantyre	with	available	coordinates	
reported	pulmonary	disease.	
	
Figure	5.10:	Estimated	notification	rates	by	census	enumeration	area	of	pulmonary	TB	disease	
using	ePAL	data	
	
This	would	not	 be	 an	 accurate	 estimate	of	 the	disease	 rates	 and,	 potentially,	 the	
location	 of	 patients	 in	 studies	 where	 outcomes	 are	 limited	 to	 microbiologically	
confirmed	disease.	In	this	study	only	43%	of	patients	had	microbiologically	confirmed	
disease	at	time	of	registration.	In	the	subset	of	patients	resident	in	urban	Blantyre	
with	 coordinates	 available,	 48%	 were	 microbiologically	 positive	 at	 time	 of	
registration.	 Therefore,	 exploring	 the	 distribution	 and	 rates	 of	 microbiologically	
positive	 disease	 could	 help	 inform	 trial	 design	 and	 recruitment	 tailored	 more	
precisely	to	the	study	endpoint	(Figure	5.11).	
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Figure	5.11:	Estimated	notification	rates	by	census	enumeration	area	of	microbiologically	confirmed	
TB	at	time	of	registration	using	ePAL	data	
	
One	 limitation	of	 this	 approach	 is	 the	delay	 in	 culture	 results	becoming	available.	
Planned	future	analyses	include	merging	the	ePAL	database	with	culture	results	from	
the	 parent	 study	 (Hit	 TB	Hard),	 to	 include	 patients	with	 culture	 results	 becoming	
available	after	the	treatment	initiation	visit.	
Mathematical	 modelling	 in	 chapters	 3	 and	 4	 also	 demonstrated	 that	 targeting	
vaccination	to	groups	most	at	risk	of	developing	disease	could	help	maximise	impact	
of	new	TB	vaccines.	In	particular,	age	targeting	of	vaccination	may	be	of	importance.	
Clinical	trials	currently	ongoing	have	recruited	adult	populations	of	ages	15-65	and	
18-50	years.	The	maps	below	(Figure	5.12	maps	B	and	C)	are	a	demonstration	of	the	
distribution	of	disease	in	these	populations.	Other	studies	have	recruited	narrower	
age	 ranges	 (e.g.	 13-15	 years).	Map	A	 in	 Figure	5.12	demonstrates	 the	anticipated	
rates	in	18-25	years	olds	as	an	example	of	the	distribution	that	could	be	expected	in	
more	 limited	young	adult	age	groups.	The	age	for	 inclusion	 in	ePAL	has	now	been	
widened	 to	 include	 birth	 upwards,	 with	 guardian	 consent	 and	 participant	 assent	
processes	in	place.	Therefore,	data	relevant	for	these	younger	age	groups	will	shortly	
be	available,	and	could	be	assessed	in	future	analyses.	
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Figure	5.12:	Distribution	of	cases	in	A)	18-25	year	olds,	B)	18-50	year	olds,	and	C)	18-65	year	olds	
	
Finally,	studies	may	want	to	include	or	exclude	certain	risk	groups,	based	upon	safety	
or	likelihood	of	mounting	an	effective	immune	response	to	a	vaccine.	For	example,	
immune	compromise	caused	by	HIV	infection	increases	the	risk	of	development	of	TB	
disease,	but	also	may	impact	an	individual’s	ability	to	develop	a	sufficient	immune	
response	 to	 vaccination.	 Therefore,	 inclusion	of	 such	populations	 in	 efficacy	 trials	
could	dilute	measures	of	efficacy,	 risking	a	no-go	decision	on	a	vaccine	that	could	
otherwise	be	effective	in	a	healthy	population.	These	risk	groups	are	often	studied	in	
separate	safety	and	immunogenicity	studies.	Therefore,	spatial	maps	are	presented	
in	Figure	5.13	limiting	the	data	set	to	HIV	negative	patients.	
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Figure	5.13:	Spatial	distribution	of	TB	cases	in	Blantyre	by	HIV	status	A)	HIV-positive	(yellow)	and	
HIV-negative	 (red)	cases,	B)	HIV-negative	cases,	and	C)	estimated	notification	rates	of	TB	 in	HIV-
negative	populations,	assuming	homogenous	distribution	of	18.2%	population-level	HIV	prevalence.	
Trial	endpoints	may	affect	the	anticipated	rates	of	disease.	As	a	demonstration	of	the	
impact	of	endpoint	selection,			Figure	5.14A	below	shows	the	enumeration	area	TB	
rates	for	all	TB,	and	Figure	5.14B	demonstrates	the	TB	rates	and	changes	in	hotspots	
when	 the	 primary	 outcome	 is	 limited	 to	 microbiologically-positive	 pulmonary	
disease.	 In	 these	 first	 two	 figures	 all	 participants	 are	 included,	whereas	 in	 Figure	
5.14C	 it	 was	 assumed	 that	 recruitment	 criteria	 would	 exclude	 HIV	 positive	
populations.	Enumeration-area	 level	HIV	prevalence	was	not	available	 to	estimate	
these	 rates,	 so	 the	 2015	 HIV	 prevalence	 estimate	 for	 Blantyre	 city	 (18.2%)	 was	
applied	to	the	population	estimate	of	each	enumeration	area.20		
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Figure	5.14:	Estimated	enumeration	area	notification	rates	for	A)	all	TB	cases,	B)	microbiologically-
confirmed	pulmonary	TB	cases,	and	C)	microbiologically-confirmed	pulmonary	TB	cases	in	HIV-
negative	populations.	HIV	negative	rates	were	estimated	by	adjusting	the	population	level	
denominators	based	upon	18.2%	HIV	prevalence	in	Blantyre	city20		*highlight	examples	of	areas	
particularly	affected	compared	to	the	map	immediately	to	the	left.	Red	circles	are	TB	clinics	or	
hospitals	
	
Limiting	the	primary	outcome	definition	and	the	HIV	inclusion	criterion	substantially	
reduced	notification	rates.	Therefore,	without	this	adjustment	to	rate	estimates,	the	
TB	vaccine	trial	sample	size	would	be	too	small	and	the	study	would	most	likely	be	
underpowered.	 Importantly,	 several	 enumeration	 areas	 marked	 with	 a	 *	 were	
particularly	affected	by	the	change	in	outcome	or	recruitment	criteria.	These	areas	
may	 be	 suitable	 for	 a	 trial	 with	 a	 broad	 outcome	 measure	 and	 recruitment	
population,	but	become	unsuitable	if	the	trial	design	is	more	restrictive.	
These	analyses	serve	as	an	example	of	mapping	to	inform	trial	design	with	the	ePAL	
data	 set.	 Once	 future	 clinical	 trials	 have	 defined	 the	 recruitment	 population	 of	
interest,	data	generated	using	ePAL	can	help	direct	study	recruitment	to	areas	where	
disease	burden	is	highest	in	those	specific	populations,	and	can	help	provide	a	more	
accurate	estimate	of	notification	rates	to	inform	sample	size	calculations.	
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5.5.2 Possible	utility	of	ePAL	for	prevention	of	relapse	studies	
In	recent	years,	the	costs	and	challenges	of	developing	new	TB	vaccines	has	led	to	
innovation	 in	 approaches	 to	 proof	 of	 concept	 studies.	 One	 such	 innovation	 is	
conducting	 prevention	 of	 relapse	 (POR)	 studies	 for	 phase	 IIB	 proof	 of	 concept	 of	
efficacy	before	progressing	to	phase	 III	POD	studies.	POR	 is	effectively	a	subset	of	
POD,	 but	 in	 a	 population	 at	 elevated	 risk	 of	 developing	 disease	 compared	 to	 the	
general	population,	therefore	minimising	the	study	sample	size.		
In	the	ePAL	database,	relapse	patients	comprised	6%	(n=120)	of	TB	patient	records	
over	a	12-month	period,	of	which	70	were	from	urban	Blantyre	and	had	coordinates	
available.	ePAL	data	can	provide	an	approximate	relapse	proportion	based	upon	the	
ratio	of	new	to	relapse	cases	(1	relapse	to	every	14	new	patients),	which	can	inform	
sample	size	by	giving	an	approximation	of	the	anticipated	relapse	rates	that	could	be	
expected	from	recruitment	of	patients	with	history	of	disease.	These	data	would	also	
be	available	from	the	NTP	registers,	so	most	importantly,	the	spatial	data	available	
from	ePAL	would	also	help	study	staff	to	locate	people	with	history	of	TB	disease	for	
targeted	 recruitment	 (Figure	5.15).	 Ethical	 considerations	may	mean	 that	 it	 is	not	
appropriate	to	use	the	data	to	seek	and	recruit	patients	at	their	home,	but	patients	
could	be	recruited	at	the	end	of	treatment	at	TB	clinics,	and	ePAL	used	to	identify	
their	place	of	residence	to	facilitate	clinical	trial	follow	up	visits	and	reducing	loss	to	
follow	up.	
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Figure	5.15:	Spatial	location	of	relapse	cases	recorded	in	ePAL	with	coordinates	available	between	
12th	February	2015	to	11th	February	2016	
	
5.5.3 Possible	utility	of	ePAL	for	pre-	versus	post-infection	studies	
Mathematical	modelling	presented	in	Chapters	3	and	4	demonstrated	that,	in	China,	
vaccines	 effective	 post	 infection	 will	 be	 important	 to	 maximise	 vaccine	 impact.	
Therefore,	 recruitment	 of	 latently	 infected	 populations	 in	 TB	 vaccine	 trials	 for	
demonstration	of	safety,	and	ideally	efficacy,	will	be	essential.	Testing	for	latency	is	
generally	 either	 an	 inclusion	 criterion	 or	 part	 of	 initial	 participant	 assessments	 to	
ensure	infection	status	is	known	at	time	of	vaccination.	The	M72	and	M.vaccae	TB	
vaccine	 clinical	 trials	 recruited	 exclusively	 IGRA-positive	 or	 TST-positive	
participants.2,19	
If	recruiting	for	a	post-infection	(latency)	study,	recruiting	from	populations	with	high	
prevalence	of	infection	can	reduce	the	number	of	prospective	participants	that	are	
excluded	at	the	screening	stage.	However,	the	ePAL	study	is	not	designed	to	identify	
latently	infected	(or	uninfected)	populations.	The	burden	of	disease	in	the	population	
identified	using	ePAL	is	likely	a	reasonable	proxy	for	the	prevalence	of	infection,	on	
the	condition	that	the	underlying	cause	of	high	disease	rates	includes	high	infection	
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risk,	not	 just	 rapid	progression	to	disease.	Therefore,	data	collected	using	ePAL	to	
inform	sample	size	calculations	and	recruitment	populations	could	also	be	indicative	
of	the	populations	with	high	prevalence	of	infection	and	therefore	may	reduce	the	
number	of	exclusions	at	the	screening	stage.	
5.5.4 Strengths	and	Limitations	of	ePAL		
The	 main	 strengths	 and	 limitations	 of	 ePAL	 as	 a	 data	 collection	 tool	 have	 been	
discussed	in	detail	in	section	5.2.	
The	main	strength	of	this	tool	for	informing	TB	vaccine	clinical	trials	is	the	ability	to	
rapidly	and	inexpensively	generate	up-to-date	information	on	the	spatial	distribution	
of	 burden	of	 TB	disease	 in	 high	burden	urban	 settings	without	municipal	 address	
systems.	 Additional	 questions	with	 regards	 to	 demographic	 or	 risk	 factors	 can	 be	
included	 in	 the	 eCRF	 to	 allow	 stratification	 of	 the	 data	 by	 potential	 recruitment	
characteristics.	
One	of	 the	main	 limitations	of	ePAL	 for	 the	estimation	of	notification	 rates	 is	 the	
availability,	quality	and	relevance	of	the	denominator	data.	In	Blantyre,	census	data	
were	 readily	 available	 to	 allow	 estimation	 of	 notification	 rates	 by	 census	
enumeration	 area	 (population	 size:	 134-4,360).7	 	 However,	 the	 census	 was	 last	
conducted	in	2008,	so	is	relatively	outdated.	Population	growth	estimates	applied	to	
the	data	provided	population	sizes	reflective	of	the	2015	population	to	estimate	more	
accurate	rates	of	disease.	It	could	be	expected	that	the	population	may	grow	faster	
in	high	density	areas	of	the	city,	therefore	rate	estimates	for	high	density	settlements	
using	 these	 denominators	 may	 be	 over-estimated.	 An	 enumeration	 study	 has	
recently	been	conducted	in	Blantyre	to	improve	these	estimates,	so	planned	future	
analyses	 will	 be	 conducted	 with	 these	 updated	 enumeration	 figures.	 Another	
limitation	was	the	lack	of	age	and	risk-factor	stratified	denominator	data,	limiting	the	
availability	of	denominators	for	analyses	of	these	sub	groups	for	clinical	trials.	
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Availability	of	denominator	data	could	potentially	be	a	limitation	for	use	of	ePAL	for	
trial	design	in	other	settings.	However,	most	settings	have	census	data	available,	or	
alternatively	 progress	 in	 the	 use	 of	 satellite	 imagery	 for	 population	 enumeration	
could	allow	the	high-resolution	satellite	maps	to	be	used	for	enumeration.21	
As	 mentioned	 in	 section	 5.5.3,	 ePAL	 would	 have	 limited	 utility	 in	 informing	
recruitment	 specifically	 of	 uninfected	 (pre-infection)	 or	 infected	 (post-infection)	
populations,	or	informing	design	of	prevention	of	infection	studies.	There	may	be	a	
role	for	ePAL	in	design	of	prevention	of	relapse	studies.	
As	ePAL	is	embedded	in	the	NTP,	this	tool	does	not	avoid	the	fundamental	limitation	
of	missed	burden	through	passive	case	finding.	From	the	perspective	of	designing	TB	
trials,	 this	would	 lead	 to	 conservative	 sample	 size	 estimates,	which	 unfortunately	
does	not	minimise	resource	use,	but	ensures	the	study	is	not	under-powered.	
5.6 ePAL	adaptations	for	other	research	studies	
ePAL	is	now	in	routine	use	at	the	Blantyre	research	site	as	an	integral	part	of	the	Hit	
TB	Hard	study,	and	several	other	research	studies.	
The	map	aspect	of	ePAL	has	been	adapted	for	compatibility	with	Open	Data	Kit	(ODK)	
for	use	in	a	pneumococcal	burden	of	disease	study	led	by	Todd	Swarthout.	With	this	
adaptation,	the	ePAL	annotated	maps	can	be	called	in	from	an	ODK	eCRF.	Similarly	to	
the	core	ePAL	app,	the	coordinates	of	the	location	selected	on	the	map	are	recorded	
in	the	study	database.	This	adaptation	has	the	advantage	of	CRF	adaptability	without	
the	need	for	support	from	app	developers.	However,	the	ODK	CRF	interface	is	not	as	
user-friendly	as	the	ePAL	CRF,	thus	it	is	suitable	for	use	by	experienced	research	staff,	
but	may	not	be	appropriate	for	integration	into	the	public	health	system.		
In	 a	 typhoid	 study	 led	 by	 Franziska	 Olgemoeller	 and	 Nick	 Feasey,	 ePAL	 has	 been	
adapted	 to	 collect	 multiple	 locations.	 This	 allows	 collection	 of	 both	 the	 place	 of	
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residence	and	key	water	sources,	used	for	following	up	patients	at	the	home,	and	
also	exploring	possible	sources	of	transmission.		
I	 am	currently	exploring	 the	potential	 use	of	 ePAL	 in	other	TB-	or	 vaccine-related	
projects	in	South	Africa	and	India.	
5.7 Conclusions	and	future	work	
The	ePAL	study	successfully	delivered	the	design,	implementation	and	evaluation	of	
a	 low-cost	 novel	 tool	 for	 clinic-based	 high-resolution	 mapping	 of	 the	 place	 of	
residence	of	TB	patients	in	Blantyre,	Malawi.	These	data	can	be	used	to	inform	design	
of	clinical	trials	for	new	tools	such	as	new	TB	vaccines.	The	data	generated	allows	for	
a	more	accurate	estimation	of	the	burden	of	disease	relevant	to	the	intended	trial	
outcomes	and	in	the	populations	of	interest	for	recruitment	in	to	TB	vaccine	clinical	
trials.	If	participants	are	recruited	at	a	location	other	than	their	place	of	residence,	
ePAL	would	provide	an	accurate	tool	for	identifying	place	of	residence	for	subsequent	
follow	up	visits.	
The	data	presented	here	establishes	the	spatial	accuracy	of	ePAL,	and	demonstrates	
examples	of	the	utility	of	such	data	to	inform	spatially	targeted	recruitment	in	to	TB	
vaccine	clinical	trials	and	appropriate	sample	size	calculations.	
A	wealth	of	data	has	been	generated	by	ePAL	in	Blantyre.	Therefore,	in	future	work	I	
plan	 to	 explore	 the	 dataset	 further	 to	 improve	 our	 understanding	 of	 the	 spatial	
distribution	of	TB	in	Blantyre	and	associated	risk	factors,	to	help	inform	current	public	
health	measures,	and	in	the	hope	of	informing	future	clinical	trials.	These	analyses	
will	include	exploring	risk	factor	data,	employing	the	new	enumeration	data	set	as	a	
denominator,	 and	 conducting	 observed	 versus	 expected	 analyses	 to	 identify	
statistically	significant	TB	hotspots.	 In	addition,	several	TB	vaccines	 in	 the	pipeline	
target	 paediatric	 populations;	 therefore,	 given	 paediatric	 ePAL	 data	 are	 now	
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available,	it	could	be	of	value	to	explore	the	rates	of	disease	in	children	in	Blantyre	to	
explore	suitability	for	paediatric	TB	vaccine	trials.	
It	is	also	hoped	that	ePAL	will	continue	to	be	employed	in	other	studies	in	Blantyre,	
and	I	am	currently	exploring	the	possibility	of	implementing	ePAL	in	studies	in	South	
Africa	and	India.	
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Summary	of	Chapter	6	
	
In	this	final	thesis	chapter,	I	provide	a	discussion	of	the	research	undertaken	in	this	
PhD	and	the	implications	of	the	results	for	the	TB	vaccine	development	community.	
The	chapter	summarises	 the	research	objectives	and	how	they	were	met,	 the	key	
findings	of	the	research,	the	strengths	and	limitations,	and	the	contribution	of	this	
thesis	to	advancing	knowledge	in	the	TB	vaccine	field.	I	place	these	findings	into	the	
context	 of	 existing	 research	 and	 the	 current	 TB	 vaccine	 pipeline.	 I	 provide	
recommendations	for	development	of	TB	vaccines	from	the	perspective	of	vaccine	
developers,	 clinical	 triallists,	 and	 country-level	 decision	makers.	 Opportunities	 for	
future	research	are	identified	and	discussed.	
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CHAPTER	6 Discussion	
6.1 Summary	of	the	PhD	Research	
New	TB	vaccines	are	urgently	needed	to	help	meet	the	WHO	goal	of	tuberculosis	(TB)	
elimination	 by	 2050.	 Epidemiological	 evidence	 to	 inform	 TB	 vaccine	 development	
strategies	and	to	assist	clinical	trial	site	selection	and	design	was	identified	as	a	critical	
research	need	to	accelerate	vaccine	development.	Existing	modelling	research	on	this	
subject	has	failed	to	fully	address	the	data	needs	for	developing	TB	vaccine	target	
product	 profiles	 (TPPs).	 Available	 data	 to	 inform	 clinical	 trial	 design	 often	 lacks	
granularity,	 and	 prospective	 data	 collection	 tends	 to	 be	 expensive	 and	 time	
consuming.	 Through	 the	 research	 presented	 in	 this	 thesis	 I	 aimed	 to	 inform	 the	
development	of	appropriate	TB	vaccines	and	target	populations	to	maximise	future	
population-level	impact,	and	help	selection	of	trial	sites	and	recruitment	populations	
to	 accelerate	 vaccine	 development.	 This	 was	 achieved,	 firstly,	 through	 the	
development	 of	mathematical	models	 to	 estimate	 the	 population-level	 impact	 of	
vaccines	with	varied	characteristics	and	implementation	strategies	to	inform	design	
of	TB	vaccine	target	product	profiles.	Secondly,	the	development	of	a	novel,	low	cost	
rapidly	implementable	tool	for	spatial	mapping	of	TB	cases	in	high	TB	burden	urban	
settings	to	accelerate	and	de-risk	clinical	trials.		
The	research	in	this	thesis	sought	to	fulfil	four	research	objectives.	These	objectives,	
and	how	they	were	fulfilled,	are	summarised	below.	
6.1.1 Objective	1	
The	first	objective	sought	to	a)	summarise	existing	literature	exploring	the	effect	of	
vaccine	characteristics	and	implementation	on	the	potential	epidemiological	impact	
of	 new	TB	 vaccines,	 and	b)	 identify	 research	needs	with	 respect	 to	mathematical	
modelling	of	possible	vaccine	characteristics	and	implementation	strategies	for	new	
TB	vaccines.	
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This	was	achieved	by	conducting	a	systematic	review	of	the	TB	vaccine	mathematical	
modelling	 literature	 exploring	 the	 epidemiological	 impact	 of	 new	 TB	 vaccines.	 A	
narrative	summary	of	the	literature	was	produced	and	research	needs	identified.	The	
most	urgent	research	needs	for	TB	vaccine	development	were	selected	for	exploring	
in	the	subsequent	modelling	research.	These	included	a	comprehensive	exploration	
of	the	impact	of	vaccine	characteristics,	modelling	the	impact	of	new	TB	vaccines	in	
China,	and	exploring	the	impact	of	vaccinating	older	adults	with	new	TB	vaccines.	
6.1.2 Objective	2	
The	second	objective	of	this	research	aimed	to	develop	a	mathematical	model	and	
calibrate	to	epidemiological	and	demographic	temporal	and	age	distribution	trends	
in	 China,	 and	 simulate	 the	 introduction	 of	 new	 TB	 vaccines	 to	 investigate	 the	
population-level	epidemiological	impact	of	varying	TB	vaccine	characteristics.	As	part	
of	this	work,	I	sought	to	identify	characteristics	that	could	help	maximise	population	
level	impact	in	this	setting	to	inform	TPP	‘ideal’	vaccine	characteristics.	Additionally,	
to	 identify	the	combination	of	vaccine	characteristics	 that	would	be	most	 likely	to	
deliver	pre-specified	minimum	incidence	rate	reductions	compared	to	 the	no	new	
vaccine	baseline	in	2050.	These	results	would	be	used	to	help	inform	minimum	TPP	
characteristics.	
This	objective	was	achieved	through	the	development	of	an	age-structured	and	age-
calibrated	 transmission	 model	 of	 TB	 epidemiology	 in	 China,	 followed	 by	 the	
incorporation	of	new	TB	vaccines	to	explore	the	epidemiological	impact	of	different	
combinations	 of	 efficacy	 against	 infection	 and	 disease,	 pre-	 versus	 post-infection	
vaccines,	 and	 varied	 durations	 of	 protection	 and	 frequencies	 of	mass	 vaccination	
campaigns.	Population-level	impact	of	these	vaccines	implemented	over	2025-50	was	
estimated,	 and	 proposals	 for	 TPP	 vaccine	 characteristics	 to	 achieve	 a	 minimum	
population	level	impact	were	made.	
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6.1.3 Objective	3	
Objective	 1	 identified	 a	 research	 need	 to	 explore	 the	 epidemiological	 impact	 of	
vaccinating	older	adults.	Therefore,	objective	3	aimed	to	 investigate	the	 impact	of	
age-targeted	programmes	vaccinating	adolescents	versus	older	adults	on	population-
level	TB	epidemiology	in	China.	
This	was	achieved	by	adapting	the	age-structured	model	developed	in	objective	2	to	
explore	age-targeted	vaccination.	A	range	of	vaccine	types	were	modelled	to	explore	
variation	in	the	relative	impact	of	new	TB	vaccines	by	age	of	vaccination.	
6.1.4 Objective	4	
To	support	the	translation	of	TB	vaccine	TPPs	into	clinical	trials,	objective	4	sought	to	
develop	a	low	cost,	rapidly	implementable	and	easy	to	use	tool	for	spatial	mapping	
of	TB	in	high	burden	urban	settings	without	municipal	address	systems.	Such	a	tool	
could	be	used	to	identify	areas	of	high	burden	in	populations	potentially	relevant	for	
TB	vaccine	trial	recruitment.	
This	was	achieved	 through	 the	development,	 implementation	and	evaluation	of	 a	
novel	 app	 (ePAL)	 integrated	 in	 to	 the	 NTP	 in	 Blantyre,	 Malawi,	 for	 clinic-based	
identification	 of	 place	 of	 residence	 of	 patients	 registering	 for	 TB	 care.	Using	 data	
collected	 with	 ePAL,	 spatial	 maps	 with	 examples	 of	 outcomes	 and	 participant	
characteristics	relevant	to	TB	vaccine	trials	were	generated.	
6.2 Summary	of	findings		
6.2.1 Mathematical	modelling	to	inform	TPP	design	
The	main	 findings	with	 regards	 to	 informing	 TB	 vaccine	 TPPs	 are	 summarised	 by	
vaccine	characteristic	below.		
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Prevention	of	infection	versus	disease:	
- In	 China,	 efficacy	 for	 prevention	of	 disease	was	 key	 to	maximising	 impact	 on	
disease	burden	with	new	TB	vaccines	over	the	2025-50	time	horizon.		
- Incidence	rate	reduction	in	2050	was	relatively	insensitive	to	changes	in	efficacy	
for	prevention	of	infection.	
	
Pre-	versus	post-infection	vaccines:	
- With	adolescent/adult	vaccination	(i.e.	routine	vaccination	of	9	year	olds	plus	10-
yearly	mass	campaigns	of	³10	year	olds)	and	with	older	adult	vaccination	(i.e.	
routine	vaccination	of	60	year	olds	and	a	one-off	mass	campaign	of	61-64	year	
olds),	greatest	epidemiological	impact	was	achieved	with	vaccines	effective	post-
infection	or	pre-	and	post-infection	(P&PI).	
- When	effective	P&PI	or	post-infection,	overall	efficacy	was	mostly	dependent	on	
efficacy	against	disease.	For	pre-infection	vaccines,	the	epidemiological	impact	
was	dependent	on	both	efficacy	against	infection	and	efficacy	against	disease.		
- The	relative	impact	of	pre-	versus	post-infection	vaccines	varied	by	age	targeted	
vaccination.	Targeted	vaccination	of	adolescents	(15	year	olds)	achieved	greater	
impact	with	pre-infection	vaccines,	whereas	older	adult	vaccination	was	more	
effective	 with	 post-infection	 vaccines.	 However,	 when	 comparing	 identical	
vaccines,	 older	 adult	 vaccination	 provided	 consistently	 greater	 impact,	 so	 to	
maximise	 population-level	 impact,	 a	 post-infection	 vaccine	 delivered	 to	 older	
adults	is	required.		
	
Duration	of	protection:		
- With	routine	vaccination	of	9	year	olds	and	10-yearly	mass	campaigns	in	China,	
a	vaccine	with	at	least	5	years	protection	would	be	required	to	achieve	at	least	
20-29%	 incidence	 rate	 reduction	 in	 2050	 compared	 to	 the	 no	 new	 vaccine	
scenario.	If	at	least	50-59%	incidence	rate	reduction	were	required,	a	duration	of	
at	least	7	years	would	be	needed	with	10-yearly	campaigns.		
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- Shorter	 durations	 of	 protection	 could	 be	 compensated	 for	 by	 increasing	 the	
frequency	of	mass	campaigns	(e.g.	5-yearly).	
- Even	 high	 efficacy	 vaccines	 would	 have	 limited	 impact	 without	 sufficient	
duration	of	protection	or	frequent	mass	vaccination	campaigns.	
	
Vaccine	efficacy:	
- In	 China,	 to	 achieve	 20-29%	 incidence	 rate	 reduction	 in	 2050	 with	 5	 years	
duration	 of	 protection	 and	 10-yearly	 mass	 campaigns,	 the	 required	 median	
vaccine	efficacies	were:	prevention	of	disease	(VE-POD)	40%	(range:	0-60%)	and	
prevention	 of	 infection	 (VE-POI)	 60%	 (range:	 0-100%).	 To	 achieve	 50-59%	
incidence	rate	reduction	in	2050,	the	VE-POI	would	be	unchanged,	but	the	VE-
POD	would	need	to	increase	to	100%	(100-100%).	Ranges	are	wide	because	the	
POD	and	POI	efficacies	to	provide	a	given	level	of	impact	are	correlated,	e.g.	for	
20-29%	incidence	rate	reduction,	if	VE-POD=0%,	a	VE-POI	of	90-100%	would	be	
required;	or	if	VE-POI=0%,	VE-POD	of	40-60%	would	be	required.	
- When	results	of	vaccine	efficacy	studies	become	available,	heatmaps	in	Chapter	
3	can	provide	an	estimate	of	the	potential	impact	of	that	vaccine.	
	
Age-targeted	vaccination:	
- With	equivalent	vaccines,	older	adult	vaccination	delivered	greater	impact	than	
adolescent	 vaccination,	 even	 if	much	 lower	 coverage	were	 achieved	 in	 older	
adult	vaccination.	
- Post-infection	 vaccines	 provided	 substantial	 impact	 when	 delivered	 to	 older	
adults,	 whereas	 impact	 was	 negligible	 when	 this	 vaccine	 was	 delivered	 to	
adolescents.	Although	pre-infection	vaccines	provided	relatively	similar	levels	of	
impact	when	vaccinating	either	age	group,	the	 impact	was	substantially	 lower	
than	 that	 achievable	 with	 vaccination	 of	 older	 adults	 with	 a	 post-infection	
vaccine.	
- Recommendations	 for	 post-infection	 vaccines	 were	 robust	 to	 substantial	
reductions	in	efficacy	and	duration	of	protection	in	older	adults,	whereas	for	pre-
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infection	 vaccines	 the	 preference	 for	 older	 adult	 vaccination	 could	 be	
diminished.	
- In	 this	 setting,	 a	 vaccine	 efficacious	 post-infection	 or	 pre-	 and	 post-infection	
delivered	to	older	adults	will	be	critical	to	maximise	population-level	impact.	
	
Maximum	achievable	impact:		
- With	 the	 adolescent/adult	 delivery	 strategy,	 the	maximum	possible	 incidence	
rate	reduction	in	2050	was	79%	(UR:	77%-81%)	reducing	incidence	to	7	(UR:	6-8)	
cases	per	100,000	population.	This	was	achieved	with	100%	protection	against	
infection	 and	 disease	 effective	 both	 pre-	 and	 post-infection	 and	 10	 years	
duration	of	protection.	This	averted	11.6	million	TB	cases	 (UR:	10.2-12.6)	and	
270,000	TB	deaths	(UR:	145,000-483,000)	over	2025-2050.	
- With	the	slightly	more	limited	profiles	explored	in	the	age	targeting	modelling,	
the	highest	 impact	vaccine	(80%	VE,	20	years	duration,	no	mass	revaccination	
campaign,	P&PI)	averted	502,000	(UR:	431,000-591,000)	cases	when	delivered	
to	 adolescents,	 or	 3.0	 million	 (UR:	 2.5-3.5m)	 cases	 through	 older	 adult	
vaccination	campaigns.		
- The	 estimated	 impact	 of	 routine	 age-targeted	 vaccination	was	 less	 than	 that	
achieved	by	broad	mass	vaccination.	However,	if	resources	are	limited,	targeted	
vaccination	of	older	adults	may	help	maximise	the	achievable	impact.	
	
6.2.2 Development	of	a	spatial	mapping	tool	to	inform	clinical	trial	design	
The	 ePAL	 study	 developed,	 implemented	 and	 evaluated	 a	 new	 tool	 for	 spatial	
mapping	of	TB	patients	registering	at	TB	clinics	in	Blantyre,	Malawi.	Data	generated	
were	used	to	explore	notification	rates	and	hotspots	of	trial-relevant	populations.	
- A	low	cost,	easy	to	use	app	for	real-time	collection	of	high-resolution	spatial	data,	
was	integrated	in	to	routine	TB	registration.		
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- 1,899	TB	patients	were	registered	using	ePAL	in	the	12-month	study	period,	with	
high	patient	acceptance	(98.7%).		
- ePAL	achieved	clinic-based	collection	of	patient	location	of	residence	accurate	to	
a	median	of	84m	(IQR:	35m-317m)	 in	a	high	population	density	urban	setting	
without	a	municipal	address	system.		
- Data	were	used	to	identify	areas	with	high	TB	burden	potentially	suitable	for	TB	
vaccine	 trials.	To	align	with	a	potential	 trial	population,	HIV-negative	Blantyre	
city	residents	with	microbiologically	confirmed	pulmonary	disease	were	mapped	
and	compared	to	the	full	data	set.	Rates	were	substantially	lower	than	the	full	
data	set,	and	some	differences	were	observed	in	the	spatial	distribution	of	cases,	
demonstrating	the	importance	of	these	data	for	 informing	clinical	trial	sample	
size	estimations	and	targeted	recruitment.	
	
6.3 Strengths	and	limitations	of	this	research	
Strengths	and	limitations	of	the	work	are	discussed	in	detail	in	each	chapter.	Below	
is	a	summary	of	some	of	the	key	strengths	and	weaknesses	of	the	work	in	this	thesis.	
6.3.1 Strengths	
6.3.1.1 Systematic	review	
The	 systematic	 review	 publication	 included	 in	 Chapter	 2	 is	 the	 first	 and	 only	
publication	 in	 the	 literature	 to	 bring	 together	 the	 available	 literature	 on	
mathematical	 modelling	 of	 the	 epidemiological	 impact	 of	 new	 TB	 vaccines.	 This	
research	provides	 a	 comprehensive	 summary	of	 the	 available	 literature,	 and	 is	 of	
significance	for	informing	TB	vaccine	development	as	it	provides	summaries	of	the	
research	available	to	inform	several	key	aspects	of	TB	vaccine	TPPs.	The	article	also	
highlights	 many	 important	 research	 gaps	 in	 the	 literature	 to	 help	 guide	 future	
modelling	to	meet	the	most	urgent	research	needs.	
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6.3.1.2 Mathematical	modelling	
In	 the	 mathematical	 modelling	 research	 in	 this	 thesis,	 I	 developed	 a	 highly	 age-
stratified	 and	 calibrated	 model	 with	 age-specific	 natural	 history	 parameters	 and	
social	contact	patterns.	At	time	of	development,	this	was	the	first	TB	vaccine	model	
to	account	for	heterogeneous	social	mixing	patterns	by	age.	All	previous	TB	vaccine	
models	had	assumed	contact	rates	between	age	groups	were	equivalent,	whereas	in	
this	model	I	incorporated	data-informed	contact	patterns	from	a	study	conducted	in	
China.	Since	development	of	this	model,	one	other	TB	vaccine	modelling	study	has	
incorporated	social	 contact	patterns.1	This	 study	confirmed	the	 importance	of	 the	
inclusion	of	social	contact	patterns	and	age	stratification	in	TB	transmission	models,	
and	demonstrated	this	in	the	context	of	TB	vaccines,	which	validates	the	decisions	
made	 in	 my	 research	 to	 create	 such	 a	 highly	 age-stratified	 model	 incorporating	
heterogeneous	 mixing.	 The	 Arregui	 publication	 is	 a	 top-level	 assessment	 of	 the	
impact	 of	 a	 single	 vaccine	 type	 at	 the	 regional	 level,	 and	 uses	 European	 mixing	
patterns	scaled	to	regional	demographics	to	inform	social	mixing.1	My	research	takes	
this	a	step	further,	modelling	a	comprehensive	range	of	vaccine	characteristics	at	the	
country	 level,	 parameterising	 with	 a	 country-specific	 contact	 matrix.	 The	 use	 of	
country	 specific	 data	was	 considered	 important,	 as	 this	 accounts	 not	 just	 for	 the	
impact	of	demographics	on	contact	patterns,	but	also	includes	any	social	influences	
on	contact	patterns.	
This	 research	 was	 the	 first	 to	 explore	 the	 potential	 impact	 of	 new	 TB	 vaccines	
targeted	to	older	age	groups,	and	to	provide	a	comparison	of	this	approach	to	the	
current	 strategic	 focus	 on	 adolescent	 vaccination.	 This	 required	 the	 age-specific	
model	parameterisation	and	calibration	mentioned	above,	and	is	the	first	China	TB	
model	 to	 include	 calibration	 to	 age-stratified	mortality	 and	notification	 rates.	 The	
results	 of	 this	 work	 were	 consistent	 with	 previous	 literature,	 and	 strengthen	 the	
recommendation	that	vaccines	effective	post-infection	will	be	needed	in	this	setting.	
Previous	modelling	research	has	focussed	on	infant	or	adolescent	vaccination,	and	
mostly	recommend	vaccination	in	adolescents	or	adults.	Whereas	in	this	research	we	
develop	the	argument	for	vaccinating	adults	further	by	demonstrating	that	in	ageing	
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epidemics,	 most	 impact	 could	 be	 achieved	 by	 targeting	 older	 adults,	 potentially	
minimising	the	resources	required	per	case	averted.	
This	is	the	first	study	to	provide	an	in-depth	exploration	of	the	impact	of	such	a	wide	
range	of	vaccine	efficacies,	durations	of	protection,	and	vaccination	populations	(pre-	
and	 post-infection).	 Such	 a	 comprehensive	 exploration	 of	 vaccine	 characteristics	
provides	a	detailed	analysis	of	the	impact	individually	and	in	tandem	of	the	different	
characteristics,	 and	 also	 ensures	 that	 once	 trial	 results	 become	 available	 that	
modelling	results	are	available	for	the	relevant	characteristics.	
This	modelling	has	been	developed	in	the	context	of	only	two	other	China	TB	vaccine	
modelling	 studies,	 one	 of	 which	was	 only	 published	 in	 2017.2,3	 	 Neither	 of	 these	
existing	 publications	 accounted	 for	 age	 specificities	 in	 epidemiology	 or	
demographics.	Further,	in	these	studies,	vaccination	was	either	at	birth	or	all-ages,	
and	vaccine	characteristics	modelled	were	unclear	or	unrealistic	(e.g.	100%	vaccine	
efficacy).	 Therefore,	 this	was	 the	 first	 study	 to	 employ	 a	model	 calibrated	 to	 age	
stratified	demographic	and	epidemiological	data	to	explore	the	impact	of	TB	vaccines	
and	age	targeted	TB	vaccination.	
6.3.1.3 ePAL	app	
The	ePAL	app	is	the	first	of	its	kind	to	allow	accurate	clinic-based	collection	of	place	
of	residence	as	part	of	routine	NTP	care	and	without	the	need	for	home	visits.	The	
tool	was	developed	 in	the	context	of	a	clear	need	for	new,	rapidly	 implementable	
methodology	for	assessing	suitability	of	trial	sites	 for	TB	vaccine	clinical	 trials,	and	
ensuring	that	local	data	relevant	to	the	populations	and	outcomes	of	interest	for	the	
trial	are	used	for	design	of	the	sample	size	and	recruitment	strategy.	Other	options	
for	 collection	 of	 such	 data	 either	 lack	 the	 appropriate	 granularity	 or	 come	 at	
substantial	cost	both	financially	and	time.	
Strengths	of	ePAL	for	collection	of	spatial	data	include	its	accuracy,	ease	of	use,	low	
cost,	integration	into	routine	NTP	data	collection	with	QAQC	processes	in	place,	real	
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time	data	accessible	via	a	web	interface,	and	ability	to	function	offline	with	infrequent	
access	to	mobile	data	and	electricity.	
A	key	strength	of	the	app	was	tailoring	of	content	and	the	user	experience	through	
stakeholder	involvement:	for	example,	community	engagement	for	identification	of	
locally-relevant	 POIs	 in	 the	 initial	 development,	 and	 ongoing	 feedback	 and	
improvement	of	the	app	and	data	collection	through	regular	meetings	with	the	TB	
officers.	 This	may	have	also	 contributed	 to	 the	 very	high	participation	 rate	 in	 the	
study.	The	app	interface	and	training	were	designed	for	ease	of	use	by	 individuals	
without	experience	of	electronic	data	collection.	Error	rates	were	low	for	single-entry	
electronic	data	capture.	ePAL-based	data	collection	was	successfully	incorporated	in	
to	the	National	Tuberculosis	Programme	through	this	integration	in	to	routine	patient	
registration.	ePAL	is	an	easy	to	use	tool,	with	NTP	staff	able	to	easily	and	effectively	
use	the	ePAL	app	after	one	day	of	training.	
ePAL	 development	 and	 implementation	 was	 rapid,	 with	 POI	 collection	 for	 local	
adaptation	 of	 the	 app,	 training	 of	 data	 collectors,	 implementation,	 and	 a	 run-in	
period	for	refining	the	app	and	field	usage	achieved	in	less	than	five	months.	With	
lessons	learned	from	this	study,	future	sites	 implementing	ePAL	could	achieve	this	
even	 faster.	 ePAL	 implementation	and	evaluation	were	also	achieved	at	 low	cost,	
thanks	to	use	of	relatively	inexpensive	technology,	and	the	need	for	minimal	full-time	
study	staff.	To	employ	the	data	to	rapidly	inform	trial	design,	the	generation	of	data	
in	real	time	will	be	beneficial,	and	data	can	be	monitored	remotely	in	real-time	via	
the	web	interface.	 	
6.3.2 Limitations	of	this	work	
6.3.2.1 Systematic	review	
The	main	 limitation	of	 the	systematic	 review	was	 the	single-reviewer	approach	 to	
literature	sifting.	Risks	from	this	approach	were	minimised	as	the	sifting	was	repeated	
in	 order	 to	 update	 the	 review,	 therefore	 effectively	 double	 sifting	 by	 a	 single	
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reviewer.	In	addition,	a	low	threshold	was	employed	for	checking	sifting	queries	with	
a	second	reviewer.	
Secondly,	although	an	adapted	quality	scoring	tool	was	developed	specifically	for	this	
study,	the	tool	was	not	well	suited	to	assessing	analytic	models.	
6.3.2.2 Mathematical	modelling		
Limitations	 in	 the	 TB	 vaccine	models	 developed	 can	 be	 considered	 as	 structural,	
assumption,	calibration	or	outcome	limitations.	
Structural	limitations	in	the	model	included	the	method	of	modelling	reinfection	of	
recovered	populations,	and	of	case	detection.		
In	this	model,	recovered	populations	experiencing	reinfection	that	does	not	progress	
directly	to	disease	transitioned	to	the	latent	state	to	become	“slow	progressors”.	This	
was	likely	an	underestimate	of	their	risk	of	progression,	and	could	be	improved	by	
retaining	 reinfected	 recovered	 populations	 in	 the	 recovered	 state.	 Such	 a	 change	
would	not	have	an	effect	on	the	direction	of	impact	or	conclusions	of	this	research.	
It	would	be	anticipated	to	marginally	increase	the	number	and	proportion	of	cases	
arising	 from	 the	 recovered	population	and	would	 likely	 strengthen	 the	conclusion	
that	 older	 adult	 vaccination	 with	 post-infection	 vaccines	 would	 provide	 greater	
impact	than	adolescent	vaccination.	
In	terms	of	case	detection,	the	model	is	structured	such	that	a	proportion	of	incident	
cases	are	detected,	parameterised	to	align	with	WHO-reported	case	detection	ratio	
data.	Those	who	are	not	detected	enter	the	prevalent	pool	and	can	only	exit	via	TB	
death,	 death	 from	 other	 causes,	 or	 natural	 cure.	 A	 more	 realistic	 approach	 to	
modelling	 case	 detection	would	most	 likely	 be	 to	 reduce	 case	 detection	 of	 those	
entering	the	prevalent	state,	and	allow	care	seeking	with	worsening	symptoms	in	the	
prevalent	state.	Data	are	not	readily	available	to	parameterise	the	model	according	
to	those	detected	within	6	months	of	symptoms	and	those	detected	later.	However,	
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if	 such	 data	 were	 available,	 the	 model	 could	 be	 re-structured	 to	 allow	 a	 certain	
proportion	of	case	detection	to	occur	within	6	months	of	onset,	and	the	remainder	
to	 occur	 over	 time,	with	 the	 rate	 of	 detection	 linked	 to	 disease	 progression.	 This	
would	be	achieved	by	developing	a	series	of	disease	states	representing	progression	
of	untreated	disease,	and	each	state	would	be	associated	with	a	case	detection	ratio.	
However,	 as	mentioned	above,	data	are	not	available	 to	parameterise	 this	model	
structure.	
Assumption	limitations	included	the	assumptions	around	the	future	of	existing	and	
new	control	measures,	natural	history	parameters	and	immunosenescence	in	elderly	
populations,	 unchanging	 contact	 patterns	 over	 time	 and	 feasibility	 of	 vaccination	
campaigns.	
In	the	model,	it	was	assumed	that	no	new	interventions	would	be	developed	over	the	
time	frame	of	this	model.	The	development	landscape	for	drugs	and	diagnostics	 is	
progressing,	 but	 was	 considered	 too	 uncertain	 to	 be	 able	 to	 include	 other	 new	
interventions	 in	 this	 research.	 The	 introduction	of	new	diagnostics	 and	 treatment	
regimens	could	potentially	alter	the	course	of	the	epidemic.	If	this	were	to	occur,	the	
estimations	 of	 absolute	 impact	 of	 new	 TB	 vaccines	 could	 potentially	 be	 an	
overestimate.	 The	 relative	 impact	 of	 the	 different	 vaccine	 types	 would	 not	 be	
anticipated	to	be	affected.	Perhaps	with	the	exception	of	a	highly	safe	and	effective	
treatment	for	clearance	of	latent	infection,	which	if	safe	in	the	elderly	could	impact	
the	 relative	 impact	 of	 the	 different	 vaccine	 types.	 Due	 to	 high	 current	 treatment	
success	and	case	detection	estimates	 in	China,	 these	were	assumed	 to	plateau.	 If	
improvements	 in	 current	 care	 measures	 were	 achieved,	 the	 impact	 achieved	 by	
vaccines	could	potentially	be	reduced.	However,	 this	would	not	affect	conclusions	
with	respect	to	age	targeting	unless	such	an	intervention	varied	in	effectiveness	by	
age.	
There	is	a	notable	data	gap	with	regards	to	elderly	TB	natural	history	parameters.	We	
represented	 this	 uncertainty	 by	 sampling	 from	 elderly	 parameter	 priors	 spanning	
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HIV-negative	and	HIV-positive	adult	ranges	in	the	calibration	process.	The	extreme	
end	 of	 the	 HIV	 ranges	 may	 not	 be	 reflective	 of	 immunesenescence,	 but	 fitting	
methods	 allowed	 sampling	 from	 this	 range	 to	 allow	 for	 the	 potential	 impact	 of	
immunosenescence.	 Immunosenescent	 waning	 of	 vaccine	 efficacy	 was	 also	 an	
unknown,	so	was	assumed	2%	per	year	waning	in	the	elderly	population	in	the	main	
analysis,	 and	 explored	 up	 to	 5%	 in	 sensitivity	 analyses.	 Results	 were	 robust	 to	
immunosenecent	sensitivity	analyses.	
Given	population	ageing,	the	assumption	that	the	contact	matrix	remained	constant	
throughout	 the	 study	 period	 may	 provide	 conservative	 impact	 estimates.	 Larger	
older	adult	and	elderly	populations	in	the	future	could	increase	the	transmission	from	
these	age	groups.	This	could	be	modelled	in	future	sensitivity	analyses,	though	could	
only	 account	 for	 demographic	 changes,	 changes	 caused	 by	 societal	 differences	
cannot	be	predicted. 
The	vaccination	 campaigns	modelled	were	 considered	 feasible	based	upon	expert	
opinion	 and	 implementation	 of	 other	 vaccines	 in	 China	 and	 elsewhere.	 In	 reality,	
success	of	campaigns	will	be	reliant	on	the	vaccine	developed,	the	prioritisation	of	TB	
as	 a	 public	 health	 problem,	 and	 the	 availability	 of	 facilities	 or	 funding	 to	 develop	
facilities	 for	 the	 large-scale	 manufacture	 of	 TB	 vaccines.	 At	 the	 global	 level,	
adolescent	 and	 adult	 vaccination	 with	 just	 20%	 coverage	 has	 been	 estimated	 to	
require	 seven	 dedicated	 manufacturers,4	 therefore	 the	 70%	 coverage	 mass	
campaigns	modelled	here	may	be	feasible	for	a	country	with	as	much	manufacturing	
capacity	as	China,5	but	may	not	be	feasible	from	a	global	perspective.	This	research	
does	 not	 explore	 all	 possible	 routine	 vaccination	 ages	 as	 those	 modelled	 were	
considered	appropriate	given	the	anticipated	future	epidemiology	and	the	existence	
of	platforms	for	vaccine	delivery.	Once	a	vaccine	is	available	and	the	characteristics	
are	known,	modelling	could	be	used	to	further	optimise	the	older	adult	vaccination	
age,	and	explore	different	mass	campaign	options. 
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Calibration	 limitations	 included	 the	 lack	of	 data	 to	 separately	 calibrate	 latent	 and	
recovered	populations,	and	the	challenge	of	calibrating	to	the	low	TB	mortality	rates	
in	China.	
It	was	found	in	the	calibration	process	that	the	rates	of	reactivation	from	latency	or	
after	recovery	from	disease	were	inversely	associated	and	mutually	compensatory.	
These	 two	 populations	 were	 the	 main	 contributors	 to	 development	 of	 disease;	
therefore,	this	inverse	relationship	was	a	function	of	calibration	to	incident	disease	
data.	Unfortunately,	incidence	data	stratified	by	latent	and	recovered	populations	do	
not	exist	to	allow	independent	calibration	for	these	two	populations.	Fitting	to	new	
versus	 previously	 treated	 TB	 notification	 data	was	 considered,	 but	 the	 data	were	
considered	 not	 directly	 reflective	 of	 the	 modelled	 population,	 and	 have	 several	
inherent	biases.		
The	empirically	derived	case	fatality	rate	(CFR)	was	particularly	low	in	China	relative	
to	historic	evidence	on	CFRs	in	untreated	populations,6	therefore	model	calibration	
employed	a	calibration	factor	to	scale	down	the	case	fatality	rate	to	align	with	the	
data.	As	with	other	modelling	exercises,7	it	was	assumed	that	good	access	to	TB	care	
through	CDC	facilities	led	to	low	case	fatality	in	China.		
The	main	outcome	limitation	was	the	time	horizon	of	the	model,	as	this	may	influence	
the	 relative	 impact	 of	 vaccine	 types.	 Pre-infection	 vaccines,	 for	 example,	 tend	 to	
perform	better	over	longer	time	horizons.8	However,	beyond	2050	there	would	be	
too	much	uncertainty	in	the	model.	Full	benefit	of	vaccines	delivered	pre-2050	would	
extend	 beyond	 2050,	 therefore	 relative	 vaccine	 impact	 may	 change	 over	 longer	
horizons.8	 Results	 presented	 from	 the	models	 were	 specific	 to	 the	 2025-50	 time	
horizon.	
The	results	presented	in	the	thesis	are	representative	of	the	Chinese	epidemic,	which	
is	 an	 epidemic	 driven	 by	 reactivation	 disease	 in	 an	 ageing	 population	 that	 has	
experienced	high	historical	exposure.	It	should	be	noted	that	the	relative	impact	of	
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different	characteristics	is	likely	to	differ	in	other	epidemiological	scenarios,	and	will	
be	investigated	in	the	continuation	of	this	work	exploring	vaccine	impact	in	India	and	
South	Africa.	
	
6.3.2.3 ePAL	app	
Study	 limitations	 included	 challenges	 associated	 with	 home	 visits	 for	 evaluation	
measurements,	initial	case	capture,	and	the	resultant	missing	data.		
The	main	limitation	was	the	difficulty	of	conducting	home	visits	in	high	density	urban	
areas.	These	were	conducted	by	contacting	the	participant	to	arrange	a	home	visit	
and	following	verbal	descriptions	given	by	the	patient	either	to	the	study	staff	or	TB	
officers.	This	was	standard	practice	before	ePAL	but	poses	challenges	for	achieving	
follow	 up	 visits.	 Use	 of	 ePAL	 coordinates	 was	 avoided	 to	 prevent	 observer	 bias.		
Tracking	down	the	correct	households	proved	very	time-consuming,	leading	to	some	
long	delays	between	registration	and	the	home	visit.	While	this	highlights	the	need	
for	 alternatives	 such	 as	 ePAL,	 and	 analyses	 indicated	 no	 significant	 bias	 in	 ePAL	
accuracy	with	 delayed	 follow	up,	 it	 is	 possible	 that	 incomplete	 capture	may	have	
biased	 our	 estimates	 of	 ePAL	 accuracy	 if,	 for	 instance,	 deliberately	 incorrect	
information	 had	 been	 provided	 or	 patients	 living	 in	 more	 distant	 locations	 were	
harder	to	track	down	for	follow	up	visits.		
Fourteen	 percent	 of	 evaluation	 visits	 were	 >1km	 from	 the	 place	 of	 residence	
registered	in	ePAL.	Analyses	suggest	this	may	be	associated	with	factors	relevant	to	
job	 insecurity/mobility	 or	 concerns	 regarding	 TB/HIV	 stigma.	 Informal	 feedback	
suggested	that	some	of	the	distant	patients	relocated	between	ePAL	collection	and	
follow	up,	due	to	staying	with	relatives	during	treatment	or	the	severe	flooding	 in	
early	2015.	More	systematic	qualitative	interviews	could	help	understand	the	issues	
underlying	large	distance	errors,	and	to	identify	potential	solutions	for	minimisation	
of	 this	 issue.	 Shortening	 the	 time	 between	 registration	 and	 follow	 up	 could	 help	
reduce	 the	number	 relocating,	but	 given	 relocation	or	multiple	 addresses	may	be	
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pertinent	 information	 for	 mapping	 and	 for	 patient	 follow	 up,	 the	 option	 for	
identifying	multiple	residencies	could	be	a	helpful	addition	to	the	ePAL	app.	
Case	capture	was	low	early	in	the	study	due	to	insufficient	resources	at	the	central	
hospital,	but	dramatically	improved	after	addition	of	a	staff	member	and	a	second	
data	collection	tablet.	
For	the	GPS	coordinates	measured	at	the	participant’s	home,	it	should	be	noted	that	
even	with	taking	averaged	waypoints	an	inherent	inaccuracy	of	several	metres	still	
exists.	In	addition,	poor	weather	conditions	and	satellite	signal	blocking	by	proximity	
to	buildings	in	high-density	areas	are	likely	to	have	affected	measurement	accuracy	
in	this	setting.	Therefore,	several	metres	of	unavoidable	‘inaccuracy’	will	have	been	
systematically	introduced,	even	if	the	correct	building	were	selected.		
	
6.4 Contribution	of	the	thesis	to	advancing	knowledge	in	TB	vaccine	
development		
Epidemiological	evidence	was	identified	by	the	TB	vaccine	development	community	
as	a	critical	research	need	for	advancing	the	development	of	new	TB	vaccines.9	This	
encompassed	two	main	areas	of	research:	1)	the	need	for	data-driven	identification	
of	vaccine	characteristics	and	target	populations	for	vaccination	that	could	achieve	
the	 greatest	 reduction	 in	 disease	 burden,	 and	 2)	 a	 better	 understanding	 of	 local	
epidemiology	 to	 inform	 the	 selection	 of	 trial	 sites,	 recruitment	 populations	 and	
design	clinical	trials.		
The	 existing	mathematical	modelling	 evidence	 to	 inform	 TB	 vaccine	 development	
strategy	 had	 not	 previously	 been	 summarised.	 To	 identify	 available	 literature	 for	
informing	the	first	research	need,	in	the	first	section	of	this	thesis	I	conducted	the	
first	 ever	 systematic	 review	 of	 the	 available	 mathematical	 modelling	 literature	
exploring	 the	epidemiological	 impact	of	new	TB	vaccines.	This	 review	provides	TB	
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vaccine	 developers	 a	 comprehensive	 summary	 of	 the	 range	 of	 available	
epidemiological	modelling	data	to	inform	vaccine	development	decisions.	This	review	
identified	several	substantial	research	gaps	for	 informing	TB	vaccine	development.	
These	 included	 the	 impact	 of	 prevention	 of	 infection	 and	 disease	 efficacy	
combinations,	 the	 division	 in	 the	 literature	 as	 to	 the	 impact	 of	 pre-	 versus	 post-
infection	 vaccines,	 the	 impact	 of	 varying	duration	of	 protection,	 the	dearth	of	 TB	
vaccine	modelling	literature	for	China,	and	the	impact	of	vaccinating	older	adults.		
Understanding	the	relative	impact	of	vaccine	characteristics	and	implementation	is	
central	 to	 data-driven	 decision	making	when	 designing	 TB	 vaccine	 target	 product	
profiles.	The	research	presented	in	the	second	section	of	the	thesis	(Chapter	3	and	4)	
provides	a	comprehensive	exploration	of	the	impact	of	new	TB	vaccine	characteristics	
and	a	comparison	of	adolescent	versus	older	adult	age	targeting	of	new	vaccines	in	
China.	 Target	 product	 profiles	 currently	 under	 development	 lacked	 the	modelling	
data	 needed	 to	 inform	 the	 ideal	 and	 minimum	 vaccine	 characteristics,	 thus	 the	
comprehensive	exploration	of	vaccine	characteristics	in	the	research	presented	can	
inform	these	characteristics.	In	particular,	the	results	highlighted	the	importance	of	
prevention	 of	 disease	 vaccines	 effective	 in	 populations	 latently	 infected	 and	
recovered	 from	disease,	which	has	direct	 implications	 for	 clinical	 trial	 design.	 The	
results	highlighted	the	need	for	duration	of	protection	of	at	 least	5	years	with	10-
yearly	mass	adult	vaccination	campaigns,	suggesting	longer	durations	of	trial	follow	
up,	 or	 for	 planning	 for	more	 frequent	mass	 adult	 vaccination	 campaigns,	 will	 be	
required.	
Older	adults	and	the	elderly	were	previously	excluded	from	most	clinical	trials,	and	
the	impact	of	older	adult	vaccination	with	new	TB	vaccines	had	never	been	explored	
in	 the	 literature.	 The	 age	 targeted	 vaccination	 modelling	 results	 informed	 the	
inclusion	of	the	elderly	population	in	the	Gates	TB	vaccine	strategy	as	a	secondary	
population	of	interest.10	
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The	results	of	this	research	can	directly	inform	the	characteristics	detailed	in	target	
product	profiles,	clinical	trial	outcomes	and	recruitment	populations	for	vaccines	with	
planned	use	in	China	and	epidemiologically	similar	settings,	to	ensure	that	vaccines	
are	developed	for	and	delivered	to	populations	that	could	maximise	population-level	
impact	of	new	TB	vaccines.	
Modelling	demonstrated	the	importance	of	disease	outcomes	in	TB	vaccine	clinical	
trials.	 Poor	 availability	 of	 epidemiological	 data	 in	 clinical	 trial	 sites	 limits	 data-
informed	 design	 of	 prevention	 of	 disease	 efficacy	 studies.	 It	 is	 hoped	 that	 data	
generated	by	the	ePAL	app	will	assist	site	selection	and	trial	design	for	TB	vaccine	
trials,	and	in	particular	allow	identification	of	hotspots	and	estimation	of	disease	rates	
in	potential	recruitment	populations.	ePAL	is	the	first	of	its	kind	to	provide	a	clinic-
based	 electronic	 data-capture	 tool	 for	 identifying	 TB	 patient	 place	 of	 residence,	
developed	 using	 high	 resolution	 satellite	 maps	 developed	 through	 community	
engagement.	For	the	research	site	in	Blantyre	it	provides	the	necessary	data	to	inform	
trial	design,	and	could	be	rapidly	and	inexpensively	translated	to	other	settings.	
Although	 further	 research	 is	 needed	 to	 completely	 fulfil	 the	 two	 epidemiological	
research	 needs	 identified	 in	 the	 TB	 vaccine	 blueprint,9	 the	 research	 in	 this	 thesis	
substantially	moves	forward	the	TB	vaccine	modelling	literature	through	its	attention	
to	 age-specificities	 in	 the	 modelling	 methodology,	 exploration	 of	 age	 targeting	
vaccination	 to	 older	 age	 groups,	 and	 comprehensive	 exploration	of	 the	 impact	 of	
vaccine	 characteristics	 in	 a	 high	 burden,	 previously	 under-modelled	 setting.	
Availability	of	appropriate	epidemiological	data	is	a	significant	obstacle	to	TB	vaccine	
trial	site	selection	and	design.	The	ePAL	app	provides	a	setting-appropriate	tool	for	
the	collection	of	the	spatial	data	required	for	new	or	existing	clinical	trial	research	
sites	 to	 generate	 the	 data	 needed	 for	 site	 selection,	 sample	 size	 calculations	 and	
recruitment	design.	It	is	hoped	that	ePAL	will	provide	the	methodology	to	fulfil	this	
second	major	epidemiological	research	need	in	a	resource	and	time	efficient	manner	
in	other	sites.	
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6.5 Discussion	of	PhD	research	in	the	context	of	recommendations	
for	TB	vaccine	development	strategy	
Decisions	 in	 TB	 vaccine	 development,	 in	 the	 form	 of	 target	 product	 profiles	 and	
clinical	 trial	design,	are	taken	by	a	variety	of	stakeholders,	 including	cross-product	
bodies	 (e.g.	Aeras,	TBVI,	WHO,	BMGF)	and	vaccine	developers	 (e.g.	academia	and	
industry).	As	an	academic	partner	to	these	stakeholders,	the	reach	of	the	research	
presented	in	this	thesis	is	limited	to	the	generation	of	evidence	and	tools	to	inform	
these	 decisions;	 however,	 it	 is	 hoped	 that	 the	 results	 of	 this	 research	will	 inform	
vaccine	 development.	 Recommendations	 for	 development	 strategists	 (e.g.	 BMGF,	
WHO,	cross-product	bodies,	developers),	clinical	triallists,	and	country	level	decision	
makers	are	provided	below.	
6.5.1 For	development	strategists	and	clinical	triallists	
Although	there	 is	some	value	 in	prevention	of	 infection,	efficacy	for	prevention	of	
disease	will	be	key	to	maximising	 impact	on	disease	burden	 in	China	during	2025-
2050.	Higher	incidence	rate	reductions	by	2050	were	only	achievable	with	non-zero	
vaccine	efficacy	against	disease.	Therefore,	knowledge	of	only	the	vaccine	efficacy	
for	prevention	of	 infection	would	be	 insufficient	 to	 guarantee	high	 incidence	 rate	
reductions.	 Therefore,	 vaccine	 development	 strategies	 for	 China	 and	 similar	
epidemics	should	aim	to	accelerate	development	of	candidate	vaccines	with	at	least	
some	anticipated	protection	against	disease.		
Stage	gating	between	trials	may	be	based	upon	the	efficacy	expected	to	deliver	a	pre-
defined	future	population-level	impact.	If	only	one	outcome	(i.e.	disease	or	infection)	
is	measured	in	a	clinical	trial,	to	be	conservative	it	must	be	assumed	that	there	is	no	
efficacy	against	the	other	clinical	outcome,	therefore	the	required	vaccine	efficacy	to	
proceed	with	that	candidate	will	be	higher	than	if	both	outcomes	were	measured.		
Vaccines	effective	post-infection	were	shown	to	be	essential	for	maximising	future	
impact	 in	 China.	 Ideally	 clinical	 trials	 should	 enrol	 both	 pre-	 and	 post-infection	
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populations	of	sufficient	sample	size	to	allow	stratification	of	efficacy	estimates	by	
infection	status.	However,	the	required	sample	size	would	likely	be	infeasible,	so	at	a	
minimum,	trials	should	recruit	post-infection	populations	to	demonstrate	safety,	and	
potentially	conduct	stratified	analyses	as	secondary	outcomes.		
To	achieve	a	minimum	incidence	rate	reduction	of	20-29%,	at	least	5	years	protection	
was	required	if	mass	campaigns	were	every	10	years.	Therefore,	clinical	trials	should	
be	designed	to	provide	data	on	duration	of	protection	beyond	the	usual	2-3	years	of	
a	 phase	 IIb	 trial.	 For	 example,	 phase	 II	 clinical	 trials	 could	 include	 an	 extended	
immunological	or	infection/disease	outcome	follow-up	in	a	subset	of	participants.	
Adolescent-targeted	vaccines,	the	focus	of	current	development	plans,	would	have	
low	impact	in	ageing,	reactivation-driven	TB	epidemics	like	China.	In	these	settings,	
an	 efficacious	 post-infection	 vaccine	 delivered	 to	 older	 adults	 will	 be	 critical	 to	
maximise	population-level	impact	and	would	provide	a	crucial	contribution	towards	
achieving	the	WHO	2050	TB	goals.	Older	adults	should,	therefore,	be	included	in	TB	
vaccine	 clinical	 development	 and	 implementation	 planning.	 To	 allow	 on-label	 use	
following	vaccine	registration,	older	age	groups	need	to	be	included	in	clinical	trials,	
ideally	 from	 phase	 IIB,	 but	 at	 a	 minimum	 by	 phase	 III,	 to	 ensure	 that	 sufficient	
participants	have	been	exposed	to	the	investigational	product	to	demonstrate	safety	
and	immunogenicity	to	the	regulators.		
Maps	generated	using	data	from	ePAL	demonstrated	the	spatial	heterogeneity	of	TB	
disease	in	Blantyre,	Malawi,	highlighting	the	importance	of	local-level	data	to	inform	
trial	recruitment	strategies.	The	large	number	of	patients	resident	outside	of	Blantyre	
but	registering	in	urban	clinics	is	consistent	with	other	literature,11	and	highlights	the	
importance	of	not	directly	using	district	level	data	for	sample	size	calculations,	as	this	
would	underpower	the	study.	In	addition,	the	rates	and	spatial	distribution	of	disease	
may	 also	 change	when	 considering	 trial-relevant	 populations	 (e.g.	microbiological	
outcomes,	HIV	positive	patients,	age	of	recruitment),	therefore	ensuring	sample	sizes	
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are	calculated	based	upon	data	relevant	to	the	outcomes	and	population	of	interest	
are	also	important	to	ensure	a	sufficiently	powered	study,	
6.5.2 For	country-level	decision	makers	
With	 longer	 durations	 of	 vaccine	 protection	 or	 more	 frequent	 revaccination	
strategies,	large	epidemiological	impact	could	be	achieved.	Therefore,	if	duration	of	
protection	 of	 new	 vaccines	 is	 found	 to	 be	 low,	 country-level	 planning	 for	 more	
frequent	 revaccination	campaigns	will	be	critical	 to	maximise	 the	population	 level	
impact.	
The	estimated	impact	of	routine	age-targeted	vaccination	was	less	than	that	achieved	
by	broad	mass	vaccination.	However,	it	is	essential	that	older	adult	age	groups	are	
included	in	whichever	vaccination	campaign	 is	conducted.	 If	resources	are	 limited,	
targeted	vaccination	of	older	adults	may	help	maximise	the	achievable	impact.	Even	
with	 reduced	coverage,	older	adult	 vaccination	was	 the	preferred	vaccination	age	
with	 post-infection	 or	 pre-	 and	 post-infection	 vaccines.	 Therefore,	 older	 adult	
platforms	may	need	to	be	developed	or	strengthened	for	delivery	of	vaccines	to	older	
age	groups.	
	
6.6 Opportunities	for	future	research	
The	 research	 presented	 in	 this	 thesis	 is	 just	 the	 first	 step	 towards	 fulfilling	 the	
epidemiological	 and	modelling	 research	needs	 for	TB	vaccine	development.	Many	
additional	questions	were	identified	in	the	systematic	review	or	have	arisen	as	this	
work	 has	 developed.	 Planned	 and	 potential	 future	 research	 is	 identified	 and	
discussed.	
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6.6.1 Mathematical	modelling	of	new	TB	vaccines	
The	modelling	in	this	thesis	aimed	to	provide	a	detailed	exploration	of	TB	vaccines	in	
China,	enabled	by	the	development	of	models	reflective	of	the	epidemiological	and	
demographic	trends	in	this	setting.	Exploration	of	vaccines	in	China	was	important,	
as	it	is	a	high	TB	burden	country	contributing	substantially	to	global	TB	burden,	with	
a	 declining	 epidemiological	 trend	 due	 to	 successful	 control	 programmes	 but	 is	
insufficient	to	meet	2050	elimination	goals,	and	an	ageing	population.	 In	addition,	
given	phase	 III	 results	 are	 imminent	 from	a	TB	 vaccine	 trial	 in	China,	 if	 efficacy	 is	
observed,	the	results	of	this	research	will	allow	estimation	of	potential	future	impact	
and	planning	for	implementation.		
Older	adult	vaccination	was	modelled	instead	of	elderly	vaccination,	due	to	concerns	
regarding	safety	and	immunogenicity.	However,	zoster	vaccines	have	recently	been	
shown	to	be	safe	and	efficacious	in	the	elderly.12,13	This	is	an	important	development	
for	 vaccination	 and	 longer	 term	protection	of	 these	oldest	 age	 groups,	 and	 could	
potentially	pave	the	way	for	how	TB	vaccines	are	developed	moving	forward.	If	the	
elderly	were	included	in	future	trials,	modelling	direct	vaccination	of	the	elderly	could	
be	of	interest	using	the	China	model.		
The	 results	 from	 China	 are	 likely	 applicable	 to	 other	 high-burden	 countries	 with	
declining,	 reactivation-driven	 epidemics	 and	 ageing	 populations	 (e.g.	 Thailand,	
Russia).	 However,	 other	 high-burden	 settings	with	 higher	 transmission	 rates	 (e.g.	
India)	 and	 substantial	 HIV	 co-epidemics	 (e.g.	 South	 Africa)	 may	 require	 slightly	
different	tailoring	of	vaccine	development	strategies.	I	have	received	funding	from	
the	Bill	and	Melinda	Gates	Foundation	to	re-calibrate	the	TB	vaccine	model	to	the	
epidemics	in	India	and	South	Africa.	Modelling	the	South	African	epidemic	will	require	
the	 incorporation	 of	 an	 HIV	 stratum	 in	 to	 the	 model,	 and	 consideration	 of	 the	
potential	relative	efficacy	of	new	TB	vaccines	in	HIV-positive	adults.	In	these	settings,	
it	may	be	of	interest	to	compare	infant,	adolescent	and	older	adult	vaccination.	
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The	systematic	review	identified	modelling	the	impact	of	TB	vaccines	on	multi-drug	
resistance	(MDR)	as	a	research	gap.	We	have	recently	received	funding	from	Aeras	to	
model	the	epidemiological,	health	economic	and	budget	impact	of	new	TB	vaccines	
on	MDR-TB.	The	addition	of	health	economic	analyses	would	be	a	valuable	addition	
to	this	work,	and	a	valuable	tool	for	advocating	investment	in	new	TB	vaccines.	
In	the	modelling	research,	I	assumed	that	no	game-changing	new	drugs	or	diagnostics	
would	be	introduced	over	the	time	frame	of	this	model.	However,	if	other	new	tools	
were	 developed,	 they	 could	 affect	 the	 impact	 of	 new	 TB	 vaccines.	 The	MRC	 has	
funded	a	PhD	student	to	join	our	research	team	to	explore	the	potential	impact	of	
other	new	interventions	on	the	future	impact	of	new	TB	vaccine.	
6.6.2 ePAL	app	
The	development	and	evaluation	of	ePAL	is	hopefully	just	the	first	step	in	the	use	of	
this	app	for	supporting	development	of	new	TB	vaccines.	
As	described	in	Chapter	5,	the	use	of	ePAL	in	Blantyre	has	generated	a	large	data	set	
that	 has	 not	 yet	 been	 fully	 explored.	 In	 future	work,	 I	 plan	 to	 conduct	 additional	
analyses	 exploring	 the	 spatial	 distribution	 of	 TB	 in	 Blantyre	 and	 associated	 risk	
factors,	to	help	inform	current	public	health	measures,	and	in	the	hope	of	informing	
future	clinical	trials.	These	analyses	will	include	exploring	risk	factor	data,	employing	
the	 new	 enumeration	 data	 set	 as	 a	 denominator,	 conducting	 observed	 versus	
expected	 analyses	 to	 identify	 statistically	 significant	 TB	 hotspots,	 exploring	 the	
distribution	of	TB	disease	in	children	in	Blantyre.	
Recent	research	has	also	indicated	the	potential	importance	of	locations	outside	of	
the	home	for	M.tb	transmission.	14	As	has	been	done	for	water	sources	in	the	Blantyre	
typhoid	 study,	 it	 would	 be	 of	 interest	 to	 use	 ePAL	 to	 explore	 other	 locations	
associated	 with	M.tb	 transmission	 risk,	 such	 as	 churches,	 bars	 and	 work	 places	
attended.	 This	 would	 likely	 be	 too	 time	 consuming	 to	 request	 of	 the	 TB	 Officers	
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currently	collecting	data	using	ePAL,	but	could	potentially	be	conducted	for	a	subset	
of	patients	in	Blantyre	by	study	staff.	
It	is	also	hoped	that	ePAL	will	continue	to	be	employed	in	other	studies	in	Blantyre,	
and	I	am	currently	exploring	the	possibility	of	implementing	ePAL	in	studies	in	South	
Africa	and	India.	
An	interesting	future	avenue	to	bring	together	the	epidemiological	and	mathematical	
modelling	 research,	 would	 be	 to	 employ	 spatial	 data	 supplied	 by	 ePAL	 to	
parameterise	a	spatial	TB	model	to	explore	impact	of	vaccination	programmes	at	the	
community	 level.	 One	 study	 has	 explored	 TB	 vaccination	 in	 a	 context	 of	 spatial	
heterogeneity	in	India.	However,	this	was	based	upon	larger	areas,	therefore	such	a	
detailed	local	data	set	could	allow	for	interesting	local-level	modelling.	Collaborators	
at	the	London	School	of	Hygiene	and	Tropical	Medicine	plan	to	employ	the	ePAL	data	
set	to	inform	mathematical	modelling	of	spatially	targeted	interventions.	The	current	
research	plans	focus	on	existing	interventions,	but	could	in	the	future	be	adapted	to	
explore	the	impact	of	spatially	targeted	new	TB	vaccines.			
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6.7 Conclusion	
There	is	a	clear	and	urgent	public	health	need	for	new	TB	vaccines.	The	TB	vaccine	
pipeline	is	the	strongest	to-date,	yet	progression	of	candidates	through	the	pipeline	
remains	slow.	Epidemiological	data	to	inform	TB	vaccine	development	strategy	and	
to	assist	trial	site	selection	and	design	was	identified	as	a	critical	research	need	to	
accelerate	development	and	maximise	impact	of	new	TB	vaccines.	
The	 research	presented	 in	 this	 thesis	 informs	 the	development	of	 appropriate	 TB	
vaccines	 and	 target	 populations	 to	 maximise	 future	 population-level	 impact	 and	
accelerate	TB	vaccine	development.	A	prevention	of	disease	vaccine	efficacious	post-
infection	 and	 delivered	 to	 older	 adults	 would	 contribute	 towards	 maximising	
population-level	impact	in	China.	Adolescent-targeted	tuberculosis	vaccines	are	likely	
to	 have	 low	 impact	 in	 ageing,	 reactivation-driven	 epidemics	 like	 China,	 which	
suggests	a	modification	of	the	current	strategic	focus	on	adolescents.	Clinical	trials	
should	assess	disease	endpoints,	include	M.tb-infected	and	older	adult	populations,	
and	 extend	 beyond	 the	 usual	 2-3	 years	 follow	 up.	 To	 support	 design	 of	 disease	
endpoint	trials,	ePAL	may	provide	an	accurate,	easily	implementable,	low-cost	tool	
for	identification	of	areas	of	high	TB	burden	in	settings	without	addresses.		
It	is	hoped	that	this	research,	and	planned	future	research,	will	inform	how	TB	vaccine	
developers,	 clinical	 triallists,	 and	 country-level	 public	 health	 decision	 makers	
prioritise	and	plan	their	approach	to	the	development	and	implementation	of	new	
TB	vaccines.	Continued	development	of	epidemiological	models	and	data	collection	
tools	 will	 be	 essential	 for	 the	 acceleration	 of	 TB	 vaccine	 development	 and	 to	
maximise	future	impact	of	new	TB	vaccines.	
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Appendix	A:	Additional	systematic	review	materials		
	
Protocol:	Systematic	review	of	models	exploring	the	epidemiological	impact	of	novel	
TB	vaccines	
The	following	protocol	was	registered	at	on	PROSPERO.1	
Prepared	by:	 	 Rebecca	Harris	
Document	date:	 15th	December	2015	
Version:	 	 1	
Literature	search	strategy	
1.0	RESEARCH	OBJECTIVES	
Background	
With	 a	 strong	 pipeline	 of	 15	 novel	 tuberculosis	 (TB)	 vaccine	 candidates	 in	 clinical	
trials,2	there	is	a	growing	modelling	literature	exploring	the	potential	impact	of	novel	
TB	vaccines.	Such	models	can	be	used	to	inform	decision	making	with	regards	to	the	
characteristics	and	target	population	for	novel	vaccines,	to	allow	limited	funding	to	
be	appropriately	prioritised	 to	ensure	 the	greatest	public	health	 impact	would	be	
achieved	when	new	vaccines	come	to	market.	To-date,	the	body	of	literature	on	this	
topic	 has	 not	 been	 summarised.	 The	 objective	 of	 this	 review	 is	 to	 narratively	
summarise	the	methodology	and	outcomes	from	modelling	research	exploring	the	
epidemiological	impact	of	pipeline	or	theoretical	TB	vaccines.		
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1.2	Research	Question	
What	 are	 the	 methods	 and	 estimated	 epidemiological	 impact	 of	 pipeline	 or	
theoretical	human	tuberculosis	vaccines	as	estimated	by	mathematical	modelling?	
The	PICOT	framework	for	this	research	question	is	as	follows:	
Table	1:	PICOT	question	
Limit	 Definition	
Population	 Humans,	of	any	age	in	any	country	or	globally	
Intervention	 Novel/theoretical/pipeline	TB	vaccines	Not	BCG-only	
Comparator	 No	 intervention,	currently	available	 interventions	 (at	current	or	scaled-up	levels),	or	other	theoretical	interventions.	
Outcome	
Tuberculosis	epidemiological	impact	(e.g.	incidence,	prevalence,	
mortality,	number	needed	to	vaccinate,	cost	effectiveness)	
Not	Mycobacterium	bovis	
Time	 No	limit	
Study	
Design	
Epidemiological	mathematical	models	
Not	within-host	impact	models	
Not	reviews/commentaries	
	
2.0	METHODS	
2.1	Search	Strategy	
Three	databases	(Pubmed,	Embase	and	WHO	Global	Index	Medicus	(GIM))	providing	
access	 to	 seven	 databases/indexes	 (Pubmed/Medline,	 Embase,	 African	 Index	
Medicus,	LILACS,	SEARO	Index	Medicus,	WPRO	Index	Medicus,	EMRO	Index	Medicus)	
will	be	searched.	Searches	will	use	free	text	and	Mesh/Emtree/DeCS	terms	tailored	
by	database	for	groups	of	terms	covering	tuberculosis,	modelling	and	vaccines	(table	
2).	Search	terms	are	combined	with	Boolean	OR	within	groups,	and	by	Boolean	AND	
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between	search	term	groups.	The	search	in	Pubmed	will	be	run	with	filter	“human”,	
and	the	WHO	GIM	search	will	be	limited	to	regional	databases	to	avoid	duplication.	
Table	2:	Search	terms	by	database	
Database	 Search	Term	Group	
Modelling	 Tuberculosis	 Vaccine	
Pubmed	
"Models,	
Theoretical"[Mesh])	
OR	 "mathematical	
model*"	
TB	 OR	 tuberculosis	
OR	
"Tuberculosis"[Mesh]	
vaccin*	 OR	
immuniz*	 OR	
immunis*	 OR	
"Tuberculosis	
Vaccines"[Mesh]	
Embase	
("mathematical	
model$".mp.	 OR	
mathematical	
model.mp.	 or	
mathematical	
model/)	
(tuberculosis	control/	
or	 exp	 tuberculosis/	
or	 Mycobacterium	
tuberculosis/	 or	
tb.mp.	 or	
tuberculosis.mp.)	
	
(exp	 vaccine/	 or	
(vaccin$	 or	
immunis$	 or	
immuniz$).mp.)	
	
WHO	
Global	
Index	
Medicus	
(regional	
databases)	
("computer	
models"	 OR	
"epidemiologic	
models"	 OR	
"mathematical	
models")	
TB	 OR	 tuberculosis	
OR	"tuberculosis"	
Not	 required	 as	
very	 few	 hits	
with	 first	 two	
search	terms	
	
Table	3:	Application	of	PICOT	through	search	limits	and	manual	search	criteria	
Limit	 Definition	 Limit	management	
Population	 	 Humans,	of	any	age	in	any	country	or	globally	
“Human”	 search	 limit	
(pubmed	only)	and	manual	
search	criterion	
Intervention	 	
Novel/theoretical/pipeline	
TB	vaccines	
Not	BCG-only	
Vaccine	 search	 terms	 and	
manual	search	criteria	
Comparator	 	
No	 intervention,	 currently	
available	 interventions	 (at	
current	 or	 scaled-up	
levels),	 or	 other	
theoretical	interventions.	
Manual	search	criteria	
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Outcome	 	
Tuberculosis	
epidemiological	 impact	
(e.g.	 incidence,	
prevalence,	 mortality,	
number	 needed	 to	
vaccinate,	 cost	
effectiveness)	
Not	Mycobacterium	bovis	
TB	 search	 terms	 and	
manual	search	criteria	
	
Time	 	 No	limit	 No	limit	applied	
Methodology	 	
Epidemiological	
mathematical	models	
Not	 within-host	 impact	
models	
Not	
reviews/commentaries	
Modelling	 search	 terms	
manual	search	criteria	
	
	
2.2	Selection	of	studies	and	data	extraction	
The	database	searching,	sifting	and	data	extraction	will	be	conducted	in	by	a	single	
reviewer	(RCH).	A	three-stage	sifting	process	will	be	employed	to	screen	publications	
first	at	title,	abstract,	then	at	full	text	level	for	eligibility	for	inclusion	using	the	below-
details	inclusion	and	exclusion	criteria.	Any	uncertainties	in	inclusion	will	be	decided	
through	discussion	with	a	second	reviewer	(RW).	Reference	lists	of	included	studies	
will	 be	 hand	 searched	 for	 studies	meeting	 the	 inclusion	 criteria.	 Onward	 citation	
searching	will	be	conducted	for	all	included	articles.	
Inclusion	Criteria	
• Mathematical	model	
• Systematic	review	of	models	of	novel	TB	vaccines,	or	commentary	adding	to	
the	analyses/interpretation	of	models	reported	elsewhere	
• Intervention	 is	novel/future/hypothetical	 vaccine	against	 tuberculosis	or	of	
an	unspecified	novel	TB	intervention	with	characteristics	in-line	with	a	vaccine	
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• Reported	outcomes	are	of	epidemiological	impact	of	vaccine	(e.g.	incidence,	
prevalence,	mortality,	number	needed	to	vaccinate,	cost	effectiveness)	
	
Exclusion	Criteria	
• Within-host/immunological	vaccine	impact	models	
• Review	or	commentary	not	adding	to	existing	body	of	knowledge	
• TB	epidemiological	models	not	reporting	impact	of	vaccine		
• TB	epidemiological	models	reporting	only	interventions	other	than	vaccines	
• Model	only	reporting	on	impact	of	BCG	with	known/fixed	efficacy	
• Disease	 or	 infection	 caused	 by	 Mycobacterium	 bovis	 or	 other	 non-
Mycobacterium	tuberculosis	strain.	
Data	 will	 be	 extracted	 from	 those	 papers	 selected	 for	 final	 inclusion	 using	 a	
standardised	Microsoft	Excel®	database.	Extracted	data	will	include	study	objectives,	
model	 methods	 (e.g.	 model	 structure,	 mixing	 patterns,	 model	 assumptions,	
parameter	data	sources),	intervention	characteristics	(e.g.	vaccine	efficacy,	duration	
of	 protection,	 waning	 of	 protection,	 vaccine	 target	 population	 and	 schedule),	
epidemiological	outcomes,	sensitivity	analyses,	and	model	limitations.	
3.0	QUALITY	ASSESSMENT	AND	DATA	SYNTHESIS		
3.1	Quality	Assessment	
Few	validated	tools	exist	for	the	assessment	of	quality	of	epidemiological	modelling	
studies.	 Fone	 et	 al.	 (2003)	 have	 proposed	 and	 tested	 an	 adapted	 version	 of	 the	
Weightman	et	 al.	 (2000)	 tool	 for	 the	 critical	 appraisal	 of	 the	 quality	 of	modelling	
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studies	in	health	care.3,4	And	more	recently	Caro	et	al.	have	detailed	the	criteria	for	
good	research	practice	in	modelling	research.5	In	this	review,	the	Fone	et	al.	tool	will	
be	used	as	a	basis	for	quality	assessment,	but	updated	based	upon	the	Caro	et	al.	
report	to	ensure	clarity	and	coverage	of	certain	criteria.3,5	Based	upon	extracted	data,	
each	included	article	will	be	critically	appraised	for	quality	using	a	piloted	version	of	
this	extraction	form.	
3.2	Data	Synthesis	
Extracted	data	will	be	synthesised	using	a	narrative	approach	and	will	focus	on	the	
modelling	 methods	 used,	 estimates	 of	 epidemiological	 impact,	 and	 identifying	
evidence	gaps	or	limitations.		
3.3	Dissemination	
The	review	manuscript	will	be	submitted	for	publication	in	a	peer	reviewed	journal.	
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Risk	of	bias	tool	for	assessment	of	epidemiological	modelling	studies	
		 Criterion	 (adapted	 from	
Fone	et	al.	and	Caro	et	al.)	
Considerations	 (adapted	 from	 Fone	
et	al.	and	Caro	et	al.)	
Score	considerations	(0,	poor	to	
2,	good)	
	
1	 Are	the	aims	and	objectives	
clear?	
Are	 the	 research	 questions	 and	
modelling	objectives	clearly	defined?	
0	Not	stated	
1	Stated	but	vague	
2	Stated	and	focussed	
	
Definitions:	max	 8	
points	
	
	
	
2	 Is	 the	 setting	 and	
population	clearly	defined?	
Does	 the	 paper	 clearly	 state	 the	
setting	 (e.g.	 geographical	 location,	
high/low	TB	burden)?	
0	Not	stated	
1	 Stated	 but	 vague	 or	 details	
missing	
2	Stated	and	focussed	In	health	economics	models,	has	the	
perspective	been	stated?	
Does	 the	 paper	 clearly	 state	 the	
modelled	population?	(e.g.	patient	or	
population	group	characteristics)	
Have	 sub-populations	 necessary	 for	
the	 research	 question	 and	 setting	
been	modelled?	
3	 Are	 the	 intervention	 and	
comparators	 adequately	
defined?	
Does	 the	 paper	 clearly	 state	 the	
population(s)	 targeted	 for	
vaccination?	
0	Not	stated	or	very	unclear	
1	Stated	but	details	missing	
2	Stated	and	all	necessary	details	
stated	Does	 the	 paper	 clearly	 define	 the	
vaccine	 characteristics	 (e.g.	 vaccine	
efficacy,	 duration	 of	 protection,	
number	of	doses,	waning,	timing)?	
If	 there	 is	a	comparator	 (no	vaccine,	
baseline	 or	 alternative	 intervention	
scenario),	is	it	clearly	defined?	
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4	 Are	the	outcome	measures	
defined	 and	 answer	 the	
research	question?	
Does	 the	 paper	 clearly	 define	 the	
outcomes	of	interest?	
0	Not	stated,	very	unclear	or	not	
suited	to	research	question	
1	Stated	but	details	missing	or	not	
directly	 aligned	 with	 research	
question	
2	 Stated,	 all	 necessary	 details	
stated,	and	aligned	with	research	
question	
Do	 the	 outcomes	 correspond	 to	 the	
research	question?	
5	 Are	 the	 model	 structure	
and	 time	 horizon	 clearly	
described	 and	 appropriate	
for	the	research	question?	
Is	 the	 model	 structure	 clearly	
reported	 and	 appropriate	 for	 the	
research	question?	
0	 Not	 appropriate	 model	
structure,	or	poor/no	description	
of	model	
1	Incomplete	description,	and/or	
appropriate	 in	 part	 for	 research	
question	
2	 Complete	 and	 reproducible,	
appropriate	 structure	 and	 time	
horizon	
Model	 methods:	
max	4	points	
	
	Does	 the	 model	 reflect	 current	
knowledge	of	disease	natural	history?	
Is	 the	 time	horizon	and	 time	step	of	
the	 model	 clearly	 stated	 and	
appropriate	to	the	research	question	
(i.e.	 is	 it	 long	 enough	 to	 capture	
health	effects)?	
6	 Are	the	modelling	methods	
appropriate	 for	 the	
research	 question	 and	
adequately	described?	
Were	 the	modelling	methods	 clearly	
described,	and	suited	to	the	research	
question?	
0	 Not	 appropriate	 model	
structure,	or	poor/no	description	
of	methods	
1	Incomplete	description,	and/or	
appropriate	 in	 part	 for	 research	
question	
2	 Complete	 and	 reproducible,	
appropriate	method	
7	
	
Are	the	parameters,	ranges	
and	data	sources	specified?	
Are	 all	 parameters	 and	 their	 ranges	
reported?	
0	Poorly	reported	
1	Some	information	missing	
Model	inputs:	max	
6	points	
Are	 the	data	 sources	 for	parameters	
reported?	
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2	 Complete	 reporting	 of	
parameters,	 ranges	 and	 data	
sources	
8	 Are	 any	 assumptions	
explicit	and	justified?	
Are	 all	 assumptions	 explicit	 and	
justified?	
0	Not	reported	
1	Explicit	
2	Explicit	and	justified	
9	 Is	 the	 quality	 of	 data	
considered	 and	 is	
uncertainty	 explored	
through	uncertainty	and/or	
sensitivity	analyses?	
Are	 data	 limitations	 discussed?	 Are	
any	 of	 the	 sources	 known	 to	 the	
reviewer	to	be	inappropriate	(e.g.	do	
not	 match	 the	 parameter,	 are	
outdated,	 or	 known	 to	 be	 poor	
quality)?		
0	No	sources	or	uncertainty	
1	 Partially	 addressed,	 and/or	
some	data	inappropriate	
2	Fully	addressed	
Is	 uncertainty	 in	 model	 structure,	
parameters	 and/or	 assumptions	
explored	through	uncertainty	and/or	
sensitivity	analyses?	
10	 Is	 the	 method	 of	 fitting	
described	and	suitable?	
Is	 the	 method	 of	 fitting/calibrating	
the	model	clearly	described?	
0	Not	done,	unsuitable	method	or	
poor/no	description	
1	 Incomplete	 description	 or	
method	not	optimal	
2	 Complete	 description	 and	
suitable	methods		
Fitting/	 validation:	
max	4	points	
Is	 the	 method	 of	 model	
fitting/calibration	suitable?	
11	 Has	 the	 model	 been	
validated?	
Has	 an	 assessment	of	 validity	 of	 the	
results	 been	 made	 by	 comparing	
across	 one	 or	more	 different	model	
structures,	 or	 against	 a	 validation	
data	set?	
0	Not	considered	
1	States	criteria	for	validation	
2	Validation	undertaken	
	
12	
Have	 the	 results	 been	
clearly	 and	 completely	
Have	 the	 outcome	 values	 and	 their	
uncertainty	 ranges	 for	 each	
0	 Not	 reported,	 very	 unclear	 or	
not	suited	to	research	question	
Results:	 max	 4	
points	
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presented,	with	a	 range	of	
uncertainty?	
intervention/scenario	 been	
reported?	
1	 Stated,	 but	 ranges	 or	 planned	
sensitivity	 analyses	 missing	
and/or	 not	 directly	 aligned	 with	
research	question	
2	Values	and	ranges	and	planned	
sensitivity	analyses	reported	and	
aligned	with	research	question.	
Do	the	results	match	the	objectives?	
Are	 sensitivity	 analyses	 clearly	
reported?	
13	 Are	 the	 results	
appropriately	 interpreted	
and	discussed	in	context?	
Does	the	discussion	reflect	a	fair	and	
balanced	 interpretation	 of	 the	
results?		
0	No/poor	discussion	
1	Some	discussion	but	key	points,	
limitations	or	context	missed	
2	Full	discussion	of	key	points	 in	
context,	 generalisability	
considered,	limitations	discussed	
Are	the	results	of	the	study	discussed	
in	 context	 and	 is	 generalisability	
considered?	
Are	 possible	 biases	 and	 limitations	
discussed?	
14	 Are	the	funding	source	and	
conflicts	 of	 interest	
reported?	
Is	 the	 funding	 and	 the	 role	 of	 the	
funder	clearly	stated?	
0	 No	 statement	 of	 funding	 or	
conflicts	
1	Funding	or	conflicts	reported	
2	Funding	and	conflict	statement	
Conflicts:	
Max	2	points	
Is	 there	 a	 conflict	 of	 interest	
statement?	
	 	
	
	
	 	
Overall	Scoring:	Max	28	points	
	
	
Very	high	 >22	 	 	
High	 19-22	 	 	
Medium	 .14-18	 	 	
Low	 <14	 	 	
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Additional	results:	Model	structures	and	fitting	methodology	
Model	structures	are	tailored	to	suit	a	given	research	question,	but	have	also	evolved	
based	on	the	growing	body	of	knowledge	about	TB	natural	history	and	epidemiology.	
The	majority	of	models	include	the	susceptible	(S),	latent	(L),	active	disease	(I)	and	
recovered	 (R)	 natural	 history	 states.	 Some	 models	 include	 latent	 fast	 and	 slow	
progressing	states,6-9	though	many	models	bypass	the	‘latent	fast’	state	to	transition	
directly	to	either	stable	latent	infection	or	active	disease.10,11	Other	features	included	
in	some	models	are:	treatment	status,6,11	variable	infectiousness	of	active	disease	or	
disease	type,12-16	different	infective	strains,17	vaccine	waning,8	and	stratification	for	
age,	HIV,11,14,18,19	community	structure,20	and	vaccination.		Markov	models	identified	
also	included	other	health	states	such	as	re-infected,21	miliary	TB,21	TB	meningitis21,	
diagnosis,18		treatment	status,18,19	and	drug	resistance	status18,19.	
Fitting	 methods	 reported	 included	 Sobol	 sequence	 sampling	 and	 approximate	
Bayesian	 computation,14	 Downhill	 simplex	 method,6	 maximum	 likelihood,22	 or	
adjustment	 of	 parameters	 to	 achieve	 required	 equilibrium	 values	 using	 Berkley	
Madonna	“curve	fit”	routine,12,13	generalised	reduced	gradient	non	linear	engine	of	
solver	in	Excel	or	manually.11-13	Fitting	methods	were	unclear	or	not	reported	in	six	
of	 the	 models.7-9,15-17	 Illustrative	 examples,	 Markov	 or	 analytical	 models	 did	 not	
require	fitting.10,18-21,23-27	
Additional	results:	summary	of	quality	scoring	
Study	aims	and	outcome	measures	tended	to	be	well	defined,	but	there	was	often	
missing	information	with	regards	to	the	modelled	population,	vaccine	characteristics,	
time	horizon,	on	occasion	model	structure	and	parameter	ranges	and	references.	The	
model	structure	and	methods	were	generally	suited	to	 the	research	question,	but	
some	 models	 had	 out-dated	 natural	 history	 structures	 or	 inappropriate	 time	
horizons.	Overall,	the	scoring	for	fitting	methods	was	relatively	low,	as	several	studies	
lacked	 or	were	 unclear	 in	 their	 reporting,	 plus	 this	 is	 not	 a	 relevant	 criterion	 for	
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theoretical	papers.	Model	assumptions	were	generally	stated	and	justified.	Studies	
were	incredibly	variable	with	respect	to	the	completeness	of	conduct	and	reporting	
of	uncertainty	ranges	and	sensitivity	analyses.	Points	were	lost	in	reporting	of	results	
due	to	poor	reporting	of	uncertainty	and	sensitivity	analyses,	but	overall	results	were	
appropriately	 interpreted	 and	 discussed	 in	 context.	 Only	 one	 model	 had	 been	
validated,	 and	 most	 papers	 were	 missing	 a	 conflict	 of	 interest	 and/or	 funding	
statement.	
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Appendix	B:	Supplementary	modelling	information		
B1.	Additional	results	from	Chapter	3	
	
Figure	B1:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2050	for	pre-	and	post-
infection	vaccine	compared	to	no	new	vaccine	baseline,	by	percentage	efficacy	against	infection	(x-
axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	
corner	of	panel),	all	with	10-yearly	mass	vaccination	campaigns.	
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Figure	B2:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2050	for	pre-infection	
vaccine	 compared	 to	 no	 new	 vaccine	 baseline,	 by	 percentage	 efficacy	 against	 infection	 (x-axis),	
percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	
of	panel),	all	with	10-yearly	mass	vaccination	campaigns.	
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Figure	B3:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2050	for	post-infection	
vaccines	 compared	 to	 no	 new	 vaccine	 baseline,	 by	 percentage	 efficacy	 against	 infection	 (x-axis),	
percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	
of	panel),	all	with	10-yearly	mass	vaccination	campaigns.	
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Figure	B4:	Median	cumulative	number	of	cases	averted	for	the	period	2025-2035	for	pre-	and	post-
infection	vaccine	compared	to	no	new	vaccine	baseline,	by	percentage	efficacy	against	infection	(x-
axis),	percentage	efficacy	against	disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	
corner	of	panel),	all	with	10-yearly	mass	vaccination	campaigns.	
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Figure	B5:	Median	incidence	rate	reduction	in	2050	for	pre-	infection	vaccines	compared	to	no	new	
vaccine	baseline,	by	percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	
(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel),	all	with	10-yearly	mass	
vaccination	campaigns.	
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Figure	B6:	Median	incidence	rate	reduction	in	2050	for	post-infection	vaccines	compared	to	no	new	
vaccine	baseline,	by	percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	
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disease	(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel),	all	with	10-
yearly	mass	vaccination	campaigns	
	
	 	
Figure	B7:	Median	mortality	rate	reduction	(%)	for	pre-	and	post-infection	vaccine	compared	to	no	new	
vaccine	baseline	in	2050,	by	percentage	efficacy	against	infection	(x-axis),	percentage	efficacy	against	disease	
(y-axis),	and	duration	of	protection	(as	indicated	in	top	left	corner	of	panel),	all	with	10-yearly	mass	
vaccination	campaigns.	
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B2.	Additional	results	Chapter	4	
Table	B1:	Cumulative	number	needed	to	vaccinate	per	case	averted	2025-2050	
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Individuals	
Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PRI	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,917	
(135,838-
135,980)	
75	(64-88)	 1822	(1551-2110)	
20	
135,917	
(135,838-
135,980)	
113	(97-134)	 1206	(1015-1407)	
60	
10	
135,917	
(135,838-
135,980)	
111	(96-130)	 1227	(1044-1422)	
20	
135,917	
(135,838-
135,980)	
167	(143-198)	 815	(686-950)	
80	
10	
135,917	
(135,838-
135,980)	
146	(126-172)	 930	(791-1077)	
20	
135,917	
(135,838-
135,980)	
220	(188-261)	 619	(521-722)	
70	
40	
10	
317,139	
(316,955-
317,287)	
169	(146-199)	 1873	(1593-2170)	
20	
317,139	
(316,955-
317,287)	
254	(218-301)	 1249	(1052-1457)	
60	
10	
317,139	
(316,955-
317,287)	
248	(214-292)	 1278	(1087-1481)	
20	
317,139	
(316,955-
317,287)	
370	(317-439)	 858	(722-1001)	
80	
10	
317,139	
(316,956-
317,288)	
323	(279-380)	 982	(834-1137)	
20	
317,139	
(316,956-
317,288)	
479	(410-568)	 663	(558-773)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
NNV	per	case	
averted		
(Uncertainty	
range)	
PRI	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
110	(85-151)	 1,473	(1,077-1,907)	
20	
162,162	
(161,417-
162,745)	
148	(114-207)	 1,093	(786-1,425)	
60	
10	
162,162	
(161,417-
162,745)	
164	(127-224)	 990	(725-1,281)	
20	
162,162	
(161,417-
162,745)	
220	(169-306)	 736	(530-959)	
80	
10	
162,162	
(161,417-
162,745)	
217	(168-296)	 748	(549-967)	
20	
162,162	
(161,417-
162,745)	
291	(224-403)	 558	(402-725)	
70	
40	
10	
378,378	
(376,639-
379,739)	
251	(195-343)	 1,505	(1,104-1,944)	
20	
378,378	
(376,639-
379,739)	
337	(260-467)	 1,123	(811-1,459)	
60	
10	
378,378	
(376,640-
379,740)	
370	(287-504)	 1,022	(752-1,318)	
20	
378,378	
(376,640-
379,740)	
494	(381-681)	 766	(556-993)	
80	
10	
378,379	
(376,640-
379,740)	
484	(377-658)	 781	(576-1,005)	
20	
378,379	
(376,640-
379,740)	
644	(499-884)	 587	(428-760)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-L	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,916		
(135,838-
135,980)	 2	(2-3)	
57,905	(42,648-
75,818)	
20	
135,916		
(135,838-
135,980)	 4	(3-5)	
35,941	(26,488-
46,864)	
60	
10	
135,916		
(135,838-
135,980)	 3	(3-5)	
38,894	(28,645-
50,932)	
20	
135,916		
(135,838-
135,980)	 6	(4-8)	
24,170	(17,812-
31,518)	
80	
10	
135,916		
(135,838-
135,980)	 5	(4-6)	
29,389	(21,644-
38,490)	
20	
135,916		
(135,838-
135,980)	 7	(6-10)	
18,285	(13,475-
23,846)	
70	
40	
10	
317,139		
(316,955-
317,287)	 5	(4-7)	
59,070	(43,503-
77,369)	
20	
317,139		
(316,955-
317,287)	 9	(7-12)	
36,781	(27,104-
47,971)	
60	
10	
317,139		
(316,955-
317,287)	 8	(6-11)	
40,065	(29,505-
52,492)	
20	
317,139	
(316,955-
317,287)	 13	(10-17)	
25,019	(18,434-
32,636)	
80	
10	
317,139		
(316,955-
317,287)	 10	(8-14)	
30,568	(22,508-
40,058)	
20	
317,139		
(316,955-
317,287)	 17	(13-22)	
19,142	(14,101-
24,974)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-L	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
193	(39-317)	 838	(511-4,212)	
20	
162,162	
(161,417-
162,745)	
280	(52-466)	 579	(348-3,138)	
60	
10	
162,162	
(161,417-
162,745)	
288	(57-473)	 562	(342-2,824)	
20	
162,162	
(161,417-
162,745)	
418	(77-694)	 389	(233-2,106)	
80	
10	
162,162	
(161,417-
162,745)	
382	(76-628)	 424	(258-2,130)	
20	
162,162	
(161,417-
162,745)	
553	(102-920)	 293	(176-1,589)	
70	
40	
10	
378,378	
(376,641-
379,740)	
445	(89-730)	 851	(518-4,275)	
20	
378,378	
(376,641-
379,740)	
643	(119-1,068)	 589	(354-3,192)	
60	
10	
378,378	
(376,642-
379,740)	
658	(131-1,081)	 574	(350-2,886)		
20	
378,379	
(376,642-
379,740)	
950	(175-1,579)	 399	(239-2,160)	
80	
10	
378,379	
(376,643-
379,741)	
867	(173-1,424)	 436	(266-2,192)	
20	
378,379	
(376,644-
379,741)	
1247	(230-2075)	 304	(182-1,644)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-LR	
Ad
ol
es
ce
nt
	
30	
40	
10	
135,916	
(135,838-
135,980)	
4	(3-5)	 38,771	(29,534-50,337)	
20	
135,916	
(135,838-
135,980)	
6	(4-7)	 23,774	(18,156-30,782)	
60	
10	
135,917	
(135,838-
135,980)	
5	(4-7)	 26,042	(19,838-33,813)	
20	
135,917	
(135,838-
135,980)	
9	(7-11)	 15,987	(12,210-20,701)	
80	
10	
135,917	
(135,838-
135,980)	
7	(5-9)	 19,679	(14,990-25,551)	
20	
135,917	
(135,838-
135,980)	
11	(9-15)	 12,094	(9,237-15,661)	
70	
40	
10	
317,139	
(316,955-
317,287)	
8	(6-11)	 39,554	(30,129-51,359)	
20	
317,139	
(316,955-
317,287)	
13	(10-17)	 24,327	(18,581-31,503)	
60	
10	
317,139	
(316,955-
317,287)	
12	(9-16)	 26,831	(20,437-34,840)	
20	
317,139	
(316,955-
317,287)	
19	(15-25)	 16,547	(12,638-21,429)	
80	
10	
317,139	
(316,955-
317,287)	
15	(12-20)	 20,471	(15,592-26,585)	
20	
317,139	
(316,955-
317,287)	
25	(19-33)	 12,660	(9,669-16,396)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(Uncertainty	
range)	
PSI-LR	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
380	(305-431)	 426	(375-532)	
20	
162,162	
(161,417-
162,746)	
547	(432-625)	 297	(259-376)	
60	
10	
162,162	
(161,417-
162,746)	
567	(455-643)	 286	(252-357)	
20	
162,162	
(161,418-
162,746)	
815	(643-931)	 199	(174-252)	
80	
10	
162,163	
(161,418-
162,746)	
752	(603-853)	 216	(190-269)	
20	
162,163	
(161,418-
162,746)	
1,079	(852-1,233)	 150	(131-190)	
70	
40	
10	
378,380	
(376,642-
379,741)	
874	(700-992)	 433	(381-541)	
20	
378,380	
(376,642-
379,741)	
1,254	(990-1,432)	 302	(264-383)	
60	
10	
378,381	
(376,644-
379,743)	
1,295	(1,037-
1,469)	 292	(257-365)	
20	
378,381	
(376,644-
379,743)	
1,852	(1,461-
2,117)	 204	(179-259)	
80	
10	
378,382	
(376,645-
379,744)	
1,704	(1,364-
1,935)	 222	(195-278)	
20	
378,383	
(376,646-
379,744)	
2,432	(1,919-
2,781)	 156	(136-197)	
	
	Appendices	 411	
Va
cc
in
e	
M
ec
ha
ni
sm
	
Ag
e	
ta
rg
et
in
g	
Co
ve
ra
ge
	(%
)	
Va
cc
in
e	
Ef
fic
ac
y	
(%
)	
Du
ra
tio
n	
Individuals	
Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(uncertainty	
range)	
PPI	
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nt
	
30	
40	
10	
135,917	
(135,838-
135,980)	
78	(68-92)	 1,743	(1,485-2,013)	
20	
135,917	
(135,838-
135,980)	
118	(102-139)	 1,149	(976-1,339)	
60	
10	
135,917	
(135,838-
135,980)	
116	(100-136)	 1,174	(1,001-1,356)	
20	
135,917	
(135,838-
135,980)	
175	(150-206)	 776	(659-905)	
80	
10	
135,917	
(135,838-
135,980)	
153	(132-179)	 890	(758-1,028)	
20	
135,917	
(135,838-
135,980)	
230	(198-271)	 590	(501-688)	
70	
40	
10	
317,139	
(316,955-
317,287)	
177	(153-208)	 1,792	(1,527-2,070)	
20	
317,139	
(316,955-
317,287)	
266	(229-314)	 1,190	(1,011-1,388)	
60	
10	
317,139	
(316,955-
317,287)	
259	(224-304)	 1,223	(1,043-1,414)	
20	
317,139	
(316,955-
317,287)	
388	(333-456)	 818	(695-954)	
80	
10	
317,139	
(316,956-
317,288)	
338	(292-396)	 939	(801-1,086)	
20	
317,139	
(316,956-
317,288)	
502	(431-591)	 632	(537-737)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Cases	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	case	averted	
2025-2050		
(uncertainty	
range)	
PPI	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
489	(418-566)	 332	(286-387)	
20	
162,162	
(161,417-
162,746)	
693	(585-807)	 234	(200-277)	
60	
10	
162,163	
(161,418-
162,746)	
727	(622-841)	 223	(192-261)	
20	
162,163	
(161,418-
162,746)	
1,028	(868-1,196)	 158	(135-187)	
80	
10	
162,163	
(161,418-
162,746)	
962	(822-1,111)	 169	(146-197)	
20	
162,163	
(161,418-
162,746)	
1,355	(1,145-
1,576)	 120	(103-141)	
70	
40	
10	
378,381	
(376,643-
379,742)	
1,116	(954-1,289)	 339	(293-396)	
20	
378,381	
(376,643-
379,742)	
1,571	(1,327-
1,824)	 241	(207-285)	
60	
10	
378,382	
(376,645-
379,744)	
1,643	(1,403-
1,893)	 230	(199-269)	
20	
378,383	
(376,645-
379,744)	
2,300	(1,944-
2,663)	 164	(142-194)	
80	
10	
378,384	
(376,647-
379,745)	
2,150	(1,837-
2,473)	 176	(153-206)	
20	
378,384	
(376,648-
379,746)	
2,995	(2,532-
3,459)	 126	(109-149)	
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Table	B2:	Cumulative	number	needed	to	vaccinate	per	death	averted	2025-2050	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Death	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
NNV	per	death	
averted		
(Uncertainty	
range)	
PRI	
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30	
40	
10	
135,917	
(135,838-
135,980)	
0.85	(0.45-1.40)	
140,995	
(108,261-
201,462)	
20	
135,917	
(135,838-
135,980)	
1.18	(0.62-1.97)	 102,019	(77,815-145,567)	
60	
10	
135,917	
(135,838-
135,980)	
1.26	(0.67-2.08)	 95,446	(73,282-136,383)	
20	
135,917	
(135,838-
135,980)	
1.74	(0.92-2.91)	 69,254	(52,823-98,818)	
80	
10	
135,917	
(135,838-
135,980)	
1.66	(0.89-2.74)	 72,682		(55,800-103,857)	
20	
135,917	
(135,838-
135,980)	
2.29	(1.21-3.83)	 52,880		(40,334-75,456)	
70	
40	
10	
317,139	
(316,955-
317,287)	
1.92	(1.03-3.17)	
146,838	
(112,726-
209,823)	
20	
317,139	
(316,955-
317,287)	
2.65	(1.39-4.43)	 107,023		(81,630-152,716)	
60	
10	
317,139	
(316,955-
317,287)	
2.81	(1.51-4.64)	 101,379		(77,813-144,867)	
20	
317,139	
(316,955-
317,287)	
3.85	(2.03-6.44)	 74,340		(56,700-106,081)	
80	
10	
317,139	
(316,956-
317,288)	
3.65	(1.96-6.04)	 78,703		(60,397-112,465)	
20	
317,139	
(316,956-
317,288)	
4.98	(2.62-8.34)	 58,048		(44,272-82,833)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PRI	
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de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
2.79	(1.40-6.41)	 64,045	(52,494-74,077)	
20	
162,162	
(161,417-
162,745)	
3.66	(1.76-8.71)	 50,007	(40,335-56,999)	
60	
10	
162,162	
(161,417-
162,745)	
4.14	(2.08-9.51)	 43,078	(35,326-49,839)	
20	
162,162	
(161,417-
162,745)	
5.43	(2.61-12.90)	 33,721	(27,189-38,416)	
80	
10	
162,162	
(161,417-
162,745)	
5.47	(2.75-12.54)	 32,596	(26,742-37,721)	
20	
162,162	
(161,417-
162,745)	
7.15	(3.44-16.98)	 25,580	(20,617-29,126)	
70	
40	
10	
378,378	
(376,639-
379,739)	
6.34	(3.19-14.53)	 65,575	(53,816-75,898)	
20	
378,378	
(376,639-
379,739)	
8.29	(3.98-19.64)	 51,546	(41,536-58,671)	
60	
10	
378,378	
(376,640-
379,740)	
9.31	(4.69-21.27)	 44,613	(36,654-51,666)	
20	
378,378	
(376,640-
379,740)	
12.13	(5.83-
28.61)	
35,270	
(28,397-40,097)	
80	
10	
378,379	
(376,640-
379,740)	
12.15	
(6.13-27.69)	
34,136	
(28,076-39,554)	
20	
378,379	
(376,640-
379,740)	
15.78	
(7.59-37.07)	
27,132	
(21,832-30,816)	
	
	
	Appendices	 415	
Va
cc
in
e	
M
ec
ha
ni
sm
	
Ag
e	
ta
rg
et
in
g	
Co
ve
ra
ge
	(%
)	
Va
cc
in
e	
Ef
fic
ac
y	
(%
)	
Du
ra
tio
n	
Individuals	
Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
NNV	per	deaths	
averted		
(Uncertainty	
range)	
PSI-L	
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30	
40	
10	
135,916	
(135,838-
135,980)	
0.03	
(0.01-0.06)	
3,706,285	
(2,958,178-
6,096,566)	
20	
135,916	
(135,838-
135,980)	
0.04	
(0.02-0.08)	
2,462,677	
(1,965,549-
4,056,801)	
60	
10	
135,916	
(135,838-
135,980)	
0.04	
(0.02-0.09)	
2,500,691	
(1,996,083-
4,113,801)	
20	
135,916	
(135,838-
135,980)	
0.06	
(0.03-0.13)	
1,663,455	
(1,327,628-
2,740,425)	
80	
10	
135,916	
(135,838-
135,980)	
0.05	
(0.03-0.11)	
1,898,161	
(1,515,252-
3,122,865)	
20	
135,916	
(135,838-
135,980)	
0.08	
(0.04-0.17)	
1,264,068	
(1,008,846-
2,082,613)	
70	
40	
10	
317,139	
(316,955-
317,287)	
0.06	
(0.03-0.13)	
3,826,806	
(3,054,996-
6,296,245)	
20	
317,139	
(316,955-
317,287)	
0.09	
(0.05-0.19)	
2,550,356	
(2,035,391-
4,202,038)	
60	
10	
317,139	
(316,955-
317,287)	
0.09	
(0.05-0.20)	
2,623,571	
(2,094,819-
4,317,445)	
20	
317,139	
(316,955-
317,287)	
0.13	
(0.07-0.28)	
1,753,138	
(1,399,062-
2,889,019)	
80	
10	
317,139	
(316,955-
317,287)	
0.12	
(0.06-0.26)	
2,023,385	
(1,615,897-
3,330,456)	
20	
317,139	
(316,955-
317,287)	
0.17	
(0.09-0.37)	
1,355,760	
(1,081,876-
2,234,576)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-L	
Ol
de
r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,745)	
4.60	
(0.65-13.31)	
45,342	
(37,100-79,890)	
20	
162,162	
(161,417-
162,745)	
6.34	
(0.85-19.17)	
32,516	
(27,191-59,563)	
60	
10	
162,162	
(161,417-
162,745)	
6.85	
(0.97-19.83)	
30,446	
(24,908-53,646)	
20	
162,162	
(161,417-
162,745)	
9.44	
(1.27-28.51)	
21,857	
(18,274-40,037)	
80	
10	
162,162	
(161,417-
162,745)	
9.08	
(1.28-26.25)	
22,999	
(18,812-40,524)	
20	
162,162	
(161,417-
162,745)	
12.48	
(1.68-37.71)	
16,528	
(13,815-30,275)	
70	
40	
10	
378,378	
(376,641-
379,740)	
10.54	
(1.49-30.48)	
46,217	
(37,799-81,436)	
20	
378,378	
(376,641-
379,740)	
14.49	
(1.95-43.76)	
33,237	
(27,778-60,881)	
60	
10	
378,378	
(376,642-
379,740)	
15.55	
(2.19-44.98)	
31,324	
(25,609-55,197)	
20	
378,379	
(376,642-
379,740)	
21.33	
(2.87-64.41)	
22,582	
(18,864-41,362)	
80	
10	
378,379	
(376,643-
379,741)	
20.41	
(2.88-59.01)	
23,879	
(19,515-42,079)	
20	
378,379	
(376,644-
379,741)	
27.92	
(3.76-84.29)	
17,257	
(14,408-31,607)	
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Vaccinated	2025-
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(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-LR	
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30	
40	
10	
135,916	
(135,838-
135,980)	
0.04	(0.02-0.09)	
1,953,107	
(1,814,214-
3,607,241)	
20	
135,916	
(135,838-
135,980)	
0.06	(0.03-0.13)	
1,264,352	
(1,173,728-
2,346,808)	
60	
10	
135,917	
(135,838-
135,980)	
0.06	(0.03-0.13)	
1,317,972	
(1,224,238-
2,434,448)	
20	
135,917	
(135,838-
135,980)	
0.09	(0.05-0.19)	
854,077	
(792,859-
1,585,394)	
80	
10	
135,917	
(135,838-
135,980)	
0.08	(0.04-0.17)	
1,000,553	
(929,387-
1,848,334)	
20	
135,917	
(135,838-
135,980)	
0.12	(0.06-0.25)	
649,058	
(602,536-
1,204,912)	
70	
40	
10	
317,139	
(316,955-
317,287)	
0.09	(0.05-0.20)	
2,017,371	
(1,873,873-
3,726,978)	
20	
317,139	
(316,955-
317,287)	
0.14	(0.07-0.29)	
1,309,585	
(1,215,717-
2,431,232)	
60	
10	
317,139	
(316,955-
317,287)	
0.14	(0.07-0.29)	
1,383,557	
(1,285,122-
2,556,696)	
20	
317,139	
(316,955-
317,287)	
0.20	(0.10-0.42)	
900,378	
(835,840-
1,671,837)	
80	
10	
317,139	
(316,955-
317,287)	
0.18	(0.09-0.376)	
1,067,459	
(991,497-
1,973,094)	
20	
317,139	
(316,955-
317,287)	
0.26	(0.13-0.55)	
696,435	
(646,515-
1,293,391)	
	
	Appendices	 418	
Va
cc
in
e	
M
ec
ha
ni
sm
	
Ag
e	
ta
rg
et
in
g	
Co
ve
ra
ge
	(%
)	
Va
cc
in
e	
Ef
fic
ac
y	
(%
)	
Du
ra
tio
n	
Individuals	
Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PSI-LR	
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r	A
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lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
9.83	(4.83-19.37)	 19,036	(14,653-21,122)	
20	
162,162	
(161,417-
162,746)	
13.70	(6.59-
27.68)	
13,582	(10,382-
15,247)	
60	
10	
162,162	
(161,417-
162,746)	
14.64	(7.20-
28.85)	
12,785	
(9,841-14,183)	
20	
162,162	
(161,418-
162,746)	
20.38	(9.80-
41.18)	
9,131	
(6,980-10,249)	
80	
10	
162,163	
(161,418-
162,746)	
19.38	(9.53-
38.19)	
9,659	
(7,435-10,713)	
20	
162,163	
(161,418-
162,746)	
26.95	(12.96-
54.45)	
6,906	
(5,279-7,750)	
70	
40	
10	
378,380	
(376,642-
379,741)	
22.50	(11.06-
44.34)	
19,413	
(14,943-21,528)	
20	
378,380	
(376,642-
379,741)	
31.27	(15.03-
63.19)	
13,890	
(10,617-15,585)	
60	
10	
378,381	
(376,644-
379,743)	
33.21	(16.32-
65.42)	
13,164	
(10,132-14,590)	
20	
378,381	
(376,644-
379,743)	
46.03	(22.11-
93.00)	
9,441	
(7,216-10,589)	
80	
10	
378,382	
(376,645-
379,744)	
43.57	(21.40-
85.83)	
10,040	
(7,727-11,122)	
20	
378,383	
(376,646-
379,744)	
60.22	(28.93-
121.71)	
7,218	
(5,517-8,092)	
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(Uncertainty	
range)	
Deaths	averted	
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Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PPI	
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30	
40	
10	
135,917	
(135,838-
135,980)	
0.89	(0.48-1.47)	
131,098	
(102,232-
190,927)	
20	
135,917	
(135,838-
135,980)	
1.23	(0.65-2.05)	 94,158	(73,049-137,194)	
60	
10	
135,917	
(135,838-
135,980)	
1.31	(0.71-2.18)	 88,762	(69,211-129,270)	
20	
135,917	
(135,838-
135,980)	
1.83	(0.97-3.04)	 63,931	(49,596-93,150)	
80	
10	
135,917	
(135,838-
135,980)	
1.73	(0.934-2.88)	 67,604	(52,708-98,455)	
20	
135,917	
(135,838-
135,980)	
2.40	(1.27-3.99)	 48,826	(37,877-71,140)	
70	
40	
10	
317,139	
(316,955-
317,287)	
2.00	(1.08-3.33)	
136,595	
(106,491-
198,928)	
20	
317,139	
(316,955-
317,287)	
2.78	(1.47-4.62)	 98,833	(76,667-143,998)	
60	
10	
317,139	
(316,955-
317,287)	
2.93	(1.58-4.87)	 94,346	(73,535-137,392)	
20	
317,139	
(316,955-
317,287)	
4.04	(2.14-6.72)	 68,685	(53,275-100,065)	
80	
10	
317,139	
(316,956-
317,288)	
3.81	(2.06-6.34)	 73,274	(57,096-106,698)	
20	
317,139	
(316,956-
317,288)	
5.22	(2.76-8.69)	 53,659	(41,615-78,168)	
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Vaccinated	2025-
2050,	Thousands	
(Uncertainty	
range)	
Deaths	averted	
2025-2050,	
Thousands	
(Uncertainty	
range)	
Cumulative	NNV	
per	death	averted	
2025-2050		
(Uncertainty	
range)	
PPI	
Ol
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r	A
du
lt	
30	
40	
10	
162,162	
(161,417-
162,746)	
12.57	(6.56-
24.13)	
14,698	
(11,502-16,502)	
20	
162,162	
(161,417-
162,746)	
17.17	(8.74-
34.06)	
10,671	
(8,303-12,097)	
60	
10	
162,163	
(161,418-
162,746)	
18.68	(9.75-
35.85)	
9,897	
(7,743-11,107)	
20	
162,163	
(161,418-
162,746)	
25.47	(12.97-
50.51)	
7,199	
(5,600-8,159)	
80	
10	
162,163	
(161,418-
162,746)	
24.66	(12.88-
47.35)	
7,496	
(5,864-8,410)	
20	
162,163	
(161,418-
162,746)	
33.58	(17.10-
66.59)	
5,464	
(4,249-6,190)	
70	
40	
10	
378,381	
(376,643-
379,742)	
28.59	(14.93-
54.90)	
15,091	
(11,804-16,927)	
20	
378,381	
(376,643-
379,742)	
38.89	(19.81-
77.10)	
11,013	
(8,564-12,474)	
60	
10	
378,382	
(376,645-
379,744)	
41.94	(21.92-
80.58)	
10,292	
(8,048-11,534)	
20	
378,383	
(376,645-
379,744)	
56.80	(28.98-
112.67)	
7,544	
(5,863-8,538)	
80	
10	
378,384	
(376,647-
379,745)	
54.71	(28.63-
105.18)	
7,893	
(6,170-8,838)	
20	
378,384	
(376,648-
379,746)	
73.73	(37.70-
146.41)	
5,810	
(4,514-6,571)	
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B3.	Additional	methods	chapter	4	
Immunosenescence	and	vaccination	
As	 discussed	 briefly	 in	 the	 Chapter	 4,	 elderly	 populations	 are	 at	 increased	 risk	 of	
infection	 and	 disease.	 This	 is	 thought	 to	 be	 likely	 due	 to	 a	 combination	 of	
immunosenescence	and	comorbid	conditions	reducing	the	immune	system’s	ability	to	
manage	 infections.1	 Age-associated	 immunosenescence	 has	 been	 shown	 to	 affect	
both	the	innate	(e.g.	reduced	phagocytic	activity)	and	the	adaptive	(e.g.	diminished	
antibody	 response	 to	new	antigens	and	 reduced	T-cell	 output)	 immune	 response.1	
Therefore,	vaccines	may	be	less	efficacious	in	this	age	group,	or	need	to	be	specifically	
designed	or	dosed	to	overcome	known	reduced	responsiveness	in	this	population.2	
Live	 attenuated	 vaccines	 are	 generally	 thought	 to	 induce	 more	 effective	 immune	
responses,	but	in	some	cases	have	been	associated	with	higher	risk	of	adverse	events,	
which	 is	of	concern	 for	older	age	groups.1	For	example,	 the	 live	attenuated	yellow	
fever	vaccine	has	been	associated	with	up	to	10	times	the	risk	of	severe	adverse	events	
in	the	elderly	compared	to	younger	populations.1	
Few	 vaccines	 have	 been	 rigorously	 assessed	 for	 efficacy	 in	 elderly	 populations.	
Influenza	 and	 varicella	 vaccines	 are	 two	 vaccines	 currently	 delivered	 to	 older	 age	
groups.	As	discussed	in	the	main	text,	one	of	the	varicella	vaccines	(Zostavax®)	was	
found	 to	have	declining	 efficacy	by	 age	 in	 the	 elderly,3	 suggestive	of	 an	 impact	 of	
immunosenescence	on	vaccine	efficacy	in	the	70-79	and	≥80	years	age	groups.	In	the	
elderly,	 a	 dose	 approximately	 14	 times	 the	 infant	 does	 was	 delivered.	 However,	
efficacy	of	a	different	zoster	vaccine	was	found	not	to	decline	with	age	in	the	elderly.4	
Therefore,	 effects	 of	 immunosenescence	 can	 potentially	 be	 counteracted	 if	 the	
vaccine	is	appropriately	designed	or	dosed.1	
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Another	 consideration	 in	 the	elderly	 is	 the	existence	of	 co-morbidities,	which	may	
affect	vaccine	efficacy,	and	for	some	comorbidities	may	lead	to	contraindication	due	
to	safety	concerns.1	Therefore	comorbidities	could	affect	coverage	and	efficacy.	
Vaccination	of	the	elderly	clearly	comes	with	safety	and	efficacy	challenges.	Some	of	
which	can	potentially	be	overcome	with	careful	design	of	the	vaccine	and	dosing,	but	
for	some	candidates	the	effects	of	 immunosenescence	may	be	unavoidable.	 In	this	
model	I	implemented	immunosenescence	in	the	elderly,	as	data	from	other	vaccines	
are	suggestive	of	a	likely	reduction	in	protective	efficacy	in	older	age	groups.	I	assumed	
2%	immunosenescent	waning	per	year	from	the	age	of	65	years	based	upon	expert	
opinion.	However,	as	there	are	few	data	to	inform	this	parameter,	I	also	conducted	a	
sensitivity	analysis	varying	this	waning	from	0%	to	5%.	The	0%	scenario	was	 in	 line	
with	data	from	the	Zoster	vaccine	that	demonstrated	invariate	efficacy	by	age.4	Data	
from	the	Zostavax®	vaccine	showing	declining	efficacy	by	age	was	used	to	inform	the	
upper	end	of	the	sensitivity	analysis	(5%).	This	vaccine	demonstrated	64%	efficacy	in	
60-69	year	olds,	41%	efficacy	70-79	years,	and	18%	efficacy	 in	≥80	year	olds.3	As	a	
back-of-the-envelope	estimation,	efficacy	would	need	to	start	at	68%	in	60-64	year	
olds,	and	decline	by	approximately	5%	per	year	from	the	age	of	65	years	to	produce	
these	results.	This	is	a	very	approximate	estimation,	but	in	the	absence	of	other	data	
sources	to	inform	this	analysis,	provides	a	quantitative	basis	for	the	upper	range	of	
the	sensitivity	analysis	for	the	immunosenescence	parameter.	
These	considerations	should	be	accounted	for	in	the	development	of	new	TB	vaccines	
–	older	adults	and	the	elderly	need	to	be	included	in	clinical	trials	for	evaluation	of	
safety	 and	efficacy	 to	 inform	vaccine	use	 in	 this	 age	 group,	 appropriate	modelling	
assumptions,	and	consideration	of	whether	alterations	to	the	vaccine	are	needed	to	
improve	efficacy	in	this	age	group.		
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B4.	Additional	results	for	Chapter	4	
Reduction	in	2050	TB	Incidence	rate		
Although	 not	 the	 primary	 aim	 of	 this	 research,	 some	 possible	 trade-offs	 between	
vaccine	characteristics	were	identified.	Results	suggest	that	with	a	40%	VE,	10	year	
protection	and	30%	coverage	vaccine	as	the	starting	point,	roughly	double	the	impact	
could	be	achieved	by	increasing	duration	of	protection	from	10	to	20	years,	or	vaccine	
efficacy	from	40%	to	80%,	or	coverage	from	30%	to	70%.		
Many	vaccines	(excepting	PSI-LR	and	some	20	year	duration	vaccines)	demonstrated	
similar	median	estimates	and	overlapping	URs	when	comparing	low	efficacy	vaccines	
with	 high	 coverage	 (40%	 VE,	 70%	 coverage)	 to	 high	 efficacy	 vaccines	 with	 low	
coverage	(80%	VE,	30%	coverage),	suggesting	that	shortfalls	in	vaccine	efficacy	could	
often	be	compensated	for	by	increased	coverage,	and	vice	versa.	
Therefore,	even	if	an	ideal	candidate	is	not	developed,	investment	in	achieving	high	
coverage	 rates	 and	ensuring	 the	highest	 burden	populations	 are	 vaccinated,	 could	
potentially	overcome	shortfalls	in	intrinsic	vaccine	characteristics.		
Incidence	 rate	 reduction	 ranged	 0.01%	 to	 32%	 with	 feasible	 vaccine	 profiles	 and	
targeted	 vaccination	 strategies	 explored.	 Although	 the	 overall	 impact	 could	 be	
improved	 by	 inclusion	 of	 broader	 mass	 campaigns,	 with	 these	 relatively	 feasible	
vaccination	 scenarios	 the	 impact	 difference	 between	 the	most	 and	 least	 effective	
vaccines	and	delivery	to	older	adults	versus	adolescents	was	substantial,	highlighting	
the	importance	of	ensuring	that	an	appropriately	designed	vaccine	is	developed	and	
delivered	to	a	suitable	population	to	maximise	impact.	
Low	vaccine	efficacy	(40%	instead	of	80%)	could	be	compensated	for	by	 increasing	
coverage	from	30%	to	70%.	
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Appendix	C:	ePAL	Protocol	
	
Clinic-based	electronic	capture	of	the	spatial	distribution	of	TB	case	place	of	residence	in	
Blantyre,	Malawi	(The	TB	ePAL	Study)	
	
Principal	Investigator:			
London	School	of	Hygiene	and	Tropical	Medicine	(LSHTM)		
Rebecca	Harris	
	 	
Host	Institute:	
Malawi-Liverpool-Wellcome	Clinical	Research	Programme	
	
Local	collaborators:		
MLW		
Professor	Elizabeth	Corbett	
Augustine	Choko	
Rodrick	Sambakunsi	
David	Matiya	
Alfred	Chimala	
Professor	Rob	Heyderman	
	 	
District	Health	Office:	
Dr	Owen	Malemiya	
	
Ministry	of	Health,	National	TB	Programme	&	HIV	unit:	
NTP	Manager:	Dr	James	Mpunga	
TB	Research:	Mr	Andrew	Dimba	
	
International	Collaborators:		
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Dr	Richard	White	 LSHTM,	UK	
Dr	Peter	MacPherson	LSTM,	UK	
Dr	Emily	Webb	 LSHTM,	UK	
	
Version	2.0	last	amended	2/6/2014	by	RCH	
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Abbreviations	
	
ACF		 Active	case-finding	for	TB	
ARV	
ART	
CEA	
Anti-retroviral	
Anti-retroviral	therapy	
Census	enumeration	area	
eCRF	 electronic	Case	Report	Form	
EDC	 Electronic	Data	Capture	
ePAL		 electronic	PArticipant	Locator	
GPS	
LSHTM	
MLW	
HSA	
Global	Positioning	System	
London	School	of	Hygiene	and	Tropical	Medicine	
Malawi-Liverpool-Wellcome	Trust	
Health	Surveillance	Assistants	(Community	Health	Workers)	
PI	 Principal	Investigator	
PII	 Personally	Identifiable	Information	
POI	
SES	
	
Point/Place(s)	Of	Interest	
Socio-Economic	Status	
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Glossary	
	
Adult	
Person	aged	≥18	years	old	at	time	of	TB	treatment	initiation	
visit	
ePAL	(electronic	
Participant	Locator)	
Software	loaded	onto	electronic	tablets	for	use	at	the	health	
centres	to	collect,	save	and	transfer	participant	 information	
and	place	of	 residence	to	a	central	database.	Contains	data	
capture	forms	and	annotated	maps	of	Blantyre	City.	
Evaluation	period	
Approximately	 6	 month	 period	 following	 the	 run-in	 period	
(below)	 during	 which	 approximately	 196	 consenting	
participants	 will	 receive	 follow-up	 visits	 at	 their	 place	 of	
residence	 to	 collect	 GPS	 coordinates	 for	 evaluation	 of	 the	
ePAL	tool.	
Participant	 Person	eligible,	consented	and	enrolled	into	the	study.	
TB	patient	
Person	 receiving	 care	 under	 the	 diagnosis	 of	 tuberculosis	
(regardless	of	method	of	diagnosis).	
Place	of	Residence	 The	place	where	a	person	usually	eats	meals	and	sleeps	
Patient	initiating	TB	
treatment	or	TB	
treatment	initiator	
TB	patient	presenting	at	health	centre	registering	for	initiation	
of	treatment	for	TB.	
Run-in	period	
Period	at	the	beginning	of	the	study	when	the	tool	 is	rolled	
out	and	data	collected	from	evaluation	visits	is	used	to	inform	
the	improvement	of	the	tool	and	its	implementation.	
Treatment	initiation	
visit	
Visit	 to	 the	 health	 centre	 as	 part	 of	 routine	 care	 at	 which	
people	 are	 registered	 as	 TB	 patients	 and	 commence	
treatment	for	TB	disease.	
Follow	up	visit	
Study-specific	visit	to	the	participant’s	place	of	residence	after	
the	treatment	initiation	visit.	Only	conducted	for	participants	
selected	and	consenting	to	participate	in	the	tool	evaluation.	
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SUMMARY	
Background	
The	burden	of	tuberculosis	(TB)	varies	geographically,	but	this	heterogeneity	is	often	
poorly	understood	at	the	local	level.	In	Malawi	(and	elsewhere)	TB	patients’	addresses	
or	description	of	residence	location	are	recorded	at	TB	registration	to	allow	patient	
follow	 up,	 but	 these	 data	 are	 rarely	 used	 for	 spatial	 analysis.	 Moreover,	 in	 areas	
without	official	address	systems,	the	accuracy	of	descriptions	is	often	low,	which	is	a	
significant	 obstacle	 for	 patient	 follow-up.	 The	 development	 of	 a	 method	 to	
systematically	 collect	 high-resolution	 TB	 patient	 location	 of	 residence	 could	 allow	
better	 retention	 in	 TB	 treatment	 programmes	 and	 could	 be	 used	 to	 maximise	
efficiency	 of	 local	 TB	 programmes	 through	 targeted	 interventions	 to	 high	 burden	
areas.	
	
In	 this	 study	 we	 aim	 to	 develop	 and	 evaluate	 a	 novel	 electronic	 mapping	 tool	
(electronic	 PArticipant	 Locator	 -	 ePAL)	 to	map	 the	 geographical	 distribution	of	 the	
place	of	residence	of	people	registering	for	TB	treatment	in	Blantyre	City,	Malawi.	If	
successful,	it	is	envisaged	that	this	tool	could	have	significant	future	utility	for	similar	
mapping	of	other	diseases	of	public	health	importance,	and	for	patient	follow	up	for	
TB	and	other	diseases	for	which	patients	are	managed	in	the	community	in	Blantyre,	
Malawi,	and	beyond.	
	
Type	of	study	
A	prospective,	single-site,	epidemiology	study	using	the	ePAL	tool	on	electronic	tablets	
at	 TB	 centres	 in	 Blantyre	 City	 for	 clinic-based	 collection	 of	 participant	 information	
including	demographics,	health	status	and	the	physical	location	of	place	of	residence	
of	patients	aged	≥18	years	initiating	TB	treatment.		
	
Development	of	the	ePAL	tool	will	require	annotation	of	Blantyre	map	images	with	
places	of	interest	(POIs)	to	help	participants	orientate	themselves	in	the	map.	This	will	
be	achieved	by	community	engagement	through	Health	Surveillance	Assistants	(HSAs)	
to	identify	important	landmarks	such	as	markets,	places	of	worship,	streets	or	shops,	
	Appendices	 430	
which	will	then	be	mapped	by	GPS	location	capture	by	study	field	staff	and	uploaded	
to	the	maps	on	the	tablets.	
The	evaluation	period	of	the	ePAL	tool	will	enrol	approximately	196	participants	to	
evaluate	the	agreement	between	the	ePAL-recorded	co-ordinates	taken	at	the	health	
centre	and	a	measurement	taken	using	GPS	at	a	follow	up	visit	at	the	participant’s	
place	of	residence.	This	group	will	also	be	asked	some	additional	questions	during	the	
treatment	 initiation	 visit	 pertaining	 to	 exposure	 to	 TB	 risk	 factors,	 care	 seeking	
behaviour	and	socio-economic	status	(SES).	The	evaluation	period	will	be	preceded	by	
a	run-in	period,	during	which	the	collected	evaluation	data	will	be	used	for	refinement	
of	the	tool	and	its	implementation.	
	
Objectives	and	endpoints:		
Primary	objectives		
• To	map	the	spatial	distribution	of	the	place	of	residence	of	all	adults	initiating	
treatment	for	pulmonary	tuberculosis.	
• To	estimate	the	census	enumeration	area	(CEA)-wise	case	notification	rates	of	
all	adults	initiating	treatment	for	pulmonary	tuberculosis.	
	
Secondary	objectives		
• To	map	the	spatial	distribution	and	calculate	CEA-wise	case	notification	rates	
of	the	place	of	residence	of	all	adults	initiating	treatment	for	tuberculosis.	
• To	map	the	spatial	distribution	and	calculate	CEA-wise	case	notification	rates	
of	the	place	of	residence	of	microbiologically-confirmed	adult	cases	initiating	
treatment	for	pulmonary	tuberculosis.	
• To	map	the	spatial	distribution	of	adult	pulmonary	tuberculosis	notifications,	
stratified	by	age,	gender	and	HIV	status.	
• To	 describe	 the	 spatial	 distribution	 of	 adult	 pulmonary	 tuberculosis	
notifications	according	to	socioeconomic	status,	care	seeking	behaviour	and	
risk	factors	for	tuberculosis.	
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Evaluation	objective		
• To	evaluate	the	spatial	accuracy	of	ePAL	for	identifying	place	of	residence	of	
adult	 TB	 cases	 resident	 in	 Chilomoni	 or	 Ndirande	 and	 presenting	 to	 the	
Ndirande,	Chilomoni	or	Queen’s	Hospital	TB	clinics.	
	
Study	population:	Adult	residents	(aged	18	years	or	above)	of	Blantyre	City	registering	
for	TB	treatment.	
	
Methods	and	Procedures:	A	new	software	programme	consisting	of	case	report	forms	
and	maps	 for	data	 collection	will	 be	developed	and	 installed	on	 to	 tablets	 for	 this	
study.	 The	 high	 resolution	 satellite	 photograph	 maps	 used	 in	 this	 software	 for	
identifying	place	of	residence	will	require	the	addition	of	places	of	interest	(POIs)	to	
allow	 the	 users	 to	 orientate	 themselves	 in	 the	map.	 These	 POIs	will	 be	 identified	
through	community	engagement	via	health	surveillance	assistants	 (HSAs),	who	will	
assist	study	field	workers	to	collect	GPS	coordinates	of	the	POIs	so	that	they	can	be	
added	to	the	maps	on	the	tablet.	
	
All	TB	patients	registering	for	treatment	in	participating	health	centres	in	Blantyre	City	
will	be	invited	to	participate	by	the	TB	officer	or	nurse	registering	them	for	treatment.	
TB	patients	will	be	provided	with	an	information	sheet,	and	verbal	consent	obtained.	
Participant	 information	such	as	demographics	and	health	status	will	be	recorded	in	
the	ePAL	electronic	case	report	forms	(eCRFs).	The	participant	will	be	guided	by	the	
TB	officer	through	maps	on	the	tablet	to	locate	and	select	their	place	of	residence.	
The	Hit	TB	Hard	 study	 (COMREC	P.011/10/1020)	 is	 an	on-going	active	 case	 finding	
study,	 for	 which	 sputum	 is	 collected	 for	 monitoring	 and	 evaluation	 purposes	
throughout	Blantyre	City.	 The	 sputum	barcode	 from	 the	Hit	 TB	Hard	 study	will	 be	
recorded	to	 link	the	data	collected	 in	this	study	to	the	participant’s	culture	results.	
Data	 will	 be	 stored	 on	 the	 tablet,	 and	 uploaded	 daily	 to	 the	MLW	 server	 via	 3G	
connection.	
	
Participants	 will	 be	 invited	 to	 participate	 in	 the	 evaluation	 group	 if	 resident	 in	
Chilomoni	or	Ndirande	and	presenting	to	the	Ndirande,	Chilomoni	or	Queen’s	Hospital	
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clinics.	All	such	patients	presenting	during	the	run-in	period	will	be	enrolled	(up	to	a	
limit	of	as	the	number	of	home	visits	possible	per	day	by	field	staff),	and	approximately	
196	 patients	 will	 be	 enrolled	 during	 the	 evaluation	 period.	 For	 those	 willing	 to	
participate	 in	 the	 evaluation,	 written	 consent	 (or	 witnessed	 thumbprint)	 will	 be	
obtained.	The	evaluation	 includes	additional	 collection	of	data	 related	 to	SES,	 care	
seeking	behaviour	and	TB	risk	factor	exposure	during	the	TB	treatment	initiation	visit,	
plus	a	study	follow-up	visit	to	the	participant’s	place	of	residence,	where	a	GPS	reading	
of	the	place	of	residence	will	be	taken.	
	
Data	collection	and	management:	Data	capture	 for	 this	study	 is	mostly	electronic.	
Data	 collected	 at	 the	 treatment	 initiation	 visit	 will	 be	 collected	 directly	 on	 the	
electronic	tablet.	For	the	evaluation	group	participants,	coordinates	collected	during	
evaluation	follow-up	visits	at	the	patient’s	place	of	residence	will	be	measured	using	
a	GPS	recorder	and	logged	on	a	paper	record	sheet.	Data	will	be	managed	by	the	study	
team	in	MLW	and	LSHTM	in	the	MLW	data	office	and	LSHTM	offices.		The	clinic-based	
tablets	will	be	password	protected	and	automatically	lock	after	5	minutes	of	inactivity	
to	protect	the	participant	data	stored	on	the	tablet.	The	electronic	database	on	the	
server	at	MLW	(and	the	daily-synced	LSHTM	database)	will	be	password	protected	and	
maintained	on	a	secure	server.		Data	will	be	backed	up	weekly	on	password-protected	
laptops,	and	secure	off-site	servers.		
	
Statistical	 considerations	 and	 analysis:	 The	 study	 will	 attempt	 to	 enrol	 all	 adults	
registering	for	TB	treatment	at	participating	health	centres	in	Blantyre	City,	estimated	
at	2800-3000	patients	in	a	12-month	study	period.	During	the	2-month	run-in	period	
at	the	start	of	the	study,	data	collected	will	be	used	for	refinement	of	the	tool	and	its	
implementation.	 The	 evaluation	 period	 of	 the	 study	 will	 enrol	 approximately	 196	
participants	 to	 assess	 the	 reliability	 of	 ePAL	 versus	GPS	measurements	 of	 place	of	
residence.	Given	the	likely	 inaccuracy	of	 locating	to	the	household	level,	but	taking	
into	account	the	high	density	of	points	of	interest	to	assist	orientation	in	the	map,	the	
expected	 level	 of	 agreement	 of	 ePAL	 to	 within	 20m	 of	 GPS	 measurements	 is	
approximately	85%,	and	the	minimum	acceptable	level	of	agreement	for	the	tool	to	
be	of	value	is	80%.	This	sample	size	of	196	participants	is	estimated	to	be	sufficient	to	
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provide	precision	of	5%	when	estimating	proportion	agreement	with	point	estimate	
of	85%	(i.e.	lower	limit	of	95%	confidence	interval	of	80%).		
Primary	analyses	will	map	the	spatial	distribution	of	pulmonary	TB	cases	in	Blantyre	
city,	and	estimate	the	case	notification	rates	per	100,000	population	per	year	for	each	
CEA.	Secondary	analyses	will	estimate	 the	spatial	distribution	and	case	notification	
rates	with	all	TB	cases	and	microbiologically-confirmed	TB	cases	as	 the	numerator.	
Mapping,	 and	 case	 notification	 rates	 where	 possible,	 will	 be	 conducted	 for	 data	
stratified	by	age,	gender	and	HIV	status.	Descriptive	analyses	of	SES,	care	seeking	and	
TB	risk	factor	data	will	also	be	conducted	with	data	from	participants	enrolled	into	the	
evaluation	group.	
	
Ethical	considerations:	This	study	is	 likely	to	benefit	the	community	through	better	
understanding	 of	 the	 distribution	 of	 TB	 cases	 in	 Blantyre	 city	 and	 potential	 for	
improved	 patient	 follow	 up.	 Application	 is	 being	made	 to	 the	 Institutional	 Review	
Boards	 of	 College	 of	Medicine,	 Blantyre	Malawi	 (COMREC),	 and	 London	 School	 of	
Hygiene	And	Tropical	Medicine,	UK.	Risks	from	study	participation	are	minimal,	and	
relate	to	linkage	of	personally	identifiable	information	(PII)	to	sensitive	health	data,	
and	 to	 the	 risk	 of	 revealing	 health	 information.	 All	 possible	 steps	will	 be	 taken	 to	
minimise	these	risks,	such	as	use	of	a	numerical	unique	identifier	instead	of	names	in	
the	 database,	 and	 conducting	 the	 home	 visit	 in	 a	 manner	 that	 minimises	 risk	 of	
revealing	health	status,	by	visiting	at	a	time	agreed	by	the	participant,	not	bearing	any	
labels	indicating	the	field	worker	is	part	of	a	TB	or	HIV	study,	and	ensuring	the	health	
information	 about	 the	 participant	 is	 not	 communicated	 to	 others	 unless	 express	
permission	is	given	by	the	participant.	
	
Data	collected	in	this	study	is	the	information	recommended	to	be	collected	as	part	
of	patient	registration	in	the	national	TB	system	(place	of	residence,	demographics,	
health	 status)	 and	 the	 potential	 for	 harm	 is	 minimal,	 therefore	 verbal	 consent	 is	
considered	 appropriate	 for	 participation	 in	 this	 study.	 Permission	 to	 obtain	 verbal	
consent	 is	 requested	 from	 the	 ethics	 committee.	 Written	 consent	 (or	 witnessed	
thumbprint	for	participants	who	are	illiterate)	will	be	obtained	for	those	participating	
in	the	evaluation	group,	as	some	information	collected	is	not	routinely	collected.	
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Expected	findings	and	their	dissemination:	It	is	anticipated	that	there	may	be	large	
differences	 in	 numbers	 of	 cases	 and	 TB	 rates	 between	 some	 census	 enumeration	
areas,	these	may	be	 linked	to	known	risk	factors	for	TB.	Weekly	reports	containing	
interim	summaries	of	 the	data	 collected	 in	 the	main	 study	and	 tool	evaluation,	by	
health	centre	and	for	the	study	as	a	whole,	will	be	sent	to	the	TB	officers	and	nurses	
involved	in	the	study	via	3G	to	the	tablets	at	the	health	centres.	Dissemination	of	final	
results	 will	 be	 through	 local	 and	 international	 conferences,	 community	 feedback	
meetings,	NTP	meetings,	and	peer-reviewed	publications.				
	
BACKGROUND	
Variation	in	the	burden	of	tuberculosis	(TB)	is	mostly	well	recognised	at	national	and	
regional	 levels	 as	 a	 result	 of	 government	 surveillance	 systems.	 However,	 such	
heterogeneity	is	often	poorly	understood	at	the	local	level,	such	as	between	areas	in	
a	city.	A	small	number	of	studies	in	Sub-Saharan	Africa	have	demonstrated	such	local	
variations	 exist	 for	 TB	 disease.	 For	 example,	 in	 Cape	 Town,	 South	 Africa,	 39	
enumerator	 districts	 (across	 two	 communities)	with	 an	 average	 population	 of	 900	
inhabitants	reported	adult	TB	notification	rates	ranging	between	0	and	2,847/100,000	
adults	per	year.1		Similar	variations	were	reported	in	a	settlement-level	study	in	the	
Gambia,	 where	 rates	 in	 settlements	 of	 4,000-68,000	 people	 ranged	 from	 48	 to	
239/100,000	 population/year.2	 The	 potential	 for	 such	 large	 local	 variations	 in	 TB	
disease	 burden	 demonstrates	 that	 regional	 or	 even	 city-level	 data	 may	 not	 be	
sufficient	 for	 designing	 targeted	 control	 programmes,	 and	 highlights	 the	 need	 for	
local-level	burden	of	disease	information.	
	
Efficient	targeting	of	control	programmes	based	on	geographical	variation	in	burden	
of	 disease	 is	 well	 documented	 for	 many	 diseases.	 Malaria,	 for	 example,	 is	
heterogeneously	distributed	in	certain	settings,	where	it	has	been	demonstrated	that	
using	 local	 epidemiology	 for	 rational	 targeting	 of	 interventions	 is	 essential	 for	
effective	 and	 efficient	 disease	 control.3	 Spatial	 mapping	 and	 an	 analysis	 of	 the	
associated	 risk	 factors	 for	 TB	 could	 play	 an	 important	 role	 in	 understanding	
transmission	 dynamics,	 targeting	 interventions	 for	 disease	 treatment	 and	 risk	
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reduction,	and	identifying	MDR	TB	disease	clusters.4	Such	local	data	could	be	essential	
for	cost-effective	targeting	of	health	interventions	to	the	localities	experiencing	the	
greatest	burden	of	TB	disease,	but	for	tuberculosis	these	data	are	rarely	available.		
	
Existing	 spatial	 studies	 often	 use	 enumerated	 DHS	 populations	 or	 prospectively	
capture	place	of	residence	using	GPS,	which	is	resource-intensive.2,5,6		Therefore,	due	
to	costs	or	logistics,	such	detailed	prospective	TB	case	mapping	in	non-enumerated	
populations	 is	 uncommon.	 In	 Sub-Saharan	Africa,	 spatial	 and	 temporal	 analyses	of	
household-level	TB	data	have	been	conducted	in	communities	in	only	a	few	countries,	
namely	South	Africa,	Ghana	and	Ethiopia.2,5,6	In	Malawi	(and	elsewhere)	TB	patients’	
addresses	are	recorded	at	TB	registration	to	allow	patient	follow	up,	but	these	data	
are	 rarely	 used	 for	 spatial	 analysis.	 Moreover,	 in	 areas	 without	 official	 address	
systems,	the	accuracy	of	such	descriptions	is	usually	low	and	patients	often	seek	care	
outside	of	the	TB	clinic	catchment	area	of	their	place	of	residence,	creating	significant	
obstacles	 for	 patient	 follow-up.	 The	 development	 of	 a	 low-cost	 method	 to	
systematically	 collect	 high-resolution	 location	 of	 residence	 when	 presenting	 at	 TB	
clinics	could	allow	better	retention	in	TB	treatment	programmes	and	could	be	used	to	
maximise	efficiency	of	 local	TB	programmes	through	targeted	interventions	to	high	
burden	areas.	
	
The	mapbook	system	developed	in	Blantyre,	Malawi	is	a	validated	paper	based	tool	
demonstrated	to	accurately	and	rapidly	identify	the	location	of	place	of	residence	of	
anti-retroviral	(ARV)	therapy	initiators	at	health	facilities.7	Such	a	tool	allows	mapping	
of	 non-enumerated	 populations,	 as	 are	 found	 in	 urban	 Blantyre’s	 informal	
settlements,	to	residential	clusters	of	approximately	1300	people.	Although	this	tool	
proved	valuable	for	identifying	participants	from	study	clusters	presenting	at	health	
centres,	paper-based	tools	are	widely	being	phased	out	in	field	studies	in	favour	of	
electronic	 data	 capture	 (EDC).	 Therefore,	 to	 improve	 its	 utility	 by	 increased	
throughput	and	automation,	 and	 to	 future-proof	 such	a	 tool,	 an	electronic	 system	
would	be	the	logical	evolution	of	the	paper	mapbook.	In	addition,	it	is	possible	that	an	
electronic	 system	 could	 be	 used	 to	 capture	 cases	 down	 to	 the	 household	 level	 as	
opposed	to	clusters	as	used	in	the	paper	mapbook	study,	which	would	provide	greater	
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resolution	in	disease	maps	and	could	be	developed	further	as	a	tool	for	patient	follow	
up	in	subsequent	studies.	In	the	future,	such	an	electronic	capture	system	could	be	an	
appropriate	tool	for	much	broader	data	collection	in	Blantyre	and	Malawi	as	part	of	
routine	case	data	capture	 to	understand	 local-level	 tuberculosis	epidemiology,	and	
target	limited	available	resources	more	effectively.	
	
Although	 Malawi	 has	 experienced	 a	 steady	 decline	 in	 TB	 incidence	 since	 1998,	
progress	has	been	 slow	and	 incidence	of	disease	 remains	high	 fuelled	by	high	HIV	
prevalence	(National	TB	incidence	163/100,000	population/year).8	Burden	of	both	HIV	
and	TB	disease	is	highest	in	Southern	Malawi,	accounting	for	approximately	60%	of	
reported	TB	cases.9	Therefore	there	remains	a	significant	need	for	research	to	assess	
and	reduce	TB	disease	burden.	Two	major	TB	and	HIV	studies	constituting	the	Hit	TB	
Hard	research	programme	are	on-going	in	Blantyre.	This	includes	one	demonstration	
project	 assessing	 the	 impact	 of	 active	 case	 finding	 (ACF)	 in	 a	 population	 of	
approximately	108,000	adults	in	North	West	Blantyre,	and	a	cluster	randomised	trial	
of	home-based	HIV	testing	in	33,600	adults	residing	in	28	clusters	nested	within	this	
area.	As	monitoring	and	evaluation	for	these	studies,	TB	culture	testing	is	available	to	
patients	 presenting	 at	 TB	 centres	 throughout	 Blantyre	 City.	 At	 time	 of	 sputum	
collection	for	culture	testing,	the	paper	mapbook	is	used	to	identify	whether	patients	
are	resident	in	one	of	the	home-based	HIV	testing	intervention	clusters.	An	electronic	
tool	for	locating	place	of	residence	would	be	a	highly	valuable	addition	to	the	Hit	TB	
Hard	 research	 programme,	 both	 to	 assist	 patient	 follow	 up,	 and	 to	 permit	 spatial	
mapping	 of	 TB	 to	 inform	 implementation	 of	 public	 health	 interventions,	 such	 as	
targeted	contact	 tracing	and	active	case	finding,	and	community	based	TB	and	HIV	
diagnosis	and	treatment	in	hotspots.		
In	South	Africa,	spatial	mapping	studies	have	been	used	to	understand	the	risk	factors	
associated	with	local	disease	clusters.3	In	this	study,	risk	factor	data	will	be	collected	
from	evaluation	participants,	if	TB	hotspots	are	identified	as	overlapping	with	specific	
risk	factors	these	data	could	inform	selection	of	appropriate	interventions	in	addition	
to	directing	where	they	should	be	implemented.	
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There	is	a	clear	need	for	tools	to	better	understand	the	local-level	distribution	of	TB	
cases	 in	Malawi.	 In	 this	 study	we	 aim	 to	 develop	 and	 evaluate	 a	 novel	 electronic	
mapping	 tool	 (electronic	 PArticipant	 Locator	 -	 ePAL)	 to	 map	 the	 geographical	
distribution	of	the	place	of	residence	of	people	registering	for	TB	treatment	in	Blantyre	
City,	Malawi.	If	successful,	it	is	envisaged	that	this	tool	could	have	significant	future	
utility	 for	 similar	 mapping	 of	 other	 diseases	 of	 public	 health	 importance,	 and	 for	
patient	 follow	up	 for	TB	and	other	diseases	 for	which	patients	are	managed	 in	 the	
community	in	Blantyre,	in	Malawi,	and	beyond.	
	
RATIONALE,	STUDY	DESIGN	AND	OBJECTIVES	
Rationale	
Understanding	 local	 variation	 in	 burden	 of	 disease	 and	 associated	 risk	 factors	 can	
permit	 more	 efficient	 selection	 and	 targeting	 of	 limited	 resources	 for	 TB	 disease	
control.	However,	studies	to	generate	these	data	usually	require	existing	enumeration	
of	the	population	of	interest	or	large	budgets	to	conduct	this	ahead	of	the	study.	Such	
studies	 are	 not	 appropriate	 where	 resources	 are	 constrained	 or	 for	 national	
tuberculosis	 programmes	where	 surveillance	 covers	 large	 populations,	 therefore	 a	
low-cost	 methodology	 for	 identifying	 location	 of	 TB	 cases	 in	 the	 context	 of	 the	
national	 TB	programme	would	be	desirable	 to	permit	 collection	of	 such	 local-level	
data.	
	
Accurate	local	TB	case	distribution	data	are	currently	not	available	in	Blantyre,	Malawi.	
This	is	primarily	due	to	the	lack	of	municipal	address	systems,	but	is	also	impeded	by	
the	inaccuracy	of	verbal	descriptions	of	place	of	residence	and	the	large	amount	of	
resources	that	would	be	required	to	collect	such	descriptions	from	the	clinic	paper	
registries.	Furthermore,	the	inaccuracy	of	verbal	descriptions	means	that	TB	staff	are	
often	unable	to	locate	patients	lost	to	treatment	follow	up.	Thus,	there	is	a	need	to	
digitise	 and	 improve	 the	 accuracy	 of	 such	 data	 collection	 to	 allow	 efficient	 and	
effective	collection	of	place	of	residence,	to	improve	both	patient-level	follow	up	and	
decision	making	by	the	TB	control	programme.	This	study	will	aim	to	meet	this	need	
through	the	development	and	evaluation	of	an	electronic	tablet	tool	to	collect	place	
of	residence	of	TB	patients	when	registering	at	TB	centres	in	Blantyre,	Malawi.	Such	a	
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tool	has	the	potential	for	broader	use	within	control	programmes	and	research	studies	
throughout	Malawi	and	beyond	for	patient	follow	up	and	to	generate	data	to	inform	
TB	control	decision	making.	
	
Study	design	
This	study	consists	of	two	components:	A)	The	prospective	collection	of	demographic	
data	 and	 home	 location	 of	 TB	 treatment	 initiators	 using	 the	 ePAL	 tool;	 and	 B)	 an	
evaluation	of	 the	 accuracy	of	 data	 collected	using	 ePAL	by	 comparison	 to	GPS	 co-
ordinates	collected	at	the	patient’s	place	of	residence.	
	
Main	Study	
This	prospective	epidemiology	study	consists	of	clinic-based	collection	of	the	place	of	
residence	of	patients	 ≥18	 years	 initiating	 TB	 treatment	 (TB	notifications)	 using	 the	
ePAL	tool	at	TB	centres	in	Blantyre	City.		
	
This	 study	 is	 an	 epidemiological	 study,	 as	 such	 there	 will	 be	 no	 study-directed	
administration	of	pharmaceutical	interventions	nor	additional	collection	of	specimens	
beyond	what	is	already	part	of	the	routine	national	system	and	existing	Hit	TB	Hard	
study	(COMREC	P.11/10/1020).	There	is	no	randomisation	to	a	medical	intervention	
or	 care	 provided,	 and	 all	 participating	 clinics	 will	 receive	 the	 ePAL	 tool	 for	 data	
collection.	
	
The	study	will	be	initiated	in	the	Queen	Elizabeth	Central	Hospital	TB	clinic,	where	any	
refinements	 required	 for	 the	 study	 logistics,	 staff	 training	or	 the	 ePAL	 tool	 can	be	
made.	The	ePAL	 tool	will	 then	be	 rolled	out	across	all	 participating	TB	 registration	
centres	 in	 Blantyre	 City	 (population	 approximately	 661,256)10.	 Enrolment	 will	
continue	 until	 the	 end	 of	 the	 ePAL	 evaluation	 phase,	 and	 if	 demonstrated	 to	 be	
accurate	will	be	continued	until	the	end	of	the	monitoring	and	evaluation	element	of	
the	Hit	TB	Hard	study,	expected	3-4Q	2015.	
	
All	patients	≥18	years	presenting	to	participating	TB	centres	for	TB	treatment	initiation	
will	be	invited	to	participate	in	the	study;	those	verbally	consenting	to	participation	
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will	be	enrolled.	Upon	enrolment,	routine	demographics	and	disease	and	treatment	
history	will	be	collected.	As	part	of	routine	care,	HIV	testing	is	offered	to	all	patients	
registering	for	TB	treatment;	therefore	HIV	status	can	be	ascertained	from	the	results	
of	 the	 test	 at	 TB	 treatment	 initiation,	 or	 alternatively	 patient	 reporting	 or	 patient	
records	are	also	a	suitable	information	source.	Patients	may	refuse	for	HIV	status	to	
be	recorded.	During	the	same	visit	physical	location	of	the	treatment	initiator’s	place	
of	residence	will	be	recorded	by	the	patient	using	ePAL,	assisted	by	the	centre’s	TB	
officer.	An	evaluation	of	the	ePAL	tool	is	nested	within	the	study.	Approximately	196	
patients	will	be	invited	to	participate	in	the	evaluation.		
Tool	Evaluation		
An	 assessment	 of	 the	 agreement	 between	 the	 clinic-based	 capture	 of	 place	 of	
residence	using	the	ePAL	tool	and	the	gold	standard	of	GPS	co-ordinates	captured	at	
the	place	of	residence	is	required	to	evaluate	the	accuracy	of	the	tool.		
	
Participants	 will	 be	 invited	 to	 participate	 in	 the	 evaluation	 group	 if	 resident	 in	
Chilomoni	or	Ndirande	and	presenting	to	the	Ndirande,	Chilomoni	or	Queen’s	Hospital	
clinics	during	the	run-in	or	evaluation	periods.	All	such	patients	presenting	during	the	
run-in	period	will	be	enrolled	(up	to	a	limit	of	as	the	number	of	home	visits	possible	
per	day	by	field	staff),	and	all	such	patients	up	to	a	limit	of	approximately	196	patients	
will	be	enrolled	during	the	evaluation	period	(See	7.1	for	sample	size	calculations).	If	
the	enrolment	limit	is	reached	before	the	end	of	the	evaluation	period,	all	participants	
will	be	automatically	assigned	to	the	main	study.	During	the	2-month	run-in	period	at	
the	start	of	the	study,	data	collected	will	be	used	for	refinement	of	the	tool	and	its	
implementation.	 The	 data	 collected	 in	 the	 evaluation	 period	 will	 be	 used	 for	 the	
formal	evaluation	of	the	accuracy	of	the	ePAL	tool	for	identifying	place	of	residence.	
	
For	those	participating	in	the	evaluation,	written	consent	(or	witnessed	thumbprint)	
will	be	obtained	in	place	of	verbal	consent.	The	evaluation	will	include	the	same	data	
collection	 as	 detailed	 in	 the	main	 study,	 but	 includes	 additional	 collection	 of	 data	
related	to	SES	and	TB	risk	factor	exposure	during	the	TB	treatment	initiation	visit,	plus	
there	will	be	a	follow	up	study	visit	to	the	participant’s	place	of	residence.	At	this	visit,	
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GPS	co-ordinates	will	be	collected	at	the	participant’s	place	of	residence	by	a	member	
of	the	study	team	using	a	mobile	GPS	device.	
	
Objectives	and	related	endpoints	
Primary	objectives	
• To	map	the	spatial	distribution	of	the	place	of	residence	of	all	adults	initiating	
treatment	for	pulmonary	tuberculosis.	
• To	 estimate	 the	 CEA-wise	 case	 notification	 rates	 of	 all	 adults	 initiating	
treatment	for	pulmonary	tuberculosis.	
Primary	endpoints	
• Occurrence	of	any	adult	pulmonary	TB	case	initiating	TB	treatment	
• Criteria/definition:	 Any	 new	 or	 retreatment	 pulmonary	 TB	 patient	 aged	 ≥18	
years	starting	a	new	course	of	TB	treatment.	
• Geospatial	characteristics	of	TB	case	place	of	residence	
• Criteria/definition:	Geospatial	reference	of	place	of	residence	as	determined	by	
the	patient	using	the	ePAL	system.	
	
Secondary	objectives	
• The	 secondary	 objectives	 aim	 to	 map	 the	 distribution	 of	 cases	 based	 on	
alternative	TB	case	definitions,	and	to	stratify	by	various	factors	of	interest.	
• To	map	the	spatial	distribution	and	calculate	CEA-wise	case	notification	rates	of	
the	place	of	residence	of	all	adults	initiating	treatment	for	tuberculosis.	
• To	map	the	spatial	distribution	and	calculate	CEA-wise	case	notification	rates	of	
the	 place	 of	 residence	 of	 microbiologically-confirmed	 adult	 cases	 initiating	
treatment	for	pulmonary	tuberculosis.	
• To	map	 the	 spatial	distribution	of	adult	pulmonary	 tuberculosis	notifications,	
stratified	by	age.	
• To	map	 the	 spatial	distribution	of	adult	pulmonary	 tuberculosis	notifications,	
stratified	by	gender.	
• To	map	 the	 spatial	distribution	of	adult	pulmonary	 tuberculosis	notifications,	
stratified	by	HIV	status.	
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• To	describe	the	spatial	distribution	of	adult	pulmonary	tuberculosis	notifications	
according	to	socio-economic	status,	care	seeking	behaviour	and	risk	factors	for	
tuberculosis.	
	
Secondary	endpoints	are	as	follows:	
• Occurrence	of	any	adult	TB	case	initiating	TB	treatment	
• Criteria/definition:	 Any	 new	 or	 retreatment	 pulmonary	 or	 extra-
pulmonary	 TB	 patient	 aged	 ≥18	 years	 starting	 a	 new	 course	 of	 TB	
treatment.	
• Occurrence	 of	 adult	 microbiologically-confirmed	 pulmonary	
Mycobacterium	tuberculosis	disease	initiating	TB	treatment	
• Criteria/definition:	New	or	retreatment	case	aged	≥18	years	starting	a	
new	course	of	TB	treatment,	determined	by	sputum	culture	(liquid	or	
solid),	smear	microscopy,	or	Genexpert.	
• Demographic	characteristics	and	TB	risk	factors	
• Criteria/definition:	Age,	gender,	socio-economic	status,	TB	history,	care	
seeking	behaviours.	
• Occurrence	of	HIV	infection	
• Criteria/definition:	 HIV	 infection	 determined	 by	 patient	 reporting,	
medical	record	of	HIV	status,	or	results	of	new	test	conducted	during	
the	visit	as	part	of	routine	care.		
	
Evaluation	objectives	
• To	 evaluate	 the	 spatial	 accuracy	 of	 ePAL	 for	 identifying	 place	 of	
residence	of	TB	cases	resident	in	Chilomoni	or	Ndirande	and	presenting	
to	the	Ndirande,	Chilomoni	or	Queen’s	Hospital	TB	clinics.	
Evaluation	Endpoints:	
• Geospatial	characteristics	of	place	of	residence	
• Criteria/definition	 1:	 Geospatial	 reference	 of	 place	 of	 residence	 as	
determined	by	the	patient	using	ePAL.	
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• Criteria/definition	 2:	 Geospatial	 reference	 of	 place	 of	 residence	 as	
determined	 by	GPS	measurement	 at	 the	 place	 of	 residence	 by	 field	
researcher.	
	
Estimation	of	population	size	
Incidence	rates	will	be	calculated	for	the	Census	Enumeration	Areas	(CEAs)	as	defined	
in	the	Malawi	2008	census.10	Denominator	data	for	these	regions	within	Blantyre	city	
will	 be	 available	 from	 the	 2008	 census.	 Current	 population	 will	 be	 estimated	 by	
applying	annual	predicted	population	growth	rates	for	Blantyre	Urban	available	from	
the	National	Statistics	Office	to	the	2008	census	population	estimates.11	It	 is	hoped	
that	denominators	stratified	by	age	group	and	gender	will	also	be	available	from	this	
database,	but	if	unavailable,	the	known	age	and	gender	structure	for	Blantyre	city	will	
be	applied	to	the	CEA	populations.	HIV	positive	and	negative	population	denominators	
will	 be	 calculated	 for	 the	 CEAs	 using	 HIV	 prevalence	 rates	 from	 the	 Malawi	
Demographic	and	Health	Survey	applied	to	the	census	population	estimates	for	the	
CEAs.12	
	
Verbal	descriptions	of	place	of	residence	have	proven	inaccurate	for	identifying	place	
of	 residence.7	 In	 Blantyre,	 a	 paper	 mapbook	 used	 at	 point	 of	 care	 has	 been	
demonstrated	 to	 allow	 accurate	 and	 rapid	 identification	 of	 whether	 ARV	 therapy	
initiators	are	residents	within	study	clusters.6	Such	a	tool	allows	cluster-level	mapping	
of	 non-enumerated	 populations,	 such	 as	 urban	 Blantyre’s	 informal	 settlements.	
Although	valuable,	paper-based	tools	are	widely	being	phased	out	in	field	studies	in	
favour	of	electronic	data	capture	(EDC).	Therefore,	the	ePAL	tool	to	collect	place	of	
residence	 electronically	 at	 the	 clinic	 will	 increase	 the	 resolution	 to	 which	 this	
information	 can	 be	 collected	 and	 improve	 its	 utility	 by	 increased	 throughput	 and	
automation.	It	will	provide	greater	resolution	in	disease	maps	and	could	be	developed	
further	as	a	tool	for	patient	follow	up	in	subsequent	studies.	
As	this	is	a	new	tool,	an	evaluation	component	has	been	built	into	this	study	to	assess	
the	resolution	to	which	ePAL	can	accurately	record	location	of	residence	in	Blantyre.	
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Choice	of	objectives	and	endpoints	
The	selection	of	pulmonary	TB	case	notification	as	the	primary	objective	is	reflective	
of	 the	 relative	 contribution	of	 pulmonary	disease	 to	burden	of	 disease	 (71%	of	 all	
notified	TB	in	Malawi	in	2003),9	its	importance	in	disease	transmission	dynamics,	and	
availability	of	TB-specific	diagnostics	providing	relative	reliability	of	diagnosis.	TB	case	
notifications	have	been	selected	as	a	proxy	for	TB	incidence	due	to	practicality	in	terms	
of	study	design,	and	due	to	the	increased	case	detection	in	Blantyre	City	provided	by	
the	extended	monitoring	and	evaluation	element	of	the	Hit	TB	Hard	study	(COMREC	
P.11/10/1020).	
	
Although	resource	constraints	usually	limit	the	availability	of	culture	diagnosis,	given	
the	 citywide	 sputum	 culture	 testing	 on-going	 as	 part	 of	 the	 Hit	 TB	 Hard	 study,	
microbiologically	 confirmed	 pulmonary	 TB	 is	 a	 viable	 outcome	 of	 interest	 for	 this	
study.	It	is	thus	included	as	a	secondary	outcome	of	interest.	
	
Extra-pulmonary	 TB	 is	 not	 analysed	 in	 isolation	 as	 it	 is	 anticipated	 that	 the	 small	
number	 of	 cases	 may	 yield	 personally	 identifiable	 information	 (PII).	 Therefore,	 a	
composite	endpoint	of	all	TB	cases	(pulmonary	and	extra-pulmonary)	 is	 included	in	
the	secondary	objectives	to	consider	extra-pulmonary	cases.		
	
Not	only	is	it	important	to	understand	where	the	hotspots	of	TB	are	occurring	to	tailor	
public	 health	 interventions	 appropriately,	 it	 is	 also	 essential	 to	 understand	 the	
demographic	 and	 risk	 factors	 associated	 with	 TB	 hotspots.	 This	 will	 be	 explored	
through	mapping	the	residence	of	TB	cases	stratified	by	demographic	and	risk	factors.	
The	use	of	routinely	collected	data	as	planned	in	this	study	is	vulnerable	to	changes	in	
the	health	system,	such	as	introduction	of	more	sensitive	tests	or	increased	screening	
rates.	 However,	 as	 this	 study	 does	 not	 aim	 to	 estimate	 temporal	 trends,	 such	
improvements	 could	 only	 affect	 study	 objectives	 if	 such	 improvements	 were	
implemented	unevenly	across	Blantyre	city.	
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Choice	of	evaluation	objectives	and	gold	standard	
The	tool	evaluation	will	be	an	accuracy	study	comparing	the	ePAL-measured	location	
of	place	of	residence	with	a	gold	standard	measurement.		
	
In	the	MacPherson	et	al.	study,	two	independent	research	assistants	were	unable	to	
identify	the	cluster	residency	based	on	verbal	descriptions	in	31.8%	and	59.7%	of	cases	
respectively;7	 therefore	when	 considering	 resolution	down	 to	 the	household	 level,	
verbal	descriptions	would	likely	be	highly	inaccurate.	Therefore,	verbal	descriptions	
will	not	be	used	as	the	gold	standard	in	this	study.	Instead	GPS	coordinates,	accurate	
to	a	resolution	of	a	few	metres,	will	be	used	as	the	gold	standard	for	place	of	residence	
in	this	study.		
	
The	 place	 of	 residence	 coordinates	 recorded	 using	 the	 ePAL	 tool	 will	 be	 the	
comparator	evaluated	against	the	gold	standard	of	GPS	coordinates	measured	at	the	
place	of	residence.	
	
Duration	of	study	
Study	 start	 is	 anticipated	 in	 3Q	 2014,	 with	 phased	 roll	 out	 across	 health	 centres,	
starting	at	Queen	Elizabeth	Central	Hospital.	The	evaluation	element	will	consist	of	
approximately	2-month	run-in	period	and	approximately	6-month	evaluation	period	
(Figure	 1).	 Data	 collection	 using	 ePAL	 will	 continue	 until	 at	 least	 the	 end	 of	 the	
evaluation	 period	 (anticipated	 2Q	2015),	 and	 if	 the	 evaluation	 demonstrates	 good	
accuracy,	data	collection	will	continue	until	the	end	of	the	extended	monitoring	and	
evaluation	of	the	Hit	TB	Hard	study,	which	is	anticipated	to	finish	in	3-4Q	2015.		
	
	
Figure	 1:	 Anticipated	 timelines	 and	 location	 of	 the	 data	 collection,	 run-in	 and	 evaluation	
periods	of	the	TB	ePAL	study	
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STUDY	POPULATION	
	
Only	patients	≥18	years	presenting	to	participating	health	centres	for	TB	treatment	
initiation	will	be	invited	to	participate	in	the	study.		
	
TB	services	and	registrations	
The	study	will	be	conducted	 in	health	centres	providing	TB	registration	and	care	 in	
Blantyre	City,	encompassing	396	CEAs	and	a	population	of	approximately	661,256.10	
Approximately	 344,500	 residents	 are	 ≥18	 years,	 therefore	 this	 study	 will	 be	
implemented	in	the	services	providing	care	to	this	population	of	study-eligible	age.	In	
Malawi,	 TB	 treatment	 is	only	 available	 through	government	 facilities,	 therefore	TB	
treatment	registration	through	these	clinics	should	provide	relatively	comprehensive	
coverage	of	the	city’s	 total	 treatment	 initiators.	The	health	centres	 in	Blantyre	City	
anticipated	to	participate	are	listed	in	Appendix	A.	
	
In	2012,	3,347	TB	cases	were	registered	in	urban	Blantyre,	of	which	3,019	were	adults	
aged	15	years	or	above	(Hit	TB	Hard	study,	unpublished).	Therefore,	in	the	planned	
study	 period	 we	 anticipate	 to	 enrol	 approximately	 2,800-3,000	 adults	 aged	 18	 or	
above.	
	
Participant	selection,	inclusion	and	exclusion	criteria	
• Participants	will	be	enrolled	from	participating	TB	clinics	in	Blantyre	(Appendix	
A)	at	registration	for	TB	treatment.		
• The	inclusion	criteria	for	participation	in	the	study	are:		
• age	18	years	or	above	
• new	registration	for	TB	treatment	(either	new	case	or	retreatment	case)	
• verbal	consent	to	participate	 in	the	study	(or	written/witnessed	thumbprint	
consent	in	evaluation	population)	
	
The	exclusion	criteria	for	participation	in	the	study	are:		
• age	less	than	18	years	
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• patients	on	continuing	TB	treatment	
• declines	to	participate	
	
All	participants	can	decide	to	withdraw	from	the	study	at	any	time.		A	record	will	be	
made	of	any	participants	withdrawing	their	participation	after	enrolment.	
	
Participant	selection	for	tool	evaluation	
Participants	 will	 be	 invited	 to	 participate	 in	 the	 evaluation	 group	 if	 resident	 in	
Chilomoni	or	Ndirande	and	presenting	to	the	Ndirande,	Chilomoni	or	Queen’s	Hospital	
clinics	during	the	run-in	or	evaluation	periods.	All	such	patients	presenting	during	the	
run-in	period	will	be	enrolled	(up	to	a	limit	of	as	the	number	of	home	visits	possible	
per	day	by	field	staff),	and	all	such	patients	up	to	approximately	196	patients	will	be	
enrolled	during	the	evaluation	period.	If	the	enrolment	limit	is	reached	before	the	end	
of	the	evaluation	period,	remaining	participants	will	be	enrolled	 in	the	main	study.	
Participants	 willing	 to	 participate	 in	 the	 study,	 but	 declining	 to	 participate	 in	 tool	
evaluation	will	be	included	in	the	main	study	and	evaluation	refusal	recorded.	
	
METHODS	AND	PROCEDURES	
Tool	development	
Software	development	
New	software	will	be	developed	for	the	purpose	of	this	study.	The	software	will	run	
from	 electronic	 tablets	 based	 in	 the	 health	 centres.	 The	 tool	 will	 consist	 of	 an	
electronic	data	collection	form	to	input	basic	demographic	and	health	status	data	as	
routinely	 collected	 in	 the	 TB	 registers.	 The	 TB	 officer/nurse	 will	 then	 help	 the	
participant	navigate	through	a	map	of	Blantyre	to	locate	and	select	the	patient’s	place	
of	residence,	automatically	recording	the	location	coordinates	upon	selection.	
Map	source	and	annotation	
	
High-resolution	satellite	photographs	of	Blantyre	city	are	available	from	Google	Earth.		
The	current	images	were	collected	on	17/09/2013,	therefore	should	accurately	depict	
the	location	of	residences	during	the	study	period.		
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As	found	by	early	testing	of	the	paper	mapbook,	existing	Google	map	points	of	interest	
(POI)	proved	ineffective	for	patient	orientation	in	the	map	(Augustine	Choko,	Personal	
Communication).	POIs	identified	through	community	engagement	proved	much	more	
effective.		
	
In	 this	 study,	 to	navigate	 to	 the	household	 level	 it	 is	 expected	 that	 a	much	higher	
density	of	POIs	may	be	required.	A	small	pilot	of	POI	densities	involving	2-5	resident	
Community	Health	Workers	(Health	Surveillance	Assistants:	HSAs)	will	be	required	to	
gauge	the	density	needed	(Figure	2).	A	field	worker	will	record	the	GPS	location	of	the	
POIs	and	maps	labelled	with	POIs	will	be	tested	in	each	area	by,	for	example,	inviting	
people	in	the	street	or	on	market	day	to	participate.	At	least	20	participants	will	take	
part	in	the	pilot.	Those	willing	to	participate	will	be	verbally	consented,	and	asked	to	
locate	their	place	of	residence	on	the	map,	followed	by	a	GPS	reading	of	their	place	of	
residence	by	the	field	worker.	Participants	in	the	pilot	will	be	compensated	1000K	for	
their	participation.		The	results	from	the	pilot	will	be	used	to	identify	the	density	of	
POIs	relative	to	population	density	that	will	be	collected	across	the	city	(i.e.	in	densely	
populated	areas	the	number	of	POIs	may	need	to	be	adjusted	to	maintain	a	similar	
POI:population	density).		
	
For	 the	 POIs	 collected	 across	 Blantyre	 City,	 resident	 HSAs	 will	 assist	 with	 the	
identification	of	POIs	 in	 their	 respective	catchment	areas.	An	 introductory	meeting	
will	be	held	with	HSAs	to	introduce	the	study	and	explain	the	methodology	to	follow	
for	 POI	 collection.	 HSAs	 will	 be	 compensated	 2000K	 for	 attending	 the	 meeting.	
Following	HSA	engagement	with	the	local	community	to	identify	POIs,	study	staff	will	
collaborate	 with	 HSAs	 to	 collect	 GPS	 coordinates	 of	 each	 POI	 using	 mobile	 GPS	
handsets.	HSAs	will	be	compensated	3000K	upon	completion	of	POI	GPS	collection.	
These	coordinates	and	POI	name	will	be	uploaded	to	the	tool	maps.	The	software	will	
include	 the	 functionality	 to	 add	 or	 update	 POIs	 during	 the	 study	 to	 ensure	 map	
annotations	are	up	to	date.	
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Training	and	implementation	
TB	officers	will	be	provided	training	at	the	beginning	of	the	study	 in	the	use	of	the	
ePAL	tool.	Roll	out	of	the	ePAL	tool	will	be	phased,	beginning	with	Queen	Elizabeth	
Central	Hospital,	where	trouble	shooting	and	tool	refinement	will	take	place.	ePAL	will	
subsequently	be	rolled	out	in	the	participating	centres	across	Blantyre	City	(Figure	2).	
Monthly	meetings	are	held	with	TB	Officers	as	part	of	the	Hit	TB	Hard	study,	so	this	
study	will	be	added	to	the	agendas	of	these	monthly	meetings	to	allow	for	minor	re-
training	and	to	resolve	any	problems	in	the	study.	If	major	problems	occur	or	if	a	more	
substantial	 re-training	 is	 deemed	 necessary	 during	 the	 course	 of	 the	 study,	 a	 re-
training	meeting	will	be	scheduled.	
	
	 	
Figure	2:	Collection	of	POIs	and	roll	out	of	ePAL	tool	
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Study	procedures	
Study	procedures	table	
The	study	procedures	for	participants	are	outlined	in	Table	1.	
Table	1:		Study	procedures	table	
Study	Procedure	
Main	
Study	
Tool	
Evaluation		
Study	Visit	1	–	At	clinic	TB	initiation	visit	
Verbal	consent	and	information	sheet	provided	at	clinic	 x	 	
Written	consent	and	information	sheet	provided	at	clinic	 	 x	
Record	barcode	of	sputum	sample	(collected	as	part	of	
Hit	TB	Hard)	
x	 x	
ePAL	collection	of	demographic	and	health	 status	data	
(e.g.	age,	HIV	status,	receipt	of	ART)	
x	 x	
ePAL	collection	of	SES	and	risk	factors	for	TB	(e.g.	type	of	
house,	number	of	people	sharing	residence)	
	 x	
Place	of	residence	collected	using	ePAL	maps	 x	 x	
Patient	data	saved	to	device	 x	 x	
Study	Visit	2	–	At	participant’s	place	of	residence	
Collect	GPS	coordinates	at	place	of	residence	 	 x	
	
ePAL	field	usage	
This	 study	 will	 consist	 of	 the	 implementation	 and	 evaluation	 of	 an	 electronic	
participant	location	capture	tool	(ePAL)	in	participating	health	centres	in	Blantyre	City.		
	
TB	 Officers	 and	 nurses	 registering	 TB	 patients	 in	 participating	 TB	 clinics	 will	 be	
responsible	for	data	collection	using	the	ePAL	tool.	Ahead	of	ePAL	implementation,	all	
relevant	staff	will	be	trained	in	collection	and	storage	of	patient	data,	and	push/pull	
of	 data	 and	 updates	 from	 the	 server.	 	 During	 the	 study,	 re-training	 and	 trouble	
shooting	will	be	added	to	the	monthly	meetings	held	with	the	TB	officers.		
Following	ePAL	launch,	all	patients	meeting	the	inclusion/exclusion	criteria	registering	
for	 TB	 treatment	 will	 be	 invited	 to	 participate.	 Following	 the	 usual	 treatment	
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registration	processes	(Figure	3,	grey),	patients	willing	to	participate	will	be	allocated	
to	 the	main	 study,	 except	 for	 during	 the	 run-in	 or	 evaluation	 phases	where	 if	 the	
patient	is	resident	in	Chilomoni	or	Ndirande,	they	will	be	allocated	to	the	evaluation	
group	(Figure	3).	
	
Participants	 eligible	 and	 willing	 to	 participate	 in	 the	 main	 study	 will	 be	 verbally	
consented	(For	information	sheet	and	verbal	consent	forms	in	English	and	Chichewa,	
see	 Appendix	 B).	 Refusals	 to	 participate	 in	 the	 study	 will	 be	 documented.	Where	
consent	is	given,	each	participant	will	be	given	a	unique	participant	identifier.	Using	
this	identifier,	the	participant	record	will	be	linked	to	the	sputum	sample	results	from	
the	Hit	TB	Hard	monitoring	and	evaluation	study.	Details	of	participant	demographics	
and	relevant	medical	 information	will	be	recorded	by	the	TB	officer	or	nurse	in	the	
ePAL	 electronic	 data	 collection	 forms.	 	 The	 TB	 officer/nurse	 will	 then	 guide	 the	
participant	 through	 the	 ePAL	 maps	 based	 on	 participant	 description	 of	 area	 of	
residence,	assisting	the	patient	to	 locate	and	select	their	place	of	residence	on	the	
tablet	screen.	The	data	are	then	saved	on	the	tablet	and	uploaded	daily	via	3G	to	the	
MLW	server.	(Figure	3,	white,	left	branch)	
	
A	weekly	back	up	of	the	data	will	be	collected	directly	from	the	tablet	by	a	field	worker	
and	stored	in	an	independent	location	from	the	main	data	set.	
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Figure	3:	Participant	flow	through	existing	(grey)	and	study	(white)	processes	
	
For	patients	eligible	and	willing	 to	participate	 in	 the	 tool	evaluation	group,	written	
consent	will	be	requested	(For	information	sheet	and	written	consent	forms	in	English	
and	Chichewa,	see	Appendix	C).	In	this	group	of	participants,	data	collection	will	be	
the	 same	as	detailed	above,	plus	 the	ePAL	data	collection	 forms	will	 include	some	
additional	questions	pertaining	to	SES,	care	seeking	behaviour	and	risk	factors	for	TB	
(Figure	 3,	white,	 right	 branch).	 These	 data	will	 be	 used	 to	 investigate	 associations	
between	hotspots	and	TB	risk	factors/SES,	but	are	only	collected	for	the	participants	
in	the	evaluation	group	since	written	consent	is	required	to	collect	this	information.	
Refusal	to	participate	in	the	evaluation	will	be	recorded	to	allow	an	estimation	of	any	
bias	potentially	caused	by	refusals.	
For	those	participating	in	tool	evaluation,	the	treatment	initiation	visit	will	be	followed	
by	 a	 visit	 to	 the	 place	 of	 residence.	 At	 this	 visit,	 GPS	 coordinates	 of	 the	 place	 of	
residence	will	be	recorded.	GPS	data	will	be	linked	to	the	ePAL	database	based	on	the	
participant	 ID.	Participants	 in	 the	evaluation	group	will	be	 compensated	1000K	 for	
their	time.	Continuation	of	care	beyond	the	registration	visit	will	not	be	impacted	by	
this	study.		
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Informed	consent	
This	protocol	requests	to	waive	the	requirement	of	signed	or	witnessed	consent	forms	
for	the	main	study,	as:	-	TB	patients	are	defined	and	investigated	in	line	with	national	
policy.	In	this	study,	place	of	residence	location	is	recorded	using	an	electronic	map	
tool	 as	 opposed	 to	 verbal	 description,	 but	 the	 target	 information	 is	 the	 same	
regardless	of	measurement	method;	The	potential	for	harm	is	minimal	
	
Verbal	consent	will	be	obtained	from	all	eligible	patients	willing	to	participate	and	an	
information	sheet	provided	specifying	that	this	is	a	research	study	(see	Appendix	B)	
and	 providing	 other	 essential	 participant	 information.	 	 The	 expression	 of	 verbal	
consent	and	the	name	of	the	person	taking	the	consent	will	be	documented.		
For	participants	participating	 in	 the	evaluation	component,	 there	will	be	questions	
included	pertaining	to	SES,	care	seeking	behaviour	and	risk	factors	for	TB	and	a	follow	
up	visit	to	the	patient’s	place	of	residence,	which	is	collection	of	information	beyond	
standard	 practice.	Written	 consent	will	 therefore	 be	 obtained	 and	 an	 information	
sheet	provided	(see	Appendix	C)	for	patients	agreeing	to	participate	in	the	evaluation	
component.	
Refusal	to	participate	in	either	the	main	study	or	evaluation	group	will	be	recorded,	
and	numbers	refusing	to	enter	the	study	or	evaluation	group	documented.	
	
Quality	assurance	and	monitoring	
Project	managers	will	be	responsible	for	day-to-day	monitoring.	A	fortnightly	meeting	
will	be	held	with	all	field	workers	involved	in	this	study	to	discuss	any	implementation	
issues.	Monthly	meetings	are	already	 in	place	 for	 the	Hit	TB	Hard	study,	so	will	be	
extended	 to	 incorporate	 trouble-shooting	of	any	 reported	problems,	 small	 training	
updates,	and	to	provide	 feedback	 to	 the	officers	on	study	progress	and	results.	TB	
officers	will	be	compensated	for	their	time	for	participation	in	these	meetings.	
	
For	 quality	 assurance	 purposes,	 spot	 visits	 to	 the	 clinics	 carrying	 out	 ePAL	 data	
collection	will	be	carried	out	to	check	the	correct	usage	of	the	tool	and	to	identify	any	
implementation	issues.		This	will	be	at	highest	frequency	(at	least	once/week)	for	the	
first	month	of	the	study	when	it	is	anticipated	that	some	implementation	issues	will	
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need	to	be	resolved.	For	the	reminder	of	the	study	monthly	visits	will	be	continued.	
Spot	checks	will	consist	of	checking	that	new	TB	registrations	are	being	recorded	in	
the	ePAL	 tool	by	comparing	 the	number	 in	ePAL	 to	 the	number	 in	 the	TB	 register,	
observing	how	ePAL	is	being	implemented,	and	discussion	with	the	TB	officers	about	
any	implementation	issues.	Once	weekly	a	member	of	the	study	team	will	check	the	
tablets	are	well	maintained	and	collect	a	backup	of	the	data	directly	from	the	tablet.	
Spot	checks	will	also	be	conducted	for	approximately	5%	of	field	worker	visits	to	place	
of	residence	to	ensure	GPS	readings	are	taken	correctly.	These	will	be	weighted	so	
that	around	a	third	of	the	checks	occur	in	the	first	month,	and	the	remainder	of	the	
spot	checks	are	distributed	throughout	 the	remainder	of	 the	run-in	and	evaluation	
period.		
	
The	RSC	and	MLW	Research	Governance	Officer	or	the	COMREC	compliance	officer	
may	carry	out	external	audit	of	 this	study,	but	otherwise,	no	external	audit	will	be	
carried	out.	
	
	
DATA	COLLECTION	AND	MANAGEMENT	
Data	management	
Data	will	be	managed	at	the	project	offices	in	Malawi-Liverpool-Wellcome	Trust,	with	
a	 daily	 live	 link	 to	 LSHTM,	 UK	 for	 additional	 data	 management.	 	 All	 data	 will	 be	
uploaded	daily	from	the	tablets	in	the	clinics	to	the	database	on	the	MLW	server	via	
the	 3G	 network.	 To	 protect	 against	 data	 loss	 due	 to	 network	 issues	 or	 tablet	
loss/damage,	a	separate	back	up	database	will	be	created	from	data	collected	directly	
from	the	tablets	once	per	week.	This	back	up	database	can	be	used	to	fill	any	gaps	in	
the	main	database	if	required.	
	
Some	data	checks	will	be	encoded	into	the	data	collection	system.	Data	checks	and	
cleaning	will	be	conducted	on	a	rolling	basis	throughout	the	duration	of	the	study.	Any	
inconsistencies	will	be	investigated	and	resolved	where	possible.	Data	analysis	will	be	
carried	out	in-house	and	at	LSHTM.	
	
	Appendices	 454	
Access	 to	 the	 final	data	 set	will	 be	 limited	 to	 the	data	manager	 (David	Matiya),	 PI	
(Rebecca	Harris)	and	statistician	(Emily	Webb).		Sensitive	information	(including	HIV	
results)	will	not	be	linked	to	the	participants	name	in	the	final	data	set.	
	
Data	capture	forms		
Data	will	be	captured	on	electronic	tablets	in	the	following	data	capture	forms:	
eCRF	to	collect	demographics,	health	status	and	symptom	information.	
Additional	eCRF	to	collect	data	on	socioeconomic	status,	care	seeking	behaviour	and	
TB	 risk	 factors	 for	 participants	 in	 the	 tool	 evaluation	 group.	 High-resolution	 map	
photographs	for	capture	of	place	of	residence.		
	
Adverse	events	and	confidentiality		
No	serious	adverse	events	(SAEs)	are	anticipated	as	there	are	no	medical	interventions	
outside	of	routine	standard	of	care.	Any	breaches	of	confidentiality	following	TB	or	
HIV	diagnosis	will	be	systematically	recorded	and	reported	back	to	the	respective	IRBs.	
All	possible	steps	will	be	taken	to	minimise	the	risk	of	confidentiality	breach.	From	a	
data	management	perspective,	a	numerical	unique	identifier	will	be	used	instead	of	
names	in	the	database,	file	names	that	do	not	overtly	identify	the	file	content	(e.g.	
data1)	will	be	used	for	sensitive	data,	and	where	possible	sensitive	health	information	
and	 location	 information	will	 be	 stored	 in	 separate	 files	 linked	only	by	 the	unique	
patient	identifier.	The	home	visit	will	be	conducted	in	a	manner	that	minimises	risk	of	
revealing	health	status,	by	visiting	at	a	time	agreed	by	the	participant,	not	bearing	any	
labels	indicating	the	field	worker	is	part	of	a	TB	or	HIV	study,	and	ensuring	the	health	
information	 about	 the	 participant	 is	 not	 communicated	 to	 others	 unless	 express	
permission	is	given	by	the	participant.	
	
Data	security	
All	 tablets	 holding	 patient	 data	 will	 be	 password	 protected,	 with	 passwords	 only	
known	by	study	staff	and	the	TB	officers	and	nurses	trained	to	use	the	tablets	at	the	
clinics.	The	tablets	will	automatically	lock	after	5	minutes	of	inactivity	to	protect	the	
patient	 data	 stored	 on	 the	 tablet.	 Unnecessary	 functionality	 on	 the	 tablet	 will	 be	
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disabled	as	much	as	possible	to	reduce	the	risk	of	non-study	related	use	of	the	tablets,	
thus	minimising	the	risk	of	damage,	loss	or	unauthorised	transfer	of	participant	data.		
The	database	stored	on	the	MLW	server	and	daily	 live	 linked	to	LSHTM,	UK	will	be	
password	protected.		All	data	will	be	backed	up	daily	by	the	MLW	Data	Office,	with	
offsite	back	up	once	weekly.			
	
Quality	assurance	
Data	will	checked	for	internal	inconsistencies	or	missing	fields	during	data	entry,	and	
on	a	rolling	basis	during	the	study.		
	
STATISTICAL	CONSIDERATIONS	
Sample	size	justifications	
In	2012,	3,347	TB	cases	were	registered	in	urban	Blantyre,	of	which	3,019	were	adults	
aged	15	years	or	above	(Hit	TB	Hard	study,	unpublished).	Therefore,	in	the	planned	
study	period	we	anticipate	 to	enrol	approximately	2,800-3,000	adults	aged	18	and	
above.	
	
The	 evaluation	 of	 the	 reliability	 of	 ePAL	 compared	 to	 the	 gold	 standard	 of	 a	 GPS	
reading	at	the	place	of	residence	will	be	conducted	for	a	sub-set	of	patients	registering	
for	TB	treatment.		
	
Given	 that	 good	 map	 literacy	 is	 not	 expected	 in	 the	 study	population,	 very	 high	
agreement	between	the	GPS	and	ePAL	readings	in	the	evaluation	component	would	
not	be	expected.	However,	experience	from	the	mapbook	project	has	demonstrated	
that	with	the	assistance	of	a	local	TB	officer	with	training	in	map	navigation,	patients	
were	able	to	locate	their	residence	to	within	and	outside	clusters	with	100%	and	95%	
agreement,	respectively.	Clusters	encompassed	populations	of	approximately	1300,	
therefore	greater	inaccuracy	is	expected	when	attempting	to	identify	at	the	residence	
level.	To	assist	with	orientation	in	the	maps,	a	higher	density	of	POI	annotations	will	
be	included	in	the	ePAL	maps	and	updates	will	be	possible	to	tailor	the	map	POIs	to	
the	evolving	needs	of	the	community.	A	few	metres	of	measurement	inaccuracy	are	
expected	 from	 GPS	 readings,	 and	 although	 the	 level	 of	 inaccuracy	 is	 currently	
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unknown	 for	 the	 ePAL	 location	 capture	 it	 is	 anticipated	 to	 be	 a	 slightly	 larger	
inaccuracy	than	the	GPS.	In	addition,	point	measurements	are	being	taken	for	houses	
that	are	an	area	not	a	point,	therefore	a	limited	range	of	coordinates	would	be	correct.	
Therefore,	approximately	10-15m	would	be	a	 reasonable	expectation	of	 the	upper	
limit	of	measurement	inaccuracy	given	the	inherent	inaccuracies	in	the	two	capture	
methods	 and	 the	 area	 of	 the	 house.	 Taking	 this	 into	 account,	 the	 sample	 size	 is	
calculated	 for	measuring	 accuracy	 of	 the	 ePAL	method	 to	 within	 20m	 of	 the	 GPS	
measurement.	Given	the	likely	elevated	inaccuracy	of	locating	to	the	household	level,	
but	taking	into	account	that	improvements	will	be	made	to	the	tool	POI	annotations	to	
assist	orientation	in	the	map,	the	expected	proportion	of	participants	for	whom	ePAL	
is	 accurate	 to	within	20m	 is	 approximately	85%.	 The	minimum	acceptable	 level	 of	
agreement	for	the	tool	to	be	of	value	is	80%.	
	
Using	methodology	for	calculating	sample	sizes	required	to	estimate	a	proportion	with	
a	pre-specified	precision,13	it	is	estimated	that	approximately	196	participants	will	be	
required	in	the	evaluation	group.	This	will	be	sufficient	to	provide	a	point	estimate	of	
the	proportion	for	whom	ePAL	is	accurate	to	within	20m	of	85%,	with	a	lower	limit	of	
the	95%	confidence	intervals	for	this	proportion	of	80%	(i.e.	a	precision	of	5%)	(Table	
2).	
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Table	2:	Sample	size	calculations	for	a	range	of	scenarios	
	 Point	estimate	of	proportion	for	whom	ePAL	is	accurate	to	within	20m	(%)	
Lo
w
er
	l
im
it	
of
	9
5%
	c
on
fid
en
ce
	
in
te
rv
al
		(
%
)	
	 75	 80	 85	 90	 95	
65	 73	 28	 13	 6	 3	
70	 289	 62	 22	 9	 3	
75	 	 246	 49	 16	 5	
80	 	 	 196	 35	 9	
85	 	 	 	 139	 19	
90	 	 	 	 	 73	
	
Although	TB	officers	will	be	given	training	 in	use	of	 the	tool	and	orientation	 in	 the	
maps,	 it	 is	anticipated	that	TB	officers	will	 improve	at	guiding	patients	through	the	
maps	during	the	run-in	phase	of	the	study.	Data	from	evaluation	visits	will	be	valuable	
during	this	phase	to	 identify	underperforming	areas	to	target	additional	training	or	
map	 POI	 annotation	 improvements.	 Therefore,	 to	 allow	 for	 this	 period	 of	
implementation	 improvement,	 evaluation	 visits	during	 this	period	are	not	 counted	
within	the	sample	size.	
	
In	the	evaluation	period,	approximately	196	participants	will	be	invited	to	participate	
in	 tool	 evaluation.	 During	 this	 period	 the	 tool	 is	 expected	 to	 be	 a	 consistently	
implemented	 part	 of	 TB	 registration	 visits,	 therefore	 demonstrating	 the	 tool’s	
capability	 in	 routine	programme	 settings.	 The	data	 from	 these	participants	will	 be	
used	for	the	formal	evaluation	of	the	accuracy	of	the	ePAL	tool	for	identifying	place	of	
residence.	
	
Planned	analyses	
The	 analysis	 of	 primary	 and	 secondary	 outcomes	 for	 patients	 registering	 for	 TB	
treatment	will	be	conducted	on	data	captured	in	the	cleaned	electronic	TB	database	
to	which	routine	quality	checks	will	have	been	applied.	Interim	analyses	will	be	carried	
out	on	a	rolling	basis	to	inform	tool	development	and	for	regular	feedback	of	results	
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to	the	TB	clinics.	Final	analyses	will	be	conducted	at	evaluation	period	conclusion	and	
at	study	conclusion.	
	
Primary	objectives	
TB	case	notifications	for	pulmonary	TB	will	be	overlaid	on	a	map	of	Blantyre	to	display	
the	spatial	distribution	of	pulmonary	TB	cases	in	Blantyre	city.	
Case	notification	rate	will	be	calculated	as	a	proxy	for	incidence	rate	in	each	of	the	
census	enumeration	areas.	The	location	of	place	of	residence,	as	recorded	using	ePAL,	
will	 be	 used	 to	 identify	 census	 enumeration	 area	 of	 residence	 of	 participating	
residents	 with	 pulmonary	 TB	 registering	 for	 TB	 treatment,	 which	 will	 form	 the	
numerator	of	case	notification	rate	calculations.	The	population	denominator	for	each	
of	the	CEAs	will	be	calculated	as	described	in	Section	0.	These	numbers	will	be	used	to	
calculate	 case	 notification	 rate	 per	 100,000	 population	 per	 year	 for	 each	 census	
enumeration	area.	Exact	95%	confidence	intervals	for	the	case-notification	rates	will	
be	 calculated.	 Maps	 and	 graphs	 showing	 the	 annual	 incidence	 rates	 by	 census	
enumeration	area	will	be	created.	
	
Secondary	objectives	
For	the	secondary	endpoint	of	the	distribution	of	all	TB	patients	and	microbiologically-
confirmed	 pulmonary	 TB,	 spatial	 distribution	 and	 case	 notification	 rates	 will	 be	
calculated	as	described	for	the	primary	objectives,	using	the	alternative	definitions	of	
all	and	microbiologically	confirmed	TB	(see	section	3.3.2	for	endpoint	definitions)	to	
define	the	numerator	populations.	
	
Stratified	TB	case	notifications	will	be	mapped	 in	Blantyre,	as	was	described	 in	 the	
primary	objectives,	but	stratified	by	age,	gender	and	HIV	status.	Age	will	be	stratified	
in	10	year	and	5-year	intervals	(though	with	first	interval	as	18-19yrs),	gender	as	male	
versus	female,	and	HIV	status	as	positive,	negative	or	unknown.	Where	possible,	case	
notification	rates	will	also	be	calculated	stratified	by	age	and	gender	using	the	same	
denominator	as	described	in	section	3.3.4	stratified	by	the	relevant	characteristics.	If	
possible,	stratification	by	HIV	status	will	also	be	reported,	using	HIV	prevalence	rates	
from	the	Malawi	Demographic	and	Health	Survey	applied	to	the	census	population	
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estimates	as	a	denominator.12	If	stratification	by	HIV	status	leads	to	so	few	patients	
per	area	that	it	risks	revealing	the	HIV	status	of	the	participant,	either	areas	will	be	
aggregated	together	or	the	information	not	reported.	
Descriptive	epidemiology	will	be	used	to	explore	areas	of	low	SES	or	high	levels	of	TB	
risk	factors.	These	will	be	compared	to	maps	of	TB	burden	to	observe	whether	areas	
of	high	risk	factors	are	also	those	with	TB	hotspots.	
	
Evaluation	objectives	
Data	collected	in	the	run-in	period	will	be	used	to	monitor	tool	implementation	and	
trigger	 tool	 improvements	 or	 additional	 staff	 training	 where	 required.	 The	 data	
collected	from	approximately	196	participants	in	the	evaluation	period	will	be	used	
for	 the	 formal	 evaluation	 of	 the	 accuracy	 of	 the	 ePAL	 tool	 for	 identifying	 place	 of	
residence	as	described	below.	
An	evaluation	of	the	accuracy	of	the	tool	compared	to	GPS	readings	taken	at	the	place	
of	residence	is	planned.	The	proportion	of	participants	for	whom	ePAL	is	accurate	to	
within	 20m	 of	 the	 GPS-recorded	 location	 will	 be	 estimated,	 along	 with	 a	 95%	
confidence	 interval.	 Further	 analyses	 of	 these	 data	 will	 assess	 the	 range	 of	 the	
horizontal	distance	between	the	ePAL-given	location	and	the	GPS-recorded	location.	
The	distance	root	mean	square	error	(defined	as	the	square	root	of	the	average	of	the	
squared	horizontal	position	errors)	will	be	calculated.		
	
LABORATORY	METHODS	
	
No	 laboratory	 tests	will	 be	 conducted	as	part	of	 this	 study.	Results	 from	HIV	 tests	
conducted	as	part	of	routine	care	will	be	collected	wherever	the	patient	is	willing	for	
such	 data	 to	 be	 recorded.	 Patients	 consenting	 to	 participate	 in	 the	 enhanced	
monitoring	and	evaluation	element	of	 the	Hit	TB	Hard	study	will	also	have	sputum	
culture	results	available	that	will	be	linked	to	the	data	collected	in	this	study	based	on	
the	anonymous	unique	patient	identifier.	
	
	
	
	Appendices	 460	
ETHICAL	CONSIDERATIONS	
	
This	study	is	likely	to	benefit	the	study	community	through	better	understanding	of	
the	 distribution	 of	 TB	 cases	 in	 Blantyre,	 which	 has	 value	 for	 governmental	 TB	
programmes	 in	 designing	 control	 strategies.	 If	 the	 evaluation	 proves	 the	 tool	 is	
accurate,	 the	 tool	 has	 potential	 for	 continued	use	 for	 creating	 on-going	 electronic	
databases	for	TB	case	notification	data	and	improved	retention	of	patients,	who	would	
otherwise	be	lost	to	follow	up,	through	more	accurate	records	of	place	of	residence.	
Application	is	being	made	to	the	Institutional	Review	Boards	of	College	of	Medicine,	
Blantyre,	Malawi	(COMREC),	and	London	School	of	Hygiene	And	Tropical	Medicine,	
UK.		
	
There	is	no	randomisation	to	a	control	versus	an	intervention,	so	issues	of	equipoise	
are	not	relevant	in	this	study.			
	
On	 submission	 for	 ethics	 review,	 permission	 for	 verbal	 informed	 consent	 will	 be	
requested	for	participants	taking	part	in	the	main	study	using	ePAL	to	identify	their	
place	of	residence.	The	grounds	for	requesting	verbal	consent	are	that:	TB	patients	
are	 defined	 and	 investigated	 in	 line	 with	 national	 policy.	 In	 this	 study,	 place	 of	
residence	 location	 is	 recorded	 using	 an	 electronic	map	 tool	 as	 opposed	 to	 verbal	
description,	 but	 the	 target	 information	 is	 the	 same	 regardless	 of	 measurement	
method;	The	potential	for	harm	is	minimal.	
	
The	 main	 potential	 for	 risk	 of	 harm	 could	 arise	 if	 patient	 identity	 were	 revealed	
through	 the	 linking	 of	 sensitive	 health	 information	 with	 personally	 identifiable	
information	(the	location	of	residence)	in	the	study	database.	As	the	objective	of	the	
study	is	to	develop	a	tool	to	accurately	identify	the	place	of	residence	when	at	a	TB	
clinic,	 collection	 of	 location	 coordinates	 and	 patient	 information	 is	 unavoidable.	
However,	risk	of	patient	identification	will	be	minimised	by	only	recording	the	unique	
patient	identifier	and	not	the	name	in	the	final	electronic	database.	Only	the	principal	
investigator,	 Rebecca	Harris,	will	 hold	 a	master	 list	 containing	 both	 the	 name	 and	
unique	identifier	of	the	participants.	
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Information	 leaflets	 will	 be	 provided	 to	 all	 participants,	 specifying	 that	 this	 is	 a	
research	study	(see	Appendix	B)	and	providing	other	essential	participant	information.			
For	 participants	 in	 the	 tool	 evaluation	 group,	 written	 (or	 witnessed	 thumbprint)	
informed	consent	will	be	obtained,	as	some	of	the	data	collected	is	beyond	what	is	
collected	under	the	national	TB	programme.		The	potential	for	harm	is	the	same	as	
described	above	for	the	main	study,	plus	there	is	an	additional	risk	for	the	participant’s	
TB	 disease	 status	 to	 be	 revealed	 through	 the	 visit	 to	 the	 place	 of	 residence.	 	 In	
addition,	due	to	the	association	between	TB	and	HIV,	revealing	a	patient’s	TB	status	
could	lead	also	to	assumptions	in	the	community	about	their	HIV	status.	These	risks	
will	be	minimised	by	conducting	 the	home	visit	 in	a	manner	 that	minimises	 risk	of	
revealing	health	status,	such	as	visiting	at	a	time	agreed	by	the	participant,	not	bearing	
any	labels	 indicating	the	field	worker	is	part	of	a	TB	or	HIV	study,	and	ensuring	the	
health	 information	 about	 the	 participant	 is	 not	 communicated	 to	 others	 unless	
express	permission	is	given	by	the	participant.	For	those	participating	in	the	evaluation	
component,	 a	 different	 information	 leaflet	 will	 be	 provided	 (see	 Appendix	 C),	
specifying	 that	 this	 is	 a	 research	 study	 and	 providing	 other	 essential	 participant	
information.			
	
To	protect	the	identity	of	study	participants,	maps	prepared	for	publication	will	not	
reveal	the	location	of	the	place	of	residence	of	the	participants.	When	overlaying	cases	
on	to	maps	of	Blantyre	city,	care	will	be	taken	to	ensure	the	size	of	case	markers	and	
resolution	of	the	map	are	insufficient	to	be	able	to	identify	the	place	of	residence	of	
the	TB	cases.		
	
DISSEMINATION	
Policy	for	sharing	data	
Data	will	be	primarily	shared	with	scientific	collaborators,	but	we	will	as	far	as	possible	
facilitate	data	sharing	with	any	group	requesting	access	to	individual	patient	records	
by	using	anonymised	data.	Where	appropriate,	and	with	the	proper	safeguards,	data	
will	be	made	 freely	available	 through	 the	Malawi-Liverpool-Wellcome	Trust	 (MLW)	
Programme	website.		
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Alongside	 original	 data,	 anonymised	 databases	will	 be	 created	 and	 stored	with	 all	
relevant	data	to	facilitate	any	data	transfer	requests	that	are	made	subsequently.		
Ethical	 clearance	 will	 be	 sought	 before	 data	 are	 transferred	 to	 other	 groups	 for	
secondary	 analysis.	 Priority	will	 be	 given	 to	 local	 investigators	 and	publicly	 funded	
international	 investigators	with	data	management	 and	 sharing	policies	 in	 line	with	
those	of	the	MLW	Programme	and	the	College	of	Medicine.	
	
Strategy	for	current	and	future	communication	with	user	communities	
Results	will	be	disseminated	to	health	centres	through	weekly	summary	reports	sent	
to	the	health	centre	tablets.	The	study	results	will	also	be	shared	with	NTP	and	District	
Health	Office	collaborators.	The	results	will	also	be	presented	at	one	of	the	regular	
community	 feedback	meetings	 organised	 by	MLW’s	 research	 dissemination	 office,	
and	the	team	will	approach	local	radio	to	propose	a	session	for	presentation	of	results	
with	 a	 community	 phone-in	 session.	 Results	 of	 the	 tool	 evaluation	 and	 final	 data	
analysis	will	be	presented	at	national	research	meetings,	such	as	the	annual	research	
day	held	by	College	Of	Medicine,	and	presented	at	international	research	meetings.		
Results	 will	 be	 prepared	 for	 publication	 in	 international	 peer	 reviewed	 scientific	
journals	and	published	in	compliance	with	the	Open	Access	policy	of	the	Wellcome	
Trust.	
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APPENDICES	
Appendix	A	–	Health	centres	anticipated	to	participate	
	
Health	centres	anticipated	to	participate	are:	
	
BTBAH	-	Blantyre	Adventist	
BTBG	-	Bangwe	
BTCH	-	Chilomoni	
BTCW	-	Chitawira	
BTMB	-	Mulambe	
BTMW	-	Mwaiwathu	
BTND	-	Ndirande	
BTQE	-	Queen	Elizabeth	Central	Hospital	
BTSL	-	South	Lunzu	
BTZG	–	Zingwangwa	
	 	
	Appendices	 465	
Appendix	B	–	Verbal	consent	form	and	information	sheet	
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Appendix	C	–	Written	consent	form	and	information	sheet	for	evaluation	group	
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Malawi'Liverpool'Wellcome!Trust!!!!!!!!!!!!!Version!1.0;!24!Feb!2014! Tel:!01876444!
Clinical!Research!Programme! ! Fax:!01875774!
Queen!Elizabeth!Central!Hospital,!Blantyre! ! www.mlw.medcol.mw!
!
Informed)Consent)Form)
The)TB1ePAL)Study:)Clinic1based)electronic)capture)of)TB)case)residence)!
Rebecca)Harris)
TBP02: Evaluation component of using ePAL to locate residence of patients initiating TB treatment 
- Study participant home visit consent form 
Please!sign!below!if!you!agree!with!the!following!statements:!
!
1. I!have!read!or!had!read!the!information!sheet!about!the!study,!which!explains!what!you!are!
trying!to!find!out!and!why!you!would!like!to!talk!to!me.!
2. I!have!discussed!and!understood!the!purpose!of!the!research,!and!of!the!electronic!tool!and!
home!visit!to!record!my!home!address.!
3. I!have!asked!all!the!questions!that!I!have!about!the!purpose!of!the!research,!the!electronic!
tool!and!home!visit!and!feel!happy!that!I!have!enough!information!about!it.!
4. I!understand!that,!by!completing!this!consent!sheet,!I!am!agreeing!to!allow!a!member!of!the!
research!team!to!contact!me!by!telephone!to!arrange!a!visit!to!my!home.!
5. I!understand!that!you!will!keep!the!information!I!give!you!confidential!and!not!use!names!
linked!to!the!information.!
6. I!know!that!my!TB!diagnosis!and!HIV!status!will!not!be!shared!with!anyone!during!the!home!
visit!unless!I!agree!to!this.!
7. If!I!do!not!agree!to!take!part!in!this!study,!I!understand!that!it!will!not!affect!my!right!to!TB!
care!at!the!health!centre!now!or!in!the!future.!
8. I!understand!that!I!can!choose!not!to!continue!participation!in!the!study!at!any!time!without!
having!to!give!a!reason!for!this!and!without!affecting!my!usual!health!care.!
You will be given a copy of the information sheet and a signed consent form to keep. 
I voluntarily agree to take part in this study. 
!
Participant!_________________________! TB!Officer!!______________________________!!!!!!
(Name!in!BLOCK!CAPITALS)! ! ! ! (Name!in!BLOCK!CAPITALS)! !
!
!
__________________________________! _______________________________________!
Signature! or!thumbprint! ! ! ! ! Signature!
)
)
__________________________________! _______________________________________!
Date! ! ! ! ! ! Date!
!
If#the#participant#gave#verbal#consent,#please#enter#the#name#of#person#who#witnessed#the#consent#
here,#and#their#signature:#
Witness!!!___________________________! ________________________________________!
(Name!in!BLOCK!CAPITALS)! ! ! ! Date!
___________________________________!
Signature!
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mukufunakulankhulanane.!
2. Takambitsanandipondamvetsetsazolingazakafukufukuyu,!
njirayamakonoyakalondolondowamapukomansokupitakunyumbakwangakutimukalembezot
handizilakudziwandikufikakwathuko.!
3. Ndafunsamafunsoonseomwendinalinawookhudzacholinga! cha! kafukufukuyu,!
njirayamakonoyakalondolondowamapukomansondondomekoyotimubwelekunyumbakwang
andipondiliokondwakutindadziwaizi.!
4. Kutikulemba! pa! pepala! lino! kukutanthauzakutindavomelakutim’modziwaanthu! a!
kafukufukuathakundiyimbilalamyakutitipangendondomekoyotiadzabwelekumyumbakwanga
.!
5. Ndamvetsetsakutimusungazimenendikuwuzenimwachinsinsindiposimugwilitsanthitomayina
aanthumokhudzanandizomwemulembe.!
6. Ndikudziwa!kuti!zotsatila!za!kuyezedwa!kwanga!kwa!TB!komanso!HIV!sizidzawululidwa!kwa!
wina!aliyense!panthawi!imene!ndayendeledwa!kunyumba,!pokhapokha!nditavomeleza!kuti!
ziwululidwe.!
7. Ndikumvetsetsakutingatindikanakutenganawombali! pa! kafukufukuuyu,!
sizikhudzaufuluwangawopezachithandizo! cha! matenda! a! TB!
kuchipatala,tsopanokapenam’tsogolo.!
8. Ndikumvetsakutindithakusankhakulekakutenganawombali! pa! kafukufukuyu! pa!
nthawiiliyonseopandakupelekachifukwacholekelandipoizisizingasokonezethandizo! la!
zaumoyolomwendimalandilanthawizonse.!
Mupatsibwa3 chikalatachomwe3 chili3
ndimbiriyakafukufukuyikomansomupatsidwachikalatachosayinidwachosonyezachilolezokutimwat
enga3nawombali3pa3kafukufukuyu.Ndikuvomeleza,3mosakakamizidwa,3kutinditengenawombali3pa3
kafukufukuyu.3
!
Wotengagawo!pa!kafukufuku_________________________________________________________!
(Dzinalolembedwa!mu!malembaakuluakulu)!
! !
____________________________________Tsiku________________________________________!
Sayinikapenachidindo!cha!chala! !
!
______________________________________________________________________________!
!
Ogwilantchitoya!TB________________________________!____________________________!
(Dzinalolembedwa!mu!malembaakuluakulu)!! ! ! !
!
Sayini_______________________________________!Tsiku_______________________________!
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From: DYE, Christopher M. dyec@who.int
Subject: RE: Permission for use of figure
Date: 24 July 2017 20:29
To: Rebecca Harris Rebecca.Harris@lshtm.ac.uk
Rebecca,	you	are	welcome	to	reproduce	the	Figures	in	your	thesis.
Best	regards…	Chris
	
From: Rebecca Harris [mailto:Rebecca.Harris@lshtm.ac.uk] 
Sent: 24 July 2017 18:40
To: DYE, Christopher M.
Subject: Re: Permission for use of figure
 
Dear Chris,
 
Apologies to email against soon, but was wondering if I could also ask for permission to use
the below image from your 2013 paper for the same purpose?
 
Many thanks,
Rebecca
 
 
 
 
On 24 Jul 2017, at 17:02, Rebecca Harris <lsh355020@lshtm.ac.uk> wrote:On 24 Jul 2017, at 17:02, Rebecca Harris <lsh355020@lshtm.ac.uk> wrote:
Dear Chris,
 
I hope this email finds you well.
 
I was wondering whether I could seek permission for including the following image from your
2013 prospects for TB elimination paper within the printed and electronic versions of my
thesis (for submission to the London School of Hygiene and Tropical Medicine). The thesis
will be made available on the  the LSHTM Research Online institutional repository, which is
non-commercial and available to all: http://researchonlint.lshtm.ac.uk/ 
 
If you are not the rights holder for this material, I would be grateful if you could advise me
who to contact.  
 
Many thanks in advance,
 
Rebecca
 
 
 
<PastedGraphic-3.pdf>
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From: permissions@who.int
Subject: ID: 233421 Permission authorization for WHO copyrighted material
Date: 24 July 2017 13:20
To: rebecca.harris@lshtm.ac.uk
Cc: permissions@who.int
Dear Ms Harris
Thank you for your request for permission to reproduce, reprint or translate certain WHO copyrighted material.
On behalf of the World Health Organization, we are pleased to authorize your request to reproduce the WHO materials as detailed in the
form below, subject to the terms and conditions of the non-exclusive licence below.
If you have questions regarding this authorization, please contact permissions@who.int.
We thank you for your interest in WHO published materials.
Kind regards,
WHO Permissions team
WORLD HEALTH ORGANIZATION (WHO)
Non-exclusive licence to use selected WHO published materials
You submitted a request, through WHO’s online platform, for permission to reprint and reproduce certain WHO copyrighted material (the
"Licensed Materials"). This is a legal agreement (the "Agreement") between you and WHO, granting you a licence to use the Licensed
Materials subject to the terms and conditions herein. 
Read this Agreement in its entirety before using the Licensed Materials.
By using the Licensed Materials, you enter into, and agree to be bound by, this Agreement.
This licence is granted only for original materials belonging to WHO. If any part of the WHO published materials you wish to
reproduce are credited by WHO to a source other than WHO, those materials are not covered by this Agreement and are not
part of the Licensed Materials. You are responsible for determining if this is the case, and if so, you are responsible for
obtaining any necessary permission from the source of those third-party materials prior to their use.
If you enter into this Agreement on behalf of an organization, by using the Licensed Materials you confirm (represent and warrant) that
you are authorized by your organization to enter into this Agreement on the organization’s behalf. In such a case, the terms "you" and
"your" in this Agreement refer to, and this Agreement applies to, the organization.
WHO grants this licence to you based on the representations and warranties you made in the licence request you submitted
through WHO’s online platform. If any of those representations and/or warranties are or become false or inaccurate, this licence
agreement shall automatically terminate with immediate effect, without prejudice to any other remedies which WHO may have.
If you have questions regarding this Agreement, please contact permissions@who.int.
1. Licence. Subject to the terms and Conditions of this Agreement, WHO grants to you a worldwide, royalty free, non-transferable, non-
sublicensable, non-exclusive licence to use, reproduce, publish, and display the Licensed Materials in the manner and using the media
indicated in the Permissions Request Form you submitted to WHO (the "Licensed Use"). This licence is limited to the current edition of
your publication. Future editions or a different use of the Licensed Materials will require additional permission from WHO. If your request
includes translation into different languages, then non-exclusive permission is hereby granted to translate the Licensed Materials into the
languages indicated.
2. Retained Rights. Copyright in the Licensed Materials remains vested in WHO, and WHO retains all rights not specifically granted under
this Agreement. 
3. Mandatory Acknowledgement. In every instance of the Licensed Use, you must make suitable acknowledgement of WHO, either as a
footnote or in a reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year)."
In addition, If the Licensed Materials originate from the WHO web site, you must also include the URL reference and the date accessed.
Translations of the Licensed Materials should be attributed as follows: 
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"Translated with permission of the publisher from Publication title, Vol /edition number, Author(s), Title of article / title of chapter,
Pages No., Year."
4. Altering or Modifying the Licensed Materials. As part of the Licensed Use, you may minimally alter or adapt figures and tables in the
Licensed Materials to match the style of your publication. Any other alteration or modification of the Licensed Materials (including
abbreviations, additions, or deletions) may be made only with the prior written authorization of WHO. 
5. Appropriate and Prohibited Uses. You must use the Licensed Materials in a factual and appropriate context. You may not use the
Licensed Materials in association with any product marketing, promotional, or commercial activities, including, without limitation, in
advertisements, product brochures, company-sponsored web sites, annual reports, or other non-educational publications or distributions.
6. No WHO endorsement. You shall not state or imply that WHO endorses or is affiliated with your publication or the Licensed Use, or
that WHO endorses any entity, organization, company, or product. 
7. No use of the WHO logo. In no case shall you use the WHO name or emblem, or any abbreviation thereof. Notwithstanding the
foregoing, if the WHO name and/or emblem appear as an integral part of the Licensed Materials (e.g. on a map) you may use the name
and/or emblem in your use of the License Materials, provided the name and/or logo is not used separately from the Licensed Materials. 
8. No Warranties by WHO. All reasonable precautions have been taken by WHO to verify the information contained in the Licensed
Materials. However, WHO provides the Licensed Materials to you without warranty of any kind, either expressed or implied, and you are
entirely responsible for your use of the Licensed Materials. In no event shall WHO be liable for damages arising from your use of the
Licensed Materials. 
9. Your Indemnification of WHO. You agree to indemnify WHO for, and hold WHO harmless against, any claim for damages, losses,
and/or any costs, including attorneys' fees, arising in any manner whatsoever from your use of the Licensed Materials or for your breach
of any of the terms of this Agreement.
10. Termination. The licence and the rights granted under this Agreement shall terminate automatically upon any breach by you of the
terms of this Agreement. Further, WHO may terminate this licence at any time with immediate effect for any reason by written notice to
you. 
11. Entire Agreement, Amendment. This Agreement is the entire agreement between you and WHO with respect to its subject matter.
WHO is not bound by any additional terms that may appear in any communication from you. This Agreement may only be amended by
mutual written agreement of you and WHO. 
12. Headings. Paragraph headings in this Agreement are for reference only. 
13. Dispute resolution. Any dispute relating to the interpretation or application of this Agreement shall, unless amicably settled, be subject
to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in
accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the rules of arbitration of the
International Chamber of Commerce. The parties shall accept the arbitral award as final.
14. Privileges and immunities. Nothing in or relating to this Agreement shall be deemed a waiver of any of the privileges and immunities
enjoyed by WHO under national or international law and/or as submitting WHO to any national court jurisdiction.
***
DataCol Web: Form for requesting permission to reproduce, reprint or translate WHO copyrighted material
===================================================
ID: 233421
Section: Contact details
---------------------------------------------------
* Title
* Ms
-------------------------
* First name 
* Rebecca
-------------------------
* Family name 
* Harris
-------------------------
* Organization/affiliation
* LSHTM
-------------------------
* Web site address
* 
-------------------------
* Type of organization
* University/Academic
-------------------------
* If other, please specify
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* If other, please specify
* 
-------------------------
* If STM signatory, please select
-------------------------
* Position
* PhD student
-------------------------
* Telephone
* +447944301012
-------------------------
* Address
* LSHTM, Keppel Street, London, WC1E 7HT
-------------------------
* Country
* United Kingdom of Great Britain and Northern Ireland
-------------------------
* Email
* rebecca.harris@lshtm.ac.uk
Section: Information about WHO material to be reproduced
---------------------------------------------------
* Full title of WHO material from which the reproduction is to be made
* TB strategy targets gif from the End TB strategy website
-------------------------
* Website URL where WHO material is published
* http://www.who.int/entity/tb/strategy/tb-strategy-targets.gif
-------------------------
* ISBN / WHO Reference Number
* 
-------------------------
* Please select the item(s) to be reproduced
* Figure/table
-------------------------
* Type of reuse
* Dissertation or thesis
-------------------------
* No of item(s) to be reproduced
* 5 items or less
-------------------------
* For each item, please provide a reference and page number. If entire document, please state "Entire document".
* published on end TB strategy website: http://www.who.int/tb/strategy/end-tb/en/
Section: Information about your publication
---------------------------------------------------
* Please provide the title of your publication that the above materials are to be published in
* Informing development strategies for new TB vaccines: mathematical modelling and novel epidemiological tools (PhD thesis)
-------------------------
* Publishing format
* Print, HTML
-------------------------
* Will you be translating?
* No
-------------------------
* If yes, please indicate languages
* 
-------------------------
* If web please provide URL / If other, please specify
* Will be posted on the LSHTM thesis repository
-------------------------
* Number of copies (if applicable)
* 
-------------------------
* Target audience and planned distribution
* PhD examiners and scientific community
-------------------------
* Planned publication/distribution date
* End 2017
-------------------------
* If your publication or the material is to be sold, indicate the planned selling price or subscription fee
* n/a
-------------------------
* Is your publication sponsored or funded by an organisation other than your own?
* No
-------------------------
* If yes, please provide additional information
* 
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* 
-------------------------
* Will there be any advertising associated with your publication?
* No
-------------------------
* If yes, please provide additional information
* 
-------------------------
* Subject(s) of interest that most correspond to your request
* Tuberculosis (TB)
-------------------------
* Additional information about your request
* 
-------------------------
* Approval
* Auto permission
-------------------------
* Latest approval modification
-------------------------
* WHO Department 
* ACP, ACT
-------------------------
* Correct WHO URL
* http://www.who.int/entity/tb/strategy/tb-strategy-targets.gif
Section: Terms and conditions
---------------------------------------------------
* By submitting this request you confirm that you will abide by the terms and conditions if WHO grants you permission.
* I have read and agree with the terms and conditions
---------------------------------------------------
Click the following link to access a format view of this record:
http://apps.who.int/datacol/survey.asp?survey_id=258&respondent_id=233421
---------------------------------------------------
This email was automatically sent to you by the WHO Intranet Data Collector.
The DataCol can send emails to accounts specified by the Form focalpoint.
---------------------------------------------------
